Sentence,class,file
http://www.hhmi.org/grants/sffp.html.,Non-OADS,/arxiv_data1/oa_pdf/3d/1a/jmbe-17-360.PMC5134939.pdf
https://stemedhub.org/groups/aau.,Non-OADS,/arxiv_data1/oa_pdf/3d/1a/jmbe-17-360.PMC5134939.pdf
"JOURNAL OF MICROBIOLOGY & BIOLOGY EDUCATION, December 2016, p. 370-379 DOI: http://dx.doi.org/10.1128/jmbe.v17i3.1083 Journal of Microbiology & Biology Education  Volume 17, Number 3 370©2016 Author(s).",Non-OADS,/arxiv_data1/oa_pdf/a6/9a/jmbe-17-370.PMC5134940.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International  license (https://creativecommons.org/licenses/by-nc-nd/4.0/ and https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode), which grants the public the nonexclusive right to copy, distribute, or display the published work.",Non-OADS,/arxiv_data1/oa_pdf/a6/9a/jmbe-17-370.PMC5134940.pdf
http://aamcdiversityfactsandfigures.org/  Accessed  31 August 2014.,Non-OADS,/arxiv_data1/oa_pdf/a6/9a/jmbe-17-370.PMC5134940.pdf
https://www.aamc.org/download/439660/data/20150803_alteringthecourse.pdf  Accessed 11 April 2015.,OADS,/arxiv_data1/oa_pdf/a6/9a/jmbe-17-370.PMC5134940.pdf
"JOURNAL OF MICROBIOLOGY & BIOLOGY EDUCATION, December 2016, p. 380-388 DOI: http://dx.doi.org/10.1128/jmbe.v17i3.1135 Journal of Microbiology & Biology Education  Volume 17, Number 3 380©2016 Author(s).",Non-OADS,/arxiv_data1/oa_pdf/be/08/jmbe-17-380.PMC5134941.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International  license (https://creativecommons.org/licenses/by-nc-nd/4.0/ and https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode), which grants the public the nonexclusive right to copy, distribute, or display the published work.",Non-OADS,/arxiv_data1/oa_pdf/be/08/jmbe-17-380.PMC5134941.pdf
http://epaa.asu.edu/ojs/article/ view/392/515.,Non-OADS,/arxiv_data1/oa_pdf/be/08/jmbe-17-380.PMC5134941.pdf
"JOURNAL OF MICROBIOLOGY & BIOLOGY EDUCATION, December 2016, p. 389-398 DOI: http://dx.doi.org/10.1128/jmbe.v17i3.1156 Journal of Microbiology & Biology Education   389 Volume 17, Number 3 ©2016 Author(s).",Non-OADS,/arxiv_data1/oa_pdf/1a/4f/jmbe-17-389.PMC5134942.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International  license (https://creativecommons.org/licenses/by-nc-nd/4.0/ and https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode), which grants the public the nonexclusive right to copy, distribute, or display the published work.",Non-OADS,/arxiv_data1/oa_pdf/1a/4f/jmbe-17-389.PMC5134942.pdf
"JOURNAL OF MICROBIOLOGY & BIOLOGY EDUCATION, December 2016, p. 399-408 DOI: http://dx.doi.org/10.1128/jmbe.v17i3.1103 Journal of Microbiology & Biology Education   399 Volume 17, Number 3 ©2016 Author(s).",Non-OADS,/arxiv_data1/oa_pdf/ac/e7/jmbe-17-399.PMC5134943.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International  license (https://creativecommons.org/licenses/by-nc-nd/4.0/ and https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode), which grants the public the nonexclusive right to copy, distribute, or display the published work.",Non-OADS,/arxiv_data1/oa_pdf/ac/e7/jmbe-17-399.PMC5134943.pdf
"Journal of Microbiology & Biology Education  SHORTLIDGE and  BROWNELL: ASSESSING CURES407 Volume 17, Number 3http://www.insightassessment.com/Products/Products- Summary/Critical-Thinking-Skills-Tests/California-Critical- Thinking-Skills-Test-CCTST.",Non-OADS,/arxiv_data1/oa_pdf/ac/e7/jmbe-17-399.PMC5134943.pdf
https://www.grinnell.edu/academics/areas/psychology/assessments/cure-survey.,Non-OADS,/arxiv_data1/oa_pdf/ac/e7/jmbe-17-399.PMC5134943.pdf
"JOURNAL OF MICROBIOLOGY & BIOLOGY EDUCATION, December 2016, p. 409-416 DOI: http://dx.doi.org/10.1128/jmbe.v17i3.1172 Journal of Microbiology & Biology Education   409 Volume 17, Number 3 ©2016 Author(s).",Non-OADS,/arxiv_data1/oa_pdf/72/33/jmbe-17-409.PMC5134944.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International  license (https://creativecommons.org/licenses/by-nc-nd/4.0/ and https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode), which grants the public the nonexclusive right to copy, distribute, or display the published work.",Non-OADS,/arxiv_data1/oa_pdf/72/33/jmbe-17-409.PMC5134944.pdf
http://www.ieg-ego.eu/ bommelb-2015 -en.,Non-OADS,/arxiv_data1/oa_pdf/72/33/jmbe-17-409.PMC5134944.pdf
http://www.sciartcenter.org/gut- instinct.html .,Non-OADS,/arxiv_data1/oa_pdf/72/33/jmbe-17-409.PMC5134944.pdf
"JOURNAL OF MICROBIOLOGY & BIOLOGY EDUCATION, December 2016, p. 417-422 DOI: http://dx.doi.org/10.1128/jmbe.v17i3.1157 Journal of Microbiology & Biology Education   417 Volume 17, Number 3 ©2016 Author(s).",Non-OADS,/arxiv_data1/oa_pdf/56/3e/jmbe-17-417.PMC5134945.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International  license (https://creativecommons.org/licenses/by-nc-nd/4.0/ and https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode), which grants the public the nonexclusive right to copy, distribute, or display the published work.",Non-OADS,/arxiv_data1/oa_pdf/56/3e/jmbe-17-417.PMC5134945.pdf
[Online] http://sloanconsortium.org/publications/ survey/class_differences .,OADS,/arxiv_data1/oa_pdf/56/3e/jmbe-17-417.PMC5134945.pdf
[Online] http://onlinelearningconsortium.org/read/online-report-card- tracking-online-education-united-states-2015/.,Non-OADS,/arxiv_data1/oa_pdf/56/3e/jmbe-17-417.PMC5134945.pdf
Retrieved from http://linkresearchlab.org/ PreparingDigitalUniversity.pdf.,Non-OADS,/arxiv_data1/oa_pdf/56/3e/jmbe-17-417.PMC5134945.pdf
"JOURNAL OF MICROBIOLOGY & BIOLOGY EDUCATION, December 2016, p. 423-429 DOI: http://dx.doi.org/10.1128/jmbe.v17i3.1115 Journal of Microbiology & Biology Education   423 Volume 17, Number 3 ©2016 Author(s).",Non-OADS,/arxiv_data1/oa_pdf/38/c4/jmbe-17-423.PMC5134946.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International  license (https://creativecommons.org/licenses/by-nc-nd/4.0/ and https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode), which grants the public the nonexclusive right to copy, distribute, or display the published work.",Non-OADS,/arxiv_data1/oa_pdf/38/c4/jmbe-17-423.PMC5134946.pdf
"SUPPLEMENTAL MATERIALS  Appendix 1: Laboratory manual  Appendix 2:  Faculty instructions, reading materials, and assessment rubrics Appendix 3:   Pre/post-class surveys and student responses, a guide for lab report, and a guide for lab notebook Appendix 4: Samples of students’ work  Appendix 5: Supplementary data ACKNOWLEDGMENTS Thanks are due to the Georgia Perimeter College and  the Bio-Bus program ( http://biobus.gsu.edu/ ) of Georgia  State University for financial support of the Summer Pilot and to the Molecular Basis of Disease and the McNair programs of Georgia State University for stipends to the participants.",Non-OADS,/arxiv_data1/oa_pdf/38/c4/jmbe-17-423.PMC5134946.pdf
"JOURNAL OF MICROBIOLOGY & BIOLOGY EDUCATION, December 2016, p. 430-435 DOI: http://dx.doi.org/10.1128/jmbe.v17i3.1149 Journal of Microbiology & Biology Education  Volume 17, Number 3 430©2016 Author(s).",Non-OADS,/arxiv_data1/oa_pdf/d3/55/jmbe-17-430.PMC5134947.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International  license (https://creativecommons.org/licenses/by-nc-nd/4.0/ and https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode), which grants the public the nonexclusive right to copy, distribute, or display the published work.",Non-OADS,/arxiv_data1/oa_pdf/d3/55/jmbe-17-430.PMC5134947.pdf
Sample data View the module itself here: https://my.vanderbilt.edu/ noahgreen/.Safety issues There are no safety concerns associated with using  this module.,Non-OADS,/arxiv_data1/oa_pdf/d3/55/jmbe-17-430.PMC5134947.pdf
"JOURNAL OF MICROBIOLOGY & BIOLOGY EDUCATION, December 2016, p. 436-443 DOI: http://dx.doi.org/10.1128/jmbe.v17i3.1137 Journal of Microbiology & Biology Education  Volume 17, Number 3 436 *Corresponding author.",Non-OADS,/arxiv_data1/oa_pdf/17/a2/jmbe-17-436.PMC5134948.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International  license (https://creativecommons.org/licenses/by-nc-nd/4.0/ and https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode), which grants the public the nonexclusive right to copy, distribute, or display the published work.",Non-OADS,/arxiv_data1/oa_pdf/17/a2/jmbe-17-436.PMC5134948.pdf
"JOURNAL OF MICROBIOLOGY & BIOLOGY EDUCATION, December 2016, p. 444-450 DOI: http://dx.doi.org/10.1128/jmbe.v17i3.1124 Journal of Microbiology & Biology Education  Volume 17, Number 3 444 *Corresponding author.",Non-OADS,/arxiv_data1/oa_pdf/ca/66/jmbe-17-444.PMC5134949.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International  license (https://creativecommons.org/licenses/by-nc-nd/4.0/ and https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode), which grants the public the nonexclusive right to copy, distribute, or display the published work.",Non-OADS,/arxiv_data1/oa_pdf/ca/66/jmbe-17-444.PMC5134949.pdf
"Self-efficacy sur - veys (SENCER-SALG, http://www.sencer.net/assessment/sencersalg.cfm ) revealed significant increased confidence  (Table 1) in understanding the nature of science and applying learned techniques as a result of the capstone experience.",OADS,/arxiv_data1/oa_pdf/ca/66/jmbe-17-444.PMC5134949.pdf
"JOURNAL OF MICROBIOLOGY & BIOLOGY EDUCATION, December 2016, p. 451-457 DOI: http://dx.doi.org/10.1128/jmbe.v17i3.1122 Journal of Microbiology & Biology Education   451 Volume 17, Number 3 ©2016 Author(s).",Non-OADS,/arxiv_data1/oa_pdf/32/0a/jmbe-17-451.PMC5134950.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International  license (https://creativecommons.org/licenses/by-nc-nd/4.0/ and https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode), which grants the public the nonexclusive right to copy, distribute, or display the published work.",Non-OADS,/arxiv_data1/oa_pdf/32/0a/jmbe-17-451.PMC5134950.pdf
"To perform in silico  PCR, we  recommend using the UCSC Genome Bioinformatics site, which can be accessed at https://genome.ucsc.edu/cgi-bin/ hgPcr .",Non-OADS,/arxiv_data1/oa_pdf/32/0a/jmbe-17-451.PMC5134950.pdf
BLAST can be accessed at https://blast.ncbi.,OADS,/arxiv_data1/oa_pdf/32/0a/jmbe-17-451.PMC5134950.pdf
https://oucc.dasa.ncsu.edu/ general-education-program-gep/gep-category-requirements/.,Non-OADS,/arxiv_data1/oa_pdf/32/0a/jmbe-17-451.PMC5134950.pdf
"JOURNAL OF MICROBIOLOGY & BIOLOGY EDUCATION, December 2016, p. 458-465 DOI: http://dx.doi.org/10.1128/jmbe.v17i3.1162 Journal of Microbiology & Biology Education  Volume 17, Number 3 458 *Corresponding author.",Non-OADS,/arxiv_data1/oa_pdf/57/5b/jmbe-17-458.PMC5134951.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International  license (https://creativecommons.org/licenses/by-nc-nd/4.0/ and https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode), which grants the public the nonexclusive right to copy, distribute, or display the published work.",Non-OADS,/arxiv_data1/oa_pdf/57/5b/jmbe-17-458.PMC5134951.pdf
"JOURNAL OF MICROBIOLOGY & BIOLOGY EDUCATION, December 2016, p. 466-468 DOI: http://dx.doi.org/10.1128/jmbe.v17i3.1107 Journal of Microbiology & Biology Education  Volume 17, Number 3 466 Corresponding author.",Non-OADS,/arxiv_data1/oa_pdf/6f/af/jmbe-17-466.PMC5134952.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International  license (https://creativecommons.org/licenses/by-nc-nd/4.0/ and https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode), which grants the public the nonexclusive right to copy, distribute, or display the published work.",Non-OADS,/arxiv_data1/oa_pdf/6f/af/jmbe-17-466.PMC5134952.pdf
"JOURNAL OF MICROBIOLOGY & BIOLOGY EDUCATION, December 2016, p. 469-471 DOI: http://dx.doi.org/10.1128/jmbe.v17i3.1142 Journal of Microbiology & Biology Education   469 Volume 17, Number 3 ©2016 Author(s).",Non-OADS,/arxiv_data1/oa_pdf/0f/00/jmbe-17-469.PMC5134953.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International  license (https://creativecommons.org/licenses/by-nc-nd/4.0/ and https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode), which grants the public the nonexclusive right to copy, distribute, or display the published work.",Non-OADS,/arxiv_data1/oa_pdf/0f/00/jmbe-17-469.PMC5134953.pdf
"Several CURE models exist for traditional laboratory  settings (1–3), and CUREs are now being developed for field settings (examples can be found on the CUREnet website at https://curenet.cns.utexas.edu) .",Non-OADS,/arxiv_data1/oa_pdf/0f/00/jmbe-17-469.PMC5134953.pdf
"JOURNAL OF MICROBIOLOGY & BIOLOGY EDUCATION, December 2016, p. 472-474 DOI: http://dx.doi.org/10.1128/jmbe.v17i3.1110 Journal of Microbiology & Biology Education  Volume 17, Number 3 472©2016 Author(s).",Non-OADS,/arxiv_data1/oa_pdf/87/b1/jmbe-17-472.PMC5134954.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International  license (https://creativecommons.org/licenses/by-nc-nd/4.0/ and https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode), which grants the public the nonexclusive right to copy, distribute, or display the published work.",Non-OADS,/arxiv_data1/oa_pdf/87/b1/jmbe-17-472.PMC5134954.pdf
"JOURNAL OF MICROBIOLOGY & BIOLOGY EDUCATION, December 2016, p. 475-476 DOI: http://dx.doi.org/10.1128/jmbe.v17i3.1151 Journal of Microbiology & Biology Education   475 Volume 17, Number 3 ©2016 Author(s).",Non-OADS,/arxiv_data1/oa_pdf/d2/4a/jmbe-17-475.PMC5134955.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International  license (https://creativecommons.org/licenses/by-nc-nd/4.0/ and https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode), which grants the public the nonexclusive right to copy, distribute, or display the published work.",Non-OADS,/arxiv_data1/oa_pdf/d2/4a/jmbe-17-475.PMC5134955.pdf
"JOURNAL OF MICROBIOLOGY & BIOLOGY EDUCATION, December 2016, p. 477-479 DOI: http://dx.doi.org/10.1128/jmbe.v17i3.1146 Journal of Microbiology & Biology Education   477 Volume 17, Number 3 ©2016 Author(s).",Non-OADS,/arxiv_data1/oa_pdf/9c/c7/jmbe-17-477.PMC5134956.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International  license (https://creativecommons.org/licenses/by-nc-nd/4.0/ and https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode), which grants the public the nonexclusive right to copy, distribute, or display the published work.",Non-OADS,/arxiv_data1/oa_pdf/9c/c7/jmbe-17-477.PMC5134956.pdf
"JOURNAL OF MICROBIOLOGY & BIOLOGY EDUCATION, December 2016, p. 480-481 DOI: http://dx.doi.org/10.1128/jmbe.v17i3.1123 Journal of Microbiology & Biology Education  Volume 17, Number 3 480©2016 Author(s).",Non-OADS,/arxiv_data1/oa_pdf/c7/0e/jmbe-17-480.PMC5134957.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International  license (https://creativecommons.org/licenses/by-nc-nd/4.0/ and https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode), which grants the public the nonexclusive right to copy, distribute, or display the published work.",Non-OADS,/arxiv_data1/oa_pdf/c7/0e/jmbe-17-480.PMC5134957.pdf
"JOURNAL OF MICROBIOLOGY & BIOLOGY EDUCATION, December 2016, p. 482-484 DOI: http://dx.doi.org/10.1128/jmbe.v17i3.1178 Journal of Microbiology & Biology Education  Volume 17, Number 3 482©2016 Author(s).",Non-OADS,/arxiv_data1/oa_pdf/d3/cc/jmbe-17-482.PMC5134958.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International  license (https://creativecommons.org/licenses/by-nc-nd/4.0/ and https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode), which grants the public the nonexclusive right to copy, distribute, or display the published work.",Non-OADS,/arxiv_data1/oa_pdf/d3/cc/jmbe-17-482.PMC5134958.pdf
"JOURNAL OF MICROBIOLOGY & BIOLOGY EDUCATION, December 2016, p. 485-486 DOI: http://dx.doi.org/10.1128/jmbe.v17i3.1192 Journal of Microbiology & Biology Education   485 Volume 17, Number 3 ©2016 Author(s).",Non-OADS,/arxiv_data1/oa_pdf/f1/d5/jmbe-17-485.PMC5134959.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International  license (https://creativecommons.org/licenses/by-nc-nd/4.0/ and https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode), which grants the public the nonexclusive right to copy, distribute, or display the published work.",Non-OADS,/arxiv_data1/oa_pdf/f1/d5/jmbe-17-485.PMC5134959.pdf
"JOURNAL OF MICROBIOLOGY & BIOLOGY EDUCATION, December 2016, p. 487-489 DOI: http://dx.doi.org/10.1128/jmbe.v17i3.1193 Journal of Microbiology & Biology Education   487 Volume 17, Number 3 ©2016 Author(s).",Non-OADS,/arxiv_data1/oa_pdf/9b/dc/jmbe-17-487.PMC5134960.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International  license (https://creativecommons.org/licenses/by-nc-nd/4.0/ and https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode), which grants the public the nonexclusive right to copy, distribute, or display the published work.",Non-OADS,/arxiv_data1/oa_pdf/9b/dc/jmbe-17-487.PMC5134960.pdf
http://phet.colorado.,Non-OADS,/arxiv_data1/oa_pdf/9b/dc/jmbe-17-487.PMC5134960.pdf
"JOURNAL OF MICROBIOLOGY & BIOLOGY EDUCATION, December 2016, p. 490-491 DOI: http://dx.doi.org/10.1128/jmbe.v17i3.1180 Journal of Microbiology & Biology Education  Volume 17, Number 3 490 Corresponding author.",Non-OADS,/arxiv_data1/oa_pdf/71/2d/jmbe-17-490.PMC5134961.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International  license (https://creativecommons.org/licenses/by-nc-nd/4.0/ and https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode), which grants the public the nonexclusive right to copy, distribute, or display the published work.",Non-OADS,/arxiv_data1/oa_pdf/71/2d/jmbe-17-490.PMC5134961.pdf
"The graduated cylinder method for testing cat - alase is especially good for collecting large amounts of data that enable students to use statistics and, unlike similar yeast catalase experiments using paper disks and a yeast solution (http://cibt.cornell.edu/labs-activities/labs/catalase/ ), the  yeast spheres are easy to manipulate, and there is very little variability.",Non-OADS,/arxiv_data1/oa_pdf/71/2d/jmbe-17-490.PMC5134961.pdf
"JOURNAL OF MICROBIOLOGY & BIOLOGY EDUCATION, December 2016, p. 492-494 DOI: http://dx.doi.org/10.1128/jmbe.v17i3.1200 Journal of Microbiology & Biology Education  Volume 17, Number 3 492©2016 Author(s).",Non-OADS,/arxiv_data1/oa_pdf/31/68/jmbe-17-492.PMC5134962.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International  license (https://creativecommons.org/licenses/by-nc-nd/4.0/ and https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode), which grants the public the nonexclusive right to copy, distribute, or display the published work.",Non-OADS,/arxiv_data1/oa_pdf/31/68/jmbe-17-492.PMC5134962.pdf
Tweets were sent from the   @SEMicrobiologia Twitter account and programmed to be posted at a frequency of one tweet per minute using the application TweetDeck  (https://tweetdeck.twitter.com/ ).,Non-OADS,/arxiv_data1/oa_pdf/31/68/jmbe-17-492.PMC5134962.pdf
"After each lesson was posted, tweets were compiled and stored online using the open tool Storify (https://storify.com/SEMicrobiologia) , so that they could  be consulted any time after the class was over.",Non-OADS,/arxiv_data1/oa_pdf/31/68/jmbe-17-492.PMC5134962.pdf
"Once the course was completed, data were analyzed using the open software Twitter analytics ( https://analytics.twitter.com/ ).",Non-OADS,/arxiv_data1/oa_pdf/31/68/jmbe-17-492.PMC5134962.pdf
"JOURNAL OF MICROBIOLOGY & BIOLOGY EDUCATION, December 2016, p. 495-498 Copyright © 2016 American Society for Microbiology Journal of Microbiology & Biology Education   495 Volume 17, Number 3Reviews JOURNAL WATCH DOI: http://dx.doi.org/10.1128/jmbe.v17i3.1237 In this section, I provide articles on recent developments  and new technology used in microbiology and related fields.",Non-OADS,/arxiv_data1/oa_pdf/45/54/jmbe-17-495a.PMC5134963.pdf
"Microbiology Instruction Using Current Foodborne  Outbreak Resources DOI: http://dx.doi.org/10.1128/jmbe.v17i3.1213 Review of: Center for Disease Control and Prevention  (CDC) Foodborne Outbreak Online Database (FOOD), wwwn.cdc.gov/foodborneoutbreaks/ , CDC Outbreaks,  www.cdc.gov/outbreaks/index.html , and Multistate Food - borne Outbreaks, www.cdc.gov/foodsafety/outbreaks/multistate-outbreaks/outbreaks-list.html.",Non-OADS,/arxiv_data1/oa_pdf/45/54/jmbe-17-495a.PMC5134963.pdf
"JOURNAL OF MICROBIOLOGY & BIOLOGY EDUCATION, December 2016, p. 495-498 Copyright © 2016 American Society for Microbiology Journal of Microbiology & Biology Education   495 Volume 17, Number 3Reviews JOURNAL WATCH DOI: http://dx.doi.org/10.1128/jmbe.v17i3.1237 In this section, I provide articles on recent developments  and new technology used in microbiology and related fields.",Non-OADS,/arxiv_data1/oa_pdf/ef/ec/jmbe-17-495b.PMC5134964.pdf
"Microbiology Instruction Using Current Foodborne  Outbreak Resources DOI: http://dx.doi.org/10.1128/jmbe.v17i3.1213 Review of: Center for Disease Control and Prevention  (CDC) Foodborne Outbreak Online Database (FOOD), wwwn.cdc.gov/foodborneoutbreaks/ , CDC Outbreaks,  www.cdc.gov/outbreaks/index.html , and Multistate Food - borne Outbreaks, www.cdc.gov/foodsafety/outbreaks/multistate-outbreaks/outbreaks-list.html.",Non-OADS,/arxiv_data1/oa_pdf/ef/ec/jmbe-17-495b.PMC5134964.pdf
http://www.cdc.gov/foodsafety/fdoss/data/food.,Non-OADS,/arxiv_data1/oa_pdf/ef/ec/jmbe-17-495b.PMC5134964.pdf
"Narveen Jandu   Gannon University   Erie, PA jandu001@gannon.edu BOOK “It’s a Microbial World; We Just Live in It”:  Microbial Symbionts Profiled Masterfully by YongDOI: http://dx.doi.org/10.1128/jmbe.v17i3.1217 Review of: I Contain Multitudes: The Microbes Within Us and A  Grander View of Life ; Ed Yong; (2016).",Non-OADS,/arxiv_data1/oa_pdf/ef/ec/jmbe-17-495b.PMC5134964.pdf
http://www.cdc.gov/foodsafety/fdoss/data/food.,Non-OADS,/arxiv_data1/oa_pdf/3a/20/jmbe-17-496.PMC5134965.pdf
"Narveen Jandu   Gannon University   Erie, PA jandu001@gannon.edu BOOK “It’s a Microbial World; We Just Live in It”:  Microbial Symbionts Profiled Masterfully by YongDOI: http://dx.doi.org/10.1128/jmbe.v17i3.1217 Review of: I Contain Multitudes: The Microbes Within Us and A  Grander View of Life ; Ed Yong; (2016).",Non-OADS,/arxiv_data1/oa_pdf/3a/20/jmbe-17-496.PMC5134965.pdf
"JOURNAL OF MICROBIOLOGY & BIOLOGY EDUCATION, December 2016, p. 499-504 DOI: http://dx.doi.org/10.1128/jmbe.v17i3.1189 Journal of Microbiology & Biology Education   499 Volume 17, Number 3ASMCUE Abstracts ©2016 Author(s).",Non-OADS,/arxiv_data1/oa_pdf/42/14/jmbe-17-499.PMC5134966.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International  license (https://creativecommons.org/licenses/by-nc-nd/4.0/ and https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode), which grants the public the nonexclusive right to copy, distribute, or display the published work.",Non-OADS,/arxiv_data1/oa_pdf/42/14/jmbe-17-499.PMC5134966.pdf
"JOURNAL OF MICROBIOLOGY & BIOLOGY EDUCATION, December 2016, p. 505 DOI: http://dx.doi.org/10.1128/jmbe.v17i3.1254 Journal of Microbiology & Biology Education   505 Volume 17, Number 3 ©2016 Author(s).",Non-OADS,/arxiv_data1/oa_pdf/d8/3b/jmbe-17-505.PMC5134967.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International  license (https://creativecommons.org/licenses/by-nc-nd/4.0/ and https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode), which grants the public the nonexclusive right to copy, distribute, or display the published work.",Non-OADS,/arxiv_data1/oa_pdf/d8/3b/jmbe-17-505.PMC5134967.pdf
BSCS is a non-profit curriculum study committed to transforming science teaching and learning ( https://bscs.org/).Correction Notice: Perspectives in Marine Citizen Science,Non-OADS,/arxiv_data1/oa_pdf/d8/3b/jmbe-17-505.PMC5134967.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/36/f8/tcrm-12-1805.PMC5135003.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Therapeutics and Clinical Risk Management 2016:12 1805–1809Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  1805ORiginal ReseaRChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/TCRM.S11046 4 Preoperative risk factors in total thyroidectomy  of substernal goiter aldo Bove Raffaella Maria Di Renzo gauro D’Urbano Manuela Bellobono Vincenzo D’ addetta alfonso lapergola giuseppe Bongarzoni Department of Medicine, Dentistry  and Biotechnology, University  “g.",Non-OADS,/arxiv_data1/oa_pdf/36/f8/tcrm-12-1805.PMC5135003.pdf
"d’annunzio” Chieti-Pescara, Via dei  Vestini, 31, 66100 Chieti scalo, italy Tel +39 0871 355 6702 Fax +39 0871 355 6753 email above@unich.i t Journal name: Therapeutics and Clinical Risk Management Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Bove et al Running head recto: Preoperative risk factors in total thyroidectomy of substernal goiter DOI: http://dx.doi.org/10.2147/TCRM.S110464",Non-OADS,/arxiv_data1/oa_pdf/36/f8/tcrm-12-1805.PMC5135003.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/36/f8/tcrm-12-1805.PMC5135003.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/36/f8/tcrm-12-1805.PMC5135003.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/60/3f/tcrm-12-1793.PMC5135004.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Therapeutics and Clinical Risk Management 2016:12 1793–1796Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  1793LeTTeRopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/TCRM.S12062 8 Comparative efficacy of bilastine, levocetirizine  and desloratadine updosing in chronic urticaria Maria T Staevska Clinical Center of Allergology, Medical  University, Sofia, BulgariaDear editor As a group of allergists who treat both allergic rhinitis and urticaria patients on a daily  basis, and involved in clinical research, we read with particular interest the review  paper “Treatment of allergic rhinitis and urticaria: a review of the newest antihista - mine drug bilastine”,1 published in your journal.",Non-OADS,/arxiv_data1/oa_pdf/60/3f/tcrm-12-1793.PMC5135004.pdf
"The study  by Krause et al3 recruited patients with cold contact urticaria whose symptoms were Correspondence: Maria T Staevska Clinical Centre of Allergology, Medical  University Sofia, 1 St George Sofiiski  Blvd, Sofia 1431, Bulgaria email mari66sta@gmail.co mJournal name: Therapeutics and Clinical Risk Management Article Designation: Letter Y ear: 2016 Volume: 12 Running head verso: Staevska Running head recto: Treatment of allergic rhinitis and urticaria DOI: http://dx.doi.org/10.2147/TCRM.S120628",Non-OADS,/arxiv_data1/oa_pdf/60/3f/tcrm-12-1793.PMC5135004.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/60/3f/tcrm-12-1793.PMC5135004.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/60/3f/tcrm-12-1793.PMC5135004.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/47/56/tcrm-12-1797.PMC5135005.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Therapeutics and Clinical Risk Management 2016:12 1797–1803Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  1797ORiginal ReseaRChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/TCRM.S12001 2 Role of anuria in the relationship between indoxyl  sulfate and anemia in peritoneal dialysis patients Jeng-Yi huang1,2 Ching-Wei hsu1,2 Chih-Wei Yang1,2 Cheng-Chieh hung1,2 Wen-hung huang1,2 1Kidney Research Center, Department  of nephrology, Chang gung Memorial  hospital, linkou Branch, Taipei, 2Chang  gung University school of Medicine,   Taoyuan, TaiwanBackground:  Experimental evidence suggests that indoxyl sulfate (IS) is associated with chronic  kidney disease-related anemia.",Non-OADS,/arxiv_data1/oa_pdf/47/56/tcrm-12-1797.PMC5135005.pdf
"It has been demonstrated in some in vitro studies that IS could suppress erythroid colony Correspondence: Wen-hung huang Department of nephrology, Chang  gung Memorial hospital, no 5, Fu hsing  street, Kuei-shan, Taoyuan 333, Taiwan Tel +886 3 328 1200, ext 2024 Fax +886 3 328 2173 email williammedia@gmail.co m Journal name: Therapeutics and Clinical Risk Management Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Huang et al Running head recto: Indoxyl sulfate and anemia DOI: http://dx.doi.org/10.2147/TCRM.S120012",Non-OADS,/arxiv_data1/oa_pdf/47/56/tcrm-12-1797.PMC5135005.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/47/56/tcrm-12-1797.PMC5135005.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/47/56/tcrm-12-1797.PMC5135005.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/aa/2f/tcrm-12-1783.PMC5135006.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Therapeutics and Clinical Risk Management 2016:12 1783–1792Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  1783ORiginal ReseaRChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/TCRM.S11801 4 health behaviors of patients diagnosed with type 2   diabetes mellitus and their influence on the patients’   satisfaction with life anna Rosiek1 T omasz Kornatowski1 Natalia Frąckowiak- Maciejewska1 Aleksandra Rosiek- Kryszewska2 Przemysław Wyżgowski3 Krzysztof leksowski1,3 1Department of Public health,   Faculty of health science, nicolaus  Copernicus University in T oruń,   2Department of inorganic and  analytical Chemistry, Faculty of  Pharmacy, nicolaus Copernicus  University in T oruń, 3Department  of general surgery, 10th Military  hospital, Bydgoszcz, PolandBackground:  The diagnosis of type 2 diabetes mellitus (T2DM) carries with it a number  of changes to the patient’s lifestyle.",Non-OADS,/arxiv_data1/oa_pdf/aa/2f/tcrm-12-1783.PMC5135006.pdf
"Pracy 8/7,   85-843 Bydgoszcz, Poland email ania.rosiek@wp.p l Journal name: Therapeutics and Clinical Risk Management Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Rosiek et al Running head recto: Influence of health behaviors of T2DM patients on life satisfaction DOI: http://dx.doi.org/10.2147/TCRM.S118014",Non-OADS,/arxiv_data1/oa_pdf/aa/2f/tcrm-12-1783.PMC5135006.pdf
Available from: http://www.cdc.gov/ chronicdisease/pdf/2009-power-of-prevention.pd f  18.,Non-OADS,/arxiv_data1/oa_pdf/aa/2f/tcrm-12-1783.PMC5135006.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/aa/2f/tcrm-12-1783.PMC5135006.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/aa/2f/tcrm-12-1783.PMC5135006.pdf
Available from: http://www.psychometric- success.com/aptitude-tests/percentiles-and-norming.htm#sthash.,Non-OADS,/arxiv_data1/oa_pdf/aa/2f/tcrm-12-1783.PMC5135006.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/45/36/cia-11-1733.PMC5135058.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Interventions in Aging 2016:11 1733–1740Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  1733RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S10461 8 Person-centered dementia care: current  perspectives Jill Manthorpe Kritika Samsi Social Care workforce Research Unit,   NIHR School for Social Care, King’s  College London, London, UKAbstract:  Person-centered dementia care is widely accepted as a value-based commitment to  supporting people with dementia and is a guiding principle in care services.",Non-OADS,/arxiv_data1/oa_pdf/45/36/cia-11-1733.PMC5135058.pdf
"It has also been described as a way of enabling people to be  involved in planning how the service they currently receive is organized or delivered.3  Initially developed in learning disability services (intellectual impairment), person- centered planning has influenced many social care services in the UK.4 However, it is  less frequently used in older people’s services, although a new variant is emerging with  the greater encouragement of advance care planning among health and care services  for people with dementia and in end-of-life care.5Correspondence: Jill Manthorpe Social Care workforce Research Unit,  King’s College London, 2nd Floor,  virginia woolf Building, 22 Kingsway,  wC2R 2LS, London, UK Tel +44 020 7848 1683 email jill.manthorpe@kcl.ac.u kJournal name: Clinical Interventions in Aging Article Designation: Review Y ear: 2016 Volume: 11 Running head verso: Manthorpe and Samsi Running head recto: Person-centered dementia care DOI: http://dx.doi.org/10.2147/CIA.S104618",Non-OADS,/arxiv_data1/oa_pdf/45/36/cia-11-1733.PMC5135058.pdf
Available from https://www.alzheimers.org.uk/site/scripts/ services_info.php?serviceID =167.,Non-OADS,/arxiv_data1/oa_pdf/45/36/cia-11-1733.PMC5135058.pdf
Available from: http://www.legislation.gov.uk/ukpga/2012/7/contents/ enacted.,Non-OADS,/arxiv_data1/oa_pdf/45/36/cia-11-1733.PMC5135058.pdf
Available from http://www.health.org.,Non-OADS,/arxiv_data1/oa_pdf/45/36/cia-11-1733.PMC5135058.pdf
"Available from  http://www.nationalvoices.org.uk/pages/evidence-person-centred-car e.  Accessed November 4, 2016.",Non-OADS,/arxiv_data1/oa_pdf/45/36/cia-11-1733.PMC5135058.pdf
Available from http://www.pickereurope.org/ about-us/principles-of-patient-centred-care /.,Non-OADS,/arxiv_data1/oa_pdf/45/36/cia-11-1733.PMC5135058.pdf
Available from http://www.legislation.gov.,Non-OADS,/arxiv_data1/oa_pdf/45/36/cia-11-1733.PMC5135058.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/45/36/cia-11-1733.PMC5135058.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/45/36/cia-11-1733.PMC5135058.pdf
"Available from http://onlinelibrary.wiley.com/doi/10.1111/ijsw.12221/ abstrac t. Accessed November 4, 2016.",Non-OADS,/arxiv_data1/oa_pdf/45/36/cia-11-1733.PMC5135058.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/a2/4e/amep-7-645.PMC5135060.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/a2/4e/amep-7-645.PMC5135060.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Advances in Medical Education and Practice 2016:7 645–646Advances in Medical Education and Practice Dovepress submit your manuscript | www.dovepress.com Dovepress 645 LETTER open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/AMEP .S123246 A student’s perspective: are medical students  adequately trained in BLS?",Non-OADS,/arxiv_data1/oa_pdf/a2/4e/amep-7-645.PMC5135060.pdf
"2016;7:241–242.Correspondence: Tobi Oyewole Cedar House, L69 3GE, Ashton St, Liverpool L3 5PS, University of Liverpool – The School of Medicine, Liverpool, UKEmail tobioyewole@aol.comJournal name: Advances in Medical Education and Practice Article Designation: LETTERY ear: 2016V olume: 7Running head verso: Oyewole and OyewoleRunning head recto: A student’ s perspectiveDOI: http://dx.doi.org/10.2147/AMEP .S123246",Non-OADS,/arxiv_data1/oa_pdf/a2/4e/amep-7-645.PMC5135060.pdf
"Advances in Medical Education and Practice Publish your work in this journal Submit your manuscript here: http://www.dovepress.com/advances-in-medical-education-and-practice-journalAdvances in Medical Education and Practice is an international, peer-  reviewed, open access journal that aims to present and publish research on Medical Education covering medical, dental, nursing and allied   health care professional education.",Non-OADS,/arxiv_data1/oa_pdf/a2/4e/amep-7-645.PMC5135060.pdf
"Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Advances in Medical Education and Practice 2016:7submit your manuscript | www.dovepress.com Dovepress Dovepress Dovepress 646 Oyewole and Oyewole Dove Medical Press encourages responsible, free and frank academic debate.",Non-OADS,/arxiv_data1/oa_pdf/a2/4e/amep-7-645.PMC5135060.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/00/06/copd-11-2965.PMC5135061.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2016:11 2965–2975International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  2965OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S12055 5 effectiveness of neuromuscular electrical  stimulation for the rehabilitation of  moderate-to-severe COPD: a meta-analysis rong-chang Chen1,* Xiao-ying li1,* li-li guan1 Bing-peng guo1 Wei-liang Wu1 Zi-qing Zhou1 Ya-ting huo1 Xin Chen2 lu-qian Zhou1 1state Key laboratory of respiratory  Disease, guangzhou Institute of  respiratory Disease, First affiliated  hospital of guangzhou Medical  University, 2Zhujiang hospital  of southern Medical University,   guangzhou, People’s republic of China *These authors contributed equally  to this workPurpose:  Patients with COPD often experience skeletal muscle dysfunction.",Non-OADS,/arxiv_data1/oa_pdf/00/06/copd-11-2965.PMC5135061.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/00/06/copd-11-2965.PMC5135061.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/00/06/copd-11-2965.PMC5135061.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/40/5e/copd-11-2977.PMC5135062.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2016:11 2977–2990International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  2977OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S11619 6 Factors influencing exacerbation-related  self-management in patients with COPD:  a qualitative study YJG Korpershoek1,2 sCJM Vervoort3 lIT nijssen2 JCA Trappenburg2 MJ Schuurmans1,2 1Research Group Chronic Illnesses,   Faculty of Health Care, University  of Applied Sciences Utrecht, 2Julius  Center for Health Sciences and  Primary Care, University Medical  Center Utrecht, 3Cancer Center,   University Medical Center Utrecht,   Utrecht, the NetherlandsBackground:  In patients with COPD, self-management skills are important to reduce the impact  of exacerbations.",Non-OADS,/arxiv_data1/oa_pdf/40/5e/copd-11-2977.PMC5135062.pdf
"Keywords:  COPD, self-management, exacerbation, qualitative research, grounded theory Introduction COPD is a highly prevalent chronic disease and a major cause of mortality worldwide.1  The natural course of COPD is interrupted by exacerbations characterized by a sus - tained worsening of patients’ respiratory symptoms, which are beyond normal day- to-day variability and may warrant medical treatment.1–3 These exacerbations have  a serious negative impact on the quality of life4,5 and are associated with accelerated  lung function decline and increased mortality.6,7 To address the burden of exacer - bations, self-management has become increasingly important.8,9 Self-management  skills are important to detect exacerbations early and to take prompt action to reduce  the impact.10 However, both detecting exacerbations and taking prompt action appear  to be difficult for patients.11–13 Previous studies have shown that approximately 50% of Correspondence: YJG Korpershoek Research Group Chronic Illnesses,  Faculty of Health Care, University  of Applied Sciences Utrecht,  Heidelberglaan 7, 3584 CS, Utrecht,  PO Box 12011-3501 AA, Utrecht,  the Netherlands Tel +31 63 876 3949 email yvonne.korpershoek@hu.n lJournal name: International Journal of COPD Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Korpershoek et al Running head recto: Factors influencing exacerbation-related self-management in COPD patients DOI: http://dx.doi.org/10.2147/COPD.S116196",Non-OADS,/arxiv_data1/oa_pdf/40/5e/copd-11-2977.PMC5135062.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/40/5e/copd-11-2977.PMC5135062.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/40/5e/copd-11-2977.PMC5135062.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/8e/f9/cia-11-1741.PMC5135063.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Interventions in Aging 2016:11 1741–1750Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  1741OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S11618 5 evaluation of quality of life in chronic, progressing  rheumatic diseases based on the example of  osteoarthritis and rheumatoid arthritis Izabela Wysocka-skurska1 Matylda sierakowska2 Wojciech Kułak3 1Department of rheumatology  and Internal Diseases, University  hospital in Bialystok, 2Department  of Integrated Medical Care, Medical  University of Bialystok, 3Clinic  rehabilitation Center for Children  with early help Disabled Children  “give a Chance”, Medical University  of Bialystok, Białystok, PolandBackground:  Rheumatic diseases, irrespective of etiology and clinical course, influence  different areas of a patient’s life.",Non-OADS,/arxiv_data1/oa_pdf/8e/f9/cia-11-1741.PMC5135063.pdf
"It reflects Correspondence: Izabela Wysocka- skurska Department of rheumatology and  Internal Diseases, University hospital  in Bialystok, Ul Mieszka I 4/187,  15-054 Białystok, Poland Tel +48 85 510 050 730 email elwirawysocka@wp.p l Journal name: Clinical Interventions in Aging Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Wysocka-Skurska et al Running head recto: Health-related quality of life in osteoarthritis and rheumatoid arthritis DOI: http://dx.doi.org/10.2147/CIA.S116185",Non-OADS,/arxiv_data1/oa_pdf/8e/f9/cia-11-1741.PMC5135063.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/8e/f9/cia-11-1741.PMC5135063.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/8e/f9/cia-11-1741.PMC5135063.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/55/6e/copd-11-2931.PMC5135064.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2016:11 2931–2938International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  2931RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/COPD.S11642 2 Coherence between self-reported and objectively  measured physical activity in patients with chronic  obstructive lung disease: a systematic review Mimi Thyregod1,2 Uffe Bodtger1,2 1Department of Respiratory Medicine,   Naestved Hospital, Naestved,   2Institute for Regional Health  Research, University of Southern  Denmark, Odense, DenmarkAbstract:  The beneficial effects of physical activity (PA) in patients with COPD, as well as the  methods of their assessment, are well known and described.",Non-OADS,/arxiv_data1/oa_pdf/55/6e/copd-11-2931.PMC5135064.pdf
"Exercise capacity tests Correspondence: Mimi Thyregod Department of Respiratory Medicine,  Naestved Hospital, 61 Ringstedgade,  DK 4700 Naestved, Denmark Tel +45 2982 8197 email mimithyregod@gmail.co m Journal name: International Journal of COPD Article Designation: Review Y ear: 2016 Volume: 11 Running head verso: Thyregod and Bodtger Running head recto: Coherence between self-reported and objectively measured PA in COPD DOI: http://dx.doi.org/10.2147/COPD.S116422",Non-OADS,/arxiv_data1/oa_pdf/55/6e/copd-11-2931.PMC5135064.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/55/6e/copd-11-2931.PMC5135064.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/55/6e/copd-11-2931.PMC5135064.pdf
Available from: http://www.ohri.ca/programs/clinical_epi - demiology/oxford.asp.,Non-OADS,/arxiv_data1/oa_pdf/55/6e/copd-11-2931.PMC5135064.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/9c/25/dddt-10-3909.PMC5135065.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2016:10 3909–3924Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3909Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S11912 2 statistical modeling methods to analyze the impacts  of multiunit process variability on critical quality  attributes of chinese herbal medicine tablets Fei sun1 Bing Xu1,2 Yi Zhang1 shengyun Dai1 chan Yang1 Xianglong cui1 Xinyuan shi1,2 Yanjiang Qiao1,2 1research center of Traditional  chinese Medicine information  engineering, school of chinese  Materia Medica, Beijing University  of chinese Medicine, 2Key laboratory  of Manufacture Process control  and Quality evaluation of chinese  Medicine, Beijing, People’s republic  of chinaAbstract:  The quality of Chinese herbal medicine tablets suffers from batch-to-batch variability  due to a lack of manufacturing process understanding.",Non-OADS,/arxiv_data1/oa_pdf/9c/25/dddt-10-3909.PMC5135065.pdf
"For oral administration, the total amount of the five APIs in PNS extracts should correspondence: Yanjiang Qiao; Bing Xu school of chinese Materia Medica,  Beijing University of chinese Medicine,  11 north Third ring east road,  chaoyang, Beijing 100029, People’s  republic of china Tel +86 10 8473 8621 Fax +86 10 8473 8661 email yjqiao@263.ne t;   xubing@bucm.edu.c n Journal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Sun et al Running head recto: Impacts of multiunit process variability on CQAs of Chinese medicine DOI: http://dx.doi.org/10.2147/DDDT.S119122",Non-OADS,/arxiv_data1/oa_pdf/9c/25/dddt-10-3909.PMC5135065.pdf
The MBPLS toolbox was down - loaded from http://www.models.life.ku.dk/~courses/MBtool - box/mbtmain.ht m. The OPLS code was downloaded from   http://www.mathworks.com/matlabcentral/fileexchange/47767- libpls-1-95-zip/content/libPLS_1.95/opls.,OADS,/arxiv_data1/oa_pdf/9c/25/dddt-10-3909.PMC5135065.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/9c/25/dddt-10-3909.PMC5135065.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/9c/25/dddt-10-3909.PMC5135065.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/da/c8/copd-11-2951.PMC5135066.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2016:11 2951–2964International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  2951OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S10957 0 screening of long non-coding rna and TUg1  inhibits proliferation with TgF- β induction in  patients with COPD Wenxiang Tang1 Zhenyu shen2 Jiang guo2 shenghua sun1 1Department of respiratory Medicine,   The Third Xiangya hospital of Central  south University, 2Department of  respiratory Medicine, Xiangtan  Central hospital, hunan, People’s  republic of ChinaObjective:  To evaluate differentially expressed long noncoding RNAs (lncRNAs) and the  potential role of lncRNA TUG1 in patients with chronic obstructive pulmonary disease (COPD).",Non-OADS,/arxiv_data1/oa_pdf/da/c8/copd-11-2951.PMC5135066.pdf
"COPD is an abnormal inflammatory reaction of lungs to harmful particles  or gases (primarily cigarette smoke).1 COPD has become a primary public health  problem and is the fourth main reason of chronic morbidity and mortality in the US.2  It has been the cause of more than 2,500,000 deaths every year worldwide, according  to the 2002 report of the World Bank/World Health Organization.3 There are several  reasons for the development of COPD, including the inspiration of nocuous particles  such as cigarette smoke, the destruction of the balance between proteolytic and antipro - teolytic molecules,4 and oxidative stress.5 However, there are difficulties in selecting Correspondence: shenghua sun Department of respiratory Medicine,  The Third Xiangya hospital of Central  south University, 3w 138 Tongzipo road,  Yuelu District, Changsha, hunan 410013,  People’s republic of China Tel +86 138 7312 3450 Fax +86 731 8861 8203 email tangwenxiang@csu.edu.c n Journal name: International Journal of COPD Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Tang et al Running head recto: LncRNA TUG1 inhibits TGF- β-induced COPD proliferation DOI: http://dx.doi.org/10.2147/COPD.S109570",Non-OADS,/arxiv_data1/oa_pdf/da/c8/copd-11-2951.PMC5135066.pdf
International Journal of COPD 2016:11submit your manuscript | www.dovepress.co m Dove press Dove press 2956Tang et al gene ontology enrichment analysis of the  differentially expressed mrnas The Gene Ontology project provides a controlled vocabulary  to describe gene and gene product attributes in any organism  (http://www.geneontology.or g).,Non-OADS,/arxiv_data1/oa_pdf/da/c8/copd-11-2951.PMC5135066.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/da/c8/copd-11-2951.PMC5135066.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/da/c8/copd-11-2951.PMC5135066.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/c9/90/cia-11-1751.PMC5135069.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Interventions in Aging 2016:11 1751–1754Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  1751OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S12373 5 Efficacy and safety outcomes of fractional flow  reserve in guiding clinical therapy of non-ST - segment elevation myocardial infarction compared  with angiography alone in elderly Chinese patients Zhao Zhang* Ke li* Jinwen Tian Department of Cardiology, Chinese  People’s Liberation Army General  Hospital and Hainan Branch, Sanya,   People’s republic of China *These authors contributed equally  to this workObjective:  Fractional flow reserve (FFR) is an innovative method for evaluating the  physiological significance of a coronary stenosis, but its validity is less certain in patients with  non-ST-segment elevation myocardial infarction (NSTEMI).",Non-OADS,/arxiv_data1/oa_pdf/c9/90/cia-11-1751.PMC5135069.pdf
"However, visual assessment of the anatomical severity of a coronary stenosis  is subjective and correlates poorly with physiological significance, potentially  resulting in inappropriate therapy strategy.3 Fractional flow reserve (FFR) is an inno - vative method for evaluating the physiological significance of a coronary stenosis and  is defined as the ratio of maximal blood flow in a stenotic artery to normal maximal Correspondence: Jinwen Tian Department of Cardiology, Chinese  People’s Liberation Army General  Hospital and Hainan Branch, Jianglin  Street, Haitang Bay, Sanya 572013,  People’s republic of China Tel +86 156 9253 8940 email tjwsqr.2000@163.co m Journal name: Clinical Interventions in Aging Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Zhang et al Running head recto: Efficacy and safety outcomes of FFR in elderly Chinese patients with NSTEMI DOI: http://dx.doi.org/10.2147/CIA.S123735",Non-OADS,/arxiv_data1/oa_pdf/c9/90/cia-11-1751.PMC5135069.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/c9/90/cia-11-1751.PMC5135069.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/c9/90/cia-11-1751.PMC5135069.pdf
Available from: http://www.who.int/cardiova scular_diseases/en /.,Non-OADS,/arxiv_data1/oa_pdf/c9/90/cia-11-1751.PMC5135069.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/38/e2/hp-4-161.PMC5135071.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/38/e2/hp-4-161.PMC5135071.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Hypoxia 2016:4 161–162Hypoxia Dovepress submit your manuscript | www.dovepress.com Dovepress 161 Editorial open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/HP .S126290the three “Musketairs” – lasker Prize 2016 goes  to the protagonists of hypoxia research roland H Wenger1 dörthe M Katschinski2 1institute of Physiology, University of  Zurich, Zurich, Switzerland; 2institute  of Cardiovascular Physiology,   Georg-august University Göttingen,  Göttingen, GermanyWho does not know them?",Non-OADS,/arxiv_data1/oa_pdf/38/e2/hp-4-161.PMC5135071.pdf
"7 Other strategies were blunt swords in this battle, because antibodies Correspondence: roland H Wenger institute of Physiology, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerlandtel +41 44 635 5065Email roland.wenger@access.uzh.ch Journal name: Hypoxia Article Designation: EditorialY ear: 2016V olume: 4Running head verso: Wenger and KatschinskiRunning head recto: The Three MusketairsDOI: http://dx.doi.org/10.2147/HP .S126290",Non-OADS,/arxiv_data1/oa_pdf/38/e2/hp-4-161.PMC5135071.pdf
"Hypoxia 2016:4submit your manuscript | www.dovepress.com Dovepress Dovepress Hypoxia Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/hypoxia-journalHypoxia is an international, peer-reviewed, open access journal that aims  to improve understanding of the biological response to hypoxia.",Non-OADS,/arxiv_data1/oa_pdf/38/e2/hp-4-161.PMC5135071.pdf
"Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 162 Wenger and Katschinski against HIF-1α  proved futile in studies using pVHL-deficient  renal cancer cell lines, simply because many of these cell  lines initially contained supramaximal toxic HIF-1α levels, which cancer selects against and instead selects for HIF-2α expression.",Non-OADS,/arxiv_data1/oa_pdf/38/e2/hp-4-161.PMC5135071.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/59/71/copd-11-2939.PMC5135072.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2016:11 2939–2950International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  2939OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S11157 3 Bronchodilator response of advanced lung  function parameters depending on COPD severity linnea Jarenbäck1 göran eriksson1 stefan Peterson2 Jaro ankerst1 leif Bjermer1 ellen T ufvesson1 1respiratory Medicine and allergology,   Department of Clinical sciences lund,   lund University, 2regional Cancer  Center south, skåne University  hospital, lund, swedenBackground:  COPD is defined as partly irreversible airflow obstruction.",Non-OADS,/arxiv_data1/oa_pdf/59/71/copd-11-2939.PMC5135072.pdf
"In addition, we showed that the lung function parameters are widely spread  in Global Initiative for chronic Obstructive Lung Disease (GOLD) stage 2.2 Post hoc Correspondence: linnea Jarenbäck respiratory Medicine and allergology,  Department of Clinical sciences  lund, BMC, D12, lund University,  221 84 lund, sweden Tel +46 46 222 7828 email linnea.jarenback@med.lu.s e Journal name: International Journal of COPD Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Jarenbäck et al Running head recto: Advanced lung function bronchodilation in COPD DOI: http://dx.doi.org/10.2147/COPD.S111573",Non-OADS,/arxiv_data1/oa_pdf/59/71/copd-11-2939.PMC5135072.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/59/71/copd-11-2939.PMC5135072.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/59/71/copd-11-2939.PMC5135072.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/e2/33/dddt-10-3899.PMC5135073.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2016:10 3899–3907Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3899Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S12208 5 Efficacy and tolerability of vilazodone for major  depressive disorder: evidence from phase iii/iV  randomized controlled trials ligen shi1,2  Jingyi Wang1 Shenbin Xu2 Yunrong lu1 1Department of Psychiatry, The  Fourth Affiliated Hospital of Zhejiang  University school of Medicine, Yiwu,   2Department of neurosurgery, The  second affiliated hospital, school  of Medicine, Zhejiang University,   Hangzhou, Zhejiang, People’s Republic  of chinaAbstract:  Vilazodone is a new molecule approved for major depressive disorder (MDD).",Non-OADS,/arxiv_data1/oa_pdf/e2/33/dddt-10-3899.PMC5135073.pdf
"Vilazodone, a 5-hydroxytryptamine-1A (5-HT1A) receptor partial agonist and  selective serotonin reuptake inhibitor (SSRI), was approved by the US Food and  Drug Administration (FDA) for treatment of MDD in January 2011.6 SSRI is a well- established first-line antidepressant,7 and its antidepressant efficacy may be enhanced  by the 5-HT1A receptor partial agonist working to improve the onset of therapeutic  action.8 This unique dual modulation of serotonin neurotransmission by vilazodone correspondence: Yunrong lu Department of Psychiatry, The Fourth  Affiliated Hospital of Zhejiang University  school of Medicine, n1 shangcheng road,  Yiwu, Zhejiang, People’s Republic of China Tel +86 579 8993 5697 Fax +86 579 8993 5555 email abeautifulmind@163.co m Journal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Shi et al Running head recto: Vilazodone for major depressive disorder DOI: http://dx.doi.org/10.2147/DDDT.S122085",Non-OADS,/arxiv_data1/oa_pdf/e2/33/dddt-10-3899.PMC5135073.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/e2/33/dddt-10-3899.PMC5135073.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/e2/33/dddt-10-3899.PMC5135073.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/07/af/copd-11-2885.PMC5135074.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2016:11 2885–2895International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  2885MethODO lOgyopen access to scientific and medical research Open Access Full text Article http: //dx.doi.org/10.2147/COPD.S11886 7 Randomized controlled trials and real-world  observational studies in evaluating cardiovascular  safety of inhaled bronchodilator therapy in COPD Peter Kardos1 Sally Worsley2 Dave Singh3 Miguel Román-Rodríguez4 David e Newby5 hana Müllerová2 1group Practice and Respiratory,   Allergy and Sleep Unit, Red Cross  Maingau hospital, Frankfurt, germany;   2gSK, Stockley Park, Middlesex,   3University of Manchester, Medicines  evaluation Unit, University hospital  of South Manchester N hS Foundation  trust, Manchester, UK; 4Primary Care  Respiratory Research Unit, Instituto  de Investigación Sanitaria de Palma  IdisPa, Palma de Mallorca, Spain;   5BhF Centre for Cardiovascular  Science, University of edinburgh, the  Queen’s Medical Research Institute,   edinburgh, UKAbstract:  Long-acting muscarinic antagonist (LAMA) or long-acting β2-agonist (LABA)  bronchodilators and their combination are recommended for the maintenance treatment  of chronic obstructive pulmonary disease (COPD).",Non-OADS,/arxiv_data1/oa_pdf/07/af/copd-11-2885.PMC5135074.pdf
"Keywords:  real-world observational study, cardiovascular, cerebrovascular, safety,  umeclidinium, vilanterol Introduction Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and  mortality, accounting for approximately three million deaths worldwide in 2012.1,2  As COPD is characterized by persistent airflow limitation, long-acting muscarinic  antagonists (LAMA) or long-acting β2-agonist (LABA) bronchodilators are recom - mended treatment options.1 Bronchodilator monotherapy with LAMAs improves  lung function and health status, and prevents exacerbations compared with placebo.3–5  Combination therapy with LAMAs and LABAs exert complementary bronchodilatory  effects, resulting in greater improvements in lung function compared with long-acting  bronchodilator monotherapies.4,6–10 These dual combination bronchodilators also  improve symptoms and health status, and reduce exacerbation risk to a greater extent  than monotherapies or inhaled corticosteroid/LABA combinations.6,7,10,11Correspondence: Peter Kardos group Practice and Respiratory, Allergy  and Sleep Unit, Red Cross Maingau  hospital, Frankfurt 60311, germany tel +49 69 553611 email pkardos@aol.co m Journal name: International Journal of COPD Article Designation: Methodology Y ear: 2016 Volume: 11 Running head verso: Kardos et al Running head recto: Cardiovascular safety of LAMA/LABA combination therapy in COPD DOI: http://dx.doi.org/10.2147/COPD.S118867",Non-OADS,/arxiv_data1/oa_pdf/07/af/copd-11-2885.PMC5135074.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/07/af/copd-11-2885.PMC5135074.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/07/af/copd-11-2885.PMC5135074.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/da/26/dddt-10-3925.PMC5135076.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2016:10 3925–3932Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3925Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S11707 8 Effect of peritoneal dialysis fluid containing osmo- metabolic agents on human endothelial cells Mario Bonomini1,2 sara Di silvestre3,4 Pamela Di T omo3,4 natalia Di Pietro2,4 Domitilla Mandatori3,4 lorenzo Di liberato1 Vittorio sirolli1,2 Francesco chiarelli2,4 cesare indiveri5 assunta Pandolfi3,4 arduino arduini6 1Unit of nephrology and Dialysis,   2Department of Medicine and  aging sciences, 3Department of  Medical, Oral and Biotechnological  sciences, 4aging research center  and Translational Medicine, CeSI-MeT,   University “ g. d’annunzio”,   Chieti-Pescara, 5Department DiBesT  (Biologia, ecologia, scienze della  Terra), Unit of Biochemistry and  Molecular Biotechnology, University  of calabria, arcavacata di rende cs,   italy; 6coreQuest, Manno, switzerlandBackground:  The use of glucose as the only osmotic agent in peritoneal dialysis (PD) solutions  (PDSs) is believed to exert local (peritoneal) and systemic detrimental actions, particularly in  diabetic PD patients.",Non-OADS,/arxiv_data1/oa_pdf/da/26/dddt-10-3925.PMC5135076.pdf
"annunziata hospital, Via dei Vestini,  66013 chieti, italy Tel +39 0871 540 120 Fax +39 0871 574 736 email m.bonomini@nephro.unich.i t Journal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Bonomini et al Running head recto: Osmo-metabolic agents in PD solution DOI: http://dx.doi.org/10.2147/DDDT.S117078",Non-OADS,/arxiv_data1/oa_pdf/da/26/dddt-10-3925.PMC5135076.pdf
"Most of the osmotic strength of our  PDSs is achieved by the presence of xylitol and carnitine,  osmo-metabolic ingredients extremely stable from the  chemical standpoint, even when steam-sterilized in an acidic  environment ( http://pubchem.ncbi.nlm.nih.go v).",Non-OADS,/arxiv_data1/oa_pdf/da/26/dddt-10-3925.PMC5135076.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/da/26/dddt-10-3925.PMC5135076.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/da/26/dddt-10-3925.PMC5135076.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/73/cf/dddt-10-3879.PMC5135077.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2016:10 3879–3898Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3879Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S11619 2 non-imidazole-based histamine h3 receptor  antagonists with anticonvulsant activity in  different seizure models in male adult rats Bassem sadek1 ali saad1 gniewomir latacz2 Kamil Kuder2 agnieszka Olejarz2 Tadeusz Karcz2 holger stark3 Katarzyna Kieć- Kononowicz2 1Department of Pharmacology and  Therapeutics, college of Medicine and  health sciences, United arab emirates  University, al ain, United arab  emirates; 2Department of Technology  and Biotechnology of Drugs, Faculty  of Pharmacy, Jagiellonian University  Medical college, Kraków, Poland;   3Department of Pharmaceutical  and Medicinal chemistry, institute  of Pharmaceutical and Medicinal  chemistry, heinrich heine University,   Düsseldorf, germanyAbstract:  A series of twelve novel non-imidazole-based ligands ( 3–14 ) was developed and  evaluated for its in vitro binding properties at the human histamine H3 receptor (hH3R).",Non-OADS,/arxiv_data1/oa_pdf/73/cf/dddt-10-3879.PMC5135077.pdf
"In addition, as long life medication is necessary, the  search for new and more effective AEDs with enhanced safety profile is a laudable correspondence: Bassem sadek Department of Pharmacology and  Therapeutics, college of Medicine and  health sciences, United arab emirates  University, PO Box 17666, al ain,   United arab emirates Tel +971 3 7137 512 Fax +971 3 7672 033 email bassem.sadek@uaeu.ac.a e Journal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Sadek et al Running head recto: Histamine H3R antagonists as potent anticonvulsant drugs DOI: http://dx.doi.org/10.2147/DDDT.S116192",Non-OADS,/arxiv_data1/oa_pdf/73/cf/dddt-10-3879.PMC5135077.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/73/cf/dddt-10-3879.PMC5135077.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/73/cf/dddt-10-3879.PMC5135077.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/94/a4/ijn-11-6297.PMC5135284.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 6297–6306International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  6297RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IJN.S12010 4 The effect of exposure to nanoparticles and  nanomaterials on the mammalian epigenome MI Sierra1 A valdés2 AF Fernández1 R T orrecillas2 MF Fraga2 1Cancer epigenetics Laboratory,   Institute of Oncology of Asturias  (IUOPA), Hospital Universitario  Central de Asturias (HUCA),   Universidad de Oviedo, Oviedo,   2Nanomaterials and Nanotechnology  Research Center (CINN-CSIC),   Universidad de Oviedo-Principado de  Asturias, el entrego, SpainAbstract:  Human exposure to nanomaterials and nanoparticles is increasing rapidly, but their  effects on human health are still largely unknown.",Non-OADS,/arxiv_data1/oa_pdf/94/a4/ijn-11-6297.PMC5135284.pdf
"FINBA-Hospital Universitario Central  de Asturias (HUCA), Avda Roma s/n,  33011 Oviedo, Spain email mffraga@cinn.e s Journal name: International Journal of Nanomedicine Article Designation: Review Y ear: 2016 Volume: 11 Running head verso: Sierra et al Running head recto: Nanoparticles and the epigenome DOI: http://dx.doi.org/10.2147/IJN.S120104",Non-OADS,/arxiv_data1/oa_pdf/94/a4/ijn-11-6297.PMC5135284.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/94/a4/ijn-11-6297.PMC5135284.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/94/a4/ijn-11-6297.PMC5135284.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/dd/83/ijn-11-6365.PMC5135285.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 6365–6378International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  6365OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S9275 5 sustained-release liquisolid compact tablets  containing artemether–lumefantrine as alternate-day  regimen for malaria treatment to improve patient  compliance Petra Obioma Nnamani,1,2  agatha adaora Ugwu,1  emmanuel chinedu  Ibezim,1 Franklin chimaobi  Kenechukwu,1 Paul  achile akpa,1 John-Dike  Nwabueze Ogbonna,1  Nicholas chinedu Obitte,3  amelia Ngozi Odo,4 Maike  Windbergs,2 claus-Michael  lehr,2,5,6 anthony amaechi  attama1 1Drug Delivery and Nanomedicines  research group, Department  of Pharmaceutics, Faculty of  Pharmaceutical sciences, University of  Nigeria, Nsukka, Nigeria; 2Department  of Drug Delivery, helmholtz Institute  for Pharmaceutical research  saarland (hIP s), helmholtz centre  for Infection research, saarland  University, saarbrücken, germany;   3Department of Pharmaceutical  T echnology and Industrial Pharmacy,   Faculty of Pharmaceutical sciences,   4Department of human Kinetics  and health education, University  of Nigeria, Nsukka, Nigeria;   5PharmBioT ec gmbh, 6Department of  Biopharmaceutics and Pharmaceutical  T echnology, saarland University,   saarbrücken, germanyAbstract:  The present study aimed to develop low-dose liquisolid tablets of two antimalarial  drugs artemether–lumefantrine (AL) from a nanostructured lipid carrier (NLC) of lumefantrine  (LUM) and estimate the potential of AL as an oral delivery system in malariogenic Wistar  mice.",Non-OADS,/arxiv_data1/oa_pdf/dd/83/ijn-11-6365.PMC5135285.pdf
"After oral administration, artemether (ART) is absorbed fairly rapidly correspondence: Petra Obioma Nnamani Faculty of Pharmaceutical sciences, Drug  Delivery and Nanomedicines research  group, Department of Pharmaceutics,  University of Nigeria, Nsukka 410001,  enugu state, Nigeria Tel +234 803 696 3979 email petra.nnamani@unn.ed u.ngJournal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Nnamani et al Running head recto: Sustained-release liquisolid compact tablets for malaria treatment DOI: http://dx.doi.org/10.2147/IJN.S92755",Non-OADS,/arxiv_data1/oa_pdf/dd/83/ijn-11-6365.PMC5135285.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/dd/83/ijn-11-6365.PMC5135285.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/dd/83/ijn-11-6365.PMC5135285.pdf
Available from: https://www.pharmacopoeia.com /.,Non-OADS,/arxiv_data1/oa_pdf/dd/83/ijn-11-6365.PMC5135285.pdf
"Available from: http://www.ipc.gov.i n. Accessed  June 19, 2010.",OADS,/arxiv_data1/oa_pdf/dd/83/ijn-11-6365.PMC5135285.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/a7/68/ijn-11-6307.PMC5135286.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 6307–6324International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  6307OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S11952 0 study of a new bone-targeting titanium  implant–bone interface Xiangning liu1,* Ye Zhang1,* shaobing li2,* Yayu Wang3 Ting sun1 Zejian li1 lizhao cai1 Xiaogang Wang3,* lei Zhou2 renfa lai1 1The Medical center of stomatology,   The First affiliated hospital of  Jinan University, 2The Department  of Oral Implantology, guangdong  Provincial stomatological hospital,   southern Medical University,   3Department of cell Biology,   Institute of Biomedicine, college of  life science and Technology, Jinan  University, guangzhou, People’s  republic of china *These authors contributed equally  to this workAbstract:  New strategies involving bone-targeting titanium (Ti) implant–bone interface are  required to enhance bone regeneration and osseointegration for orthopedic and dental implants,  especially in osteoporotic subjects.",Non-OADS,/arxiv_data1/oa_pdf/a7/68/ijn-11-6307.PMC5135286.pdf
"Thus,  the studies of bone-targeting Ti implant–bone interface with bone-targeting effect correspondence: renfa lai The First Affiliated Hospital of Jinan  University, No 613 huangpu avenue,  Tianhe District, guangzhou 510630,  People’s republic of china Tel +86 20 3868 8109 Fax +86 20 3868 8000 email p rof.dr.lai@163.co m lei Zhou guangdong Provincial stomatological  hospital, southern Medical University,  No 366 Jiangnan avenue south,  guangzhou 510280, People’s  republic of china Tel +86 20 8423 3801 Fax +86 20 8443 3177 email zho668@263.ne tJournal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Liu et al Running head recto: Study of a new bone-targeting titanium implant–bone interface DOI: http://dx.doi.org/10.2147/IJN.S119520",Non-OADS,/arxiv_data1/oa_pdf/a7/68/ijn-11-6307.PMC5135286.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/a7/68/ijn-11-6307.PMC5135286.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/a7/68/ijn-11-6307.PMC5135286.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/a4/0d/ijn-11-6337.PMC5135287.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 6337–6352International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  6337OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S11983 9 Preparation and antitumor evaluation of self- assembling oleanolic acid-loaded Pluronic P105/ d- α-tocopheryl polyethylene glycol succinate mixed  micelles for non-small-cell lung cancer treatment hao Wu,1–3 Qingxiang  Zhong,1,2 rongling Zhong,4  houcai huang,4 Zhi Xia,4  Zhongcheng Ke,1,5 Zhenhai  Zhang,1 Jie song,1,2 Xiaobin  Jia1–3 1affiliated hospital of Integrated  Traditional chinese and Western  Medicine, Nanjing University of  chinese Medicine, 2Key laboratory of  New Drug Delivery system of chinese  Materia Medica, Jiangsu Province  academy of chinese Medicine, Nanjing,  Jiangsu, 3college of Pharmacy, anhui  University of chinese Medicine, hefei,  anhui, 4laboratory animal center,  Jiangsu Province academy of chinese  Medicine, Nanjing, Jiangsu, 5college of  chemistry and chemical engineering,  huangshan University, huangshan,  anhui, People’s republic of chinaAbstract:  Oleanolic acid (OA) is a triterpenoid found in various fruits and vegetables and used  in traditional Chinese medicine.",Non-OADS,/arxiv_data1/oa_pdf/a4/0d/ijn-11-6337.PMC5135287.pdf
"Therefore,  lung cancer remains a serious threat to both health and quality of life.2correspondence: Jie song Key laboratory of New Drug Delivery  system of chinese Material Medica,  Jiangsu Province academy of chinese  Medicine, 100 shizi street, hongshan  road, Jiangsu, Nanjing 210028, People’s  republic of china Tel +86 25 8563 7960 email momo198420@hotmail.co m Xiaobin Jia Affiliated Hospital of Integrated  Traditional chinese and Western  Medicine, Nanjing University of chinese  Medicine, 100 shizi street, hongshan  road, Jiangsu, Nanjing 210028, People’s  republic of china Tel +86 25 8563 7809 Fax +86 25 8550 2829 email jiaxiaobin2015@163.co mJournal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Wu et al Running head recto: OA-loaded Pluronic P105/TPGS mixed micelles for NSCLC treatment DOI: http://dx.doi.org/10.2147/IJN.S119839",Non-OADS,/arxiv_data1/oa_pdf/a4/0d/ijn-11-6337.PMC5135287.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/a4/0d/ijn-11-6337.PMC5135287.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/a4/0d/ijn-11-6337.PMC5135287.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/fc/e6/ijn-11-6325.PMC5135288.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 6325–6336International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  6325OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S11925 2 hydrothermal synthesis of nitrogen-doped  carbon  dots with real-time live-cell imaging and  blood–brain barrier penetration capabilities shousi lu1,2 shanshan guo1 Pingxiang Xu1 Xiaorong li1 Yuming Zhao1 Wei gu3 Ming Xue1 1Department of Pharmacology,   Beijing laboratory for Biomedical  Detection T echnology and Instrument,   school of Basic Medical sciences,   capital Medical University, 2china  rehabilitation research center,   3Department of chemistry and  Biology, school of chemical Biology  and Pharmaceutical sciences, capital  Medical University, Beijing, chinaAbstract:  Nitrogen-doped carbon dots (N-CDs) were synthesized using a one-pot hydrothermal  treatment with citric acid in the presence of polyethylenimine.",Non-OADS,/arxiv_data1/oa_pdf/fc/e6/ijn-11-6325.PMC5135288.pdf
"In addition to acting as a nitrogen  dopant, PEI simultaneously serves as a surface passivation agent to further improve correspondence: Wei gu school of chemical Biology and  Pharmaceutical sciences, capital  Medical University, Number 10  You’anmenwaixitoutiao, Beijing 100069,  china Tel +86 10 8391 1525 email weigu@ccmu.edu.c n Ming Xue Department of Pharmacology, Beijing  laboratory for Biomedical Detection  Technology and Instrument, school of Basic  Medical sciences, capital Medical University,  Number 10 You’anmenwaixitoutiao, Beijing  100069, china Tel/fax +86 10 8391 1520 email xuem@ccum.edu.c n Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Lu et al Running head recto: Hydrothermal synthesis of N-CDs DOI: http://dx.doi.org/10.2147/IJN.S119252",Non-OADS,/arxiv_data1/oa_pdf/fc/e6/ijn-11-6325.PMC5135288.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/fc/e6/ijn-11-6325.PMC5135288.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/fc/e6/ijn-11-6325.PMC5135288.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/2/12/e1601414/DC1 fig.,Non-OADS,/arxiv_data1/oa_pdf/7e/35/1601414.PMC5135387.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/2/12/e1600452/DC1 section S1.,Non-OADS,/arxiv_data1/oa_pdf/37/79/1600452.PMC5135388.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/1c/94/opth-10-2363.PMC5135396.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2016:10 2363–2368Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  2363Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S10380 9 One-stage bone strip reconstruction technique  with balloon sinus dilatation surgery for chronic  maxillary atelectasis T omoyuki Kashima1 robert a goldberg1 Jocelyne C Kohn2 Daniel B rootman1 1Division of Orbital and Oculoplastic  surgery, stein eye institute, University  of California, los angeles, C a, Usa;   2Pasteur Ophthalmology Clinic,   Oculoplastic, Orbit and lacrimal  service, santiago, Vitacura, santiago  Metropolitan region, ChilePurpose:  Chronic maxillary atelectasis is characterized by unilateral spontaneous  enophthalmos and hypoglobus due to increased orbital volume secondary to maxillary sinus  inward deformation.",Non-OADS,/arxiv_data1/oa_pdf/1c/94/opth-10-2363.PMC5135396.pdf
"Keywords:  silent sinus syndrome cartilage graft, orbital floor, remodeling Introduction Chronic maxillary atelectasis (CMA) or silent sinus syndrome is a rare disorder char - acterized by inward deformation of the maxillary sinus walls producing spontaneous  enophthalmos and hypoglobus.1,2 Various hypotheses of the underlying mechanisms  have been proposed, the most commonly accepted being that the occlusion of the maxil - lary sinus generates negative pressure and that this triggers the thinning and deformation  of the bony walls.3 Endoscopic antrostomy is commonly used to reaerate the sinus.4–8  There is no consensus regarding the need for orbital reconstruction, the timing, and the  ideal technique.9 In CMA, the radiographic appearance of the orbital floor is reported  to present patchy demineralization, decreased bone density, and dramatic thinning.1,9,10 Correspondence: robert a goldberg Division of Orbital and Oculoplastic  surgery, stein eye institute, University of  California, 300 stein Plaza, los angeles,  Ca 90095, Usa Tel +1 310 206 8250 Fax +1 310 825 9263 email goldberg@jsei.ucla.ed u Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Kashima et al Running head recto: Bone strip floor reconstruction surgery for CMA DOI: http://dx.doi.org/10.2147/OPTH.S10380 9",Non-OADS,/arxiv_data1/oa_pdf/1c/94/opth-10-2363.PMC5135396.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/1c/94/opth-10-2363.PMC5135396.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/1c/94/opth-10-2363.PMC5135396.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/6e/b9/ijwh-8-677.PMC5135397.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Women’s Health 2016:8 677–682International Journal of Women’s Health Dove press submit your manuscript | www.dovepress.co m Dove press  677OrIg Inal researcHopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJWH.S12422 9 effect of ovarian endometrioma on uterine  and ovarian blood flow in infertile women akmal el-Mazny ahmed Kamel Wafaa ramadan sherine gad-allah suzy abdelaziz ahmed M Hussein Department of Obstetrics and  gynecology, Faculty of Medicine,   cairo University, cairo, egyptBackground:  Angiogenesis has been found to be among the most important factors in the  pathogenesis of endometriosis.",Non-OADS,/arxiv_data1/oa_pdf/6e/b9/ijwh-8-677.PMC5135397.pdf
"Increased levels of angiogenic factors have been identified  in the peritoneal fluid of patients with endometriomas.3 The formation of new blood  vessels is critical for the survival of newly implanted endometriotic foci, and they are  recruited by endometriotic lesions through angiogenesis.4correspondence: ahmed Kamel Department of Obstetrics and  gynecology, Faculty of Medicine, cairo  University, cairo 11431, egypt Tel +20 11 2002 2332 Fax +20 2 2364 3554 email dr.ahmed.m.kamel@gmail.co m Journal name: International Journal of Women’s Health Article Designation: Original Research Y ear: 2016 Volume: 8 Running head verso: El-Mazny et al Running head recto: Endometrioma and utero-ovarian vascularity DOI: http://dx.doi.org/10.2147/IJWH.S124229",Non-OADS,/arxiv_data1/oa_pdf/6e/b9/ijwh-8-677.PMC5135397.pdf
"International Journal of Women’s Health Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-womens-health-journa lThe International Journal of Women’s Health is an international, peer- reviewed open-access journal publishing original research, reports,  editorials, reviews and commentaries on all aspects of women’s  healthcare including gynecology, obstetrics, and breast cancer.",Non-OADS,/arxiv_data1/oa_pdf/6e/b9/ijwh-8-677.PMC5135397.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.,Non-OADS,/arxiv_data1/oa_pdf/6e/b9/ijwh-8-677.PMC5135397.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/5d/68/ott-9-7235.PMC5135398.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 7235–7245OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  7235Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OTT .S10064 3 T rastuzumab in the management of gastroesophageal   cancer: patient selection and perspectives Michael Davidson Naureen Starling Department of Gastrointestinal  Oncology, The Royal Marsden  Hospital NHS Foundation Trust,   London, UKAbstract:  The addition of trastuzumab to the treatment of a subset of patients with advanced  gastric and gastroesophageal junction cancers showing HER2 positivity has been shown to  confer clinical benefit; however, questions remain over the optimal methods for defining and  selecting such patients.",Non-OADS,/arxiv_data1/oa_pdf/5d/68/ott-9-7235.PMC5135398.pdf
"This review describes the Correspondence: Naureen Starling Department of Gastrointestinal  Oncology, The Royal Marsden Hospital  NHS Foundation Trust, Fulham Road,  London Sw3 6JJ, UK Tel +44 20 7352 8171 Fax +44 20 7351 2477 email naureen.starling@rmh.nhs.u k Journal name: OncoTargets and Therapy Article Designation: Review Y ear: 2016 Volume: 9 Running head verso: Davidson and Starling Running head recto: Trastuzumab in the management of gastroesophageal cancer DOI: http://dx.doi.org/10.2147/OTT.S100643",Non-OADS,/arxiv_data1/oa_pdf/5d/68/ott-9-7235.PMC5135398.pdf
Available from: https://www.nice.org.uk/guidance/ta107/documents/ summary-of-product-characteristics 2.,Non-OADS,/arxiv_data1/oa_pdf/5d/68/ott-9-7235.PMC5135398.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/5d/68/ott-9-7235.PMC5135398.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/5d/68/ott-9-7235.PMC5135398.pdf
"Available from: https://www.nice.org.uk/ guidance/TA107/chapter/1-guidanc e. Accessed August 15, 2016.",Non-OADS,/arxiv_data1/oa_pdf/5d/68/ott-9-7235.PMC5135398.pdf
"Available from: http://www.ema.europa.eu/docs/ en_GB/document_library/Summary_of_opinion/human/000278/ WC500059913.pd f. Accessed August 10, 2016.",Non-OADS,/arxiv_data1/oa_pdf/5d/68/ott-9-7235.PMC5135398.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/62/d2/opth-10-2391.PMC5135399.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2016:10 2391–2402Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  2391Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S12034 5 role of the treating surgeon in the consent  process for elective refractive surgery steven C schallhorn1–3 stephen J hannan3 David T eenan3 Julie M schallhorn1 1Department of Ophthalmology,   University of California, san Francisco,   san Francisco, 2roski eye institute,   University of southern California, los  angeles, C a, Usa; 3Optical express,   glasgow, UKPurpose:  To compare patient’s perception of consent quality, clinical and quality-of-life  outcomes after laser vision correction (LVC) and refractive lens exchange (RLE) between  patients who met their treating surgeon prior to the day of surgery (PDOS) or on the day of  surgery (DOS).",Non-OADS,/arxiv_data1/oa_pdf/62/d2/opth-10-2391.PMC5135399.pdf
"On one hand, patients should be informed in  detail about their surgical procedure; on the other hand, overloading patients with too  much technical/medical information may have unintended negative effects by confusing Correspondence: steven C schallhorn gordon schanzlin new Vision institute,  8910 University Center lane, suite 800,  la Jolla, san Diego, Ca 92122, Usa Tel +1 858 455 6800 email scschallhorn@yahoo.co m Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Schallhorn et al Running head recto: Consent process for elective refractive surgery DOI: http://dx.doi.org/10.2147/OPTH.S120345",Non-OADS,/arxiv_data1/oa_pdf/62/d2/opth-10-2391.PMC5135399.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/62/d2/opth-10-2391.PMC5135399.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/62/d2/opth-10-2391.PMC5135399.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/52/79/opth-10-2377.PMC5135400.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2016:10 2377–2382Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  2377Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S11456 8 rebound macular edema following oral  acetazolamide therapy for juvenile X-linked  retinoschisis in an italian family Maria silvana galantuomo1,* Maurizio Fossarello1 alberto Cuccu1 roberta Farci1 Markus n Preising2 Birgit lorenz2 Pietro emanuele napoli1,* 1Department of surgical sciences, eye  Clinic, University of Cagliari, Cagliari,   italy; 2Department of Ophthalmology,   Faculty of Medicine, Justus-liebig- University, giessen, germany *These authors contributed equally  to this workBackground:  Juvenile X-linked retinoschisis (RS1, OMIM: 312700) is a hereditary vitreoretinal  dystrophy characterized by bilateral foveal schisis and, in half of the patients, splitting through  the nerve fiber layer in the peripheral retina.",Non-OADS,/arxiv_data1/oa_pdf/52/79/opth-10-2377.PMC5135400.pdf
"Keywords:  juvenile X-linked retinoschisis, oral acetazolamide, topical dorzolamide, cystoid  macular edema, macular schisis, foveal zone thickness Introduction Juvenile X-linked retinoschisis (RS1) is a hereditary vitreoretinal disorder that shows  radiating cystoid changes in the macula with or without peripheral retinoschisis,  early onset of visual loss, abnormal electroretinograms (ERGs) and, in some cases, Correspondence: Pietro emanuele napoli Department of surgical sciences,  University of Cagliari, via Ospedale 46,  Cagliari 09124, italy Tel +39 320 864 3697 email pietronapoli@ymail.co m Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Galantuomo et al Running head recto: Oral acetazolamide therapy for juvenile X-linked retinoschisis DOI: http://dx.doi.org/10.2147/OPTH.S114568",Non-OADS,/arxiv_data1/oa_pdf/52/79/opth-10-2377.PMC5135400.pdf
"Retinoschisin promotes cell adhesion and  its dysfunction leads to the formation of cystoid cavities in the inner nuclear and outer plexiform layers of the retina.15  Clinical effects of CAI are presumed to be attributed to their  facilitation effect on the fluid transport across the retinal  pigment epithelium, decreasing the volume of the subretinal  space and increasing retinal adhesiveness.21 Apushkin and  Fishman19 in their study demonstrated a reduction in the  foveal thickness in seven of the eight patients affected by  RS1, who were treated with 2% dorzolamide eye drops, and  a concomitant improvement in the VA in five patients.19 In  a further small case study, it was found that the response to  dorzolamide eye drops was independent of the type of the  underlying mutation.15 To date, 196 different mutations in the RS1 gene are  known to cause RS1 (Leiden Open Variation Database,  LOVD, version 2.0, Build 35; http://grenada.lumc.nl/ LOVD2/eye/home.php?select_db =RS1).",Non-OADS,/arxiv_data1/oa_pdf/52/79/opth-10-2377.PMC5135400.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/52/79/opth-10-2377.PMC5135400.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/52/79/opth-10-2377.PMC5135400.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/e8/2e/imcrj-9-373.PMC5135402.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/e8/2e/imcrj-9-373.PMC5135402.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).International Medical Case Reports Journal 2016:9 373–376International Medical Case Reports Journal Dovepress submit your manuscript | www.dovepress.com Dovepress 373 CASE SERIES open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IMCRJ.S106248T wo cases of Vogt–Koyanagi–Harada’s disease in  sub-Saharan Africa T unji S Oluleye1 Adekunle O Rotimi-Samuel2 Adetunji Adenekan2 Olubanke T Ilo2 Folashade B Akinsola2 Adeola O Onakoya2 Olufisayo T Aribaba2 Adebukunola  Adefule-Ositelu2 Kareem O Musa2 Yele Oyefeso2 1Retina and Vitreous Unit, Department  of Ophthalmology, University College  Hospital, Ibadan, 2Department of  Ophthalmology, Guinness Eye Center,  Lagos University T eaching Hospital,  Lagos, NigeriaAbstract: V ogt–Koyanagi–Harada’ s (VKH) disease has been reported to be rare in sub-Saharan  Africa.",Non-OADS,/arxiv_data1/oa_pdf/e8/2e/imcrj-9-373.PMC5135402.pdf
"Slit-lamp examination showed multiple  medium-sized keratic  Correspondence: Tunji S Oluleye Retina and Vitreous Unit, Department of Ophthalmology, University College Hospital, 1 Queen ElizabethWay, Mokola, Ibadan PMB 5116, Ibadan, Nigeria Email t_oluleye@yahoo.co.ukJournal name: International Medical Case Reports Journal Article Designation: CASE SERIESY ear: 2016V olume: 9Running head verso: Oluleye et alRunning head recto: VKH disease in sub-Saharan AfricaDOI: http://dx.doi.org/10.2147/IMCRJ.S106248",Non-OADS,/arxiv_data1/oa_pdf/e8/2e/imcrj-9-373.PMC5135402.pdf
"International Medical Case Reports Journal 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress International Medical Case Reports Journal Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/international-medical-case-reports-journal-journalThe International Medical Case Reports Journal is an international,  peer-reviewed open-access journal publishing original case reports from all medical specialties.",Non-OADS,/arxiv_data1/oa_pdf/e8/2e/imcrj-9-373.PMC5135402.pdf
"Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 376 Oluleye et al To diagnose VKH, the condition must be bilateral with no  evidence of other ocular disease, trauma, or surgery.",Non-OADS,/arxiv_data1/oa_pdf/e8/2e/imcrj-9-373.PMC5135402.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/1b/d9/ott-9-7247.PMC5135403.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 7247–7252OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  7247Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OTT .S10021 4 The evolution of the diminishing role of  extrapleural pneumonectomy in the surgical  management of malignant pleural mesothelioma Abdel-Ghani Azzouqa1 James P Stevenson2 1Department of Hematology and  Oncology, Mayo Clinic, Jacksonville,   FL, 2Department of Hematology and  Oncology, Cleveland Clinic Taussig  Cancer institute, Cleveland, OH, USAAbstract:  Malignant pleural mesothelioma is an uncommon and aggressive thoracic malignancy  that is rarely curable, even when multimodality therapy is used.",Non-OADS,/arxiv_data1/oa_pdf/1b/d9/ott-9-7247.PMC5135403.pdf
"Keywords:  mesothelioma, pneumonectomy, thoracic surgical procedure, multimodal treatment Introduction Malignant pleural mesothelioma (MPM) is a pleural mesothelial cancer that is  aggressive in nature with a median survival of ,12 months, a number that has shown  little change in the past four decades, according to the results of a recent analysis of the  Surveillance, Epidemiology, and End-Results (SEER) database.1 Asbestos exposure,  typically in the workplace, has been well established as the major risk factor in the  development of this malignancy, and the risk for the development of MPM among  asbestos workers was at one time thought to be as high as 17% in those exposed at  younger ages.2 The latency period between initial asbestos exposure and diagnosis is  typically .30 years, which renders any effective screening effort nearly impossible.3  According to the World Health Organization (WHO) database, between the years 1994  and 2008, 92,253 deaths from MPM were reported in 83 countries with a mean age of  70 years and a 3.6:1 male to female ratio; 54% of reported deaths were in Europe and  not surprisingly during the time frame studied, the reported cases were noted to shift  to countries where workplace asbestos exposures have continued.4–6Correspondence: James P Stevenson Cleveland Clinic Taussig Cancer  institute, 9500 euclid Avenue,  Cleveland, OH 44195, USA Tel +1 216 636 6888 Fax +1 216 636 2498 email stevenj5@ccf.or g Journal name: OncoTargets and Therapy Article Designation: Review Y ear: 2016 Volume: 9 Running head verso: Azzouqa and Stevenson Running head recto: Extrapleural pneumonectomy in mesothelioma DOI: http://dx.doi.org/10.2147/OTT.S100214",Non-OADS,/arxiv_data1/oa_pdf/1b/d9/ott-9-7247.PMC5135403.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/1b/d9/ott-9-7247.PMC5135403.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/1b/d9/ott-9-7247.PMC5135403.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/4e/a4/opth-10-2345.PMC5135404.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2016:10 2345–2361Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  2345Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OPTH.S9486 6 vogt–Koyanagi–Harada syndrome – current  perspectives Abeir Baltmr1 Sue Lightman1,2 Oren T omkins-Netzer1–3 1Uveitis Service, Moorfields eye  Hospital, London, UK; 2Department of  Clinical Ophthalmology, UCL institute  of Ophthalmology, London, UK;   3Faculty of Medicine, Technion, israel  institute of T echnology, Haifa, israelAbstract:  Vogt–Koyanagi–Harada syndrome is a cause of noninfectious panuveitis, leading  to significant vision loss in many patients.",Non-OADS,/arxiv_data1/oa_pdf/4e/a4/opth-10-2345.PMC5135404.pdf
"Novel diagnostic techniques, which can  demonstrate choroidal structure and precise retinal function, are now employed to  assist in early diagnosis, leading to prompt treatment and monitoring of ongoing  ocular inflammation.Correspondence: Oren Tomkins-Netzer institute of Ophthalmology, UCL City Road, London eC1v 2PD, UK  email o.tomkins-netzer@ucl.ac.u kJournal name: Clinical Ophthalmology Article Designation: Review Y ear: 2016 Volume: 10 Running head verso: Baltmr et al Running head recto: Vogt–Koyanagi–Harada syndrome DOI: http://dx.doi.org/10.2147/OPTH.S94866",Non-OADS,/arxiv_data1/oa_pdf/4e/a4/opth-10-2345.PMC5135404.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/4e/a4/opth-10-2345.PMC5135404.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/4e/a4/opth-10-2345.PMC5135404.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/38/c9/ndt-12-3041.PMC5135406.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 3041–3049Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  3041OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S12158 8 a randomized trial of aripiprazole vs blonanserin  for the treatment of acute schizophrenia and  related disorders Taro Kishi1 Yuki Matsuda1 shinji Matsunaga1 T omohiko Mukai1,2 Masatsugu Moriwaki1,2 hideaki Tabuse3 Kiyoshi Fujita2 Nakao iwata1 1Department of Psychiatry, Fujita  health University school of Medicine,   T oyoake, aichi, 2Department of  Psychiatry, Okehazama hospital,   T oyoake, aichi, 3Department of  Psychiatry, holy cross hospital,   T oki, gifu, JapanObjective:  There has been no direct comparison of aripiprazole and blonanserin for  schizophrenia treatment.",Non-OADS,/arxiv_data1/oa_pdf/38/c9/ndt-12-3041.PMC5135406.pdf
"Our meta-analysis7 revealed that blonanserin (one of the SGAs) is superior to  haloperidol in the improvement of the negative symptoms.8 In addition, blonanserin  carries a lower risk of hyperprolactinemia and weight gain than risperidone.7,9 One  recent randomized trial reported that there were no significant differences for change in correspondence: Taro Kishi Department of Psychiatry, Fujita  health University school of Medicine,  1-98 Dengakugakubo, Kutsukake-cho,  Toyoake, aichi 470-1192, Japan Tel +81 562 93 9250 Fax +81 562 93 1831 email tarok@fujita-hu.ac.j pJournal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Kishi et al Running head recto: Aripiprazole vs blonanserin in schizophrenia DOI: http://dx.doi.org/10.2147/NDT.S121588",Non-OADS,/arxiv_data1/oa_pdf/38/c9/ndt-12-3041.PMC5135406.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/38/c9/ndt-12-3041.PMC5135406.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/38/c9/ndt-12-3041.PMC5135406.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/cd/b9/ott-9-7253.PMC5135407.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 7253–7261OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  7253Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S11612 7 let-7a enhances the sensitivity of hepatocellular  carcinoma cells to cetuximab by regulating  sTaT3 expression Fei Xue1 Yanhui liu2 hongwei Zhang1 Yu Wen1 lei Yan1 Qiang Tang1 erhui Xiao1 Dongyi Zhang1 1Department of hepatobiliary and  Pancreatic surgery, henan Provincial  People’s hospital, Zhengzhou  University People’s hospital,   Zhengzhou, People’s republic of  china; 2Department of hematology,   henan Provincial People’s hospital,   Zhengzhou University People’s  hospital, Zhengzhou, People’s  republic of chinaBackground:  Let-7 miRNAs are reported to play an inhibitory role in carcinogenesis, tumor  progression, recurrence, and pluripotency of cancer.",Non-OADS,/arxiv_data1/oa_pdf/cd/b9/ott-9-7253.PMC5135407.pdf
"While cetuximab, an epidermal growth factor receptor (EGFR) inhibitor, was shown  to display satisfactory curative effect in patients with non-small cell lung cancer,5 correspondence: Fei Xue Department of hepatobiliary and  Pancreatic surgery, henan Provincial  People’s hospital, Zhengzhou University  People’s hospital, 7 Weiwu road, Jinshui,  Zhengzhou, henan, 410003, People’s  republic of china Tel +86 371 6558 0365 email xuefeidoctor@163.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Xue et al Running head recto: Let-7a enhances HCC sensitivity to cetuximab DOI: http://dx.doi.org/10.2147/OTT.S116127",Non-OADS,/arxiv_data1/oa_pdf/cd/b9/ott-9-7253.PMC5135407.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/cd/b9/ott-9-7253.PMC5135407.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/ott-9-7253.PMC5135407.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/c7/e4/ott-9-7199.PMC5135408.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 7199–7205OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  7199Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S11695 3 high expression of hMga2 predicts poor survival  in patients with clear cell renal cell carcinoma correspondence: Jianguang Qiu Department of Urology, The Third  Affiliated Hospital of Sun Yat-sen  University, guangzhou, guangdong  Province 510630, People’s republic  of china Tel +86 20 8525 2175 Fax +86 20 8525 3336 email qiujianguang_sysu@126.co m ning na1,* T ujie si2,* Zhengyu huang1,* Bin Miao1 liangqing hong1 heng li1 Jiang Qiu2 Jianguang Qiu3 1Department of Kidney  Transplantation, The Third affiliated  Hospital of Sun Yat-sen University,   2Department of Organ Transplant,   The First affiliated hospital of sun  Yat-sen University, 3Department of  Urology, The Third affiliated hospital  of Sun Yat-sen University, Guangzhou,   People’s republic of china *These authors contributed equally  to this workAbstract:  High-mobility group AT-hook 2 (HMGA2) is involved in a wide spectrum of  biological processes and is upregulated in several tumors, but its role in renal carcinoma remains  unclear.",Non-OADS,/arxiv_data1/oa_pdf/c7/e4/ott-9-7199.PMC5135408.pdf
"However, sometimes discrepancies arise between predictions and  practical clinical outcomes.4 Recent studies have revealed a number of prognostic bio - markers that are associated with different features of RCC biology, and novel models  that combine conventional clinicopathological factors with molecular biomarkers  have been established to allow for more a precise prediction of clinical outcomes.5–8  Therefore, it is of great value to seek molecular markers that will improve the individual  therapeutic management and clinical outcome of patients with ccRCC.Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Na et al Running head recto: HMGA2 predicts survival in renal carcinoma DOI: http://dx.doi.org/10.2147/OTT.S116953",Non-OADS,/arxiv_data1/oa_pdf/c7/e4/ott-9-7199.PMC5135408.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/c7/e4/ott-9-7199.PMC5135408.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/c7/e4/ott-9-7199.PMC5135408.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/40/b3/opth-10-2383.PMC5135409.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2016:10 2383–2390Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  2383Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S11807 9 interactive navigation-guided ophthalmic plastic   surgery: assessment of optical versus  electromagnetic modes and role of dynamic  reference frame location using navigation-enabled  human skulls Mohammad Javed ali1 Milind n naik1 Chetan Mallikarjuniah  girish1 Mohammad hasnat ali2 swathi Kaliki2 Tarjani Vivek Dave1 gautam Dendukuri1 1Ophthalmic Plastic surgery service,   2The Operation eyesight Universal  institute for eye Cancer, l.V.",Non-OADS,/arxiv_data1/oa_pdf/40/b3/opth-10-2383.PMC5135409.pdf
"Prasad eye institute, hyderabad  500001, india email milind@drmilindnaik.co m Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Ali et al Running head recto: Interactive navigation-guided ophthalmic plastic surgery DOI: http://dx.doi.org/10.2147/OPTH.S118079",Non-OADS,/arxiv_data1/oa_pdf/40/b3/opth-10-2383.PMC5135409.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/40/b3/opth-10-2383.PMC5135409.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/40/b3/opth-10-2383.PMC5135409.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/d9/ff/opth-10-2369.PMC5135410.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2016:10 2369–2376Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  2369Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S11674 3 Central corneal thickness of iraqi population  in relation to age, gender, refractive errors,  and corneal curvature: a hospital-based   cross-sectional study Yasir Jawad Kadhim1 Qasim K Farhood2 1ibn al haitham Teaching eye  hospital, Baghdad, 2Department of  Ophthalmology, College of Medicine,   University of Babylon, Babylon, iraqBackground:  Central corneal thickness (CCT) is an important indicator of corneal status.",Non-OADS,/arxiv_data1/oa_pdf/d9/ff/opth-10-2369.PMC5135410.pdf
"The cornea has one of the body’s highest densities of nerve  endings, and the sensitivity of the cornea is 100 times that of the conjunctiva.1Correspondence: Qasim K Farhood Department of Ophthalmology,  College of Medicine, University of  Babylon, Babylon, 52001, iraq Tel +964 780 117 9098 email qasim_1964@ymail.co m Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Kadhim and Farhood Running head recto: Central corneal thickness of Iraqi population DOI: http://dx.doi.org/10.2147/OPTH.S116743",Non-OADS,/arxiv_data1/oa_pdf/d9/ff/opth-10-2369.PMC5135410.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/d9/ff/opth-10-2369.PMC5135410.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/d9/ff/opth-10-2369.PMC5135410.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/fe/7b/ndt-12-3031.PMC5135476.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 3031–3039Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  3031OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S12090 9 Functional cortical changes in relapsing–remitting  multiple sclerosis at amplitude configuration:  a resting-state fMri study heng liu1,* hua chen1,* Bo Wu1 Tijiang Zhang1 Jinhui Wang2,3 Kexin huang1 ganjun song1 Jian Zhan4 1Department of radiology, affiliated  hospital of Zunyi Medical University,   Medical imaging center of guizhou  Province, Zunyi, guizhou, 2Department  of Psychology, hangzhou Normal  University, 3Zhejiang Key laboratory  for research in assessment of  cognitive impairments, hangzhou,   4Department of Neurology, affiliated  hospital of Zunyi Medical University,   Zunyi, guizhou, People’s republic  of china *These authors contributed equally  to this workObjective:  The aim of this study was to explore the amplitude of spontaneous brain activity  fluctuations in patients with relapsing–remitting multiple sclerosis (RRMS) using the amplitude  of low-frequency fluctuation (ALFF) method.",Non-OADS,/arxiv_data1/oa_pdf/fe/7b/ndt-12-3031.PMC5135476.pdf
"Typically, the extent of motor dysfunction is relative to the correspondence: Tijiang Zhang Department of Radiology, Affiliated  hospital of Zunyi Medical University,  149 Dalian road, Zunyi 563000, guizhou,  People’s republic of china email tijzhang@163.co m Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Liu et al Running head recto: Functional cortical changes in RRMS at amplitude configuration DOI: http://dx.doi.org/10.2147/NDT.S120909",Non-OADS,/arxiv_data1/oa_pdf/fe/7b/ndt-12-3031.PMC5135476.pdf
"fil.ion.ucl.ac.u k/spm), the remaining 200 volumes were  corrected for differences in slice times and were analyzed  using Data Processing Assistant for RS-fMRI (DPARSFA;  http://rfmri.org/DPARS F) toolbox.",OADS,/arxiv_data1/oa_pdf/fe/7b/ndt-12-3031.PMC5135476.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/fe/7b/ndt-12-3031.PMC5135476.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/fe/7b/ndt-12-3031.PMC5135476.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/98/1d/jpr-9-1109.PMC5135477.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/98/1d/jpr-9-1109.PMC5135477.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Pain Research  2016:9 1109–1120Journal of Pain Research Dovepress submit your manuscript | www.dovepress.com Dovepress  1109 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JPR.S119851Are patients’ and doctors’ accounts of the first  specialist consultation for chronic back pain in  agreement?",Non-OADS,/arxiv_data1/oa_pdf/98/1d/jpr-9-1109.PMC5135477.pdf
"5Correspondence: Amanda C de  C WilliamsResearch Department of Clinical, Educational and Health Psychology, University College London, Gower Street, London WC1E 6BT, UKTel +44 20 7679 1608Fax +44 20 7916 1989Email amanda.williams@ucl.ac.ukJournal name: Journal of Pain Research  Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 9Running head verso: White et alRunning head recto: Patient–doctor agreement in first specialist pain consultationDOI: http://dx.doi.org/10.2147/JPR.S119851",Non-OADS,/arxiv_data1/oa_pdf/98/1d/jpr-9-1109.PMC5135477.pdf
Available from: http://www.iasp-pain.org/Taxonomy#Pain.,Non-OADS,/arxiv_data1/oa_pdf/98/1d/jpr-9-1109.PMC5135477.pdf
University College London Doctorate in Clinical Psychology thesis; 2012. http://discovery.ucl.ac.uk/1368818/.,Non-OADS,/arxiv_data1/oa_pdf/98/1d/jpr-9-1109.PMC5135477.pdf
Available from: https://www.nice.org.uk/guidance/cg76.,Non-OADS,/arxiv_data1/oa_pdf/98/1d/jpr-9-1109.PMC5135477.pdf
"Journal of Pain Research  2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Pain Research  Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/journal-of-pain-research-journal The Journal of Pain Research is an international, peer reviewed, open  access, online journal that welcomes laboratory and clinical findings   in the fields of pain research and the prevention and management of pain.",Non-OADS,/arxiv_data1/oa_pdf/98/1d/jpr-9-1109.PMC5135477.pdf
"Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 1120 White et al Interview schedule for doctor interviews •	From your perspective, what were the messages you said to the patient?",Non-OADS,/arxiv_data1/oa_pdf/98/1d/jpr-9-1109.PMC5135477.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/be/08/jpr-9-1101.PMC5135478.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/be/08/jpr-9-1101.PMC5135478.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Pain Research  2016:9 1101–1107Journal of Pain Research Dovepress submit your manuscript | www.dovepress.com Dovepress  1101 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JPR.S111733Effects of parecoxib on postoperative pain and  opioid-related symptoms following gynecologic  surgery Bruce Parsons1 Qijiang Zhu2 Li Xie3 Chunming Li1 Raymond Cheung1 1Pfizer Inc, New Y ork, NY, USA;   281st Hospital of Chinese People’s  Liberation Army, Nanjing, People’s  Republic of China; 3Pfizer Investment  Co., Ltd, Beijing, People’s Republic of ChinaObjective: To examine the analgesic and opioid-sparing effects of parecoxib following major  gynecologic surgery.",Non-OADS,/arxiv_data1/oa_pdf/be/08/jpr-9-1101.PMC5135478.pdf
"5Correspondence: Bruce Parsons Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USATel +1 212 573 1649Email bruce.parsons@pfizer.comJournal name: Journal of Pain Research  Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 9Running head verso: Parsons et alRunning head recto: Effects of parecoxib in patients following gynecologic surgeryDOI: http://dx.doi.org/10.2147/JPR.S111733",Non-OADS,/arxiv_data1/oa_pdf/be/08/jpr-9-1101.PMC5135478.pdf
Available from: http://www.womenshealth.gov/publications/our-publications/fact-sheet/hysterec-tomy.html.,Non-OADS,/arxiv_data1/oa_pdf/be/08/jpr-9-1101.PMC5135478.pdf
"Journal of Pain Research  2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Pain Research  Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/journal-of-pain-research-journal The Journal of Pain Research is an international, peer reviewed, open  access, online journal that welcomes laboratory and clinical findings   in the fields of pain research and the prevention and management of pain.",Non-OADS,/arxiv_data1/oa_pdf/be/08/jpr-9-1101.PMC5135478.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 1107 Effects of parecoxib in patients following gynecologic surgery,Non-OADS,/arxiv_data1/oa_pdf/be/08/jpr-9-1101.PMC5135478.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/3e/28/jpr-9-1121.PMC5135479.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/3e/28/jpr-9-1121.PMC5135479.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Pain Research  2016:9 1121–1129Journal of Pain Research Dovepress submit your manuscript | www.dovepress.com Dovepress  1121 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JPR.S118412Involvement of spinal glutamate transporter-1  in the development of mechanical allodynia and  hyperalgesia associated with type 2 diabetes Jinshan Shi1,*  Ke Jiang2,*  Zhaoduan Li3 1Department of Anesthesiology,   Guizhou Provincial People’s Hospital,   2Department of Anesthesiology, The  Affiliated Hospital of Guizhou Medical  University, Guiyang, 3Department  of Anesthesiology, Tianjin Nankai Hospital, Tianjin, People’s Republic of China *These authors contributed equally to this workAbstract:  Little is known about the effects of the development of type 2 diabetes on glutamate  homeostasis in the spinal cord.",Non-OADS,/arxiv_data1/oa_pdf/3e/28/jpr-9-1121.PMC5135479.pdf
"13 However, few studies Correspondence: Zhaoduan Li Department of Anesthesiology, Tianjin Nankai Hospital, Tianjin 300100, People’s Republic of China Email lizhaoduan1984@126.comJournal name: Journal of Pain Research  Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 9Running head verso: Shi et alRunning head recto: GLT -1 and diabetic neuropathyDOI: http://dx.doi.org/10.2147/JPR.S118412",Non-OADS,/arxiv_data1/oa_pdf/3e/28/jpr-9-1121.PMC5135479.pdf
"Journal of Pain Research  2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Pain Research  Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/journal-of-pain-research-journal The Journal of Pain Research is an international, peer reviewed, open  access, online journal that welcomes laboratory and clinical findings   in the fields of pain research and the prevention and management of pain.",Non-OADS,/arxiv_data1/oa_pdf/3e/28/jpr-9-1121.PMC5135479.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 1129 GLT -1 and diabetic neuropathy 15.,Non-OADS,/arxiv_data1/oa_pdf/3e/28/jpr-9-1121.PMC5135479.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/19/32/ott-9-6333.PMC5135560.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 6333–6336OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  6333Case repO rTopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S10684 2 alveolar rhabdomyosarcoma of the sphenoid  sinus mimicking optic neuritis presenting with  intermittent visual loss in an adult Wendong Liu1 Libin Jiang1 Yulan Jin2 Bentao Yang3 Timothy YY Lai4 1Beijing T ongren eye Center, Beijing  T ongren Hospital, Capital Medical  University, Beijing Ophthalmology  and Visual sciences Key Laboratory,   2Department of p athology,   3Department of radiology, Beijing  T ongren Hospital, Capital Medical  University, Beijing, 4Department of  Ophthalmology & Visual sciences,   The Chinese University of Hong  Kong, shatin, Hong Kong, people’s  republic of ChinaAbstract:  A 23-year-old male with intermittent visual loss in his left eye for 4 months was  originally treated as optic neuritis elsewhere.",Non-OADS,/arxiv_data1/oa_pdf/19/32/ott-9-6333.PMC5135560.pdf
"Case report A 23-year-old male with a right artificial eye due to previous ocular trauma presented  to our hospital complaining of episodes of left eye progressive visual loss without any Correspondence: Libin Jiang Beijing Tongren eye Center, Beijing  Tongren Hospital, Capital Medical  University, Beijing Ophthalmology  and Visual sciences Key Laboratory,  No 1, Dong Jiao Min Xiang, Dongcheng  District, Beijing 100730, people’s republic  of China Tel +86 10 5826 9920 email jlbjlb@sina.co m Journal name: OncoTargets and Therapy Article Designation: Case report Y ear: 2016 Volume: 9 Running head verso: Liu et al Running head recto: Alveolar rhabdomyosarcoma of the sphenoid sinus DOI: http://dx.doi.org/10.2147/OTT.S106842",Non-OADS,/arxiv_data1/oa_pdf/19/32/ott-9-6333.PMC5135560.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/19/32/ott-9-6333.PMC5135560.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/19/32/ott-9-6333.PMC5135560.pdf
"Developmental  Cognitive  Neuroscience  22  (2016)  1–8 Contents  lists  available  at  ScienceDirect Developmental  Cognitive  Neuroscience j  o  ur  nal  ho  me  pa  ge:  http://www.elsevier.com/locate/dcn The  application of neuroimaging  to  social  inequity  and  language disparity:  A cautionary examination Monica  E.  Ellwood-Lowea,∗,  Matthew  D.  Saccheta,b,  Ian  H.  Gotliba,b aDepartment  of  Psychology,  Stanford  University,  Stanford,  CA  94305,  USA bNeurosciences  Program,  Stanford  University,  Stanford,  CA  94305,  USA a r t i c l  e  i  n  f  o Article history: Received  17  August  2016 Received  in  revised  form 28  September  2016 Accepted  2  October  2016 Available  online 3 October 2016 Keywords:Socioeconomic status (SES) NeuroimagingReverse inference LanguageDevelopmentChildhood povertya b s t r  a  c  t In the nascent ﬁeld of  the  cognitive  neuroscience  of  socioeconomic  status  (SES),  researchers  are  using neuroimaging to  examine  how  growing  up  in  poverty  affects  children’s  neurocognitive  development, particularly their language  abilities.",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"These  studies  in  the  growing  area  of  the  cognitive neuroscience  of  SES  focus  speciﬁcally  on  neural  aspects  of  language development,  assessing  the  relation  of  SES  to  the  structure  and function  of  brain  regions  that  support  language  comprehension  and http://dx.doi.org/10.1016/j.dcn.2016.10.001 1878-9293/© 2016  The  Authors.",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.,Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"465  (1),  72–89,  http://dx.doi.org/10.1002/cne.10829 .",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"6  (2),  115–116,  http://dx.doi.org/10.1038/nn1003 .",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"19,  144–151,  http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"11  (2),  282–298,  http://dx.doi.org/10.1111/j.1467- 7687.2008.00675.x .",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"6,  1–17, http://dx.doi.org/10.3389/fnhum.2012.00254/abstract .",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"3, 377–386, http://dx.doi.org/10.1002/wcs.1176 .",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"16  (2), 234–248, http://dx.doi.org/10.1111/desc.12019 .",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"31 (6),  879–890,  http://dx.doi.org/10.1002/hbm.21029 .",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"13  (2),  65–73,  http://dx.doi.org/10.1016/j.tics.2008.11.003 .",OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"169  (9),  822, http://dx.doi.org/10.1001/jamapediatrics.2015.1475 .",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"PLoS  One  8  (12), e80954–e80959,  http://dx.doi.org/10.1371/journal.pone.0080954 .",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"John  Wiley  &  Sons,  Inc., Hoboken, NJ,  USA,  http://dx.doi.org/10.1002/0471264385.wei0607 .",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"PLoS  One  7  (8), e42486–e42489, http://dx.doi.org/10.1371/journal.pone.0042486 .",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"Pediatrics  137  (4),  e20153075,  http://dx.doi.org/10.1542/ peds.2015-3075 .",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"44  (1),  1–12,  http://dx.doi.org/10.1016/j.brainresrev.2003.10.001 .",OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"21  (11),  1716–1723,  http://dx.doi.org/10.1177/ 0956797610387613 .",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"119  (3),  546–572,  http://dx.doi.org/10.1037/a0028756 .",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"126 (2),  309–337,  http://dx.doi.org/10.1037//0033-2909.126.2.309 .",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"Psychol.,  http://dx.doi.org/10.1002/ijop.",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"10  (4),  464–480, http://dx.doi.org/10.1111/j.1467-7687.2007.00600.x .",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"15  (4),  516–527, http://dx.doi.org/10.1111/j.1467-7687.2012.01147.x .",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"18  (5),  773–778,  http://dx.doi.org/10.1038/nn.3983 .",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"11  (3),  381–398,  http://dx.doi.org/10.1177/ 1745691616635592 .",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"Neuron  72  (5),  692–697,  http://dx.doi.org/ 10.1016/j.neuron.2011.11.001 .",OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"Neuroimage  40  (3),  1392–1401,  http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"Neurosci.,  1–11,  http://dx.doi.org/10.3389/neuro.09.003.2010 .",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"35 (01),  185–205,  http://dx.doi.org/10.1017/S0305000907008343 .Sharkey,  P.,  2010.",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"Nature  440  (7084),  676–679,  http://dx.doi.org/10.1038/nature04513 .",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"Public  Policy  Law  11  (2),  320–327, http://dx.doi.org/10.1037/1076-8971.11.2.320 .",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"99  (2),  253–273,  http://dx.doi.org/10.1037/0022-0663.99.2.253 .",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"Psychophysiology  53  (1),  71–82,  http://dx.doi.org/10.1111/psyp.12547 .",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"27  (1),  45–73,  http://dx.doi.org/ 10.1353/rhe.2003.0044 .",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"92  (1),  82–96,  http://dx.doi.org/10.1037/ 0022-3514.92.1.82 .",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
"24  (11), 2143–2152,  http://dx.doi.org/10.1177/0956797613488145 .",Non-OADS,/arxiv_data1/oa_pdf/00/78/main.PMC5135574.pdf
Keywords Autism spectrum disorder; β-Hydroxybutyrate; EL mouse; Glucose; Grooming; Female;  Ketogenic diet; Ketosis; Comorbidity; Sex differences; Sociability; Social transmission of food  preference This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c2/c1/nihms830873.PMC5135580.pdf
2016. http://dx.doi.org/10.1016/ j.neuroscience.2016.01.070Ruskin et al.,OADS,/arxiv_data1/oa_pdf/c2/c1/nihms830873.PMC5135580.pdf
"Developmental  Cognitive  Neuroscience  22  (2016)  27–35 Contents  lists  available  at  ScienceDirect Developmental  Cognitive  Neuroscience j  o  ur  nal  ho  me  pa  ge:  http://www.elsevier.com/locate/dcn Development  of relational memory  processes  in  monkeys Maria C.  Alvaradoa,∗,  Ludise  Malkovab,c, Jocelyne Bachevaliera aYerkes  National  Primate  Research  Center,  Emory  University,  United  States bGeorgetown  University,  United  States cNational  Institute  of  Mental  Health,  United  States a  r  t  i  c  l  e  i  n  f  o Article  history: Received  22  April  2016 Received  in  revised  form  20  October  2016 Accepted  28  October  2016 Available  online 2 November 2016 Keywords:Relational memory DevelopmentMedial temporal lobe PrefrontalMacaquea  b  s  t  r  a  c  t The  present  study  tested  whether  relational  memory  processes,  as  measured  by  the  transverse  patterning problem, are late-developing in nonhuman primates  as  they  are  in  humans.",Non-OADS,/arxiv_data1/oa_pdf/91/22/main.PMC5135601.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/91/22/main.PMC5135601.pdf
"Similarly,  neonatal hippocampal  lesions  did  not  impact  spatial  recognition  or  delay- dependent  recognition  until  18  months,  when  presumably  this http://dx.doi.org/10.1016/j.dcn.2016.10.007 1878-9293/© 2016  The  Authors.",Non-OADS,/arxiv_data1/oa_pdf/91/22/main.PMC5135601.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.,Non-OADS,/arxiv_data1/oa_pdf/91/22/main.PMC5135601.pdf
"19  (10), 1053–1064, http://dx.doi.org/10.1017/S1355617713000799 .",Non-OADS,/arxiv_data1/oa_pdf/91/22/main.PMC5135601.pdf
"127  (1),  9–22,  http://dx.doi.org/10.1037/a0031498 .",Non-OADS,/arxiv_data1/oa_pdf/91/22/main.PMC5135601.pdf
"Neuroimage  58  (4),  1158–1168,  http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/91/22/main.PMC5135601.pdf
"519  (6),  1051–1070,  http://dx.doi.org/10.1111/j.1460-9568.",Non-OADS,/arxiv_data1/oa_pdf/91/22/main.PMC5135601.pdf
"Cortex  2014,  http://dx.doi.org/10.1093/ cercor/bhu227 .",OADS,/arxiv_data1/oa_pdf/91/22/main.PMC5135601.pdf
"278,  293–302,  http://dx.doi.org/10.1016/j.bbr.",OADS,/arxiv_data1/oa_pdf/91/22/main.PMC5135601.pdf
"37 (6),  485–497,  http://dx.doi.org/10.1177/0165025413493876 .",Non-OADS,/arxiv_data1/oa_pdf/91/22/main.PMC5135601.pdf
"Neuroscientist  14,  345–358,  http://dx.doi.org/10.1177/ 1073858408316002 .",Non-OADS,/arxiv_data1/oa_pdf/91/22/main.PMC5135601.pdf
"30  (July  (27)),  9157–9165,  http://dx.doi.org/ 10.1523/JNEUROSCI.",Non-OADS,/arxiv_data1/oa_pdf/91/22/main.PMC5135601.pdf
"11,  31–41,  http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/91/22/main.PMC5135601.pdf
"Developmental  Cognitive  Neuroscience  22  (2016)  18–26 Contents  lists  available  at  ScienceDirect Developmental  Cognitive  Neuroscience jo  ur  nal  ho  me  pag  e:  http://www.elsevier.com/locate/dcn Early  math and reading  achievement  are  associated  with  the  error positivity Matthew  H.  Kim∗,1,  Jennie  K.  Grammer2,  Loren  M.  Marulis3,  Melisa  Carrasco4, Frederick J.  Morrison,  William  J.  Gehring University  of  Michigan,  530  Church  Street,  Ann  Arbor,  MI  48109-1043,  United  States a  r t i  c  l  e  i  n  f  o Article  history: Received  6  January  2016 Received  in  revised  form  28  June  2016 Accepted  14 September 2016 Available online  21  September  2016 Keywords:MotivationAttentionError positivity MathReadingChildrena b s  t  r  a  c  t Executive  functioning  (EF)  and  motivation  are  associated  with  academic  achievement  and  error-related ERPs.",Non-OADS,/arxiv_data1/oa_pdf/f3/40/main.PMC5135606.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f3/40/main.PMC5135606.pdf
"The  error-related negativity  (ERN)  is  an  ERP  component  that  is  elicited  when  an  indi- vidual  makes a mistake  on  a  speeded  target  discrimination  task, and  is  thought  to  reﬂect  error  detection  and  conﬂict  resolution http://dx.doi.org/10.1016/j.dcn.2016.09.002 1878-9293/© 2016  The  Authors.",Non-OADS,/arxiv_data1/oa_pdf/f3/40/main.PMC5135606.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.,Non-OADS,/arxiv_data1/oa_pdf/f3/40/main.PMC5135606.pdf
Data  were  recorded  referenced  to  a  ground  formed from  a  common  mode  sense  (CMS)  active  electrode  and  driven right  leg  (DRL)  passive  electrode  (see  http://www.biosemi.com/ faq/cms&drl.htm ).,OADS,/arxiv_data1/oa_pdf/f3/40/main.PMC5135606.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/22/8f/num-08-06-41505.PMC5135728.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/59/ce/num-08-06-40371.PMC5135729.pdf
"The study was conducted in adherence to the ARVO guide - lines regarding the ethical use of human subjects in research.Molecular Vision  2016; 22:1352-1360 <http://www.molvis.org/molvis/v 22/1352 > Received 13 July 2015 | Accepted 30 November 2016 | Published 2 December 2016© 2016 Molecular Vision 1352Increased serum level of homocysteine correlates with retinal  nerve fiber layer thinning in diabetic retinopathy Khushboo Srivastav,1 Sandeep Saxena,1 Abbas A. Mahdi,2 Rajendra K. Shukla,3 Carsten H. Meyer,4 Levent  Akduman,5 Vinay K. Khanna3 1Retina Service, Department of Ophthalmology, King George’ s Medical University, Lucknow, India; 2Department of  Biochemistry, King George’ s Medical University, Lucknow, India; 3CSIR - Indian Institute of Toxicology and Research, Lucknow,  India; 4Department of Ophthalmology, Pallas Clinic, Aarau, Switzerland; 5Vitreoretinal and uveitis service, Department of  Ophthalmology, Saint Louis University School of Medicine,St.",Non-OADS,/arxiv_data1/oa_pdf/93/34/mv-v22-1352.PMC5135738.pdf
"Molecular Vision  2016; 22:1352-1360 <http://www.molvis.org/molvis/v 22/1352 > © 2016 Molecular Vision  1353In this tertiary care center–based cross-sectional study,  60 consecutive cases of type 2 diabetes mellitus and 20  healthy controls (presenting for refraction) aged between 40  and 65 years were included after informed voluntary consent  was obtained.",Non-OADS,/arxiv_data1/oa_pdf/93/34/mv-v22-1352.PMC5135738.pdf
Molecular Vision  2016; 22:1352-1360 <http://www.molvis.org/molvis/v 22/1352 > © 2016 Molecular Vision  1354Standard sample diluent (300 µl) was added to each of the  seven microtiter wells.,Non-OADS,/arxiv_data1/oa_pdf/93/34/mv-v22-1352.PMC5135738.pdf
Molecular Vision  2016; 22:1352-1360 <http://www.molvis.org/molvis/v 22/1352 > © 2016 Molecular Vision  1355Table  1.,Non-OADS,/arxiv_data1/oa_pdf/93/34/mv-v22-1352.PMC5135738.pdf
Molecular Vision  2016; 22:1352-1360 <http://www.molvis.org/molvis/v 22/1352 > © 2016 Molecular Vision  1356calculated based on the standard curve.,OADS,/arxiv_data1/oa_pdf/93/34/mv-v22-1352.PMC5135738.pdf
Molecular Vision  2016; 22:1352-1360 <http://www.molvis.org/molvis/v 22/1352 > © 2016 Molecular Vision  1357with a chi-square (χ2) test.,Non-OADS,/arxiv_data1/oa_pdf/93/34/mv-v22-1352.PMC5135738.pdf
Molecular Vision  2016; 22:1352-1360 <http://www.molvis.org/molvis/v 22/1352 > © 2016 Molecular Vision  1358of normal.,Non-OADS,/arxiv_data1/oa_pdf/93/34/mv-v22-1352.PMC5135738.pdf
Molecular Vision  2016; 22:1352-1360 <http://www.molvis.org/molvis/v 22/1352 > © 2016 Molecular Vision  135911.,Non-OADS,/arxiv_data1/oa_pdf/93/34/mv-v22-1352.PMC5135738.pdf
Molecular Vision  2016; 22:1352-1360 <http://www.molvis.org/molvis/v 22/1352 > © 2016 Molecular Vision  136038.,Non-OADS,/arxiv_data1/oa_pdf/93/34/mv-v22-1352.PMC5135738.pdf
"Therefore, the increased focus on exploration of  novel transcription factors that regulate the expression of Molecular Vision  2016; 22:1375-1386 <http://www.molvis.org/molvis/v 22/1375 > Received 5 May 2016 | Accepted 30 November 2016 | Published 2 December 2016© 2016 Molecular Vision 1375Role of endogenous insulin gene enhancer protein ISL-1 in  angiogenesis Si-qi Xiong, Hai-bo Jiang, Yan-xiu Li, Hai-bo Li, Hui-zhuo Xu, Zhen-kai Wu, Wei Zheng, Xiao-bo Xia Department of Ophthalmology, Xiangya Hospital, Central South University, Changsha, P .R.China Objective:  To elucidate the role of insulin gene enhancer protein ISL-1 (Islet-1) in angiogenesis and regulation of vascular  endothelial growth factor (VEGF) expression in vitro and in vivo.",Non-OADS,/arxiv_data1/oa_pdf/ef/7b/mv-v22-1375.PMC5135739.pdf
Molecular Vision  2016; 22:1375-1386 <http://www.molvis.org/molvis/v 22/1375 > © 2016 Molecular Vision  1376angiogenic factors provides insight into the mechanism of  angiogenesis and offers a potential target for gene therapy.,Non-OADS,/arxiv_data1/oa_pdf/ef/7b/mv-v22-1375.PMC5135739.pdf
Molecular Vision  2016; 22:1375-1386 <http://www.molvis.org/molvis/v 22/1375 > © 2016 Molecular Vision  137765–95 °C with increment of 0.5 °C for 10 s to confirm the  authenticity of the amplified product by its specific melting  temperature (Tm).,Non-OADS,/arxiv_data1/oa_pdf/ef/7b/mv-v22-1375.PMC5135739.pdf
Molecular Vision  2016; 22:1375-1386 <http://www.molvis.org/molvis/v 22/1375 > © 2016 Molecular Vision  1378(5 μg) complex or 1 µl control complex (liposome-negative  control siRNA) into the vitreous cavity.,Non-OADS,/arxiv_data1/oa_pdf/ef/7b/mv-v22-1375.PMC5135739.pdf
Molecular Vision  2016; 22:1375-1386 <http://www.molvis.org/molvis/v 22/1375 > © 2016 Molecular Vision  1379Islet-1 affects invasion and migration of HUVECs in vitro:   The in vitro motility was assessed using wound healing  and Transwell assays of the HUVECs.,Non-OADS,/arxiv_data1/oa_pdf/ef/7b/mv-v22-1375.PMC5135739.pdf
Molecular Vision  2016; 22:1375-1386 <http://www.molvis.org/molvis/v 22/1375 > © 2016 Molecular Vision  1380HUVECs.,Non-OADS,/arxiv_data1/oa_pdf/ef/7b/mv-v22-1375.PMC5135739.pdf
Molecular Vision  2016; 22:1375-1386 <http://www.molvis.org/molvis/v 22/1375 > © 2016 Molecular Vision  1381This assessment revealed that the retinas of the un-injected  eyes from the hypoxic mice contained multiple neovascular  tufts extending into the vitreous (Figure 5B).,Non-OADS,/arxiv_data1/oa_pdf/ef/7b/mv-v22-1375.PMC5135739.pdf
"Molecular Vision  2016; 22:1375-1386 <http://www.molvis.org/molvis/v 22/1375 > © 2016 Molecular Vision  1382DISCUSSION Islet-1 plays an important role in the development and forma - tion of various organs and tissues [ 13,22].",Non-OADS,/arxiv_data1/oa_pdf/ef/7b/mv-v22-1375.PMC5135739.pdf
"Molecular Vision  2016; 22:1375-1386 <http://www.molvis.org/molvis/v 22/1375 > © 2016 Molecular Vision  1383VEGF, and decreased the migration, proliferation, and tube  formation of the vascular endothelial cells.",Non-OADS,/arxiv_data1/oa_pdf/ef/7b/mv-v22-1375.PMC5135739.pdf
Molecular Vision  2016; 22:1375-1386 <http://www.molvis.org/molvis/v 22/1375 > © 2016 Molecular Vision  1384 Figure 6.,Non-OADS,/arxiv_data1/oa_pdf/ef/7b/mv-v22-1375.PMC5135739.pdf
"Molecular Vision  2016; 22:1375-1386 <http://www.molvis.org/molvis/v 22/1375 > © 2016 Molecular Vision  1385other unknown angiogenic factors regulated by Islet-1, may  be reduced by siRNA targeting Islet-1.",Non-OADS,/arxiv_data1/oa_pdf/ef/7b/mv-v22-1375.PMC5135739.pdf
Molecular Vision  2016; 22:1375-1386 <http://www.molvis.org/molvis/v 22/1375 > © 2016 Molecular Vision  1386Through Monocyte Chemoattractant Protein-3.,Non-OADS,/arxiv_data1/oa_pdf/ef/7b/mv-v22-1375.PMC5135739.pdf
"PKR was previously considered  to function primarily as a mediator of the antiviral response,  but after extensive research, PKR is currently regarded to Molecular Vision  2016; 22:1361-1374 <http://www.molvis.org/molvis/v 22/1361 > Received 9 June 2016 | Accepted 30 November 2016 | Published 2 December 2016© 2016 Molecular Vision 1361PKR promotes choroidal neovascularization via upregulating the  PI3K/Akt signaling pathway in VEGF expression Manhui Zhu,1,4 Xiaojuan Liu,2,4 Shengcun Wang,3,4 Jin Miao,3,4 Liucheng Wu,3,4 Xiaowei Yang,1,4 Ying Wang,1,4  Lihua Kang,1,4 Wendie Li,1,4 Chen Cui,1,4 Hui Chen,1,4 Aimin Sang1,4 (The first two and last two authors contributed equally to this work.)",Non-OADS,/arxiv_data1/oa_pdf/63/cf/mv-v22-1361.PMC5135740.pdf
Molecular Vision  2016; 22:1361-1374 <http://www.molvis.org/molvis/v 22/1361 > © 2016 Molecular Vision  1362 Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/63/cf/mv-v22-1361.PMC5135740.pdf
Molecular Vision  2016; 22:1361-1374 <http://www.molvis.org/molvis/v 22/1361 > © 2016 Molecular Vision  1363 Figure 2.,Non-OADS,/arxiv_data1/oa_pdf/63/cf/mv-v22-1361.PMC5135740.pdf
Molecular Vision  2016; 22:1361-1374 <http://www.molvis.org/molvis/v 22/1361 > © 2016 Molecular Vision  1364be versatile.,Non-OADS,/arxiv_data1/oa_pdf/63/cf/mv-v22-1361.PMC5135740.pdf
"Molecular Vision  2016; 22:1361-1374 <http://www.molvis.org/molvis/v 22/1361 > © 2016 Molecular Vision  1365harvested after 1, 3, 6, 12, 24, and 48 h. Cells without CoCl2  treatment were regarded as the normal control.",Non-OADS,/arxiv_data1/oa_pdf/63/cf/mv-v22-1361.PMC5135740.pdf
Molecular Vision  2016; 22:1361-1374 <http://www.molvis.org/molvis/v 22/1361 > © 2016 Molecular Vision  1366 Figure 5.,Non-OADS,/arxiv_data1/oa_pdf/63/cf/mv-v22-1361.PMC5135740.pdf
Molecular Vision  2016; 22:1361-1374 <http://www.molvis.org/molvis/v 22/1361 > © 2016 Molecular Vision  1367 Figure 6.,Non-OADS,/arxiv_data1/oa_pdf/63/cf/mv-v22-1361.PMC5135740.pdf
"Molecular Vision  2016; 22:1361-1374 <http://www.molvis.org/molvis/v 22/1361 > © 2016 Molecular Vision  1368in RPMI 1640 with 10% FBS for an additional 48 h. Then, the  cells were collected for western blot analysis.",Non-OADS,/arxiv_data1/oa_pdf/63/cf/mv-v22-1361.PMC5135740.pdf
"Molecular Vision  2016; 22:1361-1374 <http://www.molvis.org/molvis/v 22/1361 > © 2016 Molecular Vision  1369Western blot:  To detect the protein levels of the molecules, we  extracted the mouse choroid-RPE-retina complex from three  mice at 1 day and 3, 7, 14, and 28 days after the laser injury  and used in vitro cell lysates.",Non-OADS,/arxiv_data1/oa_pdf/63/cf/mv-v22-1361.PMC5135740.pdf
"Molecular Vision  2016; 22:1361-1374 <http://www.molvis.org/molvis/v 22/1361 > © 2016 Molecular Vision  1370antibodies (1:2,000; Thermo Scientific, Rockford, IL) at 37 °C  for 2 h. Extensive washes in 0.05% Tween-20 in Tris-buffered  saline (TBS) were followed by incubation with anti-GAPDH  (1:1,000; Sigma-Aldrich, Saint Louis, MO).",Non-OADS,/arxiv_data1/oa_pdf/63/cf/mv-v22-1361.PMC5135740.pdf
Molecular Vision  2016; 22:1361-1374 <http://www.molvis.org/molvis/v 22/1361 > © 2016 Molecular Vision  1371showed that PKR overexpression in RF/6A cells signifi - cantly increased cell proliferation under hypoxic conditions  in the coculture system compared to the normoxia group.,Non-OADS,/arxiv_data1/oa_pdf/63/cf/mv-v22-1361.PMC5135740.pdf
"Molecular Vision  2016; 22:1361-1374 <http://www.molvis.org/molvis/v 22/1361 > © 2016 Molecular Vision  1372(Aβ) peptide accumulation [ 29,30], or through PACT [ 31,32].",Non-OADS,/arxiv_data1/oa_pdf/63/cf/mv-v22-1361.PMC5135740.pdf
Molecular Vision  2016; 22:1361-1374 <http://www.molvis.org/molvis/v 22/1361 > © 2016 Molecular Vision  1373therapeutic opportunities.,Non-OADS,/arxiv_data1/oa_pdf/63/cf/mv-v22-1361.PMC5135740.pdf
Molecular Vision  2016; 22:1361-1374 <http://www.molvis.org/molvis/v 22/1361 > © 2016 Molecular Vision  137426.,Non-OADS,/arxiv_data1/oa_pdf/63/cf/mv-v22-1361.PMC5135740.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/56/49/rru-8-217.PMC5136356.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/56/49/rru-8-217.PMC5136356.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Research and Reports in Urology 2016:8 217–224Research and Reports in Urology Dovepress submit your manuscript | www.dovepress.com Dovepress  217 REVIEW open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/RRU.S104789Impact of enzalutamide on patient-related  outcomes in metastatic castration-resistant  prostate cancer: current perspectives Jia Luo1 Julie N Graff2,3 1Department of Medicine; 2Knight  Cancer Institute, Oregon Health  & Science University, 3VA Portland  Health Care System, Portland,  OR, USAAbstract:  Prostate cancer claims the lives of more than 25,000 men in the United States yearly,  most from metastatic disease.",Non-OADS,/arxiv_data1/oa_pdf/56/49/rru-8-217.PMC5136356.pdf
"4,5 Prostate cancer eventually becomes resistant to castration, and an early Correspondence: Julie N Graff Knight Cancer Institute, 3303 SW Bond Ave, MC CH14R, Portland, OR 97239, USAEmail graffj@ohsu.eduJournal name: Research and Reports in Urology Article Designation: REVIEWY ear: 2016V olume: 8Running head verso: Luo and GraffRunning head recto: Impact of enzalutamide on PORs in mCRPCDOI: http://dx.doi.org/10.2147/RRU.S104789",Non-OADS,/arxiv_data1/oa_pdf/56/49/rru-8-217.PMC5136356.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/12050481.,Non-OADS,/arxiv_data1/oa_pdf/56/49/rru-8-217.PMC5136356.pdf
Available from: http://www.nccn.org/professionals/physi-cian_gls/pdf/prostate.pdf.,Non-OADS,/arxiv_data1/oa_pdf/56/49/rru-8-217.PMC5136356.pdf
Available from: http://www.accessdata.fda.gov/.,OADS,/arxiv_data1/oa_pdf/56/49/rru-8-217.PMC5136356.pdf
"Research and Reports in Urology 2016:8submit your manuscript | www.dovepress.com Dovepress Dovepress Research and Reports in Urology Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/research-and-reports-in-urology-journalResearch and Reports in Urology is an international, peer-reviewed,  open access journal publishing original research, reports, editorials, reviews and commentaries on all aspects of adult and pediatric urology in the clinic and laboratory including the following topics: Pathology, pathophysiology of urological disease; Investigation and treatment of urological disease; Pharmacology of drugs used for the treatment of urological disease.",Non-OADS,/arxiv_data1/oa_pdf/56/49/rru-8-217.PMC5136356.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 224 Luo and Graff 21.,Non-OADS,/arxiv_data1/oa_pdf/56/49/rru-8-217.PMC5136356.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/11491192.,Non-OADS,/arxiv_data1/oa_pdf/56/49/rru-8-217.PMC5136356.pdf
Available from: http://www.mdanderson.org/education-and-research/departments-programs-and-labs/departments-and-divisions/symptom-research/symptom-assessment-tools/BPI_UserGuide.pdf.,Non-OADS,/arxiv_data1/oa_pdf/56/49/rru-8-217.PMC5136356.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/77/ce/copd-11-3001.PMC5136357.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2016:11 3001–3006International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  3001OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S11698 2 association of serum ferritin levels with smoking  and lung function in the Korean adult population:  analysis of the fourth and fifth Korean National  health and nutrition examination survey Chan ho lee eun Kyung goag su hwan lee Kyung soo Chung Ji Ye Jung Moo suk Park Y oung sam Kim se Kyu Kim Joon Chang Joo han song Division of Pulmonology and Critical  Care Medicine, Department of  Internal Medicine, Institute of Chest  Disease, severance hospital, Yonsei  University College of Medicine, seoul,   republic of KoreaBackground:  Iron-catalyzed oxidative stress contributes to lung injury after exposure to various  toxins, including cigarette smoke.",Non-OADS,/arxiv_data1/oa_pdf/77/ce/copd-11-3001.PMC5136357.pdf
"Smoking has been suggested to increase Correspondence: Joo han song Division of Pulmonology and Critical  Care Medicine, Department of Internal  Medicine, Yonsei University College of  Medicine, 50 Yonsei-ro, seodaemun-gu,  seoul 120-752, republic of Korea Tel +82 2 2228 1930 Fax +82 2 2228 2273 email augustin76md@yuhs.a c Journal name: International Journal of COPD Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Lee et al Running head recto: Serum ferritin, smoking, and lung function DOI: http://dx.doi.org/10.2147/COPD.S116982",Non-OADS,/arxiv_data1/oa_pdf/77/ce/copd-11-3001.PMC5136357.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/77/ce/copd-11-3001.PMC5136357.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/77/ce/copd-11-3001.PMC5136357.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/3d/29/ndt-12-3051.PMC5136358.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 3051–3059Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  3051OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S11733 7 a novel herbal treatment reduces depressive- like behaviors and increases brain-derived  neurotrophic factor levels in the brain of type 2  diabetic rats chun luo1,* Yuting Ke1,* Yanyan Yuan1 Ming Zhao1 Fuyan Wang1 Yisheng Zhang2 shizhong Bu1 1runliang Diabetes laboratory,   Diabetes research center,   Ningbo University, 2Department  of gynaecology and Obstetrics,   Ningbo Medical center, li huili  eastern hospital, Ningbo, Zhejiang,   People’s republic of china *These authors contributed equally  to this workBackground:  Radix Puerariae and hawthorn fruit have been demonstrated to treat diabetes.",Non-OADS,/arxiv_data1/oa_pdf/3d/29/ndt-12-3051.PMC5136358.pdf
"Previous studies demonstrated that there is a bidirectional association correspondence: shizhong Bu runliang Diabetes laboratory, Diabetes  research center, Ningbo University, 818  Fenghua road, Ningbo 315211, Zhejiang,  People’s republic of china Tel +86 574 8760 9607 email bushizhong@nbu.edu.c n Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Luo et al Running head recto: Radix Puerariae and hawthorn fruit prevent depression DOI: http://dx.doi.org/10.2147/NDT.S117337",Non-OADS,/arxiv_data1/oa_pdf/3d/29/ndt-12-3051.PMC5136358.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/3d/29/ndt-12-3051.PMC5136358.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/3d/29/ndt-12-3051.PMC5136358.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/c0/e3/ijnrd-9-313.PMC5136359.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/c0/e3/ijnrd-9-313.PMC5136359.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).International Journal of Nephrology and Renovascular Disease 2016:9 313–317International Journal of Nephrology and Renovascular Disease Dovepress submit your manuscript | www.dovepress.com Dovepress 313 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IJNRD.S120562 IgA1 dominant subclass of latent IgA mesangial  deposition in donated kidney Kazumasa Oka1 Kenji Nishimura2 Hidefumi Kishikawa2 Yasuji Ichikawa3 1Department of Pathology, Hyogo  Prefectural Nishinomiya Hospital,   Hyogo, Japan; 2Department of Urology,   Hyogo Prefectural Nishinomiya Hospital, Hyogo, Japan;  3Department  of Urology, Joyo Ejiri Hospital, Hyogo,  JapanBackground: In the pathogenesis of immunoglobulin A nephropathy (IgAN), the IgA1 subclass  is more important than the IgA2 subclass.",Non-OADS,/arxiv_data1/oa_pdf/c0/e3/ijnrd-9-313.PMC5136359.pdf
"Mesangial IgA deposition has been observed in 10%–30% of renal specimens through necropsy of patients without any Correspondence: Kazumasa Oka Department of Pathology, Hyogo Prefectural Nishinomiya Hospital, Rokutanji-cho 13-9, Nishinomiya, Hyogo 662-0918, JapanTel +81 798 345 151Fax +81 798 234 594Email oka1004@hp.pref.hyogo.jpJournal name: International Journal of Nephrology and Renovascular Disease Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 9Running head verso: Oka et alRunning head recto: IgA1 in latent IgA mesangial depositionDOI: http://dx.doi.org/10.2147/IJNRD.S120562",Non-OADS,/arxiv_data1/oa_pdf/c0/e3/ijnrd-9-313.PMC5136359.pdf
"The procedure for informed consent was that our study protocol was open to the public via our homepage (http://www.nishihosp.nishinomiya.hyogo.jp/   aboutus/rinshou_kenkyu.html ); if a participant did not want to  be included in the study, they could make contact with us.",Non-OADS,/arxiv_data1/oa_pdf/c0/e3/ijnrd-9-313.PMC5136359.pdf
"International Journal of Nephrology and Renovascular Disease 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress International Journal of Nephrology and Renovascular Disease Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/international-journal-of-nephrology-and-renovascular-disease-journalThe International Journal of Nephrology and Renovascular Disease is   an international, peer-reviewed open access journal focusing on the  pathophysiology of the kidney and vascular supply.",Non-OADS,/arxiv_data1/oa_pdf/c0/e3/ijnrd-9-313.PMC5136359.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published   authors.Dovepress 317 IgA1 in latent IgA mesangial deposition C3 deposition as IgAN.,Non-OADS,/arxiv_data1/oa_pdf/c0/e3/ijnrd-9-313.PMC5136359.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/82/9f/jaa-9-209.PMC5136360.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/82/9f/jaa-9-209.PMC5136360.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Asthma and Allergy 2016:9 209–213Journal of Asthma and Allergy Dovepress submit your manuscript | www.dovepress.com Dovepress 209 REVIEW open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JAA.S91505Aquagenic urticaria: diagnostic and management  challenges Robert Rothbaum Jean S McGee Department of Dermatology, Boston  University School of Medicine, Boston,  MA, USAAbstract:  Aquagenic urticaria (AU) is a rare inducible form of physical urticaria, which occurs  in response to cutaneous exposure to water, including sweat and tears.",Non-OADS,/arxiv_data1/oa_pdf/82/9f/jaa-9-209.PMC5136360.pdf
"4–6 One familial cohort presented with coexistent Bernard–Soulier syndrome  in the affected patients, raising the possibility of an associated genetic locus for AU; Correspondence: Jean S McGee  Department of Dermatology, Boston University School of Medicine, 609 Albany Street, Boston, MA 02118, USAEmail jeanmcgee@gmail.comJournal name: Journal of Asthma and Allergy Article Designation: REVIEWY ear: 2016V olume: 9Running head verso: Rothbaum and McGeeRunning head recto: AU: diagnostic and management challengesDOI: http://dx.doi.org/10.2147/JAA.S91505",Non-OADS,/arxiv_data1/oa_pdf/82/9f/jaa-9-209.PMC5136360.pdf
"Journal of Asthma and Allergy 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Asthma and Allergy Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/journal-of-asthma-and-allergy-journalThe Journal of Asthma and Allergy is an international, peer-reviewed  open access journal publishing original research, reports, editorials and commentaries on the following topics: Asthma; Pulmonary physi-ology; Asthma related clinical health; Clinical immunology and the immunological basis of disease; Pharmacological interventions and new therapies.",Non-OADS,/arxiv_data1/oa_pdf/82/9f/jaa-9-209.PMC5136360.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/83/56/mder-9-419.PMC5136361.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/83/56/mder-9-419.PMC5136361.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Medical Devices: Evidence and Research 2016:9 419–421Medical Devices: Evidence and Research Dovepress submit your manuscript | www.dovepress.com Dovepress 419 LETTER open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/MDER.S125211 Letter to the editor regarding “Clinical  effectiveness and safety of powered exoskeleton- assisted walking in patients with spinal cord injury:  systematic review with meta-analysis” Marcel P Dijkers1  Katherine G Akers2  Sujay S Galen3  Diane E Patzer4  Phuong T Vu4 1Department of Physical Medicine  and Rehabilitation, Wayne State  University, Detroit, 2Shiffman Medical  Library, Wayne State University,   Detroit, 3Physical Therapy Program,   Wayne State University, Detroit,   4Center for Spinal Cord Injury  Recovery, Rehabilitation Institute of Michigan, Detroit, MI, USADear editor In the article “Clinical effectiveness and safety of powered exoskeleton-assisted walking  in patients with spinal cord injury: systematic review with meta-analysis”, published in the March issue of Medical Devices: Evidence and Research, Miller et al 1 present  a meta-analysis of the clinical effectiveness and safety of powered exoskeletons for spinal cord injury (SCI) patients.",Non-OADS,/arxiv_data1/oa_pdf/83/56/mder-9-419.PMC5136361.pdf
"Miller et al 1 should Correspondence: Marcel P Dijkers Department of Physical Medicine and Rehabilitation, Wayne State University, Detroit, MI 48202, USA Email marcellinus.P.dijkers@wayne.eduJournal name: Medical Devices: Evidence and Research Article Designation: LETTERY ear: 2016V olume: 9Running head verso: Dijkers et alRunning head recto: Clinical effectiveness and safety of powered exoskeleton-assisted walkingDOI: http://dx.doi.org/10.2147/MDER.S125211",Non-OADS,/arxiv_data1/oa_pdf/83/56/mder-9-419.PMC5136361.pdf
"Medical Devices: Evidence and Research 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Medical Devices: Evidence and Research Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/medical-devices-evidence-and-research-journalMedical Devices: Evidence and Research is an international, peer- reviewed, open access journal that focuses on the evidence, technology, research, and expert opinion supporting the use and application of   medical devices in the diagnosis, monitoring, treatment and management of clinical conditions and physiological processes.",Non-OADS,/arxiv_data1/oa_pdf/83/56/mder-9-419.PMC5136361.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/32/be/hmer-8-115.PMC5136362.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/32/be/hmer-8-115.PMC5136362.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Hepatic Medicine: Evidence and Research 2016:8 115–134Hepatic Medicine: Evidence and Research Dovepress submit your manuscript | www.dovepress.com Dovepress  115 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/HMER.S116852Targeted transplantation of mitochondria to  hepatocytes Nidhi Gupta Catherine H Wu George Y Wu Department of Medicine, Division  of Gastroenterology–Hepatology,  University of Connecticut Health Center, Farmington, CT, USABackground: Mitochondrial defects in hepatocytes can result in liver dysfunction and death.",Non-OADS,/arxiv_data1/oa_pdf/32/be/hmer-8-115.PMC5136362.pdf
"Figure S1 shows a proposed Correspondence: George Y Wu Department of Medicine, Division of Gastroenterology–Hepatology, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030, USATel +1 860 679 2509Fax +1 860 679 8562Email wu@uchc.eduJournal name: Hepatic Medicine: Evidence and Research Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 8Running head verso: Gupta et alRunning head recto: Internalization of mitochondria by hepatocytesDOI: http://dx.doi.org/10.2147/HMER.S116852",Non-OADS,/arxiv_data1/oa_pdf/32/be/hmer-8-115.PMC5136362.pdf
"Hepatic Medicine: Evidence and Research 2016:8submit your manuscript | www.dovepress.com Dovepress Dovepress Hepatic Medicine: Evidence and Research Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/hepatic-medicine-evidence-and-research-journalHepatic Medicine: Evidence and Research is an international, peer- reviewed, open access journal covering all aspects of adult and pediatric hepatology in the clinic and laboratory including the following topics: Pathology, pathophysiology of hepatic disease; Investigation and treat-ment of hepatic disease; Pharmacology of drugs used for the treatment of hepatic disease.",Non-OADS,/arxiv_data1/oa_pdf/32/be/hmer-8-115.PMC5136362.pdf
"Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 134 Gupta et al Table S1  Sequences of primers used for quantification Primers Sequences LDHA FW 5’-TAATGAAGGACTTGGCAGATGAACT-3’ LDHA RV 5’-ACGGCTTTCTCCCTCTTGCT-3’ HTC-Mito FW 5’-AGGCTTAAAAGCAGCCATCA-3’ HTC-Mito RV 5’-GACAATGGTTATCCGGGTTG-3’ Huh7-Mito FW 5’-CCTGACTCCTACCCCTCA-3’ Huh7-Mito RV 5’-ATCGGGTGATGATAGCCAAG-3’ Abbreviations:  FW, forward; RV, reverse.",Non-OADS,/arxiv_data1/oa_pdf/32/be/hmer-8-115.PMC5136362.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/cf/6d/copd-11-2991.PMC5136363.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2016:11 2991–3000International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  2991OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S11311 3 Three-minute constant rate step test for detecting  exertional dyspnea relief after bronchodilation  in COPD Correspondence: François Maltais Centre de Pneumologie, Institut  Universitaire de Cardiologie et de  Pneumologie de Québec, 2725 Chemin  sainte-Foy, Québec, QC g1V 4g5,  Canada Fax +1 418 656 4762 email francois.maltais@fmed.ulaval.c a Journal name: International Journal of COPD Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Borel et al Running head recto: Stepping exercise to evaluate dyspnea in COPD DOI: http://dx.doi.org/10.2147/COPD.S113113 Benoit Borel1,2 Courtney a Wilkinson- Maitland3 alan hamilton4 Jean Bourbeau5 hélène Perrault6 Dennis Jensen3,5,7 François Maltais2 1laboratoire haVae, Université de  limoges, limoges, France; 2Centre de  recherche, Institut Universitaire de  Cardiologie et de Pneumologie de  Québec, Université laval, Québec,   3Clinical exercise and respiratory  Physiology laboratory, Department  of Kinesiology and Physical education,   Mcgill University, Montréal, QC,   4Boehringer Ingelheim (Canada)  limited, Burlington, On , 5respiratory  epidemiology and Clinical research  Unit, Montreal Chest Institute, Mc gill  University health Center, Montreal,   QC, 6Faculty of health sciences,   University of Ottawa, Ottawa, On ,   7Translational research in respiratory  Diseases Program, research Institute  of the Mc gill University health  Centre, Montreal, QC, CanadaBackground:  The aim of this study was to evaluate the responsiveness of the 3-minute constant  rate step test (3-MST) to detect the relief of exertional dyspnea (respiratory discomfort) after  acute bronchodilation in COPD patients.",Non-OADS,/arxiv_data1/oa_pdf/cf/6d/copd-11-2991.PMC5136363.pdf
The poster’s abstract was published in  “Poster Abstracts” in the American Journal of Respiratory  and Critical Care Medicine  (ATS International Conference  Abstracts Issue): http://www.atsjournals.org/doi/abs/10.1164/ ajrccm-conference.2014.189.1_Me etingAbstracts.A58 62.,Non-OADS,/arxiv_data1/oa_pdf/cf/6d/copd-11-2991.PMC5136363.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/cf/6d/copd-11-2991.PMC5136363.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/cf/6d/copd-11-2991.PMC5136363.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/7a/c6/opth-10-2403.PMC5136365.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2016:10 2403–2415Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  2403Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S11749 4 The measurement repeatability using different  partition methods of intraretinal tomographic  thickness maps in healthy human subjects Jia Tan1,2,* Ye Yang2,3,* hong Jiang2,4 Che liu2 Zhihong Deng1,2 Byron l lam2 liang hu3 Jonathan Oakley5 Jianhua Wang2 1Department of Ophthalmology,   Xiangya hospital, Changsha, hunan,   People’s republic of China; 2Bascom  Palmer eye institute, University of  Miami, Miami, Fl, Usa; 3school of  Ophthalmology and Optometry,   Wenzhou Medical University,   Wenzhou, Zhejiang, People’s republic  of China; 4Department of n eurology,   University of Miami, Miami, Fl,   5Voxeleron llC, Pleasanton, C a, Usa *These authors contributed equally  to this workPurpose:  To determine the repeatability and profiles with different partition methods in intraretinal  thickness layers in healthy human subjects, using optical coherence tomography (OCT).",Non-OADS,/arxiv_data1/oa_pdf/7a/c6/opth-10-2403.PMC5136365.pdf
"For CNS  disorders, macular ganglion cell–inner plexiform layer (GCIPL) thickness has been Correspondence: hong Jiang Bascom Palmer eye institute, University of  Miami, Miller school of Medicine, 1638  nW  10th avenue, McKnight Building  – room  202a, Miami, Fl 33136, Usa Tel +1 305 482 5010 email h.jiang@med.miami.ed u Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Tan et al Running head recto: The measurement repeatability of intraretinal tomographic thickness DOI: http://dx.doi.org/10.2147/OPTH.S117494",Non-OADS,/arxiv_data1/oa_pdf/7a/c6/opth-10-2403.PMC5136365.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/7a/c6/opth-10-2403.PMC5136365.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/7a/c6/opth-10-2403.PMC5136365.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6a/79/jjm-09-09-19552.PMC5136423.pdf
"Recent studies had been suggested ORIGINAL PAPER © 2016 Ali Torkaman, Hamidreza Yazdi,  Mohammad Ghorban Hosseini This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.351-353 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/89/0b/MA-70-351.PMC5136424.pdf
"Also, no palpable axillary lymphadenopathy was detected.CASE REPORT © 2016 Akin Firat Kocaay, Suleyman Utku  Celik, Ilkin Hesimov, Tevfik Eker, Sibel Percinel and Seher Demirer This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.392-394 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/a5/31/MA-70-392.PMC5136425.pdf
"kidney) (3) Indications for plasmapheresis treatment are: myas - thenia gravis- acute phase, second-ary glomerulonephritis which does ORIGINAL PAPER © 2016 Verica Misanovic, Danka  Pokrajac, Smail Zubcevic, Admir Hadzimuratovic, Samra Rahmanovic, Selma Dizdar, Asmir Jonuzi and Edin Begic This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.332-335 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/95/c7/MA-70-332.PMC5136426.pdf
"Adi Mulabdic,  Ismar Rasic, and Lejla Aksamija This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.369-372 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/eb/e6/MA-70-369.PMC5136427.pdf
"• It is now common to use the first classification because the anatomical site is of limited benefit in treatment and the causing organisms may be un-detected (1-5).ORIGINAL PAPER © 2016 Vesna Cukic and Armin Hadzic This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.354-358 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/f2/a0/MA-70-354.PMC5136428.pdf
2014. http://www.nice.org.uk/guidance/cg191 5.,Non-OADS,/arxiv_data1/oa_pdf/f2/a0/MA-70-354.PMC5136428.pdf
2014. https://www.britthoracic.org.uk/audit-and-quality-improvement/bts-care- bundles-for-cap-and-copd/ 6.,Non-OADS,/arxiv_data1/oa_pdf/f2/a0/MA-70-354.PMC5136428.pdf
"The histopathologic examination  showed hamartoma (Figure 4).CASE REPORT © 2016 Mojtaba Ahmadinejad, Asghar  Alie Pour, Peyman Khadem Hosseini, Amir Masoud Hashemian, and Koorosh Ahmadi This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.398-400 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/a7/c0/MA-70-398.PMC5136429.pdf
"According to unclear circumstances of his death, the deceased was transported to our CASE REPORT © 2016 Biserka Pigac and Silvija Masic This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.395-397 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/9c/47/MA-70-395.PMC5136430.pdf
"Bone is important in pharmacological sciences since different medications can either improve or worsen bone health, with different studies having analyzed the link between drug use and adverse effects in MSH, some of ORIGINAL PAPER © 2016 Ermira Krasniqi, Mynyr Koni,  Harald Tchan, Blerim Krasniqi, Antigona Kobashi and Arben Boshnjaku This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.359-363 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/e5/69/MA-70-359.PMC5136431.pdf
"NSQ, www.salute.gov.it; http://www.iss.it/chis/?lang=2 last accessed March 2015; 20. WHO, www.who.int.",OADS,/arxiv_data1/oa_pdf/e5/69/MA-70-359.PMC5136431.pdf
"Agjencia e Statistikave të Kosovës: http://ask.rks-gov.net/sq/, accessed on January 2016 35.",OADS,/arxiv_data1/oa_pdf/e5/69/MA-70-359.PMC5136431.pdf
"PATIENTS AND METHODS Forty patients with nasal septal  deviation for study group and 30 healthy adult volunteers participat - ed belonged to the control group ORIGINAL PAPER © 2016 Sekib Umihanic, Fuad Brkic,  Munevera Osmic, Sefika Umihanic, Suad Imamovic, Samir Kamenjakovic and Samir Hodzic This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.336-338 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/c2/42/MA-70-336.PMC5136432.pdf
"Thus,  uremic patients exhibit decreased levels of  apolipoproteins AI and AII, diminished activ - ity of lecithin-cholesterol acyl-transferase, as  well as increased activity of cholesteryl ester ORIGINAL PAPER © 2016 Valdete Topçiu–Shufta, Ramë  Miftari, Valdete Haxhibeqiri, Shpend Haxhibeqiri This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.348-350 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/08/aa/MA-70-348.PMC5136433.pdf
2013; 35( 6): 791-8. http://dx.doi.org/10.1155/2013/518945 2.,Non-OADS,/arxiv_data1/oa_pdf/08/aa/MA-70-348.PMC5136433.pdf
2010; 31: 2844 -53. doi: http://dx.doi.org/10.1093/eurheartj/ehq386  11.,Non-OADS,/arxiv_data1/oa_pdf/08/aa/MA-70-348.PMC5136433.pdf
"Since the secretion of FSH is in ORIGINAL PAPER © 2016 Zafer Gashi, Shkelzen Elezaj,  Afrim Zeqiraj, Driton Grabanica, Isak Shabani, Bujar Gruda and Fitore Gashi This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.364-368 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/37/59/MA-70-364.PMC5136434.pdf
"Previous methods of CHD screening (ultrasonography in the second tri-mester, postnatal examination of the PROFESSIONAL PAPER © 2016 Mediha Kardasevic, Ida Jovanovic  and Jelica Predojevic Samardzic This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.384-388 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/e5/0c/MA-70-384.PMC5136435.pdf
Available from:http://pediatrics.aappublications.org/con - tent/107/3/e32.full.Html.,Non-OADS,/arxiv_data1/oa_pdf/e5/0c/MA-70-384.PMC5136435.pdf
"HD-induced myo-cardial stunning driven by ischemia is a recognized complication of HD, which can be ameliorated by HD ORIGINAL PAPER © 2016 Hamidreza Omrani, Sanam  Golshani, Vahid Sharifi, Afshin Almasi and Masoud Sadeghi This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.328-331 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/11/ec/MA-70-328.PMC5136436.pdf
"This can be accomplished by opening the cranial vault and dura (7), or by re-moving non-viable or non-essential brain tissue (9).ORIGINAL PAPER © 2016 Zikrija Dostovic, Ernestina  Dostovic, Dzevdet Smajlovic, Omer C. Ibrahimagic and Leila Avdic This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.339-341 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/69/65/MA-70-339.PMC5136437.pdf
"BACKGROUND Ischaemic heart disease is the  commonest cause of death in many  countries, including Iran and coro-nary artery bypass grafting surgery (CABG) is one of the few treatment options for these patients (1).For on-pump coronary artery  bypass grafting surgery we cross-clamp the ascending aorta and con-sequently deprive cardiomyocytes of oxygenated blood, after surgical procedure releasing the cross-clamp ORIGINAL PAPER © 2016 Seyed Mahmoud Nouraei, Afshin  Gholipour Baradari and  Asieh Jazayeri This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.373-378 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/3b/7d/MA-70-373.PMC5136438.pdf
"It has been demonstrated that except long-lasting hospitaliza-tion, the inept elevation or turning of the patient, the folds of the sheets, and the foreign bodies such as food remains or fragments of plaster cast, were the most common risk factors contributing to the development of ORIGINAL PAPER © 2016 Konstantinos Tsaras, Maria  Chatzi, Christos F. Kleisiaris, Evangelos C. Fradelos, Lambrini Kourkouta and Ioanna V. Papathanasiou This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.379-383 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/cf/03/MA-70-379.PMC5136439.pdf
"Although the R-CHOP is the best existing first-line therapy for DLBCL, it is curative in about ORIGINAL PAPER © 2016 Alma Sofo-Hafizovic, Adisa  Chikha, Refet Gojak, and Emina Suljovic Hadzimesic This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.342-347 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/51/94/MA-70-342.PMC5136440.pdf
"Accessory spleens are found near the splenic hilum, in the gastrosplenic ligament, in the sple-norenal ligament, in the mesentery, in the greater omentum, around the CASE REPORT © 2016 Shabnam Mohammadi, Arya  Hedjazi, Maryam Sajjadian, Naser Ghrobi, Maliheh Dadgar Moghadam and Maryam Mohammadi This is an Open Access article distributed  under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/ ) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi: 10.5455/medarh.2016.70.389-391 Med Arch.",Non-OADS,/arxiv_data1/oa_pdf/a2/75/MA-70-389.PMC5136441.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/7b/42/jjm-09-10-33879.PMC5136442.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/2e/33/jjm-09-10-20224.PMC5136443.pdf
Avail- able from: http://apps.who.int/iris/bitstream/10665/191102/1/ 9789241565059_eng.pdf?ua=1 .,Non-OADS,/arxiv_data1/oa_pdf/2e/33/jjm-09-10-20224.PMC5136443.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/1e/02/jjm-09-10-36070.PMC5136444.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5c/9b/jjm-09-10-37897.PMC5136445.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/84/04/jjm-09-10-36135.PMC5136446.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/df/43/jjm-09-10-37148.PMC5136447.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f8/db/jjm-09-10-36617.PMC5136448.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5f/f4/jjm-09-10-33990.PMC5136449.pdf
"The types of 16S rRNA methyltransferase, carbapenemase, and ESBL genes were identiﬁed by com- paring them with sequences from the GenBank database (http://blast.ncbi.nlm.nih.gov/Blast.cgi).",OADS,/arxiv_data1/oa_pdf/5f/f4/jjm-09-10-33990.PMC5136449.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/9a/9a/jjm-09-10-29147.PMC5136450.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f7/3e/jjm-09-10-35591.PMC5136451.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/2b/8d/jjm-09-10-36666.PMC5136452.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/19/aa/ijem-14-03-36080.PMC5136456.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f0/03/ijem-14-03-37123.PMC5136457.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/2c/bc/ijem-14-03-32444.PMC5136462.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6f/a7/ijem-14-03-36317.PMC5136464.pdf
"To view a copy of thislicense, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ rThe Author(s) 2016 Supplementary Information accompanies this paper on Cell Death and Differentiation website (http://www.nature.com/cdd)Post-translational modi ﬁcation of AMPK by PARylation JM Rodríguez-Vargas et al 2018 Cell Death and Differentiation",Non-OADS,/arxiv_data1/oa_pdf/c7/26/cdd201680a.PMC5136490.pdf
Population and Projection for Japan:  2011 to 2060. http://www.ipss.go.jp/site-ad/index_english/ esuikei/gh2401e.asp .,Non-OADS,/arxiv_data1/oa_pdf/1c/37/indhealth-54-477.PMC5136603.pdf
2014. http://www.stat.go.jp/english/data/ nenkan/1431-02.htm .,OADS,/arxiv_data1/oa_pdf/a1/0f/indhealth-54-480.PMC5136604.pdf
http://www.gender.go.jp/ english_contents/about_danjo/whitepaper/pdf/ewp2004.,Non-OADS,/arxiv_data1/oa_pdf/a1/0f/indhealth-54-480.PMC5136604.pdf
2016. http://www.nsf.gov/ statistics/2016/nsb20161/#/report/chapter-2/international-s- e-higher-education/s-e-first-university-degrees-by-sex .,Non-OADS,/arxiv_data1/oa_pdf/a1/0f/indhealth-54-480.PMC5136604.pdf
http://www.djrenrakukai.org/doc_pdf/3rd_enq_report_en.,OADS,/arxiv_data1/oa_pdf/a1/0f/indhealth-54-480.PMC5136604.pdf
2002. http://www.djrenrakukai.org/orga - nizations.html .,OADS,/arxiv_data1/oa_pdf/a1/0f/indhealth-54-480.PMC5136604.pdf
https://www.teikyo-u.ac.jp/university/ upload/8-1_daigaku_senninkyoin_danjyobetu2016.pdf .,Non-OADS,/arxiv_data1/oa_pdf/a1/0f/indhealth-54-480.PMC5136604.pdf
https://www.teikyo-u.ac.jp/university/ upload/9-1_daigaku_senninkyoin_nenreibetu2016.pdf .,Non-OADS,/arxiv_data1/oa_pdf/a1/0f/indhealth-54-480.PMC5136604.pdf
March 2015. http://sukoyaka21.jp/pdf/H27manyual_ yamazaki.pdf .,Non-OADS,/arxiv_data1/oa_pdf/95/f1/indhealth-54-488.PMC5136605.pdf
http://sukoyaka21.jp/ .,Non-OADS,/arxiv_data1/oa_pdf/95/f1/indhealth-54-488.PMC5136605.pdf
http://sukoyaka21.jp/ english.html .,Non-OADS,/arxiv_data1/oa_pdf/95/f1/indhealth-54-488.PMC5136605.pdf
"Annual  Health, Labour and Welfare Report 2015. http://www.mhlw.",Non-OADS,/arxiv_data1/oa_pdf/95/f1/indhealth-54-488.PMC5136605.pdf
http://www8.cao.go.jp/shoushi/shoushika/whitepa - per/measures/w-2015/27webgaiyoh/indexg.html .,Non-OADS,/arxiv_data1/oa_pdf/94/93/indhealth-54-498.PMC5136606.pdf
http://www.ilo.org/public/english/bureau/stat/isco/isco08/ index.htm .,Non-OADS,/arxiv_data1/oa_pdf/94/93/indhealth-54-498.PMC5136606.pdf
"[Medline]  [CrossRef] 25) Statistics Bureau, Japan Ministry of Internal affairs and  Communications (2011) Survey on time use and lei - sure activities 2011. http://www.stat.go.jp/english/data/ shakai/2011/gaiyo.htm .",OADS,/arxiv_data1/oa_pdf/94/93/indhealth-54-498.PMC5136606.pdf
http://www.jil.go.jp/press/ documents/20101207.pdf  (in Japanese).,Non-OADS,/arxiv_data1/oa_pdf/94/93/indhealth-54-498.PMC5136606.pdf
"[Medline]  [CrossRef]  7) Ministry of Health, Labour and Welfare (2007) Survey on  State of Employees’ Health 2007. http://www.mhlw.go.jp/ toukei/itiran/roudou/saigai/anzen/kenkou07/ .",Non-OADS,/arxiv_data1/oa_pdf/3e/20/indhealth-54-505.PMC5136607.pdf
70歳雇用に向けた高年 齢者の体力等に関する調査研究結果  http://www.jeed.or.,Non-OADS,/arxiv_data1/oa_pdf/3e/20/indhealth-54-505.PMC5136607.pdf
http://www.who.int/ dietphysicalactivity/factsheet_recommendations/en/ .,Non-OADS,/arxiv_data1/oa_pdf/3e/20/indhealth-54-505.PMC5136607.pdf
2014. http://www.stat.go.jp/english/data/ nenkan/1431-02.htm .,OADS,/arxiv_data1/oa_pdf/88/8e/indhealth-54-515.PMC5136608.pdf
http://www.ilo.org/ilostat/faces/home/statisticaldata/ ContryProfileId?_adf.ctrl-state = 152gz252kr_158&_   afrLoop = 1204527589690526 .,OADS,/arxiv_data1/oa_pdf/88/8e/indhealth-54-515.PMC5136608.pdf
"Statistics Catalogue  table1, http://www.mhlw.go.jp/file/04-Houdouhappyou- 10904750-Kenkoukyoku-Gantaisakukenkouzoushi nka/0000117311.pdf .",Non-OADS,/arxiv_data1/oa_pdf/88/8e/indhealth-54-515.PMC5136608.pdf
2014. http://www.mhlw.go.jp/wp/hakusyo/kousei/14/ backdata/1-2-2-21.html .,Non-OADS,/arxiv_data1/oa_pdf/88/8e/indhealth-54-515.PMC5136608.pdf
http://www.nhlbi.nih.gov/health/ educational/lose_wt/risk.htm .,Non-OADS,/arxiv_data1/oa_pdf/88/8e/indhealth-54-515.PMC5136608.pdf
2006. http://www8.cao.go.jp/syokuiku/data/eng_pamph/ .,OADS,/arxiv_data1/oa_pdf/88/8e/indhealth-54-515.PMC5136608.pdf
Labour Force Survey 2015. http://www.stat.go.jp/ data/roudou/sokuhou/4hanki/dt/index.htm .,OADS,/arxiv_data1/oa_pdf/dd/93/indhealth-54-521.PMC5136609.pdf
Survey on Salary in Private Sector  2013 https://www.nta.go.jp/kohyo/tokei/kokuzeicho/ minkan2013/minkan.htm .,Non-OADS,/arxiv_data1/oa_pdf/dd/93/indhealth-54-521.PMC5136609.pdf
Table 4  (Total) http://www.e-stat.go.jp/SG1/estat/List.do?bid =   000001015843&cycode= 0.,OADS,/arxiv_data1/oa_pdf/dd/93/indhealth-54-521.PMC5136609.pdf
"19) Special Report on the Longitudinal Survey of Newborns in  the 21st Century and the Longitudinal Survey of Adults in  the 21st Century: Ten-Year Follow-up, 2001 – 2011, Figure  2 (in Japanese) http://www.mhlw.go.jp/toukei/saikin/hw/ judan/tokubetsu13/index.html .",Non-OADS,/arxiv_data1/oa_pdf/dd/93/indhealth-54-521.PMC5136609.pdf
http://www8.cao.go.jp/youth/whitepaper/h26honpen/ b1_03_03.html  (in Japanese).,Non-OADS,/arxiv_data1/oa_pdf/dd/93/indhealth-54-521.PMC5136609.pdf
Time Use and Leisure Activities Survey 2011.  http://www.stat.go.jp/data/shakai/2011/gaiyou.htm .,OADS,/arxiv_data1/oa_pdf/dd/93/indhealth-54-521.PMC5136609.pdf
School Basic Survey 2015. http://www.e-stat.go.jp/ SG1/estat/List.do?bid = 000001015843&cycode = 0 .,Non-OADS,/arxiv_data1/oa_pdf/dd/93/indhealth-54-521.PMC5136609.pdf
http://www.tac.vic.gov.,Non-OADS,/arxiv_data1/oa_pdf/15/48/indhealth-54-528.PMC5136610.pdf
http://roadsafety.transport.nsw.gov.au/ stayingsafe/fatigue/stoprevivesurvive.html .,Non-OADS,/arxiv_data1/oa_pdf/15/48/indhealth-54-528.PMC5136610.pdf
http://think.direct.gov.uk/ fatigue.html .,Non-OADS,/arxiv_data1/oa_pdf/15/48/indhealth-54-528.PMC5136610.pdf
http://www.mhlw.,Non-OADS,/arxiv_data1/oa_pdf/4e/61/indhealth-54-564.PMC5136614.pdf
"ORIGINAL ARTICLE Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease Brian Lipworth,1Derek Skinner,2Graham Devereux,3Victoria Thomas,4 Joanna Ling Zhi Jie,5Jessica Martin,6Victoria Carter,2David B Price5,7 1Scottish Centre for Respiratory Research, University of Dundee, Dundee, UK 2Optimum Patient Care, Cambridge, UK 3Applied Health Sciences, University of Aberdeen,Aberdeen, UK 4Cambridge Research Support, Cambridge, UK 5Observational and Pragmatic Research Institute, Singapore,Singapore 6Research in Real Life, Cambridge, UK 7Centre for Academic Primary Care, University of Aberdeen, Aberdeen, UK Correspondence to Dr Brian Lipworth, ScottishCentre for Respiratory Research, University of Dundee, Ninewells Hospitaland Medical School,Dundee DD1 9SY, UK; b.j.lipworth@dundee.ac.uk Received 10 February 2016 Revised 31 May 2016Accepted 7 June 2016 Published Online First 5 July 2016 ▸http://dx.doi.org/10.1136/ heartjnl-2016-310557 ▸http://dx.doi.org/10.1136/ heartjnl-2016-310579 To cite: Lipworth B, Skinner D, Devereux G, et al.Heart 2016; 102:1909 –1914.ABSTRACT Objective Although β-blockers are an established therapy in heart failure (HF) guidelines, including forpatients with chronic obstructive pulmonary disease(COPD), there remain concerns regardingbronchoconstriction even with cardioselective β-blockers.",Non-OADS,/arxiv_data1/oa_pdf/16/6c/heartjnl-2016-309458.PMC5136686.pdf
"See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1 Lozano R, Naghavi M, Foreman K, et al.",Non-OADS,/arxiv_data1/oa_pdf/16/6c/heartjnl-2016-309458.PMC5136686.pdf
See: http://creativecommons.org/ licenses/by-nc/4.0/ REFERENCES 1 Lemp MA.,Non-OADS,/arxiv_data1/oa_pdf/83/97/bjophthalmol-2015-306930.PMC5136692.pdf
METHODS Source population A cohort study was conducted within the Clinical Practice Research Datalink (CPRD) (http://www.cprd.com).,OADS,/arxiv_data1/oa_pdf/d3/a5/annrheumdis-2015-208958.PMC5136695.pdf
"Competing interests The Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, employing authors CKand FdV, has received unrestricted funding from the Netherlands Organisation for Health Research and Development (ZonMW), the Dutch Health Care Insurance Board (ZIN), the Royal Dutch Pharmacists Association (KNMP), the private –public funded Top Institute Pharma (http://www.tipharma.nl), includes cofunding fromuniversities, government and industry, the EU Innovative Medicines Initiative (IMI), the EU 7th Framework Program (FP7), the Dutch Ministry of Health and industry (including GlaxoSmithKline, P ﬁzer and others); HGML is a researcher at The WHO Collaborating Centre for Pharmaceutical Policy and Regulation, which receives nodirect funding or donations from private parties, including pharma industry.",Non-OADS,/arxiv_data1/oa_pdf/d3/a5/annrheumdis-2015-208958.PMC5136695.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ REFERENCES 1 Kaz H, Johnson D, Kerry S, et al.",Non-OADS,/arxiv_data1/oa_pdf/d3/a5/annrheumdis-2015-208958.PMC5136695.pdf
http://ncook.bwh.harvard.edu/sas-macros.html (assessed 26 Sept 2015).,OADS,/arxiv_data1/oa_pdf/d3/a5/annrheumdis-2015-208958.PMC5136695.pdf
To viewplease visit the journal online(http://dx.doi.org/10.1136/ annrheumdis-2015-208029).,OADS,/arxiv_data1/oa_pdf/be/08/annrheumdis-2015-208029.PMC5136696.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ REFERENCES 1 Allanore Y, Distler O.",Non-OADS,/arxiv_data1/oa_pdf/be/08/annrheumdis-2015-208029.PMC5136696.pdf
"See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1 Hill NS, Brennan J, Garpestad E. Non-invasive ventilation in acute respiratory failure.",Non-OADS,/arxiv_data1/oa_pdf/39/ef/emermed-2015-205377.PMC5136697.pdf
http://www.ambulance.nsw.gov.au/about-us/aeromedical.html(accessed 21 Dec 2014).,Non-OADS,/arxiv_data1/oa_pdf/39/ef/emermed-2015-205377.PMC5136697.pdf
2011. http://www.abs.,Non-OADS,/arxiv_data1/oa_pdf/39/ef/emermed-2015-205377.PMC5136697.pdf
http://www.draeger.net/media/10/ 08/29/10082917/9066099_Oxylog_3000_plus_EN_170510.pdf (accessed 20 Jan2015).,Non-OADS,/arxiv_data1/oa_pdf/39/ef/emermed-2015-205377.PMC5136697.pdf
To view please visit the journal online(http://dx.doi.org/10.1136/thoraxjnl-2016-208481).,Non-OADS,/arxiv_data1/oa_pdf/37/9d/thoraxjnl-2016-208481.PMC5136700.pdf
"All authors were involved in writing and revising the article before submission.Funding This study was funded by the European Respiratory Society through a Clinical Research Collaboration grant to EMBARC, the European BronchiectasisRegistry (https://www.bronchiectasis.eu/).",Non-OADS,/arxiv_data1/oa_pdf/37/9d/thoraxjnl-2016-208481.PMC5136700.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ REFERENCES 1 Chalmers JD, Aliberti S, Blasi F. State of the Art: management of bronchiectasis in adults.",Non-OADS,/arxiv_data1/oa_pdf/37/9d/thoraxjnl-2016-208481.PMC5136700.pdf
To viewplease visit the journal online (http://dx.doi.org/10.1136/ gutjnl-2016-312043).,OADS,/arxiv_data1/oa_pdf/97/44/gutjnl-2016-312043.PMC5136701.pdf
"See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1 Atkin WS, Edwards R, Kralj-Hans I, et al.",Non-OADS,/arxiv_data1/oa_pdf/97/44/gutjnl-2016-312043.PMC5136701.pdf
"Secondary UK Cancer Incidence (2010) and Mortality (2010)Summary, December 2012, 2012. http://publications.cancerresearchuk.org/ downloads/Product/CS_DT_INCMORTRATES.pdf 34 Baxter NN, Sutradhar R, Forbes SS, et al.",Non-OADS,/arxiv_data1/oa_pdf/97/44/gutjnl-2016-312043.PMC5136701.pdf
To viewplease visit the journal online(http://dx.doi.org/10.1136/ annrheumdis-2015-208476).,OADS,/arxiv_data1/oa_pdf/67/9f/annrheumdis-2015-208476.PMC5136702.pdf
"See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1 Chang X, Wei C. Glycolysis and rheumatoid arthritis.",Non-OADS,/arxiv_data1/oa_pdf/67/9f/annrheumdis-2015-208476.PMC5136702.pdf
To view please visit the journal online(http://dx.doi.org/10.1136/annrheumdis-2015-208444).,Non-OADS,/arxiv_data1/oa_pdf/8d/2f/annrheumdis-2015-208444.PMC5136703.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ REFERENCES 1 Konttinen YT, Kemppinen P, Segerberg M, et al.",OADS,/arxiv_data1/oa_pdf/8d/2f/annrheumdis-2015-208444.PMC5136703.pdf
"Table 1 The Informed Consent and Assent Tool Kit —informed consent requirements for paediatric clinical trials in Europe Consent/assent from child* Consent from parent(s)/guardian(s) General informed consent information CountryLegal age of consent †Mandatory/suggested age ranges defined for assent(or consent if assent notused) ‡ Number of required signatoriesOfficial language requirements Consent template(s)/guidelines/information sources Austria Not specifiedPractice –– 14 years8–13 years EC may require youngerassentsBoth parents German http://www.medunigraz.at/ethikkommission/Forum/index.htm http://www.ethikkommissionen.at/http://www.uibk.ac.at/strafrecht/scheil/scheil-einfuehrung-in-die-arzneimittelpruefung-bei-kindern-und-jugendlichen---kks--kids-ip.pdf Belgium 18 years 4 –11 years (some sites do not use under 12 years) 12–14 years 14–17 yearsOne parent at recruitment, but both parents at some point for signaturesDutch, French; German at site requesthttp://www.fagg-afmps.be/en/human_use/medicines/medicines/research_development/ethic_ committee/templates_informed_consent/ Do not have paediatric templates Bulgaria 18 years 6 –11 years 12–14 years 14–17 years —use own consent+parental signature also requiredBoth parents Bulgarian No national EC websites available in English Bulgarian Drug Agency -> clinical trialshttp://en.bda.bg/index.php?option=com_ content&view=category&layout=blog&id=14&Itemid=34 Croatia Nothing specifiedNothing specified Nothing specified Croatian Agency for Medicinal Products and Medical Devices of Croatia -> Central Ethics Committee -> http://www.almp.hr/?ln=en&w=o_SEPuInformation on clinical trials not available in English.",Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
"Where the child ’s parents (or one of them) are foreign nationals, the information sheetshall be presented in bilingualformat.State Institute for Drug Control -> Details of clinical trials / Guidelines and Forms / KLH-22 V.1: http://www.sukl.eu/medicines/klh-22-version-1 Denmark 18 years 15 –17 years ––proxy consent Both parents Exception —no parents if aged 15 –17 and non-interventional no-risk study(EC dispensation required)Danish The National Committee on Health Research Ethics -> Guidelines about notification http://www.cvk.sum.dk/CVK/Home/English.aspx http://cvk.sum.dk/English/guidelinesaboutnotification.aspx -> 4.4.",Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
"Medicinal product trials and clinical investigations of medicinal devices involving legally incompetent subjects; 4.4.1 Trialswith children and young people under the age of 18 http://cvk.sum.dk/English/guidelinesaboutnotification.aspx#Afsnit%205.0 Act on Research Ethics Review of Health Research Projects Estonia 18 years 0 –7 years 7–17 years ––mandatoryBoth parents Estonian State Agency of Medicine -> Clinical trials -> Conditions and procedure for conducting clinical trials of medicinal productshttp://www.ravimiamet.ee/en/clinical-trials-medicinal-products-estonia Finland 15 years Written separate consent as soon as child is literate; under 15 years ––own consent +parental consent;15–17 years ––own consent +parental notification if minor can understand thesignificance of research+directhealth benefit is expectedParent or legal guardian and the child, when they are literate, need to sign the consent.",Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
Table 1 Continued Consent/assent from child* Consent from parent(s)/guardian(s) General informed consent information CountryLegal age of consent †Mandatory/suggested age ranges defined for assent (or consent if assent notused) ‡ Number of required signatoriesOfficial language requirements Consent template(s)/guidelines/information sources France 18 years Based on EC —usually two or three age groups 4–6 years 7–12 years 13–17 years Picture ICFs for young childrenBoth parents French Comité de Protection des Personnes Sud-Méditerranée II : http://www.cpp-sudmed2.fr/ Information-et-autorisation-des?lang=fr National Consultative Ethics Committee for Health and Life Sciences: http://www.ccne-ethique.fr/en Germany 18 years 7 –11 years 12–16 years 17 years ––own consent +parental consent requiredBoth parents German German Ethics Council; http://www.ethikrat.org/ —no information for clinical trials Landesärztekammer Brandenburg —information available ONLY in German.,Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
https://www.laekb.de/ICF Guidance https://www.laekb.de/files/146A97FF999/AMG_Patienteninfo_Kinder_7bis11.pdf Hungary 18 years Under 6 years 6–10 years 11–14 years 15–17 yearsOne parent Hungarian National Institute of Pharmacy and Nutrition -> Laws and regulations (only available in Hungarian) -> Miniszteri rendeletekhttp://ogyei.gov.hu/search/index.php?searchPhrase=decree&from=10http://www.ogyei.gov.hu/magyar_jogszabalyok/ -> Decree 35/2005 (VIII.,Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
of the Minister of Health on the clinical trial and application of correct clinical practices of investigational medicinal products intended for use in humans7§ Clinical trials conducted on minorshttp://net.jogtar.hu/jr/gen/getdoc.cgi?docid=A0500035.eum Iceland 18 years Under 12 years One parent —the EC can request both parents ’signatures in some cases.Icelandic or English.,Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
")The National Bioethics Committee (http://www.vsn.is/en/node/189) The Parliament; http://www.althingi.is/english -> http://www.althingi.is/lagasafn/log-samthykkt-a-althingi/ ->The Act of Law, No.",Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
"44/2014, on scientific research within the health sector defines the conditions for biomedical research and the role of the bioethics committees http://www.althingi.is/lagas/nuna/2014044.htmlSeveral laws and regulations on data protection, medicines, biobanks and health informationcollections (2014), etc Ireland 16 years (clinical trials)18 years(all other research)7 years, or according to capacity of childOne parent English List of Research Ethics Committees for clinical trials of IMP: http://health.gov.ie/ european-communities-clinical-trials-on-medicinal-products-for-human-use-regulations-2004/Research Ethics Committee Standard Application Form:http://www.molecularmedicineireland.ie/research_ethics National Consent Policy: http://www.hse.ie/eng/about/Who/qualityandpatientsafety/National_ Consent_Policy/consenttrainerresource/trainerfiles/NationalConsentPolicyDOC.htmlClinical Trial Regulation: S.I.",Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
"190/2004 —European Communities (Clinical Trials on Medicinal Products For Human Use) Regulations, 2004 http://www.irishstatutebook.ie/2004/en/si/0190.html Continued 1020 Lepola P, et al.Arch Dis Child 2016; 101:1017 –1025.",Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
"Differentage-tailored assents aresubmitted voluntarily, and are evaluated by the ECsBoth parents Italian The Italian Medicines Agency http://www.agenziafarmaco.gov.it/en/content/clinical-trials the Italian regulation on CTs include the following:D.lgs 211/2003 http://www.agenziafarmaco.gov.it/sites/default/files/decreto_24062003_inglese.pdf DM 21/12/07 https://www.agenziafarmaco.gov.it/ricclin/sites/default/files/files_wysiwyg/files/ Normativa/MD_21_December_2007_CTAform_English.pdf Latvia 18 years 0 –7 years 7–17 yearsOne parent or legal representative Latvian State Agency of Medicines of the Republic of Latvia -> Clinical trials and non-interventional trials -> legislation http://www.zva.gov.lv/?setlang=en -> http://www.zva.gov.lv/?id=396&sa=396&top=386 ->http://www.zva.gov.lv/index.php?id=381&sa=381&top=333&langhttp://www.zva.gov.lv/doc_upl/MK_not_289_English_02062010.pdf Lithuania 18 years No set ages Both parents Lithuanian The Lithuanian Bioethics Committee -> Biomedical Research -> favourable opinion on clinical drug trial http://bioetika.sam.lt/index.php?3202747546Informed Consenthttp://bioetika.sam.lt/index.php?3221858831 -> http://bioetika.sam.lt/index.php?577320631 —information available only in Lithuanian http://bioetika.sam.lt/index.php?3202747546 Malta 18 years 6 –17 years Parents or legal representative Practice —both parentsOne of the official languages of Malta (eg, Maltese) or in alanguage understandable to the clinical trial subject and/or his legalrepresentative.Malta Health Ethics Committee https://health.gov.mt/en/appbodies/hec/Pages/Links.aspxMaltese Clinical Trials Regulations 2004 (LN490 of 2004) MEDICINES ACT, 2003 (ACT NO.",Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
III OF 2003); http://justiceservices.gov.mt/DownloadDocument.aspx?app=lp&itemid=16860&l=1 The Netherlands18 years 12 –17 years Both parents.,Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
"http://www.ccmo.nl/en/ -> http://www.ccmo.nl/en/minors Continued Lepola P, et al.Arch Dis Child 2016; 101:1017 –1025.",Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
Table 1 Continued Consent/assent from child* Consent from parent(s)/guardian(s) General informed consent information CountryLegal age of consent †Mandatory/suggested age ranges defined for assent(or consent if assent notused) ‡ Number of required signatoriesOfficial language requirements Consent template(s)/guidelines/information sources Norway 18 years 16 –17 years ––with own signature12–16 years ––in special circumstancesMain rule: both parents sign the consent form if they have parentalresponsibility for the child.Required for all children under 12 years old.Norwegian The Norwegian National Research Ethics Committees -> Clinical Trials -> Regulations https://www.etikkom.no/en/ethical-guidelines-for-research/http://www.legemiddelverket.no/English/Clinical_trials/Regulations/Documents/Norwegian%20regualtion%20for%20Clinical%20Trials.pdf National database for Laws and Acts -> Lov om medisinsk og helsefaglig forskning (helseforskningsloven) —information available only in Norwegian.,Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
https://lovdata.no/dokument/NL/lov/2008-06-20-44?q=helseforskningAct on medical and health research (Helseforsknings-loven) Guidance to Helseforsknings-loven (in Norwegian only) Additional info: Norwegian Medicines Agency: Website on clinical trials.,Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
"Poland 18 years 6 –11 years 12–15 years 16–17 yearsOne parent Practice —both parentsPolish http://www.eurecnet.org/information/poland.html No national EC websites available in English Portugal 18 years 0 –8 years 8–12 years 12–17 yearsBoth parents Portuguese http://www.eurecnet.org/information/portugal.html CEIC—National Ethics Committee for Clinical Research http://www.infarmed.pt/portal/page/portal/CEIC/English No national regulations/acts available in English Romania 18 years Under 6 years 6–10 years 11–14 years 15–18 yearsBoth parents Romanian National Ethics Committee of Romania http://www.adsm.ro/ro/comisia+nationala+de+bioetica+a+medicamentului+si+a+dispozitivelor+medicale# No information available in English Scotland (UK)16 years 0 –5 years 6–10 years 11–15 years Consent with own signature under 16 years, if they are competent to do soOne parent English NRES Guidance http://www.hra-decisiontools.org.uk/consent/principles-children.html andhttp://www.ukctg.nihr.ac.uk/default.aspx Slovakia n.a.",Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
Slovakian The State Institute for Drug Control (SIDC) -> Clinical trials -> Instructions http://www.sukl.sk/en?page_id=256 ->http://www.sukl.sk/en/clinical-trials/instructions?page_id=2821 No national regulations/acts available in English Slovenia 18 years 9 years —assent 15 years —with own signatureOne parent Slovenian Republic of Slovenia National Medical Ethics Committee -> http://kme-nmec.si/ —only front page No additional information available.,Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
"Spain 18 years 0 –11 years 12–17 years ––with own signatureOne parent Spanish The Agencia Española de Medicamentos y Productos Sanitarios (AEMPS); A state agency within the Spanish Ministry of Health, Social Services and Equality -> Medicines for Human use —> Clinical research with medicines http://www.aemps.gob.es/en/investigacionClinica/medicamentos/home.htmThe Ministry of Health, section about regulation of clinical trials:http://www.aemps.gob.es/en/legislacion/espana/investigacionClinica/ensayos.htm The Spanish Regulation about Clinical trials: the ROYAL DECREE 223/2004-section 7.3 (English version is available by request) Continued 1022 Lepola P, et al.Arch Dis Child 2016; 101:1017 –1025.",Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
"Table 1 Continued Consent/assent from child* Consent from parent(s)/guardian(s) General informed consent information CountryLegal age of consent †Mandatory/suggested age ranges defined for assent(or consent if assent notused) ‡ Number of required signatoriesOfficial language requirements Consent template(s)/guidelines/information sources Sweden 18 years Written separate consent as soon as child is literate6–10 years 11–14 years 15–17 years ––with own signatureBoth parents and the child, when literate, need to sign the consentSwedish The Central Ethical Review Board -> Documents -> Information for Research Participants http://www.epn.se/en/start/the-organisation/ -> http://www.epn.se/en/start/central-ethical-review-board-documents/ -Etikprövningslagen 2008.Regulatory requirement for clinical trials LVFS 2011:19 Läkemedelslagen —1992 Biobank law ––2002 Personal Data Act 1998National Medicines Agency -> Legislation -> Codes of Statutes -> 1996:17 Clinical trials of medicinal products https://lakemedelsverket.se/english/ -> https://lakemedelsverket.se/english/overview/Legislation/Codes-of-statutes/ UK 16 years 0 –5 years 6–10 years 11–15 yearsOne parent English NRES Guidance; http://www.hra-decisiontools.org.uk/consent/principles-children.html andhttp://www.ukctg.nihr.ac.uk/default.aspx © European Medicines Agency, 2015.",Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
"This toolkit being publiclyavailable free of cost on the Enpr-EMA website meets this aim.Please go to: http://www.ema.europa.eu/Partners&Networks/Networks/Enpr-EMA/Enpr-EMA activities, or directly at: http://tinyurl.com/h2xrlvr.",Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1 European Union.,Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
26 January 2007. http://ec.europa.eu/health/ﬁles/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf (accessed 16 Dec 2014).,Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
http://ec.europa.eu/health/human-use/clinical-trials/ regulation/index_en.htm (accessed 16 Dec 2014).,Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
1990. http://www.ohchr.org/en/professionalinterest/pages/crc.aspx (accessed 15 Dec 2014).,Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
1948. http://www.un.,Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
"64th WMA General Assembly,Fortaleza, Brazil, October 2013. http://www.wma.net/en/30publications/10policies/b3/ (accessed 15 Dec 2014).",Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
1996. http://www.ich.org/products/guidelines/ef ﬁcacy/article/ efﬁcacy-guidelines.html (accessed 16 Dec 2014).,Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
2000. http://www.ich.org/products/ guidelines/ef ﬁcacy/article/ef ﬁcacy-guidelines.html (accessed 16 Dec 2014).,Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
1995. http://www.nus.edu.sg/irb/Articles/WHO%20GCP%201995.pdf (accessed 15 Dec 2014).,Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
2002. http://apps.who.int/prequal/info_general/ documents/GCP/gcp1.pdf (accessed 15 Dec 2014).,OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
06 October 2008. http://ec.europa.eu/health/ ﬁles/paediatrics/docs/paeds_ethics_consultation20060929_en.pdf (accessed 9 Feb 2015).,Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
http://ec.europa.eu/health/human-use/clinical-trials/directive/index_en.htm (accessed 16 Dec 2014).,Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
February 2006. http://ec.europa.eu/ health/documents/eudralex/vol-10/index_en.htm (accessed 16 Dec 2014).,Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
"Detailed guidance on the application format anddocumentation to be submitted in an application for an Ethics Committee opinion on the clinical trial on medici nal products for human use, February 2006. http://ec.europa.eu/health/ ﬁles/eudralex/vol-10/12_ec_guideline_ 20060216_en.pdf 17 PRA Health Sciences International, http://prahs.com/ (accessed 9 Feb 2015).",Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
"18 Regulinx, UK, http://www.regulinx.eu/ (accessed 9 Feb 2015).",Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
2014. http://www.hc-sc.gc.ca/ sr-sr/advice-avis/reb-cer/consent/index-eng.php (accessed 16 Dec 2014).,Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
"50. http:// www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=50, 201 http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?",Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
"CFRPart=201, 814 http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=814 (accessed 16 Dec 2014).",OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
UK Medical Research Council 2004. http://www.mrc.ac.uk/documents/pdf/ medical-research-involving-children/ (accessed 9 Feb 2015).,Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
"TCPS 2 —2nd edition of Tri-Council Policy Statement:Ethical Conduct for Research Involving Humans, 2010. http://www.pre.ethics.gc.ca/eng/ policy-politique/initiatives/tcps2-eptc2/default/ 24 U.S. Department of Health and Human Services.",Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
"Ethical Research Involving Children; Ethical Guidance: Informed Consent, 2013. http://childethics.com/wp-content/uploads/2013/10/ERIC-compendium-Ethical-Guidance-Informed-consent-section-only.pdf (accessed 25 Feb 2015).",Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
"NordForsk, 2014 Stensberggata 25 N –0170 Oslo, http://www.nordforsk.org.",Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
ISSN 1504-8640 http://www.nordforsk.org/en/publications/publications_container/ legislation-on-biotechnology-in-the-nordic-countries-2013-an-overview-2014/view (accessed 11 Dec 2014).,Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
http://ec.europa.eu/health/ ﬁles/paediatrics/2012-09_ pediatric_report-annex1-2_en.pdf (accessed 13 Dec 2013).,Non-OADS,/arxiv_data1/oa_pdf/65/87/archdischild-2015-310001.PMC5136704.pdf
To view please visit the journal online(http://dx.doi.org/10.1136/emermed-2015-205444).,Non-OADS,/arxiv_data1/oa_pdf/95/22/emermed-2015-205444.PMC5136705.pdf
See: http://creativecommons.org/ licenses/by-nc/4.0/ REFERENCES 1 Statistics Denmark.,Non-OADS,/arxiv_data1/oa_pdf/95/22/emermed-2015-205444.PMC5136705.pdf
http://www.dst.dk/en 2 OECD.Stat.,Non-OADS,/arxiv_data1/oa_pdf/95/22/emermed-2015-205444.PMC5136705.pdf
"http://stats.oecd.org/3 Rosman M, Rachminov O, Segal O, et al.",OADS,/arxiv_data1/oa_pdf/95/22/emermed-2015-205444.PMC5136705.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1 Eschenbach DA.,Non-OADS,/arxiv_data1/oa_pdf/f6/c0/sextrans-2015-052475.PMC5136707.pdf
To view please visit the journal online(http://dx.doi.org/10.1136/gutjnl-2016-311964).,Non-OADS,/arxiv_data1/oa_pdf/1e/4e/gutjnl-2016-311964.PMC5136710.pdf
"),University of Bologna, St. Orsola-Malpighi Hospital, Bologna, Italy 3Celiac Disease Center, Columbia University Medical Center, New York, New York, USA 4Institute of Human Nutrition, Columbia University Medical Center, New York, New York, USA Correspondence to Dr Armin Alaedini, Department of Medicine, Columbia University Medical Center,1130 Saint Nicholas Ave.,Room 937; New York, NY 10032, USA; aa819@columbia.edu Received 31 March 2016 Revised 9 June 2016 Accepted 20 June 2016 Published Online First26 July 2016 ▸http://dx.doi.org/10.1136/ gutjnl-2016-312471 To cite: Uhde M, Ajamian M, Caio G, et al.",Non-OADS,/arxiv_data1/oa_pdf/1e/4e/gutjnl-2016-311964.PMC5136710.pdf
"See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1 Guandalini S, Assiri A. Celiac disease: a review.",Non-OADS,/arxiv_data1/oa_pdf/1e/4e/gutjnl-2016-311964.PMC5136710.pdf
"See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1 James C, Ugo V, Le Couédic JP, et al.",Non-OADS,/arxiv_data1/oa_pdf/83/a7/jclinpath-2016-203625.PMC5136711.pdf
To viewplease visit the journal online (http://dx.doi.org/10.1136/ neurintsurg-2015-012209).,OADS,/arxiv_data1/oa_pdf/36/07/neurintsurg-2015-012209.PMC5136713.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ REFERENCES 1 Saver JL, Goyal M, Bonafe A, et al .",Non-OADS,/arxiv_data1/oa_pdf/36/07/neurintsurg-2015-012209.PMC5136713.pdf
To viewplease visit the journal online (http://dx.doi.org/10.1136/ bjsports-2016-i3740rep).,OADS,/arxiv_data1/oa_pdf/8e/35/bjsports-2016-i3740rep.PMC5136715.pdf
Statistical analysis The statistical analyses were performed according to the a prioripublished statistical analysis plan (http://static.sdu.dk/media ﬁles// 5/E/5/%7B5E568A02-9475-4127-9B6C-0ADA7235DF77%7DSAP%20OMEX%2020.03.15.pdf).,OADS,/arxiv_data1/oa_pdf/8e/35/bjsports-2016-i3740rep.PMC5136715.pdf
"See: http://creativecommons.org/licenses/by-nc/3.0/ REFERENCES 1 Abrams GD, Frank RM, Gupta AK, et al.",Non-OADS,/arxiv_data1/oa_pdf/8e/35/bjsports-2016-i3740rep.PMC5136715.pdf
"RESEARCH PAPER A clinical tool for predicting survival in ALS Jonathan A Knibb,1Noa Keren,2Anna Kulka,2P Nigel Leigh,3Sarah Martin,2 Christopher E Shaw,2Miho Tsuda,4Ammar Al-Chalabi2 1Brighton and Sussex University Hospitals NHS Trust,Royal Sussex County Hospital,Brighton, UK 2Maurice Wohl Clinical Neuroscience Institute, Instituteof Psychiatry, Psychology andNeuroscience, King ’s College London, London, UK 3Trafford Centre for Biomedical Research, Brighton and SussexMedical School, Falmer, UK 4Maccles ﬁeld District General Hospital, Maccles ﬁeld, Cheshire, UK Correspondence to Professor Ammar Al-Chalabi, Maurice Wohl Clinical Neuroscience Institute, Instituteof Psychiatry, Psychology andNeuroscience, King ’s College London, London SE5 8AF, UK; ammar.al-chalabi@kcl.ac.uk Received 13 December 2015 Revised 24 March 2016 Accepted 6 April 2016 Published Online First4 July 2016 ▸http://dx.doi.org/10.1136/ jnnp-2016-313683 To cite: Knibb JA, Keren N, Kulka A, et al.J Neurol Neurosurg Psychiatry2016; 87:1361–1367.ABSTRACT Background Amyotrophic lateral sclerosis (ALS) is a progressive and usually fatal neurodegenerative disease.Survival from diagnosis varies considerably.",Non-OADS,/arxiv_data1/oa_pdf/2a/9f/jnnp-2015-312908.PMC5136716.pdf
2013. http://cran.r-project.org/package= ﬂexsurv).,Non-OADS,/arxiv_data1/oa_pdf/2a/9f/jnnp-2015-312908.PMC5136716.pdf
ISBN 3-900051-07-0. http://www.r-project.org/) running on Linux (Lubuntu 13.04).,Non-OADS,/arxiv_data1/oa_pdf/2a/9f/jnnp-2015-312908.PMC5136716.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ REFERENCES 1 Johnston CA, Stanton BR, Turner MR, et al.",Non-OADS,/arxiv_data1/oa_pdf/2a/9f/jnnp-2015-312908.PMC5136716.pdf
"ac.uk Received 12 January 2015 Revised 12 February 2016 Accepted 14 March 2016 Published Online First11 April 2016 ▸http://dx.doi.org/10.1136/ emermed-2016-205877 To cite: Cotterill S, Rowland AG, Kelly J, et al.",OADS,/arxiv_data1/oa_pdf/c0/e5/emermed-2015-204647.PMC5136718.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ REFERENCES 1 Pearson GA, ed.",Non-OADS,/arxiv_data1/oa_pdf/c0/e5/emermed-2015-204647.PMC5136718.pdf
11 ManChEWS website https://sites.google.com/site/emmedapps/home/manchews (accessed 2 Feb 2016).,Non-OADS,/arxiv_data1/oa_pdf/c0/e5/emermed-2015-204647.PMC5136718.pdf
13 Leicester POPS website http://www2.le.ac.uk/departments/cardiovascular-sciences/ research/cardiovascular-physiology-and-pathophysiology/emergency-medicine-group/ research/pemla/pops/pops-front-sheet (accessed 2 Feb 2016).,Non-OADS,/arxiv_data1/oa_pdf/c0/e5/emermed-2015-204647.PMC5136718.pdf
To viewplease visit the journal online (http://dx.doi.org/10.1136/ thoraxjnl-2015-208039).,Non-OADS,/arxiv_data1/oa_pdf/09/33/thoraxjnl-2015-208039.PMC5136722.pdf
"Received 6 November 2015 Revised 12 July 2016Accepted 27 July 2016Published Online First 24 August 2016 ▸http://dx.doi.org/10.1136/ thoraxjnl-2016-209273 To cite: Garcia-Arcos I, Geraghty P, Baumlin N, et al .Thorax 2016; 71:1119 –1129.ABSTRACT Background The use of electronic (e)-cigarettes is increasing rapidly, but their lung health effects are notestablished.",Non-OADS,/arxiv_data1/oa_pdf/09/33/thoraxjnl-2015-208039.PMC5136722.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ REFERENCES 1 Murphy BS, Xu J, Kochanek KD.",Non-OADS,/arxiv_data1/oa_pdf/09/33/thoraxjnl-2015-208039.PMC5136722.pdf
"Correspondence to Professor Gary B Smith, Faculty of Health and Social Sciences, University of Bournemouth, Royal London House, Christchurch Road, BournemouthBH1 3LT, UK; gbsresearch@ virginmedia.com Received 21 March 2015 Revised 27 October 2015 Accepted 9 November 2015Published Online First 11 December 2015 ▸http://dx.doi.org/10.1136/ bmjqs-2015-005037 To cite: Robinson EJ, Smith GB, Power GS, et al.",Non-OADS,/arxiv_data1/oa_pdf/32/2d/bmjqs-2015-004223.PMC5136724.pdf
"See: http://creativecommons.org/licenses/by- nc/4.0/ REFERENCES 1 Bell CM, Redelmeier DA.",Non-OADS,/arxiv_data1/oa_pdf/32/2d/bmjqs-2015-004223.PMC5136724.pdf
"See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1 Berwick DM, James B, Coye MJ.",Non-OADS,/arxiv_data1/oa_pdf/5f/91/bmjqs-2015-004120.PMC5136725.pdf
To view please visit the journal online(http://dx.doi.org/10.1136/jnnp-2016-313959).,Non-OADS,/arxiv_data1/oa_pdf/d4/ad/jnnp-2016-313959.PMC5136726.pdf
Image preprocessing T1-weighted images were preprocessed using Freesurfer V .5.3(http://surfer.nmr.mgh.harvard.edu/).,OADS,/arxiv_data1/oa_pdf/d4/ad/jnnp-2016-313959.PMC5136726.pdf
"See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1 van Rheenen W, van Blitterswijk M, Huisman MH, et al.",Non-OADS,/arxiv_data1/oa_pdf/d4/ad/jnnp-2016-313959.PMC5136726.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ REFERENCES 1 Bukh J, Miller RH, Kew MC et al .",Non-OADS,/arxiv_data1/oa_pdf/65/a1/gutjnl-2015-310300.PMC5136728.pdf
To viewplease visit the journal online (http://dx.doi.org/10.1136/ bjsports-2015-094715).,Non-OADS,/arxiv_data1/oa_pdf/46/e9/bjsports-2015-094715.PMC5136729.pdf
MATERIALS AND METHODS This systematic review was registered in an inter-national database of systematic reviews in healthand social care (registration numberCRD42015016538; http://www.crd.york.ac.uk/PROSPERO/).,Non-OADS,/arxiv_data1/oa_pdf/46/e9/bjsports-2015-094715.PMC5136729.pdf
16 17If trials were already listed on the PEDro database (http://www.pedro.,Non-OADS,/arxiv_data1/oa_pdf/46/e9/bjsports-2015-094715.PMC5136729.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ REFERENCES 1 Alberti KG, Eckel RH, Grundy SM, et al., International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Lemes ÍR, et al.Br J Sports Med 2016; 50:1438 –1442.",Non-OADS,/arxiv_data1/oa_pdf/46/e9/bjsports-2015-094715.PMC5136729.pdf
To view please visit the journal online(http://dx.doi.org/10.1136/gutjnl-2014-308971).,Non-OADS,/arxiv_data1/oa_pdf/5c/9e/gutjnl-2014-308971.PMC5136730.pdf
"See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1 Ciesek S, Wedemeyer H. Immunosuppression, liver injury and post-transplant HCV recurrence.",Non-OADS,/arxiv_data1/oa_pdf/5c/9e/gutjnl-2014-308971.PMC5136730.pdf
"See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1 Rex DK, Cutler C, Lemmel GT, et al.",Non-OADS,/arxiv_data1/oa_pdf/b7/cb/gutjnl-2016-312044.PMC5136732.pdf
"Available from: http://www.foodauthority.nsw.gov.au/_Doc uments/retailfactsheets/doner_kebabs.pdf Vazgecer B, Ulu H, Oztan A, 2004.",Non-OADS,/arxiv_data1/oa_pdf/b6/8b/ijfs-2016-4-6149.PMC5136744.pdf
"PCR prod-ucts were sequenced and all sequences were analyzed using Ittiobase (http://90.147.123.23/ ittiobase/), GenBank (http://www.ncbi.nlm.nih.",OADS,/arxiv_data1/oa_pdf/6c/9b/ijfs-2016-4-5723.PMC5136746.pdf
gov/genbank/) and BOLD Identification System (http://www.boldsystems.org) databases for species identification.,OADS,/arxiv_data1/oa_pdf/6c/9b/ijfs-2016-4-5723.PMC5136746.pdf
2010; Available  from: http://journal.crossfit.com/2010/05/  crossfit-level-1-training-guide.tpl  5.,Non-OADS,/arxiv_data1/oa_pdf/aa/86/or-2016-4-6571.PMC5136753.pdf
Available from: http://www.crossfit.com/cf-  seminars/crossfit_credentials_faq.pdf  7.,Non-OADS,/arxiv_data1/oa_pdf/aa/86/or-2016-4-6571.PMC5136753.pdf
Available from: http://globocan.iarc.fr/Default.aspx 11.,Non-OADS,/arxiv_data1/oa_pdf/03/bc/onco-2016-2-302.PMC5136756.pdf
Available from: http://www.ncbi.nlm.nih.gov/books/NBK9630/ Accessed: 29 May 2016.,Non-OADS,/arxiv_data1/oa_pdf/c4/f9/onco-2016-2-298.PMC5136757.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, dist ribution, and reproduction in any medium, pro- vided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/73/cb/ijda-5-024.PMC5136975.pdf
"1, 24 –28 http://dx.doi.org/10.1080/21556660.2016.1252380 Article 0008.R1/1252380 All rights reserved: reproduction in whole or part not permitted",Non-OADS,/arxiv_data1/oa_pdf/73/cb/ijda-5-024.PMC5136975.pdf
"Available from: http://www.apiindia.org/medicine_update_2013/chap130.pdf [2] Hamer RA, El Nahas AM.",Non-OADS,/arxiv_data1/oa_pdf/73/cb/ijda-5-024.PMC5136975.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, dist ribution, and reproduction in any medium, pro- vided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/4d/21/ijda-5-029.PMC5136976.pdf
"1, 29 –33 http://dx.doi.org/10.1080/21556660.2016.1252379 Article 0006.R1/1252379 All rights reserved: reproduction in whole or part not permitted",Non-OADS,/arxiv_data1/oa_pdf/4d/21/ijda-5-029.PMC5136976.pdf
"August 27,2013. http://onlinelibrary.wiley.com/doi/10.1111/1753-0407.12078/ full[cited 2014 May]; 6:237 –242.",Non-OADS,/arxiv_data1/oa_pdf/4d/21/ijda-5-029.PMC5136976.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/0b/7f/main.PMC5137169.pdf
Contents lists available at ScienceDirect Annals of Medicine and Surgery journal homepage: www.annalsjournal.com http://dx.doi.org/10.1016/j.amsu.2016.11.002 2049-0801/ ©2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/0b/7f/main.PMC5137169.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/80/35/main.PMC5137170.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/80/35/main.PMC5137170.pdf
http://dx.doi.org/10.1016/j.eucr.2016.11.015Urology Case Reports 10 (2017) 36 e37,Non-OADS,/arxiv_data1/oa_pdf/80/35/main.PMC5137170.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: ADHDMethylphenidateDopamineAge Cerebral blood ﬂow Arterial spin labeling 1.,Non-OADS,/arxiv_data1/oa_pdf/0a/5e/main.PMC5137172.pdf
http://dx.doi.org/10.1016/j.nicl.2016.11.021 2213-1582/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/0a/5e/main.PMC5137172.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/0a/5e/main.PMC5137172.pdf
"Additionally, explorative voxel-wise chang- es in CBF were determined non-parametrically using the Randomise toolbox in the Functional Magnetic Resonance Imaging of the Brain (FMRIB) Software Library (FSL 4.0, Oxford, UK; http://www.fmrib.ox.",OADS,/arxiv_data1/oa_pdf/0a/5e/main.PMC5137172.pdf
http://dx.doi.org/10.1002/mrm.25197 .,Non-OADS,/arxiv_data1/oa_pdf/0a/5e/main.PMC5137172.pdf
27:3 –18.http://dx.doi.org/10.1016/S0149- 7634(03)00005-8 .,OADS,/arxiv_data1/oa_pdf/0a/5e/main.PMC5137172.pdf
http://dx.doi.org/10.1016/j.neuroimage.2007.07.007 .,OADS,/arxiv_data1/oa_pdf/0a/5e/main.PMC5137172.pdf
http://dx.doi.org/10.1371/journal.pone.0137326 .,Non-OADS,/arxiv_data1/oa_pdf/0a/5e/main.PMC5137172.pdf
http://dx.doi.org/10.1002/jmri.,OADS,/arxiv_data1/oa_pdf/0a/5e/main.PMC5137172.pdf
http://dx.doi.org/10.1016/j.neuroimage.,OADS,/arxiv_data1/oa_pdf/0a/5e/main.PMC5137172.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0a/5e/main.PMC5137172.pdf
http://dx.doi.org/10.1016/0893- 133X(95)00077-Q .,OADS,/arxiv_data1/oa_pdf/0a/5e/main.PMC5137172.pdf
http://dx.doi.org/10.1159/000286215 .,Non-OADS,/arxiv_data1/oa_pdf/0a/5e/main.PMC5137172.pdf
http://dx.doi.org/10.1038/npp.2013.349 .,Non-OADS,/arxiv_data1/oa_pdf/0a/5e/main.PMC5137172.pdf
http://dx.doi.org/10.1002/ana.410040410 .,Non-OADS,/arxiv_data1/oa_pdf/0a/5e/main.PMC5137172.pdf
http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/0a/5e/main.PMC5137172.pdf
12. http://dx.doi.org/10.1186/1471-2431-12-78 .,Non-OADS,/arxiv_data1/oa_pdf/0a/5e/main.PMC5137172.pdf
http://dx.doi.org/10.1097/00004583-199203000-00006 .,Non-OADS,/arxiv_data1/oa_pdf/0a/5e/main.PMC5137172.pdf
http://dx.doi.org/ 10.1016/j.jaac.2014.05.003 .,OADS,/arxiv_data1/oa_pdf/0a/5e/main.PMC5137172.pdf
http://dx.doi.or g/10.4088/JCP.12r08287 .,Non-OADS,/arxiv_data1/oa_pdf/0a/5e/main.PMC5137172.pdf
http://dx.doi.org/10.1038/74737 .,Non-OADS,/arxiv_data1/oa_pdf/0a/5e/main.PMC5137172.pdf
http://dx.doi.org/ 10.1001/archpsyc.64.8.932 .,Non-OADS,/arxiv_data1/oa_pdf/0a/5e/main.PMC5137172.pdf
http://dx.doi.org/10.1016/j.neubiorev.2009.12.007 .,OADS,/arxiv_data1/oa_pdf/0a/5e/main.PMC5137172.pdf
http://dx.doi.org/10.1080/87565641.2013.783833 .,Non-OADS,/arxiv_data1/oa_pdf/0a/5e/main.PMC5137172.pdf
http://dx.doi.org/10.1016/j.neuroimage.2013.,OADS,/arxiv_data1/oa_pdf/0a/5e/main.PMC5137172.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/61/2c/main.PMC5137173.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/61/2c/main.PMC5137173.pdf
http://dx.doi.org/10.1016/j.eucr.2016.11.003Urology Case Reports 10 (2017) 38 e41,Non-OADS,/arxiv_data1/oa_pdf/61/2c/main.PMC5137173.pdf
e00207 http://dx.doi.org/10.1016/j.heliyon.2016.e00207 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
The regimens comprising of Lamivudine (3TC) and Tenofovir DF are also of choice inHIV/Hepatitis B co-infected patients as 3TC and TDF are effective against both Article No~e00207 2 http://dx.doi.org/10.1016/j.heliyon.2016.e00207 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
Article No~e00207 3 http://dx.doi.org/10.1016/j.heliyon.2016.e00207 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
"Formulation development For the purpose of this formulation the particle size distribution for Lamivudine and Tenofovir Disoproxil Fumarate (TDF) was set at D90 > 250 μm to prevent the possibility of capping, picking and sticking of formulation during direct Article No~e00207 4 http://dx.doi.org/10.1016/j.heliyon.2016.e00207 2405-8440/© 2017 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
Component 1 Component 2 Component 3 Component 4 Constant 1 Constant 2 F A:PVP CL %B:PVP K30 %C:Starch 1500 (%)D:Avicel PH102 (%)Talc (%) MgSt (%) 1 1.0 1.0 12.5 9.2 0.5 0.75 2 1.0 9.8 10.9 2.0 0.5 0.75 3 1.0 1.0 2.5 19.2 0.5 0.75 4 1.0 10.0 2.6 10.1 0.5 0.755 12.0 5.5 2.9 3.3 0.5 0.75 6 6.2 10.0 4.3 3.2 0.5 0.75 7 4.2 2.6 12.5 4.5 0.5 0.75 8 10.9 1.0 2.5 9.3 0.5 0.75 9 12.0 1.1 8.4 2.2 0.5 0.75 10 1.0 4.9 7.2 10.7 0.5 0.75 11 6.2 5.8 3.3 8.5 0.5 0.75 12 4.9 1.8 3.3 13.8 0.5 0.75 13 8.1 2.1 7.1 6.5 0.5 0.75 14 4.4 1.0 8.4 9.9 0.5 0.7515 12.0 1.3 5.1 5.4 0.5 0.75 16 1.0 9.8 10.9 2.0 0.5 0.75 17 1.0 10.0 2.6 10.1 0.5 0.75 18 1.0 1.0 2.5 19.2 0.5 0.75 19 1.0 1.0 12.5 9.2 0.5 0.7520 6.2 10.0 4.3 3.2 0.5 0.75 Article No~e00207 5 http://dx.doi.org/10.1016/j.heliyon.2016.e00207 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
Formulation Weight varia- tion(% rsd)Friability (%)Disintegration (min)Dissolution % at 30 minAssay % LTLT F-1 1.02 0.50 6.67 98.95 96.83 100.85 101.22 F-2 1.55 0.06 40.83 93.96 95.85 98.23 99.27 F-3 1.35 0.25 66.33 99.23 99.87 99.25 100.38 F-4 1.71 0.12 38.42 98.50 102.84 98.88 99.85F-5 0.66 0.31 2.5 100.55 103.15 100.56 100.36 F-6 2.27 0.25 10.32 99.58 101.20 100.35 99.50 F-7 1.015 0.3 6.17 99.45 101.25 99.50 98.25 F-8 2.55 0.24 8.5 100.16 99.86 99.58 100.16 F-9 0.69 0.38 1.33 98.93 100.88 101.95 100.87F-10 0.82 0.37 20.87 99.97 98.99 98.50 99.87 F-11 1.87 0.19 1.92 98.88 99.98 97.96 98.87 F-12 1.18 0.29 8 97.75 98.89 98.13 98.55 F-13 1.61 12.56 5.16 99.26 99.97 98.98 99.89 F-14 1.71 0.19 4.85 99.98 100.35 99.87 101.74F-15 1.01 0.30 8.33 98.88 101.35 97.93 99.57 F-16 1.50 0.30 42.5 98.88 98.98 99.96 98.87 F-17 2.00 0.14 37.75 99.95 98.89 98.13 98.55 F-18 1.03 0.18 38.42 98.26 97.97 99.98 99.99 F-19 1.29 0.48 2.56 99.85 100.95 100.97 102.84F-20 2.04 0.25 10.2 99.89 102.35 100.83 99.87 Article No~e00207 6 http://dx.doi.org/10.1016/j.heliyon.2016.e00207 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
Component 1 Component 2 Component 3 Component 4 Response 1 Response 2 Std Run A:PVP CL %B:PVP K30 %C:Starch 1500 (%)D:Avicel PH102 (%)Disintegration time (Min)Friability (%) 13 1 8.1 2.1 7.1 6.5 5.16 12.56 2 2 1.0 9.8 10.9 2.0 40.83 0.06 3 3 1.0 1.0 2.5 19.2 66.33 0.25 11 4 6.2 5.8 3.3 8.5 1.92 0.1914 5 4.4 1.0 8.4 9.9 4.85 0.19 7 6 4.2 2.6 12.5 4.5 6.17 0.3 18 7 1.0 1.0 2.5 19.2 38.42 0.18 9 8 12.0 1.1 8.4 2.2 1.33 0.38 4 9 1.0 10.0 2.6 10.1 38.42 0.12 17 10 1.0 10.0 2.6 10.1 37.75 0.14 19 11 1.0 1.0 12.5 9.2 2.56 0.48 16 12 1.0 9.8 10.9 2.0 42.5 0.30 10 13 1.0 4.9 7.2 10.7 20.87 0.37 1 14 1.0 1.0 12.5 9.2 6.67 0.506 15 6.2 10.0 4.3 3.2 10.32 0.25 20 16 6.2 10.0 4.3 3.2 10.2 0.25 5 17 12.0 5.5 2.9 3.3 2.5 0.31 12 18 4.9 1.8 3.3 13.8 8.0 0.29 8 19 10.9 1.0 2.5 9.3 8.5 0.24 15 20 12.0 1.3 5.1 5.4 8.33 0.30 Article No~e00207 7 http://dx.doi.org/10.1016/j.heliyon.2016.e00207 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
Article No~e00207 8 http://dx.doi.org/10.1016/j.heliyon.2016.e00207 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
Article No~e00207 9 http://dx.doi.org/10.1016/j.heliyon.2016.e00207 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
Final Equation in Terms of Actual Components: Disintegration time = +3.85225 * PVP CL +4.88321 * PVP K30 +1.02884 * Starch 1500+3.77274 * Microcrystalline PH102 -0.70695 * PVP CL * PVP K30 -0.31655 * PVP CL * Starch 1500 -0.49076 * PVP CL * Microcrystalline PH102 -0.033147 * PVP K30 * Starch 1500 -0.33317 * PVP K30 * Microcrystalline PH102 -0.32293 * Starch 1500 * Microcrystalline PH102 Article No~e00207 10 http://dx.doi.org/10.1016/j.heliyon.2016.e00207 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
Article No~e00207 11 http://dx.doi.org/10.1016/j.heliyon.2016.e00207 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
Article No~e00207 12 http://dx.doi.org/10.1016/j.heliyon.2016.e00207 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
"s/n Parameters Reference product Test product 1 Appearance White film coated tablet White uncoated tablet 2 Assay L-101.15%, T-99.06% L-102.03%, T-100.03%3 Disintegration time 19 Min 5.42 Min 4 Friability 0.01% 0.3% Article No~e00207 13 http://dx.doi.org/10.1016/j.heliyon.2016.e00207 2405-8440/© 2017 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
Article No~e00207 14 http://dx.doi.org/10.1016/j.heliyon.2016.e00207 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
Article No~e00207 15 http://dx.doi.org/10.1016/j.heliyon.2016.e00207 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
Article No~e00207 16 http://dx.doi.org/10.1016/j.heliyon.2016.e00207 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
Article No~e00207 17 http://dx.doi.org/10.1016/j.heliyon.2016.e00207 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/c8/25/main.PMC5137174.pdf
This  is  an  open access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/6f/34/main.PMC5137175.pdf
Children  who  have  hemolytic http://dx.doi.org/10.1016/j.ijscr.2016.11.008 2210-2612/© 2016  The  Author(s).,Non-OADS,/arxiv_data1/oa_pdf/6f/34/main.PMC5137175.pdf
"33  (3)  (2010)  291–300,  http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/6f/34/main.PMC5137175.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Multigene panel next generation sequencing Lysosomal storage disease NEU1 geneSialidosisc.699C NA( p .,Non-OADS,/arxiv_data1/oa_pdf/df/0a/main.PMC5137178.pdf
http://dx.doi.org/10.1016/j.ymgmr.2016.11.004 2214-4269/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/df/0a/main.PMC5137178.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/df/0a/main.PMC5137178.pdf
"Additionally, all re- ported NEU1 mutations within the Human Gene Mutation Database (HGMD, https://portal.biobase-international.com/cgi-bin/portal/login.",OADS,/arxiv_data1/oa_pdf/df/0a/main.PMC5137178.pdf
"In the 60,706 controls of the ExacBrowser, the allele c.699A is found once in a heterozygous state in a control of African ori- gin while c.803G is absent; no homozygous carriers are present in the database ( http://exac.broadinstitute.org /).",Non-OADS,/arxiv_data1/oa_pdf/df/0a/main.PMC5137178.pdf
"Both variants are predicted to damage protein function with high scores in standard in silico predic- tion tools (PolyPhen2, http://genetics.bwh.harvard.edu/pph2 ,a n d MutationTaster, http://www.mutationtaster.org ) using the NEU1 tran- script NM_000434.3.",Non-OADS,/arxiv_data1/oa_pdf/df/0a/main.PMC5137178.pdf
Data are available via NCBI Gene Expression Omnibus (GEO) with the ac-cession number GSE85777 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE85777 ) © 2016 The Authors.,OADS,/arxiv_data1/oa_pdf/df/f7/main.PMC5137179.pdf
"This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Mycoplasma gallisepticumMollicutes Gene expression Knockout mutantsAntibiotic treatmentHeat stress Speci ﬁcations Organism/cell line/tissue Mycoplasma gallisepticum S6 Sex NASequencer or array type Agilent one-color custom gene expression microarray Data format normalized and processed microarray data, qPCR data Experimental factors transcriptional pro ﬁling of genetic knock-out mutants of Mycoplasma gallisepticum , cell culture exposed to sublethal concentrations of antibiotics and under heat stress.",Non-OADS,/arxiv_data1/oa_pdf/df/f7/main.PMC5137179.pdf
Direct link to deposited data Data are available via NCBI Gene Expression Omnibus (GEO) with accession number GSE85777 (http://www.ncbi.nlm.nih.gov/geo/ query/acc.cgi?acc=GSE85777 ) 2.,OADS,/arxiv_data1/oa_pdf/df/f7/main.PMC5137179.pdf
http://dx.doi.org/10.1016/j.gdata.2016.11.021 2213-5960/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/df/f7/main.PMC5137179.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/df/f7/main.PMC5137179.pdf
"42 (2014) 13254 –13268, http://dx.doi.org/10.1093/nar/gku976 .",Non-OADS,/arxiv_data1/oa_pdf/df/f7/main.PMC5137179.pdf
"Microbiology 154 (2008) 2571 –2580, http://dx.doi.org/10.1099/mic.0.2008/019208-0 .",Non-OADS,/arxiv_data1/oa_pdf/df/f7/main.PMC5137179.pdf
"BMC Genomics 14 (2013) 726, http://dx.doi.org/10.",OADS,/arxiv_data1/oa_pdf/df/f7/main.PMC5137179.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Cerebrovascular reserve Blood-oxygen level dependenceCerebrovascular diseaseCerebrovascular stenosisAcetazolamideMR perfusion 1.,Non-OADS,/arxiv_data1/oa_pdf/76/e0/main.PMC5137181.pdf
http://dx.doi.org/10.1016/j.nicl.2016.11.018 2213-1582/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/76/e0/main.PMC5137181.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/76/e0/main.PMC5137181.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: FornixDiffusion tensor imagingAging Aβamyloid Tau 1.,Non-OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
http://dx.doi.org/10.1016/j.nicl.2016.11.024 2213-1582/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
http://dx.doi.org/10.1016/j.neubiorev.2011.09.005 .,OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
http://dx.doi.org/10.1006/nimg.2000.0582 .,OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
http://dx.doi.org/10.1016/S0006-3495(94)80775-1 .,OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
http://dx.doi.org/10.1002/mrm.10609 .,Non-OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
http://dx.doi.org/10.1016/j.neuroimage.2006.09.018 .,OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
http://dx.doi.org/10.1136/jnnp.72.6.742 .,OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
7. http://dx.doi.org/10.3389/fnagi.2015.00194 .,Non-OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
13:33 –46.http://dx.doi.org/10.1111/j.2044-8317.1960.tb00037.x .,Non-OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
http://dx.doi.org/10.1016/j.neuroimage.2010.05.036 .,OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
http://dx.doi.org/10.1016/j.bbadis.2011.07.009 .,OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
http://dx.doi.org/10.1006/nimg.2001.0857 .,OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
http://dx.doi.org/10.1016/j.neuropsychologia.,OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
http://dx.doi.org/10.1016/j.cortex.2014.12.006 .,OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
NeuroImage 100:75 –90.http://dx.doi.org/ 10.1016/j.neuroimage.2014.04.048 .,OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
http://dx.doi.org/10.1016/j.neuroimage.2011.08.032 .,OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
NeuroImage 39: 62–79.http://dx.doi.org/10.1016/j.neuroimage.2007.06.041 .,OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
http://dx.doi.org/10.1016/j.neuroimage.2011.11.094 .,OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
Aging http://dx.doi.org/10.1016/j.neurobiolaging.2014.05.027 .,OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
http://dx.doi.org/10.3389/fnagi.,Non-OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
38:725. http://dx.doi.org/10.1001/archneurpsyc.1937.02260220069003 .,Non-OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
http://dx.doi.org/10.1093/ brain/awm102 .,Non-OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
http://dx.doi.org/10.1136/jnnp.2005.074336 .,OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
http://dx.doi.org/10.1016/j.neurobiolaging.2004.09.017 .,OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
http://dx.doi.org/10.1002/ana.21610 .,Non-OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
http://dx.doi.org/10.1002/hbm.10062 .,Non-OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
http://dx.doi.org/10.1016/j.neuroimage.2006.02.024 .,OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
http://dx.doi.org/10.1016/j.neurobiolaging.,OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
NeuroImage 54:49 –59.http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
Cortex 11:1 –16.http://dx.doi.org/10.1093/cercor/11.1.1 .,OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
Imaging 20:45 –57.http://dx.doi.org/10.1109/42.906424 .,Non-OADS,/arxiv_data1/oa_pdf/9b/9b/main.PMC5137184.pdf
"1284 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/3a/80/cww075.PMC5137251.pdf
Available from:  http://www.ncbi.nlm.nih.gov/pubmed/14506307 .,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/19120701.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/2181476.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/11707462.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/11096123.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/ pubmed/15136561.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/ pubmed/7364052.,OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/7076667.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/6771267.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/1671041.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://joi.jlc.jst.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2115938&tool=pmcentrez&rendertype=abstract.,OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/15690429.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/ pubmed/18400874.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/16340016.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/21204258.,OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.pubmedcentral.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.pubmedcentral.nih.gov/articler - ender.fcgi?artid=2887992&tool=pmcentrez&rendertype=abstract.,OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.nature.com/ki/journal/,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/8318680.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/2405711.,OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/ pubmed/8872972.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/ pubmed/9535426.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/11213061.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/11384979.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/11278951.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/24770446.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/3839510.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://linkinghub.elsevier.com/retrieve/ pii/0006291X85913373.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/2966156.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/7548006.,OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/2521481.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/15637442.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/9416904.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/10615430.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/7644000.,OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/8454033.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/21378385.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from:  http://www.ncbi.nlm.nih.gov/pubmed/10027938.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/12352321.,Non-OADS,/arxiv_data1/oa_pdf/85/53/jsmr-52-045.PMC5137254.pdf
The free [Ca2+] calculated with the program Maxchelator (http://www.stanford.edu/~cpatton/maxc.html) were  20 and 100 nM for 1 and 3.9 mM CaCl 2 respectively.,OADS,/arxiv_data1/oa_pdf/fd/0a/jsmr-51-058.PMC5137259.pdf
"In later  studies on about 13  000 subjects of the Ukrainian-American  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/cc/b7/bgw102.PMC5137265.pdf
Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2044737/.,Non-OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/9533825.,Non-OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from: http://www.pubmedcentral.nih.gov/articleren - der.fcgi?artid=2439854&tool=pmcentrez&rendertype=abstract.,OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/9522179.,Non-OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/9049160 6.,Non-OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1665188&tool=p mcentrez&rendertype=abstract 7.,OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from: http://www.ncbi.nlm.,Non-OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/8574819.,Non-OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/6214623.,Non-OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from: http://www.ncbi.nlm.nih.,Non-OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/3035385.,OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/3036577.,Non-OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1191760&tool=pmcentrez&rendertype=abstract.,OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from:  http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1854834&tool=pmcentrez&rendertype=abs tract.,OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1854712&tool=pmcentrez&rendertype=abstract.,OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/2764949.,Non-OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/1710986.,Non-OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Avail - able from: http://www.ncbi.nlm.nih.gov/pubmed/8186262.,Non-OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1136572&tool=pm centrez&rendertype=abstract.,OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from: http://www.ncbi.nlm.nih.gov/ pubmed/7478929.,Non-OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from: http://www.ncbi.,Non-OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from:  http://www.ncbi.nlm.nih.gov/pubmed/14506307.,Non-OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from:  http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2544441&tool=pmcentrez&rendertype=abstract.,OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from: http://linkinghub.elsevier.com/retrieve/pii/ S0014579397012106.,Non-OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/20028386.,OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/18835557.,Non-OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from: http://www.ncbi.nlm.nih.gov/ pubmed/19729958.,Non-OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/2545866.,OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from: http://www.ncbi.nlm.,Non-OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/11606042.,Non-OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/12139772.,Non-OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/10586950.,Non-OADS,/arxiv_data1/oa_pdf/1b/e8/jsmr-51-010.PMC5137268.pdf
Avail- able from: http://www.atsdr.cdc.gov/spl/ .,Non-OADS,/arxiv_data1/oa_pdf/65/f7/jsmr-50-093.PMC5137271.pdf
"ASL Analysis ASL images were preprocessed using the toolbox “ASLtbx” ( Wang  et  al., 2008 ), which was compatible with MATLAB and the SPM  software package ( http://www.fil.ion.ucl.ac.uk/spm/ ), used for  group comparison analysis.",OADS,/arxiv_data1/oa_pdf/c1/47/pyw067.PMC5137281.pdf
"Global CBF Calculation First, a brain mask template was created for each subject to  exclude all nonbrain voxels from the normalized CBF map  (using the FSL software package, http://fsl.fmrib.ox.ac.uk/fsl/ fslwiki/ ).",OADS,/arxiv_data1/oa_pdf/c1/47/pyw067.PMC5137281.pdf
"The occipi - tal cortex contains both 5HT 1A and 2A receptors (Allen Brain  Atlas, http://www.brain-map.org ), which could suggest a direct  serotonergic effect of QT in these regions.",Non-OADS,/arxiv_data1/oa_pdf/c1/47/pyw067.PMC5137281.pdf
"These were  identified using dbSNP (Map to Genome Build: 36.3) and HapMap  (Public Release #24), were screened using the tagging SNP method  (http://hapmap.ncbi.nlm.nih.gov/cgi-perl/gbrowse/hapmap24_ B36/), and then polymorphisms with reported minor allele fre - quency (MAF) values of ≥5% were prioritized.",OADS,/arxiv_data1/oa_pdf/ea/b2/pyw070.PMC5137282.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/79/28/rrw033.PMC5137284.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d8/7e/rrw037.PMC5137285.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/fe/66/rrw040.PMC5137286.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/af/6b/rrw043.PMC5137287.pdf
ACKNOWLEDGEMENTS The authors would like to express our gratitude to all members in Arimura laboratory ( http://web.shs.kyushu-u.ac.jp/~arimura/ ) for insightful comments and suggestions.,Non-OADS,/arxiv_data1/oa_pdf/af/6b/rrw043.PMC5137287.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/13/e6/rrw048.PMC5137288.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/4e/fb/rrw049.PMC5137289.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f8/3e/rrw058.PMC5137290.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a5/04/rrw067.PMC5137291.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/9f/c7/rrw070.PMC5137292.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the originalwork is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f6/8c/rrw072.PMC5137293.pdf
"Evaluation of measurement data-Guide to the expres- sion of uncertainty in measurement .http://www.bipm.org/utils/ common/documents/jcgm/JCGM_100_2008_E.pdf (15 May 2016, date last accessed).",OADS,/arxiv_data1/oa_pdf/f6/8c/rrw072.PMC5137293.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/7e/fe/rrw073.PMC5137294.pdf
"http://www.rtog.org/ CoreLab/Contouring Atlases/BreastCancerAtlas.aspx (18 June 2013, date last accessed).",Non-OADS,/arxiv_data1/oa_pdf/7e/fe/rrw073.PMC5137294.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/e1/10/rrw077.PMC5137295.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/2d/db/rrw079.PMC5137296.pdf
"ACKNOWLEDGEMENTS This report makes use of publicly available databases, ‘DS02can ’, ‘lssins07 ’and ‘lssinc07ahs ’, released from RERF ( http://www.rerf.",OADS,/arxiv_data1/oa_pdf/2d/db/rrw079.PMC5137296.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ec/1c/rrw090.PMC5137297.pdf
"(Available from: NationalInstitutes of Health, Of ﬁce for Protection from Research Risks, 6100 Executive Boulevard, Suite 3B01, MSC 7507, Rockville, MD 20892-7507) Washington, DC, 1986. http://grants.nih.",Non-OADS,/arxiv_data1/oa_pdf/ec/1c/rrw090.PMC5137297.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b0/f9/rrw092.PMC5137298.pdf
"This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Aeromonas veroniiAquarium ﬁsh Multidrug resistantFish pathogenMotile Aeromonas septicaemia Genome sequencing Speci ﬁcations Organism/cell line/tissueAeromonas veronii Strain Ae52 Sex N/ASequencer or array typeIon PGM Data format Analyzed Experimental factorsGenomic DNA extracted from pure bacterial culture isolated from the kidney of a septicaemic gold ﬁsh Experimental featuresDraft genome sequence of A.veronii Ae52, assembly and annotation Consent N/ASample source locationNittambuwa, Gampaha District, Sri Lanka (7°09 ′0″N 80°06 ′ 00″E) 1.",Non-OADS,/arxiv_data1/oa_pdf/ad/17/main.PMC5137324.pdf
http://dx.doi.org/10.1016/j.gdata.2016.11.011 2213-5960/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/ad/17/main.PMC5137324.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ad/17/main.PMC5137324.pdf
"PLoS One 6 (2) (2011), e16751, http://dx.doi.org/10.1371/ journal.pone.0016751 .",Non-OADS,/arxiv_data1/oa_pdf/ad/17/main.PMC5137324.pdf
"PLoS One 10 (2) (2015), e0117821, http://dx.doi.org/10.1371/journal.",Non-OADS,/arxiv_data1/oa_pdf/ad/17/main.PMC5137324.pdf
"39 (2016) 777 –781, http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/ad/17/main.PMC5137324.pdf
"103 (2013) 53 –67, http://dx.doi.org/10.1007/s10482-012-9786-z .",Non-OADS,/arxiv_data1/oa_pdf/ad/17/main.PMC5137324.pdf
"109 (2014) 127 –137, http://dx.doi.org/10.3354/ dao02733 .",Non-OADS,/arxiv_data1/oa_pdf/ad/17/main.PMC5137324.pdf
"19 (2012) 455 –477, http://dx.doi.org/10.1089/cmb.2012.0021 .",Non-OADS,/arxiv_data1/oa_pdf/ad/17/main.PMC5137324.pdf
"Bioinformatics 29 (8) (2013) 1072 –1075, http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/ad/17/main.PMC5137324.pdf
"BMC Genomics 9 (2008) 75, http://dx.doi.",OADS,/arxiv_data1/oa_pdf/ad/17/main.PMC5137324.pdf
"57 (2013) 3348 –3357, http://dx.doi.org/10.1128/AAC.00419-13 .",Non-OADS,/arxiv_data1/oa_pdf/ad/17/main.PMC5137324.pdf
"67 (2012) 2640 –2644, http://dx.doi.org/10.1093/jac/ dks261 .48 S.S.S.",Non-OADS,/arxiv_data1/oa_pdf/ad/17/main.PMC5137324.pdf
"Only human chorionic gonadotropin (HCG) 5000 IU (Gonadotropin; ASKA Pharmaceutical, Tokyo, Japan) was administered to the patient 24 h prior to the surgery, to increase the maturation rate of the collected Contents lists available at ScienceDirect Gynecologic Oncology Reports journal homepage: www.elsevier.com/locate/gynor http://dx.doi.org/10.1016/j.gore.2016.11.009 2352-5789/© 2016 The Author(s).",Non-OADS,/arxiv_data1/oa_pdf/3b/e5/main.PMC5137325.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/3b/e5/main.PMC5137325.pdf
MALDI-TOF MS spectrum accession number The MALDI-TOF MS spectrum of L. massiliensis is available online ( http://www.mediterranee-infection.com/article.php?,Non-OADS,/arxiv_data1/oa_pdf/06/72/main.PMC5137330.pdf
Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious DiseasesThis is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) http://dx.doi.org/10.1016/j.nmni.2016.10.006,Non-OADS,/arxiv_data1/oa_pdf/06/72/main.PMC5137330.pdf
"Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI ,15,4 0 –41 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/06/72/main.PMC5137330.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2d/8e/main.PMC5137331.pdf
http://dx.doi.org/10.1016/j.idcr.2016.10.013 2214-2509/ ã  2016  The  Authors.,OADS,/arxiv_data1/oa_pdf/2d/8e/main.PMC5137331.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).IDCases  7  (2017)  19–22 Contents  lists  available  at  ScienceDirect IDCases journal  homepage:  www.elsevier.com/locate/idcr,Non-OADS,/arxiv_data1/oa_pdf/2d/8e/main.PMC5137331.pdf
Available  from  URL:  http://www.bio ﬁredx.com/research/ .,OADS,/arxiv_data1/oa_pdf/2d/8e/main.PMC5137331.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f0/b4/main.PMC5137333.pdf
Contents lists available at ScienceDirect Annals of Medicine and Surgery journal homepage: www.annalsjournal.com http://dx.doi.org/10.1016/j.amsu.2016.11.012 2049-0801/ ©2016 The Author(s).,Non-OADS,/arxiv_data1/oa_pdf/f0/b4/main.PMC5137333.pdf
"Production and hosting by ElsevierJournal of Advanced Research (2017) 8, 33–43 Cairo University Journal of Advanced Research http://dx.doi.org/10.1016/j.jare.2016.10.004 2090-1232 /C2112016 Production and hosting by Elsevier B.V. on behalf of Cairo University.",Non-OADS,/arxiv_data1/oa_pdf/52/f3/main.PMC5137336.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/52/f3/main.PMC5137336.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/ 4.0/).,Non-OADS,/arxiv_data1/oa_pdf/52/f3/main.PMC5137336.pdf
"Supplementary material Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.jare.2016.",OADS,/arxiv_data1/oa_pdf/52/f3/main.PMC5137336.pdf
Arab J Chem 2013. http://dx.doi.org/10.1016/j.arabjc.2013.03.007 .Molecular modeling and docking of some anticonvulsant agents 43,OADS,/arxiv_data1/oa_pdf/52/f3/main.PMC5137336.pdf
Sequence retrievaland alignments Information for sequence alignments was collected using BlastN searches ( http://www.ncbi.nlm.nih.gov/ sutils/genom table.cgi) of the following genome se- quences (accession numbers are given in parentheses): Salmonella typhimurium LT2 (NC 003197);Salmonella typhiTy2 (NC 004631);Citrobacter koseri ATCC BAA- 895 (NC 009792);Escherichia coli K12 (NC 000913); Shigella flexneri 2a str 301 (NC 004337);Enterobac- terSp.638 (NC 009436);Cronobacter turicensis z30232 (NC013282);Klebsiella pneumoniae 342 (NC 011283); Serratia proteamaculans 568 (NC009832);Yersinia pestis KIM (NC 004088);Yersinia enterocolitica subsp.,OADS,/arxiv_data1/oa_pdf/b7/15/gkw632.PMC5137417.pdf
"ACCESSION NUMBERS RNA-seqdatasupportingtheconclusionsofthisarticleare available in the NCBI GEO repository [accession numberGSE82336, http://www.ncbi.nlm.nih.gov/geo/ ].",OADS,/arxiv_data1/oa_pdf/17/17/gkw649.PMC5137419.pdf
"MATERIALS AND METHODS Cell culture, purification of nuclei and MNase digestion T. thermophila wild-type strain CU428, obtained from the Tetrahymena StockCenter( https://tetrahymena.vet.cornell.",Non-OADS,/arxiv_data1/oa_pdf/1f/83/gkw684.PMC5137421.pdf
"Paired-end MNase-Seq results were mapped back to the Tetrahymena reference genome assemblies using Tophat2, with spliced alignments fil- teredout( 32).TheMACreferenceisfromthe Tetrahymena genomedatabase(TGD: http://ciliate.org )(33,34);theMIC reference is from the Tetrahymena Comparative Sequenc- ing Project ( http://www.broadinstitute.org/annotation/ genome/Tetrahymena/MultiHome.html ).",OADS,/arxiv_data1/oa_pdf/1f/83/gkw684.PMC5137421.pdf
Software for the Segal model was downloadedfrom the Segal Lab website ( http://genie.weizmann.ac.il/ software/nucleo prediction.html ).Thesemodelsandexper- imental occupancy data were compared in pairs usingSpearman’s rank correlations.,OADS,/arxiv_data1/oa_pdf/1f/83/gkw684.PMC5137421.pdf
ACKNOWLEDGEMENTS WTTetrahymena strain CU428 was obtained from the Tetrahymena StockCenter( https://tetrahymena.vet.cornell.,Non-OADS,/arxiv_data1/oa_pdf/1f/83/gkw684.PMC5137421.pdf
The compiled annotations for Tetrahymena MAC genome sequence were obtained from the Tetrahymena Genome Database ( http://ciliate.org ).Tetrahymena MIC genome sequence was obtained from the Tetrahymena Comparative Sequencing Project (Broad Institute of Har- vard and MIT: http://www.broadinstitute.org/annotation/,OADS,/arxiv_data1/oa_pdf/1f/83/gkw684.PMC5137421.pdf
"Encrypted SRA files of HeLa-S3 were converted to raw reads using fastq- dump command from sratoolkit ( https://github.com/ncbi/ sratoolkit , Version 2.3.2).",OADS,/arxiv_data1/oa_pdf/96/4f/gkw691.PMC5137422.pdf
"For each TF, we trained a separate gkmSVM model (ver- sion 2.0) with default parameters using 5000 randomly selected ChIP-seq peaks following ( 36) and the associ- ated tutorial ( http://www.beerlab.org/gkmsvm/ ).",Non-OADS,/arxiv_data1/oa_pdf/96/4f/gkw691.PMC5137422.pdf
"NucleicAcidsResearch,2016,Vol.44,No.21 10109 was downloaded from http://folk.uio.no/junbaiw/BayesPI- BAR/, and BayesPI-BAR scores were calculated with de- faultparameters.",OADS,/arxiv_data1/oa_pdf/96/4f/gkw691.PMC5137422.pdf
"The WGS data of HeLa-S3 cell line used in this research were derived from a HeLa cellline( http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/ study.cgi?study id=phs000640.v2.p1 ).HenriettaLacksand theHeLacelllinethatwasestablishedfromhertumorcells without her knowledge or consent in 1951, have made sig-nificantcontributionstoscientificprogressandadvancesin humanhealth.TheauthorsaregratefultoHenriettaLacks, now deceased, and to her surviving family members fortheir contributions to biomedical research.",OADS,/arxiv_data1/oa_pdf/96/4f/gkw691.PMC5137422.pdf
February 2015) was down- loaded from NCBI ( http://www.ncbi.nlm.nih.gov/ ).,OADS,/arxiv_data1/oa_pdf/55/a0/gkw692.PMC5137423.pdf
( A) Bar chart depicting the frequency of orthologous hits (n = 618)aspredictedbyPSI-BLAST( 39)(e-value ≤0.005)acrossseveralordersofthephylumActinobacteriaandphagesasannotatedintheNCBIdatabase (http://www.ncbi.nlm.nih.gov/ ).,OADS,/arxiv_data1/oa_pdf/55/a0/gkw692.PMC5137423.pdf
"Vienna, http://www.R-project.org 44.",Non-OADS,/arxiv_data1/oa_pdf/55/a0/gkw692.PMC5137423.pdf
Genomic DNA was isolated according tothe ‘NIB-n-grab’ method ( http://fangman-brewer.genetics.,OADS,/arxiv_data1/oa_pdf/61/ca/gkw720.PMC5137426.pdf
The muscle expressed genes identified by reporter or immuno-staining assay were downloaded from WormBase(ftp://caltech.wormbase.org/pub/wormbase/expr dump).,OADS,/arxiv_data1/oa_pdf/6a/16/gkw734.PMC5137427.pdf
"Enrichment analysis Tissue enrichment predictions were analysed by the Tis- sue Expression Predictions for C.elegans program, version 1.0 (http://worm-tissue.princeton.edu/search/multi ).DEGs weresubmittedtotheDAVIDwebsite(version6.7)forGO enrichment analysis with all trans-spliced genes as back-ground (32,33).",OADS,/arxiv_data1/oa_pdf/6a/16/gkw734.PMC5137427.pdf
Coding potential analysis CPCscoreswerecalculatedbytheCodingPotentialCalcu- lator(http://cpc.cbi.pku.edu.cn/ ).APythonscriptwasused to calculate the distances from TSASs to the first down-stream ATG or CAT.,OADS,/arxiv_data1/oa_pdf/6a/16/gkw734.PMC5137427.pdf
The DAC and DERblacklisted regions were downloaded from the UCSC ta- ble browser ( http://hgwdev.cse.ucsc.edu/cgi-bin/hgFileUi?,OADS,/arxiv_data1/oa_pdf/c6/77/gkw741.PMC5137431.pdf
The images were processed using XDS ( 45)a n ds c a l e d with Aimless ( 46) from the CCP4 program suite ( 47) with the help of the autoxds script developed by Ana Gonza- lezandYingssuTsai( http://smb.slac.stanford.edu/facilities/ software/xds ).,OADS,/arxiv_data1/oa_pdf/10/f2/gkw768.PMC5137436.pdf
"ACCESSION NUMBERS Coordinates and structure factors have been deposited in the Protein Data Bank ( http://www.rcsb.org/ ) with acces- sion numbers 5HF7, 5FF8 and 5JXY.",OADS,/arxiv_data1/oa_pdf/10/f2/gkw768.PMC5137436.pdf
AnalysisoftheSarA-protectedsequencesonthe srn3610sprCandsrn9340promoters.Thealignmentofthe sprC47andsrn934051sequences wasperformedusingClustalOmegasoftware( http://www.ebi.ac.uk/Tools/msa/clustalo/ ).Boxesoutlinethe −35(yellow)and −10(red)boxes.TheTSSis indicatedwithablackarrow;theSarAbindingsitedefinedbySterba etal.,OADS,/arxiv_data1/oa_pdf/3e/6c/gkw777.PMC5137438.pdf
This DNA seg- ment is inserted between the SacI and KpnI sites of the pMA plasmid (map available from the Thermofisher website:https://www.thermofisher.com/content/dam/LifeTech/ Documents/geneart/geneart-vector-map.pdf ).,OADS,/arxiv_data1/oa_pdf/da/d5/gkw821.PMC5137440.pdf
All individual compounds and media conditions used can be found under http://www.biolog.com/products-static/ phenotype microbial cellsuse.php.,OADS,/arxiv_data1/oa_pdf/68/47/gkw856.PMC5137444.pdf
In silicosearch for PARbinding motifs PARP1 was screened for PAR-binding motifs (PBMs) using the PATTINPROT tool ( https://npsa-prabi.ibcp.,OADS,/arxiv_data1/oa_pdf/9f/57/gkw859.PMC5137445.pdf
"The PBM-pattern [HKR]- X-[AVILFWP]-[AVILFWP]-[HKR]- [HKR]-[AVILFWP]- [AVILFWP] ( 42) was searched against the full-length pro- tein sequence of PARP1 ( http://www.uniprot.org/ ; P09874 PARP1HUMAN), allowing for one (PBM1) or two mis- matches(PBM2).",OADS,/arxiv_data1/oa_pdf/9f/57/gkw859.PMC5137445.pdf
"Acquisition of time lapses at multiple positions was facilitated by an automated macro (LIC macro, Uni-versity of Freiburg, Germany) and analysis was performed with a line analysis macro for ImageJ which is available for download on http://www.bioimaging-center.uni-konstanz.",OADS,/arxiv_data1/oa_pdf/9f/57/gkw859.PMC5137445.pdf
"Thus, it can readily be used to evaluate the effects of large numbers ofSNVs.Wealsoprovidesourcecodefortheworkflowonour GitHubpage ( https://github.com/gersteinlab/frustration ).",Non-OADS,/arxiv_data1/oa_pdf/4d/e3/gkw927.PMC5137452.pdf
A full list of contribut- ing groups can be found at http://exac.broadinstitute.org/ about.,Non-OADS,/arxiv_data1/oa_pdf/4d/e3/gkw927.PMC5137452.pdf
**Values fromMolprobityserver ( http://molprobity.biochem.duke.edu/ ).,OADS,/arxiv_data1/oa_pdf/75/a6/gkw941.PMC5137455.pdf
"Motivatedby the above, we have developed the ProTraits resource, a comprehensive atlas of 424 microbial phenotypes, cov- ering 3046 Bacterial and Archaeal species, each receivingon average 165 novel high-confidence annotations in ad- dition to 23 previously known labels; available online at http://protraits.irb.hr/ .",OADS,/arxiv_data1/oa_pdf/34/51/gkw964.PMC5137458.pdf
"Validating theaccuracy of novel annotations In summary, we provide predictions for a comprehensive set of 424 microbial traits using six independent text cor- pora, and five independent sources of genomic data; avail- able athttp://protraits.irb.hr/ .O ft h e s e ∼545 000 novel an- notations (at FDR <10%, including both positive and negativeannotations;SupplementaryFigureS3), ∼308000 are supported in two or more independent data sources (Figure5A).",OADS,/arxiv_data1/oa_pdf/34/51/gkw964.PMC5137458.pdf
Availableat: https://code.google.com/archive/p/stop-words/ 30.,Non-OADS,/arxiv_data1/oa_pdf/34/51/gkw964.PMC5137458.pdf
http://fast-random-forest.googlecode.com 51.,Non-OADS,/arxiv_data1/oa_pdf/34/51/gkw964.PMC5137458.pdf
"UserBulletinno.2.PEAppliedBiosystems,ABwebsite,bulletinreference:4303859B777802-002, http://docs.appliedbiosystems.com/pebiodocs/04303859.pdf 42.",OADS,/arxiv_data1/oa_pdf/ba/e5/gkw981.PMC5137460.pdf
Dane statystyczne dotyczące zatrudnienia; http://ec.europa.,Non-OADS,/arxiv_data1/oa_pdf/df/a9/MR-15-28452.PMC5137474.pdf
Zadowolenie z  pracy i  jej oceny; http://www.cbos.pl/SPISKOM.POL/2013/K_010_13.PDF.,Non-OADS,/arxiv_data1/oa_pdf/df/a9/MR-15-28452.PMC5137474.pdf
Zadowolenie z życia; http://cbos.pl/SPISKOM.POL/2015/K_003_15.PDF.,Non-OADS,/arxiv_data1/oa_pdf/df/a9/MR-15-28452.PMC5137474.pdf
http://onkologia.org.pl/k/epide-miologia/ dostęp z dnia 18/04/2016.,Non-OADS,/arxiv_data1/oa_pdf/82/71/MR-15-28568.PMC5137477.pdf
"Silver  Spring, MD: US Department of Health and Human Services, Food and Drug Administration; http://www.fda.gov/BiologicsBloodVaccines/Vac- cines/ApprovedProducts/ucm426520.htm (access 2014.12.10).",Non-OADS,/arxiv_data1/oa_pdf/a5/e1/MR-15-28662.PMC5137481.pdf
"Sil- ver Spring, MD: US Department of Health and Human Services, Food   and Drug Administration, 2014; http://www.fda.gov/downloads/Bio- logics-BloodVaccines/Vaccines/ApprovedProducts/UCM426457.pdf (ac-cess 2015.08.01).",Non-OADS,/arxiv_data1/oa_pdf/a5/e1/MR-15-28662.PMC5137481.pdf
"Atlanta, GA: US Department of Health and Human Services; http://www.cdc.gov/vaccines/acip/recs/ grade/table-refs.html (access 2015.03.27).",Non-OADS,/arxiv_data1/oa_pdf/a5/e1/MR-15-28662.PMC5137481.pdf
"Presentation before the Advisory Committee on Immunization Practices (ACIP), Atlanta, GA: US Department of Health and Human   Services, CDC; http://www.cdc.gov/vaccines/acip/meetings/downloads/ min-archive/min-2014-10.pdf (access 2014.10.30).",Non-OADS,/arxiv_data1/oa_pdf/a5/e1/MR-15-28662.PMC5137481.pdf
"Silver Spring, MD: US Department of Health and Human Ser - vices; Food and Drug Administration; http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM186981.pdf.",Non-OADS,/arxiv_data1/oa_pdf/a5/e1/MR-15-28662.PMC5137481.pdf
"IARC,  Lyon 2008; http://globocan.iarc.fr/Tab.",Non-OADS,/arxiv_data1/oa_pdf/cf/75/MR-15-28663.PMC5137482.pdf
"11, 1197 –1205 http://dx.doi.org/10.1080/15384047.2016.1235668",Non-OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
Eur J Cell Biol 2005; 84:97-107; PMID:15819393; http://dx.doi.org/10.1016/j.ejcb.2004.12.012 3.,OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
Cancer Cell 2002; 2:103-12; PMID:12204530; http://dx.doi.org/10.1016/S1535-6108(02)00102-2 4.,Non-OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
Genes Dev 2000; 14:2393-409; PMID:11018009; http://dx.doi.org/10.1101/gad.813200 6.,OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
Science 1996; 274:1672-7; PMID:8939849; http://dx.doi.org/10.1126/science.274.5293.1672 7.,Non-OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
JBiol Chem 1997; 272:4528-35; PMID:9020179; http://dx.doi.org/ 10.1074/jbc.272.7.4528 9.,OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
Cancer Res 2008; 68:9686-92;PMID:19047146; http://dx.doi.org/10.1158/0008-5472.CAN-08-1083 10.,Non-OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
Mol Cell Biol 2000; 20:7751-63; PMID:11003670; http://dx.doi.org/10.1128/MCB.20.20.7751-7763.2000 11.,Non-OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
Cancer Res 2006; 66:4299-308;PMID:16618755; http://dx.doi.org/10.1158/0008-5472.CAN-05-2507 12.,Non-OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
Cancer Bio Ther 2008; 17:833-9; http://dx.doi.org/10.4161/cbt.7.6.5839 14.,Non-OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
Cell Cycle 2014; 13:3611-7; PMID:25483096; http://dx.doi.org/10.4161/15384101.2014.964093 17.,Non-OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
Nature Rev Cancer 2002; 2:442-54; http://dx.doi.org/10.1038/nrc822 18.,Non-OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
Cancer Res 2008; 68:5104-12; PMID:18593909; http://dx.doi.org/10.1158/0008-5472.CAN-07-5680 19.,Non-OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
J Biol Chem 2012; 287:7896-906; PMID:22262832;http://dx.doi.org/10.1074/jbc.M111.313759 20.,OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
J Biol Chem 2013; 288:11572-80; http://dx.doi.org/10.1074/jbc.M112.434951 21.,OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
J Boil Chem 2014; 289:4116-25; http://dx.doi.org/10.1074/jbc.M113.533505 22.,OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
Mod Pathol 2005; 18:565-72;PMID:15502804; http://dx.doi.org/10.1038/modpathol.3800324 23.,Non-OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
Cancer Res 2016; 76:193- 96; PMID:27309387; http://dx.doi.org/10.1158/0008-5472.CAN-15-2091 25.,Non-OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
FEBS J2013; 280:627-43; PMID:22299668; http://dx.doi.org/10.1111/j.1742-4658.2012.08511.x 27.,OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
ExpCell Res 2006; 312:2757-63; PMID:16764854; http://dx.doi.org/10.1016/j.yexcr.2006.05.002 30.,OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
Biochem Biophys Res Comm 2002; 297:463-7; http://dx.doi.org/10.1016/S0006-291X(02)02236-2 31.,OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
J Biol Chem 2003; 278:13819-28;PMID:12574161; http://dx.doi.org/10.1074/jbc.M209621200 33.,OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
Methods 2003; 30:256-68;PMID:12798140; http://dx.doi.org/10.1016/S1046-2023(03)00032-X 35.,OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
Semin Cancer Biol 1995; 6:175-84;PMID:7495986; http://dx.doi.org/10.1006/scbi.1995.0021 3 6 .,Non-OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
Nat Methods 2007; 4:359- 65; PMID:17396127; http://dx.doi.org/10.1038/nmeth1015 37.,OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
Nat Rev Mol Cell Bio 2014; 15:178-96;http://dx.doi.org/10.1038/nrm3758 39.,OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
Dev Cell 2008; 14:818-29; PMID:18539112; http://dx.doi.org/10.1016/j.devcel.2008.05.009 42.,OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
Breast Dis 2010; 32:35-48; PMID:21778573; http://dx.doi.org/10.3233/BD-2010-0307 43.,Non-OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
Cancer Res2013; 73:205-14; PMID:23117887; http://dx.doi.org/10.1158/0008- 5472.CAN-12-1394 44.,Non-OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
Nat Rev Drug Discovery 2015; 14:130-46; PMID:25633797; http://dx.doi.org/10.1038/nrd4504 46.,Non-OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
Lancet Oncol 2015; 16:25-35; PMID:25524798; http://dx.doi.org/10.1016/S1470-2045(14)71159-3 4 7 .,Non-OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
Breast Cancer Re s 2009; 11:25-35; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
Oncogene 2000; 19:5464-70; PMID:11114723; http://dx.doi.org/10.1038/sj.onc.1203930CANCER BIOLOGY & THERAPY 1205,Non-OADS,/arxiv_data1/oa_pdf/25/a2/kcbt-17-11-1235668.PMC5137485.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License ( http://creativecommons.org/licenses/by-nc/3.0/ ), which permits unre- stricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
"11, 1158 –1167 http://dx.doi.org/10.1080/15384047.2016.1235663",Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
Dig Dis Sci 2009; 54:2410-7; PMID:19101799; http://dx.doi.org/10.1007/s10620-008-0649-4 3.,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
Oncol Rep 2004; 11:605-11;PMID:14767510; http://dx.doi.org/10.3892/or.11.3.6054 .,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
Clin Cancer Res 2016; 22:230-42; PMID:26283684; http://dx.doi.org/10.1158/1078-0432.CCR-15-0603 5.,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
Int J Cancer 2003; 103:657-63; PMID:12494475; http://dx.doi.org/10.1002/ijc.10860 6.,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
Clin Cancer Res 2009; 15:4423-30;PMID:19531623; http://dx.doi.org/10.1158/1078-0432.CCR-09-0473 7.,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
Am JPathol 2003; 163:2271-6; PMID:14633601; http://dx.doi.org/10.1016/S0002-9440(10)63584-5 10.,OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
Clin Cancer Res 2004;10:5145-50; PMID:15297418; http://dx.doi.org/10.1158/1078-0432.,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
Clin Exp Metastasis 2006; 23:357-65; PMID:17146615; http://dx.doi.org/10.1007/s10585-006-9045-7 12.,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
Clin Cancer Res2006; 12:353-60; PMID:16428472; http://dx.doi.org/10.1158/1078-0432.CCR-05-1505 13.,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
Int J Med Sci 2008; 5:121-6; PMID:18566674; http://dx.doi.org/10.7150/ijms.5.121 14.,OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
Oncol Rep 2008; 19:151-6; PMID:18097589; http://dx.doi.org/10.3892/or.19.1.151 17.,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
J Cancer Res Clin Oncol 2011; 137:761-9; PMID:20614133; http://dx.doi.org/10.1007/s00432-010-0936-2 18.,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
Am J Pathol 2002; 160:1009-19; PMID:11891198; http://dx.doi.org/10.1016/S0002-9440(10)64922-X1166 J. HASEGAWA ET AL.,OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
Cancer Cell 2005; 8:111-8; PMID:16098464;http://dx.doi.org/10.1016/j.ccr.2005.07.005 20.,OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
Oncogene 2007; 26:3279-90; PMID:17496922; http://dx.doi.org/10.1038/sj.onc.1210421 21.,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
CancerRes 2015; 75:3327-39; PMID:26130649; http://dx.doi.org/10.1158/ 0008-5472.CAN-14-2798 22.,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
J Cell Biol 2013; 201:467-84; PMID:23629968; http://dx.doi.org/10.1083/jcb.201205176 23.,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
Nat Rev Cancer 2012; 12:278-87; PMID:22437872; http://dx.doi.org/10.1038/nrc3236 24.,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
Immunotherapy2014; 6:1187-206; PMID:25496334; http://dx.doi.org/10.2217/imt.14.94 26.,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
Oncol Res Treat 2015; 38:185-92; PMID:25877943; http://dx.doi.org/ 10.1159/000381524 27.,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
J Immunother Cancer 2014; 2:29; http://dx.doi.org/10.1186/ s40425-014-0029-x 28.,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
Nat Rev Immunol 2002; 2:735-47; PMID:12360212; http://dx.doi.org/10.1038/nri911 29.,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
Cell 2015; 161:1035-45; PMID:25976835;http://dx.doi.org/10.1016/j.cell.2015.04.016 30.,OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
Fc-receptor interactions regulate both cyto- toxic and immunomodulatory therapeutic antibody effector functions.Cancer Immunol Res 2015; 3:704-13; PMID:26138698; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
J Biol Chem 2002; 277:26733-40; PMID:11986321; http://dx.doi.org/10.1074/jbc.M202069200 32.,OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
J Biol Chem 2003; 278:3466-73; PMID:12427744; http://dx.doi.org/10.1074/jbc.M210665200 33.,OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
Cancer Discov 2015; 5:274-87; PMID:25542448; http://dx.doi.org/ 10.1158/2159-8290.CD-14-029534.,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
MAbs 2012; 4:419-25; PMID:22699226;http://dx.doi.org/10.4161/mabs.20996 35.,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
Clin Cancer Res 2004; 10:6248-55; PMID:15448014; http://dx.doi.org/10.1158/1078-0432.CCR-04-0850 36.,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
J Immunol 2014; 192:5618-24; PMID:24795454; http://dx.doi.org/10.4049/jimmunol.1400288 37.,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
Clin Cancer Res 2013; 19:1126-38; PMID:23209031;http://dx.doi.org/10.1158/1078-0432.CCR-12-0989 38.,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
Clin Cancer Res 2013; 19:1858-72; PMID:23444227; http://dx.doi.org/10.1158/1078-0432.CCR-12-2426 39.,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
Blood 2011; 117:2423-32; PMID:21193697; http://dx.doi.org/10.1182/ blood-2010-08-301945 4 1 .,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
J Clin Invest 2012; 122:1066-75; PMID:22326955; http://dx.doi.org/10.1172/JCI61226 42.,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
J Clin Invest 2014; 124:2668-82; PMID:24837434; http://dx.doi.org/10.1172/JCI73014 43.,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
Nucleic Acids Res 1997; 25:3389-402; PMID:9254694; http://dx.doi.org/10.1093/nar/25.17.3389 45.,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
J Mol Biol 2004; 340:783-95; PMID:15223320; http://dx.doi.org/10.1016/j.jmb.2004.05.028 46.,OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
J Mol Biol 2001; 305:567-80; PMID:11152613; http://dx.doi.org/10.1006/jmbi.2000.4315 47.,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
Nucleic Acids Res 2015; 43:D222-6; PMID:25414356; http://dx.doi.org/10.1093/nar/gku1221CANCER BIOLOGY & THERAPY 1167,Non-OADS,/arxiv_data1/oa_pdf/75/28/kcbt-17-11-1235663.PMC5137487.pdf
"11, 1206 –1212 http://dx.doi.org/10.1080/15384047.2016.1210742",Non-OADS,/arxiv_data1/oa_pdf/f1/0e/kcbt-17-11-1210742.PMC5137495.pdf
N Engl J Med 2004; 350:2343-51; PMID:15175436; http://dx.doi.org/10.1056/NEJMoa032709 4.,OADS,/arxiv_data1/oa_pdf/f1/0e/kcbt-17-11-1210742.PMC5137495.pdf
Crit Rev Oncol Hemato 2006; 59:159-68; PMID: 16806962; http://dx.doi.org/10.1016/j.critrevonc.2006.01.001 6.,OADS,/arxiv_data1/oa_pdf/f1/0e/kcbt-17-11-1210742.PMC5137495.pdf
Muscle Nerve2005; 32:51-60; PMID:15880395; http://dx.doi.org/10.1002/mus.20340 7.,Non-OADS,/arxiv_data1/oa_pdf/f1/0e/kcbt-17-11-1210742.PMC5137495.pdf
Cancer Che mother Pharmacol 2008; 61:349-54; PMID:17849118; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/0e/kcbt-17-11-1210742.PMC5137495.pdf
J Pharmacol Sci 2014; 126:47-55;PMID:25141998; http://dx.doi.org/10.1254/jphs.14134FP 10.,Non-OADS,/arxiv_data1/oa_pdf/f1/0e/kcbt-17-11-1210742.PMC5137495.pdf
Mol Pain 2013; 9:53; PMID:24152430; http://dx.doi.org/10.1186/1744-8069-9-53 11.,Non-OADS,/arxiv_data1/oa_pdf/f1/0e/kcbt-17-11-1210742.PMC5137495.pdf
J Pain 2012; 13:276-84; PMID:22325298; http://dx.doi.org/10.1016/j.jpain.2011.11.009CANCER BIOLOGY & THERAPY 1211,Non-OADS,/arxiv_data1/oa_pdf/f1/0e/kcbt-17-11-1210742.PMC5137495.pdf
Diabetes ResClin Pract 1994; 26:121-8; PMID:7705193; http://dx.doi.org/10.1016/ 0168-8227(94)90149-X 13.,Non-OADS,/arxiv_data1/oa_pdf/f1/0e/kcbt-17-11-1210742.PMC5137495.pdf
Jpn J Pharmacol 1999; 79:387-91; PMID:10230868; http://dx.doi.org/10.1254/jjp.79.387 14.,Non-OADS,/arxiv_data1/oa_pdf/f1/0e/kcbt-17-11-1210742.PMC5137495.pdf
J Oncol 2013; 2013:139740; PMID:24307899; http://dx.doi.org/10.1155/2013/139740 16.,Non-OADS,/arxiv_data1/oa_pdf/f1/0e/kcbt-17-11-1210742.PMC5137495.pdf
Eur J Cancer 2012; 48:1407-13; PMID:21907570; http://dx.doi.org/10.1016/j.ejca.2011.08.009 17.,Non-OADS,/arxiv_data1/oa_pdf/f1/0e/kcbt-17-11-1210742.PMC5137495.pdf
Sci Rep 2015;5:16078; PMID:26542342; http://dx.doi.org/10.1038/srep16078 18.,OADS,/arxiv_data1/oa_pdf/f1/0e/kcbt-17-11-1210742.PMC5137495.pdf
J Pharmacol Sci 2014; 125:91- 8; PMID:24784702; http://dx.doi.org/10.1254/jphs.13244FP 19.,Non-OADS,/arxiv_data1/oa_pdf/f1/0e/kcbt-17-11-1210742.PMC5137495.pdf
Am J Chin Med 1994; 22:83-94; PMID:8030622; http://dx.doi.org/10.1142/S0192415X94000115 20.,Non-OADS,/arxiv_data1/oa_pdf/f1/0e/kcbt-17-11-1210742.PMC5137495.pdf
PLoS One 2011; 6:e23510; PMID:21876755; http://dx.doi.org/10.1371/journal.pone.0023510 21.,Non-OADS,/arxiv_data1/oa_pdf/f1/0e/kcbt-17-11-1210742.PMC5137495.pdf
Mol Pain 2008; 4:25; PMID:18620588; http://dx.doi.org/10.1186/1744-8069-4-25 23.,Non-OADS,/arxiv_data1/oa_pdf/f1/0e/kcbt-17-11-1210742.PMC5137495.pdf
J Comp Neurol 2005; 493:596-606; PMID:16304633; http://dx.doi.org/10.1002/cne.20794 24.,Non-OADS,/arxiv_data1/oa_pdf/f1/0e/kcbt-17-11-1210742.PMC5137495.pdf
Neurosci Lett 2009; 458:93-5; PMID:19375484; http://dx.doi.org/10.1016/j.neulet.2009.04.029 25.,OADS,/arxiv_data1/oa_pdf/f1/0e/kcbt-17-11-1210742.PMC5137495.pdf
Mol Pain 2012; 8:55; PMID:22839205; http://dx.doi.org/10.1186/1744-8069-8-55 26.,Non-OADS,/arxiv_data1/oa_pdf/f1/0e/kcbt-17-11-1210742.PMC5137495.pdf
Nature 2003; 424:778-83;PMID:12917686; http://dx.doi.org/10.1038/nature01786 27.,Non-OADS,/arxiv_data1/oa_pdf/f1/0e/kcbt-17-11-1210742.PMC5137495.pdf
J Pain 2013; 14:205-14; PMID:23374942; http://dx.doi.org/10.1016/j.jpain.2012.11.002 28.,OADS,/arxiv_data1/oa_pdf/f1/0e/kcbt-17-11-1210742.PMC5137495.pdf
J Pain 2012; 13:293-303;PMID:22285612; http://dx.doi.org/10.1016/j.jpain.2011.12.002 29.,OADS,/arxiv_data1/oa_pdf/f1/0e/kcbt-17-11-1210742.PMC5137495.pdf
PLoS One 2013; 8:e60733; PMID:23585846; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/0e/kcbt-17-11-1210742.PMC5137495.pdf
Phyt- other Res 2000; 4:505-9; PMID: 11054839; http://dx.doi.org/ 10.1002/1099-1573(200011)14:7%3c505::AID-PTR648%3e3.0.CO;2-S 31.,OADS,/arxiv_data1/oa_pdf/f1/0e/kcbt-17-11-1210742.PMC5137495.pdf
Biol Pharm Bull 2009; 32:1741-8; PMID:19801837; http://dx.doi.org/10.1248/bpb.32.1741 32.,Non-OADS,/arxiv_data1/oa_pdf/f1/0e/kcbt-17-11-1210742.PMC5137495.pdf
J Eth-nopharmacol 2005; 96:165-9; PMID:15588666; http://dx.doi.org/10.1016/j.jep.2004.09.0281212 K. MIZUNO ET AL.,OADS,/arxiv_data1/oa_pdf/f1/0e/kcbt-17-11-1210742.PMC5137495.pdf
"11, 2790 –2796 http://dx.doi.org/10.1080/21645515.2016.1198455",Non-OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Lancet 2000;356:1795-9; PMID:11117911; http://dx.doi.org/10.1016/S0140-6736 (00)03231-1 [3] Herberman RB, Nunn ME, Holden HT, Lavrin DH.",OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Int J Cancer 1975; 16:230-9; PMID:1080480; http://dx.doi.org/10.1002/ijc.2910160205 [4] Herberman RB, Nunn ME, Lavrin DH.",Non-OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
Int J Cancer 1975; 16:216- 29; PMID:50294; http://dx.doi.org/10.1002/ijc.29101602042794 S. S. TAY ET AL.,OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Front Immunol 2012; 3:335; PMID:23162553;http://dx.doi.org/10.3389/ ﬁmmu.2012.00335 [6] Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or adaptive immunity?",Non-OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Science 2011; 331:44-9; PMID:21212348;http://dx.doi.org/10.1126/science.1198687 [7] Wallin RP, Screpanti V, Michaelsson J, Grandien A, Ljunggren HG.",OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Regulation of perforin-independent NK cell-mediated cytotoxicity.Eur J Immunol 2003; 33:2727-35; PMID:14515256; http://dx.doi.org/10.1002/eji.200324070 [8] Farag SS, Caligiuri MA.",Non-OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Blood Rev 2006; 20:123-37; PMID:16364519; http://dx.doi.org/10.1016/j.blre.2005.10.001 [9] Morvan MG, Lanier LL.",Non-OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Nat Rev Cancer 2015; 16:7-19; http://dx.doi.org/ 10.1038/nrc.2015.5 [10] Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor.",OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
Annu Rev Immunol 2013; 31:413-41; PMID:23298206; http://dx.doi.org/10.1146/ annurev-immunol-032712-095951 [11] Karre K. Immunology.,Non-OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Science 2002; 295:2029- 31; PMID:11896262; http://dx.doi.org/10.1126/science.1070538 [12] Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang B, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lewis D, Hippen K, et al.Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.",Non-OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Blood 2014; 123:3855-63; PMID:24719405; http://dx.doi.org/10.1182/blood-2013-10-532531 [13] Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, et al.",Non-OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Blood 2005; 105:3051-7; PMID:15632206; http://dx.doi.org/10.1182/ blood-2004-07-2974 [14] Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, Pui CH, Leung W. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.",Non-OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"J Clin Oncol 2010; 28:955-9;PMID:20085940; http://dx.doi.org/10.1200/JCO.2009.24.4590 [15] Childs RW, Carlsten M. Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens.",Non-OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Nat Rev Drug Discov 2015; 14:487-98; PMID:26000725; http://dx.doi.org/10.1038/nrd4506 [16] Wiernik A, Foley B, Zhang B, Verneris MR, Warlick E, Gleason MK, Ross JA, Luo X, Weisdorf DJ, Walcheck B, et al.",OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Clin Cancer Res 2013; 19:3844-55; PMID:23690482; http://dx.doi.org/10.1158/1078- 0432.CCR-13-0505 [17] Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, Spellman S, Haagenson MD, Lenvik AJ, Litzow MR, et al.",Non-OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Blood 2014; 123:3016-26; PMID:24652987; http://dx.doi.org/10.1182/blood-2013-10-533398 [18] Baluna R, Vitetta ES.",Non-OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Immunopharmacology 1997; 37:117-32; PMID:9403331;http://dx.doi.org/10.1016/S0162-3109(97)00041-6 [19] Stern M, Passweg JR, Meyer-Monard S, Esser R, Tonn T, Soerensen J, Paulussen M, Gratwohl A, Klingebiel T, Bader P, et al.",OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Bone Marrow Transplant 2013; 48:433-8; PMID:22941380; http://dx.doi.org/ 10.1038/bmt.2012.162 [20] Barrett AJ, Battiwalla M. Relapse after allogeneic stem cell transplan- tation.",Non-OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
Semin Immunol2014; 26:173-9; PMID:24613727; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Blood 2011; 118:2784-92; PMID:21757615;http://dx.doi.org/10.1182/blood-2011-04-347070 [23] Klingebiel T, Cornish J, Labopin M, Locatelli F, Darbyshire P, Handgretinger R, Balduzzi A, Owoc-Lempach J, Fagioli F, Or R,et al.",OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Blood 2010; 115:3437-46; PMID:20040760; http://dx.doi.org/ 10.1182/blood-2009-03-207001 [24] Miller JS, Rooney CM, Curtsinger J, McElmurry R, McCullar V, Verneris MR, Lapteva N, McKenna D, Wagner JE, Blazar BR, et al.Expansion and homing of adoptively transferred human natural killer cells in immunode ﬁcient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy.Biol Blood Marrow Transplant 2014; 20:1252-7; PMID:24816582; http://dx.doi.org/10.1016/j.bbmt.2014.05.004 [25] Schmohl JU, Felices M, Taras L, Miller JS, Vallera DA.",Non-OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Mol Cancer Ther 2012; 11:2674-84; PMID:23075808; http://dx.doi.org/10.1158/1535- 7163.MCT-12-0692 [27] Romain G, Senyukov V, Rey-Villamizar N, Merouane A, Kelton W, Liadi I, Mahendra A, Charab W, Georgiou G, Roysam B, et al.",Non-OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Blood 2014; 124:3241-9; PMID:25232058; http://dx.doi.org/10.1182/blood-2014-04-569061 [28] Bowles JA, Wang SY, Link BK, Allan B, Beuerlein G, Campbell MA, Marquis D, Ondek B, Wooldridge JE, Smith BJ, et al.",OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Blood 2006; 108:2648-54; PMID:16825493; http://dx.doi.org/ 10.1182/blood-2006-04-020057 [29] Belting L, Homberg N, Przewoznik M, Brenner C, Riedel T, Flatley A, Polic B, Busch DH, Rocken M, Mocikat R. Critical role of the NKG2D receptor for NK cell-mediated control and immune escape of B-cell lymphoma.",OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Eur J Immunol 2015; 45:2593-601;PMID:26151313; http://dx.doi.org/10.1002/eji.201445375 [30] Deng W, Gowen BG, Zhang L, Wang L, Lau S, Iannello A, Xu J, Rovis TL, Xiong N, Raulet DH.",Non-OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Science 2015; 348:136-9; PMID:25745066; http://dx.doi.org/10.1126/science.1258867 [31] Dahlberg CI, Sarhan D, Chrobok M, Duru AD, Alici E. Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gainand Sustain Anti-Tumor Activity.",OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Front Immunol 2015; 6:605; PMID:26648934; http://dx.doi.org/10.3389/ ﬁmmu.2015.00605 [32] Choi I, Yoon SR, Park SY, Kim H, Jung SJ, Jang YJ, Kang M, Yeom YI, Lee JL, Kim DY, et al.",OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Biol Blood Marrow Trans- plant 2014; 20:696-704; PMID:24525278; http://dx.doi.org/10.1016/j.bbmt.2014.01.031 [33] Shah NN, Baird K, Delbrook CP, Fleisher TA, Kohler ME, Rampertaap S, Lemberg K, Hurley CK, Kleiner DE, Merchant MS, et al.",Non-OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"125:784-92; PMID:25452614; http://dx.doi.org/10.1182/blood-2014- 07-592881 [34] Shiokawa M, Takahashi T, Murakami A, Kita S, Ito M, Sugamura K, Ishii N. In vivo assay of human NK-dependent ADCC using NOD/ SCID/gammac(null) (NOG) mice.",OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Biochem Biophys Res Commun 2010; 399:733-7; PMID:20696130; http://dx.doi.org/10.1016/j.bbrc.2010.07.145 [35] Frey NV, Porter DL.",OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Am J Hematol 2016; 91:146-50; PMID:26574400; http://dx.doi.org/10.1002/ajh.24238 [36] Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, et al.",OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
Lancet 2015; 385:517-28; PMID:25319501; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"N Engl J Med 2014; 371:1507-17; PMID:25317870; http://dx.doi.org/ 10.1056/NEJMoa1407222 [38] van den Berg JH, Gomez-Eerland R, van de Wiel B, Hulshoff L, van den Broek D, Bins A, Tan HL, Harper JV, Hassan NJ, Jakobsen BK, et al.",OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Mol Ther 2015; 23:1541-50; PMID:25896248; http://dx.doi.org/ 10.1038/mt.2015.60[39] Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA.",OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Mol Ther 2010; 18:843-51; PMID:20179677; http://dx.doi.org/10.1038/mt.2010.24 [40] Minagawa K, Zhou X, Mineishi S, Di Stasi A. Seatbelts in CAR ther- apy: How Safe Are CARS?",Non-OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Oncoimmunology 2014; 3:e28147; PMID:25340009; http://dx.doi.org/10.4161/onci.28147 [42] Boissel L, Betancur-Boissel M, Lu W, Krause DS, Van Etten RA, Wels WS, Klingemann H. Retargeting NK-92 cells by means ofCD19- and CD20-speci ﬁc chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity.",Non-OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"Oncoimmu- nology 2013; 2:e26527; PMID:24404423; http://dx.doi.org/10.4161/ onci.26527 [43] Suck G, Odendahl M, Nowakowska P, Seidl C, Wels WS, Klingemann HG, Tonn T. NK-92: an ‘off-the-shelf therapeutic ’for adoptive natural killer cell-based cancer immunotherapy.",Non-OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
Blood 2012; 119:2665-74; PMID:22180440; http://dx.doi.org/ 10.1182/blood-2011-10-3869952796 S. S. TAY ET AL.,OADS,/arxiv_data1/oa_pdf/34/42/khvi-12-11-1198455.PMC5137511.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License ( http://creativecommons.org/licenses/by-nc/3.0/ ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/67/2f/khvi-12-11-1202389.PMC5137517.pdf
"11, 2946 –2952 http://dx.doi.org/10.1080/21645515.2016.1202389",Non-OADS,/arxiv_data1/oa_pdf/67/2f/khvi-12-11-1202389.PMC5137517.pdf
"Lancet 2009; 374:893-902;PMID:19748398; http://dx.doi.org/10.1016/S0140-6736(09)61204-6 [2] Mof ﬁtt KL, Malley R. Next generation pneumococcal vaccines.",Non-OADS,/arxiv_data1/oa_pdf/67/2f/khvi-12-11-1202389.PMC5137517.pdf
"Curr Opin Immunol 2011; 23:407-13; PMID:21514128; http://dx.doi.org/10.1016/j.coi.2011.04.002 [3] Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L, Reithinger R, Muenz LR, O ’Brien KL.",OADS,/arxiv_data1/oa_pdf/67/2f/khvi-12-11-1202389.PMC5137517.pdf
"Paediatr Respir Rev 2012; 13:258-64; PMID:23069126; http://dx.doi.org/10.1016/j.prrv.2011.12.001 [5] Pittet LF, Posfay-Barbe KM.",OADS,/arxiv_data1/oa_pdf/67/2f/khvi-12-11-1202389.PMC5137517.pdf
"Pneu mococcal vaccines for children: a global public health priorit y. Clin Microbiol Infect 2012; 18 (Suppl 5):25-36; PMID:22862432; http://dx.doi.org/10.1111/j.1469-0691.2012.03938.x [6] Kallio A, Sepponen K, Hermand P, Denoel P, Godfroid F, Melin M. Role of Pht proteins in attachment of Streptococcus pneumoniae torespiratory epithelial cells.",Non-OADS,/arxiv_data1/oa_pdf/67/2f/khvi-12-11-1202389.PMC5137517.pdf
"Infect Immun 2014; 82:1683-91;PMID:24491577; http://dx.doi.org/10.1128/IAI.00699-13 [7] Khan MN, Pichichero ME.",Non-OADS,/arxiv_data1/oa_pdf/67/2f/khvi-12-11-1202389.PMC5137517.pdf
"Infect Immun 2001; 69:949-58; PMID:11159990; http://dx.doi.org/10.1128/IAI.69.2.949-958.2001 [9] Turner P, Turner C, Green N, Ashton L, Lwe E, Jankhot A, Day N P ,W h i t eN J ,N o s t e nF ,G o l d b l a t tD .S e r u ma n t i b o d yr e s p o n s e sto pneumococcal colonization in the ﬁrst 2 years of life: results from an SE Asian longitudinal cohort study.",Non-OADS,/arxiv_data1/oa_pdf/67/2f/khvi-12-11-1202389.PMC5137517.pdf
"Clin Microbiol Infect2013; 19:E551-8; PMID:24255996; http://dx.doi.org/10.1111/1469-0691.12286 [10] Simell B, Ahokas P, Lahdenkari M, Poolman J, Henckaerts I, Kilpi TM, Kayhty H. Pneumococcal carriage and acute otitis media induceserum antibodies to pneumococcal surface proteins CbpA and PhtD in children.",Non-OADS,/arxiv_data1/oa_pdf/67/2f/khvi-12-11-1202389.PMC5137517.pdf
"FEMS Microbiol Lett 2006; 262:14-21; PMID:16907734;http://dx.doi.org/10.1111/j.1574-6968.2006.00360.x [12] Rioux S, Neyt C, Di Paolo E, Turpin L, Charland N, Labbe S, Mortier MC, Mitchell TJ, Feron C, Martin D, et al.",OADS,/arxiv_data1/oa_pdf/67/2f/khvi-12-11-1202389.PMC5137517.pdf
"Microbiology 2011; 157:336-48; PMID:20966093;http://dx.doi.org/10.1099/mic.0.042184-0 [13] Yun KW, Lee H, Choi EH, Lee HJ.",OADS,/arxiv_data1/oa_pdf/67/2f/khvi-12-11-1202389.PMC5137517.pdf
"PloS One 2015; 10:e0134055; PMID:26252211; http://dx.doi.org/10.1371/ journal.pone.0134055 [14] Kaur R, Surendran N, Ochs M, Pichichero ME.",OADS,/arxiv_data1/oa_pdf/67/2f/khvi-12-11-1202389.PMC5137517.pdf
"Infect Immun 2014; 82:5069-75; PMID:25245804; http://dx.doi.org/10.1128/IAI.02124-14 [15] Khan MN, Pichichero ME.",Non-OADS,/arxiv_data1/oa_pdf/67/2f/khvi-12-11-1202389.PMC5137517.pdf
"Infect Immun 2013; 81:3781-92; PMID:23897609; http://dx.doi.org/10.1128/IAI.00313-13 [16] Godfroid F, Hermand P, Verlant V, Denoel P, Poolman JT.",Non-OADS,/arxiv_data1/oa_pdf/67/2f/khvi-12-11-1202389.PMC5137517.pdf
"Infect Immun 2011; 79:238-45; PMID:20956575; http://dx.doi.org/10.1128/IAI.00378-10 [17] Verhoeven D, Perry S, Pichichero ME.",Non-OADS,/arxiv_data1/oa_pdf/67/2f/khvi-12-11-1202389.PMC5137517.pdf
"Vaccine 2011; 29:5495-501; PMID:21624422; http://dx.doi.org/ 10.1016/j.vaccine.2011.05.051 [19] Seiberling M, Bologa M, Brookes R, Ochs M, Go K, Neveu D, Kamtchoua T, Lashley P, Yuan T, Gurunathan S. Safety and immu-nogenicity of a pneumococcal histidine triad protein D vaccine can- didate in adults.",Non-OADS,/arxiv_data1/oa_pdf/67/2f/khvi-12-11-1202389.PMC5137517.pdf
"J Bacteriol 2010;192:4489-97; PMID:20601473; http://dx.doi.org/10.1128/JB.00064-10 [24] Bologa M, Kamtchoua T, Hopfer R, Sheng X, Hicks B, Bixler G, Hou V, Pehlic V, Yuan T, Gurunathan S. Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-bind-ing protein A (PcpA) vaccine and bivalent PcpA-pneumococcal his- tidine triad protein D vaccine.",Non-OADS,/arxiv_data1/oa_pdf/67/2f/khvi-12-11-1202389.PMC5137517.pdf
"Vaccine 2012; 30:7461-8; PMID:23123106; http://dx.doi.org/10.1016/j.vaccine.2012.10.076 [25] Verhoeven D, Xu Q, Pichichero ME.",Non-OADS,/arxiv_data1/oa_pdf/67/2f/khvi-12-11-1202389.PMC5137517.pdf
"Vaccine 2014; 32:3205-10; PMID:24731814; http://dx.doi.org/10.1016/j.vaccine.2014.04.004 [26] Briles DE, Hollingshead SK, King J, Swift A, Braun PA, Park MK, Ferguson LM, Nahm MH, Nabors GS.",Non-OADS,/arxiv_data1/oa_pdf/67/2f/khvi-12-11-1202389.PMC5137517.pdf
"J Infect Dis 2000;182:1694-701; PMID:11069242; http://dx.doi.org/10.1086/317602 [27] Tian H, Weber S, Thorkildson P, Kozel TR, Pirofski LA.",OADS,/arxiv_data1/oa_pdf/67/2f/khvi-12-11-1202389.PMC5137517.pdf
"Infect Immun 2009; 77:1502-13; PMID:19168739; http://dx.doi.org/10.1128/IAI.01075-08 [28] Posfay-Barbe KM, Galetto-Lacour A, Grillet S, Ochs MM, Brookes RH, Kraehenbuhl JD, Cevey-Macherel M, Gehri M, Gervaix A, Sieg- rist CA.",OADS,/arxiv_data1/oa_pdf/67/2f/khvi-12-11-1202389.PMC5137517.pdf
Immunity to pneumococcal surface proteins in children with community-acquired pneumonia: a distinct pattern of responsesto pneumococcal choline-binding protein A. Clin Microbiol Infect2011; 17:1232-8; PMID:21040158; http://dx.doi.org/10.1111/j.1469- 0691.2010.03389.x2952 M. M. OCHS ET AL.,Non-OADS,/arxiv_data1/oa_pdf/67/2f/khvi-12-11-1202389.PMC5137517.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License ( http://creativecommons.org/licenses/by-nc/3.0/ ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/64/e8/khvi-12-11-1201622.PMC5137522.pdf
"11, 2742 –2748 http://dx.doi.org/10.1080/21645515.2016.1201622",Non-OADS,/arxiv_data1/oa_pdf/64/e8/khvi-12-11-1201622.PMC5137522.pdf
Pediatr Infect Dis J2007; 26:293-9; PMID:17414390; http://dx.doi.org/10.1097/01.inf.0000258699.64164.6d [3] Cherry JD.,OADS,/arxiv_data1/oa_pdf/64/e8/khvi-12-11-1201622.PMC5137522.pdf
"Pediatr Infect Dis J 2006; 25:361-2; PMID:16567990; http://dx.doi.org/10.1097/01.inf.0000210478.60841.69 [4] Bisgard KM, Pascual FB, Ehresmann KR, Miller CA, Cianfrini C, Jen- nings CE, Rebmann CA, Gabel J, Schau er SL, Lett SM.",OADS,/arxiv_data1/oa_pdf/64/e8/khvi-12-11-1201622.PMC5137522.pdf
"Pediatr Infect Dis J 2004; 23:985-9;PMID:15545851; http://dx.doi.org/10.1097/01.inf.0000145263.37198.2b [5] Lavine J BH, Harvill ET, Bjornstad ON.",OADS,/arxiv_data1/oa_pdf/64/e8/khvi-12-11-1201622.PMC5137522.pdf
"Vaccine 2011; 29:11-6; http://dx.doi.org/10.1016/j.vaccine.2010.10.029 [6] Edwards K, Decker M. Pertussis Vaccines.",Non-OADS,/arxiv_data1/oa_pdf/64/e8/khvi-12-11-1201622.PMC5137522.pdf
Pediatrics 2005; 115:1422-7; PMID:15867059; http://dx.doi.org/10.1542/peds.2004-2648 [8] Centers for Disease Control and Prevention.,Non-OADS,/arxiv_data1/oa_pdf/64/e8/khvi-12-11-1201622.PMC5137522.pdf
"JAMA 1996; 275:1672-4; PMID:8637142; http://dx.doi.org/10.1001/jama.1996.03530450062034 [10] Tan T, Trindade E, Skowronski D. Epidemiology of pertussis.",OADS,/arxiv_data1/oa_pdf/64/e8/khvi-12-11-1201622.PMC5137522.pdf
Pediatr Infect Dis J 2005; 24:S10-8; PMID:15876918; http://dx.doi.org/10.1097/01.inf.0000160708.43944.99 [11] Centers for Disease Control and Prevention.,Non-OADS,/arxiv_data1/oa_pdf/64/e8/khvi-12-11-1201622.PMC5137522.pdf
Vac- cine 2009; 27:4257-62; PMID:19486957; http://dx.doi.org/10.1016/j.vaccine.2009.05.036 [14] Andrews NJ.,Non-OADS,/arxiv_data1/oa_pdf/64/e8/khvi-12-11-1201622.PMC5137522.pdf
"Vaccine 2001; 20 (Suppl 1):S49-53; PMID:11587812; http://dx.doi.org/10.1016/S0264-410X(01)00280-8 [15] Jacobsen SJ, Sy LS, Ackerson BK, Chao CR, Slezak JM, Chee- t h a mT C ,T a k h a rH S ,V e l i c e rC M ,H a n s e nJ ,K l e i nN P .A nHUMAN VACCINES & IMMUNOTHERAPEUTICS 2747",Non-OADS,/arxiv_data1/oa_pdf/64/e8/khvi-12-11-1201622.PMC5137522.pdf
"Vaccine2012; 30:4585-7; PMID:22580356; http://dx.doi.org/10.1016/j.vaccine.2012.04.103 [16] Baxter R, Toback SL, Sifakis F, Hansen J, Bartlett J, Aukes L, Lewis N, Wu X, Ambrose CS.",Non-OADS,/arxiv_data1/oa_pdf/64/e8/khvi-12-11-1201622.PMC5137522.pdf
"Vaccine 2012; 30:3053-60; PMID:22425787; http://dx.doi.org/ 10.1016/j.vaccine.2012.02.080 [17] Baxter R, Toback SL, Sifakis F, Hansen J, Bartlett J, Aukes L, Lewis N, Wu X, Ambrose CS.",Non-OADS,/arxiv_data1/oa_pdf/64/e8/khvi-12-11-1201622.PMC5137522.pdf
"Vaccine 2012; 30:2989-98; PMID:22386746; http://dx.doi.org/10.1016/j.vaccine.2012.02.039[18] Baxter R, Tran TN, Hansen J, Emery M, Fireman B, Bartlett J, Lewis N, Saddier P. Safety of Zostavax –a cohort study in a managed care organization.",Non-OADS,/arxiv_data1/oa_pdf/64/e8/khvi-12-11-1201622.PMC5137522.pdf
"Vaccine 2012; 30:6636-41; PMID:22963800; http://dx.doi.org/10.1016/j.vaccine.2012.08.070 [19] Rowhani-Rahbar A, Klein NP, Dekker CL, Edwards KM, Marchant CD, Vellozzi C, Fireman B, Sejvar JJ, Halsey NA, Baxter R. Biologi-cally plausible and evidence-based risk intervals in immunization safety research.",Non-OADS,/arxiv_data1/oa_pdf/64/e8/khvi-12-11-1201622.PMC5137522.pdf
"11, 2934 –2939 http://dx.doi.org/10.1080/21645515.2016.1210730",Non-OADS,/arxiv_data1/oa_pdf/f5/32/khvi-12-11-1210730.PMC5137530.pdf
"Available at: http://www.who.int/immunization/diseases/MNTE_initiative/en/ [2] Groom HC, Henninger ML, Smith N, Koppolu P, Cheetham TC, Glanz JM, Hambidge SJ, Jackson LA, Kharbanda EO, Klein NP, et al.",Non-OADS,/arxiv_data1/oa_pdf/f5/32/khvi-12-11-1210730.PMC5137530.pdf
"N Engl J Med 2008; 359:1555e64; http://dx.doi.org/10.1056/NEJMoa0708630 [4] Benowitz I, Esposito DB, Gracey KD, Shapiro ED, Vazquez M. In ﬂu- enza vaccine given to pregnant women reduces hospitalization due to inﬂuenza in their infants.",Non-OADS,/arxiv_data1/oa_pdf/f5/32/khvi-12-11-1210730.PMC5137530.pdf
AmJ Obstet Gynecol 2011; 204:S141e8; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/f5/32/khvi-12-11-1210730.PMC5137530.pdf
"Arch Pediatr Adolesc Med 2011; 165:104e11; http://dx.doi.org/10.1001/archpediatrics.2010.192 [7] Moro PL, Tepper NK, Grohskopf NK, Vellozzi C, Broder K. Safety of seasonal in ﬂuenza and in ﬂuenza A (H1N1) 2009 monovalent vac- cines in pregnancy.",Non-OADS,/arxiv_data1/oa_pdf/f5/32/khvi-12-11-1210730.PMC5137530.pdf
Expert Rev Vacc 2012; 11:911e21; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f5/32/khvi-12-11-1210730.PMC5137530.pdf
"AmJ Public Health 2012; 102:e33e40; http://dx.doi.org/10.2105/AJPH.2011.300606 [9] Oppermann M, Fritzsche J, Wever-Schoendorfer C, Keller- Stanislawski B, Allignol A, Meister R, Schaefer C. A(H1N1)v2009: a controlled observational prospective cohort study on vaccine safetyin pregnancy.",Non-OADS,/arxiv_data1/oa_pdf/f5/32/khvi-12-11-1210730.PMC5137530.pdf
Vaccine 2012; 30:4445e52; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/f5/32/khvi-12-11-1210730.PMC5137530.pdf
2015 Nov; 126(5):1075-84; http://dx.doi.org/10.1097/AOG.0000000000001068 [11] Minutes of the Joint Committee on Immunisation.,Non-OADS,/arxiv_data1/oa_pdf/f5/32/khvi-12-11-1210730.PMC5137530.pdf
"Available at http://webarchive.nationalarchives.gov.uk/20120907090205/ http://www.dh.gov.uk/prod_consum_dh/groups/ dh_digitalassets/@dh/@ab/documents/digitalasset/dh_124596.pdf [12] Jit M, Cromer D, Baguelin M, Stowe J, Andrews N, Miller E. The cost-effectiveness of vaccinating pregnant women against seasonal inﬂuenza in England and Wales.",Non-OADS,/arxiv_data1/oa_pdf/f5/32/khvi-12-11-1210730.PMC5137530.pdf
"Epub 2011 Feb 23; http://dx.doi.org/10.1016/j.ajog.2010.12.033 [14] Knight M, Kenyon S, Brocklehurst P, Neilson J, Shakespeare J, Kurinczuk JJ (Eds.)",OADS,/arxiv_data1/oa_pdf/f5/32/khvi-12-11-1210730.PMC5137530.pdf
"Euro Surveill 2014 Nov 13; 19(45):20959; http://dx.doi.org/10.2807/1560-7917.ES2014.19.45.20959 [16] Campbell H1, Amirthalingam G, Andrews N, Fry NK, George RC, Harrison TG, Miller E. Accelerating control of pertussis in Englandand Wales.",Non-OADS,/arxiv_data1/oa_pdf/f5/32/khvi-12-11-1210730.PMC5137530.pdf
2012 Jan; 18(1):38-47; http://dx.doi.org/10.3201/eid1801.110784 [17] Clark TA.,Non-OADS,/arxiv_data1/oa_pdf/f5/32/khvi-12-11-1210730.PMC5137530.pdf
"2014 Apr 1; 209(7):978-81; http://dx.doi.org/10.1093/infdis/jiu001 [18] Pillsbury A, Quinn HE, McIntyre PB.",Non-OADS,/arxiv_data1/oa_pdf/f5/32/khvi-12-11-1210730.PMC5137530.pdf
Epub 2015 Nov 10; http://dx.doi.org/10.1016/j.vaccine.2015.10.136 [20] Minutes of Joint Committee and Vaccination meeting 30th August 2012.,Non-OADS,/arxiv_data1/oa_pdf/f5/32/khvi-12-11-1210730.PMC5137530.pdf
Available at https://app.box.com/s/iddfb4ppwkmtjusir2tc#/s/ iddfb4ppwkmtjusir2tc/1/2199012147/18992156735/1?,Non-OADS,/arxiv_data1/oa_pdf/f5/32/khvi-12-11-1210730.PMC5137530.pdf
"Available at https://app.box.com/s/iddfb4ppwkmtju sir2tc#/s/iddfb4ppwkmtjusir2t c/1/2199012147/66698939189/1?&_suid= 14646125933740573408186897023 [22] Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Kara E, Donegan K, Fry NK, Miller E, Ramsay M. Effectiveness of maternal pertussis vaccination in England: an observational study.",Non-OADS,/arxiv_data1/oa_pdf/f5/32/khvi-12-11-1210730.PMC5137530.pdf
"Epub 2014 Oct 19; http://dx.doi.org/10.1093/cid/ciu821 [24] Donegan K, King B, Bryan P. Safety of pertussis vaccination in preg- nant women in UK: observational study.",Non-OADS,/arxiv_data1/oa_pdf/f5/32/khvi-12-11-1210730.PMC5137530.pdf
Available at https://app.box.co m/s/iddfb4ppwkmtju sir2tc#/s/iddfb4ppwkmtjusir2t c/1/2199012147/19052160649/1?&_suid= 146461913062403050649573322316 [26] Public Health England Flu plan: Winter 2016 and 2017.,Non-OADS,/arxiv_data1/oa_pdf/f5/32/khvi-12-11-1210730.PMC5137530.pdf
Available at https://www.gov.uk/government/publications/ ﬂu-plan-winter-2016- to-2017 [27] Immunisation against Infectious disease.,Non-OADS,/arxiv_data1/oa_pdf/f5/32/khvi-12-11-1210730.PMC5137530.pdf
Available at https://www.gov.uk/government/publications/in ﬂuenza- the-green-book-chapter-19 [28] Public Health England.,Non-OADS,/arxiv_data1/oa_pdf/f5/32/khvi-12-11-1210730.PMC5137530.pdf
In ﬂuenza immunisation programme for England: GP patient groups data collection survey season 2014 to 2015.Available at https://www.gov.uk/government/statistics/seasonal- ﬂu-vac cine-uptake-in-gp-pa tients-in-england-wi nter-season-2014-to-2015 [30] Seasonal ﬂu vaccine uptake: data collection.,Non-OADS,/arxiv_data1/oa_pdf/f5/32/khvi-12-11-1210730.PMC5137530.pdf
Available at https://www.gov.uk/gove rnment/publications/ pertussis-vaccine-uptake-in-pregnant-women-october-2012-to-sep tember-2013 [32] Public Health England.,Non-OADS,/arxiv_data1/oa_pdf/f5/32/khvi-12-11-1210730.PMC5137530.pdf
"Available at https://www.gov.uk/government/uploads/system/ uploads/attachment_data/ ﬁle/526208/hpr1816_prntl-prtsss.pdf [33] Harriman K, Winter K. Pertussis vaccine uptake during pregnancy: we need to do better in the U.S. Prev Med.",Non-OADS,/arxiv_data1/oa_pdf/f5/32/khvi-12-11-1210730.PMC5137530.pdf
"doi.org/10.12968/bjom.2015.23.8.566 [37] Public Health England: Available at https://www.gov.u k/govern ment/pub lications/pregnancy-how-to-hel p-protect-you-and-your-baby [38] Yarwood J, Noakes K, Kennedy D, Campbell H, Salisbury D. Tracking mothers ’attitudes to childhood immunisation 1991- 2001.",Non-OADS,/arxiv_data1/oa_pdf/f5/32/khvi-12-11-1210730.PMC5137530.pdf
Vaccine 2005; 23:5670-5687. http://ac.els-cdn.com/ S0264410X05009667/1-s2.0-S0264410X05009667-main.pdf?,Non-OADS,/arxiv_data1/oa_pdf/f5/32/khvi-12-11-1210730.PMC5137530.pdf
_tid=a20c2c12-a54c-11e3-8371-00000aab0f6b&acdnat=1394123611_9d842fbd0ea61d440a6e5b009815ce54 ;PMID:16243412; http://dx.doi.org/10.1016/j.vaccine.2004.11.081 [39] Public Health England.,Non-OADS,/arxiv_data1/oa_pdf/f5/32/khvi-12-11-1210730.PMC5137530.pdf
Available at https://www.gov.uk/govern ment/publications/vaccination-aga inst-pertussis-whooping-cough- for-pregnant-women [40] Public Health England.,Non-OADS,/arxiv_data1/oa_pdf/f5/32/khvi-12-11-1210730.PMC5137530.pdf
"Available at https://www.gov.uk/ government/publications/resources-to-support-whooping-cough-vac cination [41] Green D 2015 Fighting Flu, Midwives, autumn edition, p66-67, Royal College of Midwives [42] Green D 2015 Preventing Pertussis, Midwives, winter edition, p60-61, Royal College of MidwivesHUMAN VACCINES & IMMUNOTHERAPEUTICS 2939",Non-OADS,/arxiv_data1/oa_pdf/f5/32/khvi-12-11-1210730.PMC5137530.pdf
"11, 2969 –2971 http://dx.doi.org/10.1080/21645515.2016.1200777",Non-OADS,/arxiv_data1/oa_pdf/91/be/khvi-12-11-1200777.PMC5137532.pdf
Available online at: http://www.who.int/ mediacentre/factsheets/fs363/en/ (cited 2016 May 27) [3] Health Department Decree n 0820/2012.,Non-OADS,/arxiv_data1/oa_pdf/91/be/khvi-12-11-1200777.PMC5137532.pdf
"Available online at: http://www.epicentro.iss.it/ temi/vaccinazioni/pdf/Normative/Sicilia%20_%20Maggio%202012/ CALENDARIO%202012/Delibera%20D.A.%20n%C2%B0%200820- 12%20del%207.5.12.pdf (cited 2016 May 27) [4] Costantino C, Amodio E, Vitale F. Impact on rotavirus gastro- enteritis hospitalisation during the ﬁrst year of universal vaccination in Sicily.",Non-OADS,/arxiv_data1/oa_pdf/91/be/khvi-12-11-1200777.PMC5137532.pdf
Paediatr Int Child Health 2015; 35(4):342-3;PMID:26744161; http://dx.doi.org/10.1080/20469047.2015.1109240 [5] Rationale for Italian Lifetime Immu nization Schedule (2nd edition).,Non-OADS,/arxiv_data1/oa_pdf/91/be/khvi-12-11-1200777.PMC5137532.pdf
"Available online at: http://www.vaccinarsi .org/assets/uploads/ ﬁles/359/ Calendario_per_la_vita_2014_FINALE.pdf (cited-2016-May-27) [6] Signorelli C, Odone A, Bonanni P, Russo F. New Italian immunisa- tion plan is built on scienti ﬁc evidence: Carlo Signorelli and col- leagues reply to news article by Michael Day.",Non-OADS,/arxiv_data1/oa_pdf/91/be/khvi-12-11-1200777.PMC5137532.pdf
”Available from: http://pti.regione.sicilia.,Non-OADS,/arxiv_data1/oa_pdf/91/be/khvi-12-11-1200777.PMC5137532.pdf
"Vaccine 2011; 29:2791-6; PMID:21320539; http://dx.doi.org/10.1016/j.vaccine.2011.01.104 [9] Raes M, Strens D, Vergison A, Verghote M, Standaert B.",Non-OADS,/arxiv_data1/oa_pdf/91/be/khvi-12-11-1200777.PMC5137532.pdf
Pediatr Infect Dis J 2011; 30:e120-5;PMID:21436757; http://dx.doi.org/10.1097/INF.0b013e318214b811 [10] Monovalent human rotavirus vaccination technical sheet.,Non-OADS,/arxiv_data1/oa_pdf/91/be/khvi-12-11-1200777.PMC5137532.pdf
"Pediatr Infect Dis J 2015; Jun; 34(6):635-43;PMID:25860532; http://dx.doi.org/10.1097/INF.0000000000000683 [12] Fischer TK, Bihrmann K, Perch M, Koch A, Wohlfahrt J, Ka /C14re M, Melbye M. Intussusception in early c hildhood: a cohort study of 1.7 mil- lion children.",OADS,/arxiv_data1/oa_pdf/91/be/khvi-12-11-1200777.PMC5137532.pdf
"Pediatrics 2004; Sep; 114(3):782-5; PMID:15342854; http://dx.doi.org/10.1542/peds.2004-0390 [13] Samad L, Cortina-Borja M, Bashir HE, Sutcliffe AG, Marven S, Cameron JC, Lynn R, Taylor B. Intussusception incidence among infants in the UKand Republic of Ireland: a pre-rotavirus vaccine prospective surveillance study.",Non-OADS,/arxiv_data1/oa_pdf/91/be/khvi-12-11-1200777.PMC5137532.pdf
J Pediatr 2010; 156(5):761-5; PMID:20138300; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/91/be/khvi-12-11-1200777.PMC5137532.pdf
"N Engl J Med 2011; 364(24):2283-92; PMID:21675888; http://dx.doi.org/ 10.1056/NEJMoa1012952 [16] Costantino C, Restivo V, Cuccia M, Furnari R, Amodio E, Vitale F. Analysis of hospitalizations due to intussusception in Sicily in2970 F. VITALE ET AL.",OADS,/arxiv_data1/oa_pdf/91/be/khvi-12-11-1200777.PMC5137532.pdf
"Ital J Pediatr 2015; Aug 1; 41:52; PMID:26232152; http://dx.doi.org/10.1186/s13052-015-0160-4 [17] Palupi-Baroto R, Lee KJ, Carlin JB, Bines JE.",OADS,/arxiv_data1/oa_pdf/91/be/khvi-12-11-1200777.PMC5137532.pdf
"Aust N Z J Public Health 2015; Feb; 39(1):11-4;PMID:25558780; http://dx.doi.org/10.1111/1753-6405.12297 [18] Haber P, Parashar UD, Haber M, DeStefano F. Intussusception after monovalent rotavirus va ccine-United States, Vaccine Adverse Event Reporting System (VAERS), 2008-2014.",Non-OADS,/arxiv_data1/oa_pdf/91/be/khvi-12-11-1200777.PMC5137532.pdf
"Vaccine2015; Sep 11; 33(38):4873-7; PMID:26276687; http://dx.doi.org/ 10.1016/j.vaccine.2015.07.054[19] Hviid A, Svanstrom H. Antibiotic use and intussusception in early childhood.",Non-OADS,/arxiv_data1/oa_pdf/91/be/khvi-12-11-1200777.PMC5137532.pdf
"J Antimicrob Chemother 2009; 64:642-8;PMID:19549670; http://dx.doi.org/10.1093/jac/dkp217 [20] Spiro DM, Arnold DH, Barbone F. Association between antibiotic use and primary idiopathic intussusception.",Non-OADS,/arxiv_data1/oa_pdf/91/be/khvi-12-11-1200777.PMC5137532.pdf
"Arch Pediatr Adolesc Med 2003; 157:54-9; PMID:12517195; http://dx.doi.org/10.1001/archpedi.157.1.54 [21] Jenke AC, Klaassen-Mielke R, Zilbauer M, Heininger U, Trampisch H, Wirth S. Intussusception: incidence and treatment-insights fromthe nationwide German surveillance.",OADS,/arxiv_data1/oa_pdf/91/be/khvi-12-11-1200777.PMC5137532.pdf
J Pediatr Gastroenterol Nutr2011; Apr; 52(4):446-51; PMID:21415671; http://dx.doi.org/10.1097/ MPG.0b013e31820e1becHUMAN VACCINES IMMUNOTHERAPEUTICS 2971,Non-OADS,/arxiv_data1/oa_pdf/91/be/khvi-12-11-1200777.PMC5137532.pdf
"11, 2772 –2776 http://dx.doi.org/10.1080/21645515.2016.1208329",Non-OADS,/arxiv_data1/oa_pdf/3d/6d/khvi-12-11-1208329.PMC5137533.pdf
"Vaccine 2015; 33(38):4994-9; PMID:26151543; http://dx.doi.org/10.1016/j.vaccine.2015.06.097 [2] Greco A, De Virgilio A, Rizzo MI, Tombolini M, Gallo A, Fusconi M, Ruoppolo G, Pagliuca G, Martellucci S, de Vincentiis M. Kawasaki disease: an evolving paradigm.",Non-OADS,/arxiv_data1/oa_pdf/3d/6d/khvi-12-11-1208329.PMC5137533.pdf
"Autoimmun Rev 2015; 14:703-9;PMID:25882057; http://dx.doi.org/10.1016/j.autrev.2015.04.002 [3] Jamieson N, Singh-Grewal D. Kawasaki disease: A clinician ’s update.",Non-OADS,/arxiv_data1/oa_pdf/3d/6d/khvi-12-11-1208329.PMC5137533.pdf
"Int J Pediatr 2013; 2013:645391; PMID:24282419; http://dx.doi.org/10.1155/2013/645391 [4] Bonetto C, Trotta F, Felicetti P, Alarc /C19on GS, Santuccio C, Bachtiar NS, Brauchli Pernus Y, Chandler R, Girolomoni G, Hadden RD, et al.",OADS,/arxiv_data1/oa_pdf/3d/6d/khvi-12-11-1208329.PMC5137533.pdf
"Vaccine 2015 [Epub ahead of print];pii: S0264-410X(15)01292-X; PMID:26398442; http://dx.doi.org/ 10.1016/j.vaccine.2015.09.026 [5] Gorman KM, Gavin PJ, Capra L. Bacillus calmette-gu /C19erin scar erythema: “Haloing ”the diagnosis in Kawasaki disease.",Non-OADS,/arxiv_data1/oa_pdf/3d/6d/khvi-12-11-1208329.PMC5137533.pdf
"J Pediatr 2015; 167:774; PMID:26205182; http://dx.doi.org/10.1016/j.jpeds.2015.06.043 [6] Uda K, Hataya H. Ulceration at bacillus calmette-gu /C19erin inoculation site in a patient with Kawasaki disease.",OADS,/arxiv_data1/oa_pdf/3d/6d/khvi-12-11-1208329.PMC5137533.pdf
"J Pediatr 2015; 167(5):1167-7.e1; PMID:26342720; http://dx.doi.org/10.1016/j.jpeds.2015.08.018 [7] Sethuraman G, Ramesh V. Cutaneous tuberculosis in children.",Non-OADS,/arxiv_data1/oa_pdf/3d/6d/khvi-12-11-1208329.PMC5137533.pdf
"Pediatr Dermatol 2013; 30:7-16; PMID:23173930; http://dx.doi.org/10.1111/j.1525-1470.2012.01794.x [8] Muto J, Kuroda K, Tajima S. Papular tuberculides post-BCG vaccina- tion: case report and review of the literature in Japan.",Non-OADS,/arxiv_data1/oa_pdf/3d/6d/khvi-12-11-1208329.PMC5137533.pdf
"Clin Exp Der- matol 2006; 31:611-2; PMID:16716184; http://dx.doi.org/10.1111/j.1365-2230.2006.02083.x [9] Takada T, Yamashita T, Sato M, Kawakami Y, Tominaga A, Ono I, Jim- bow M, Tsutsumi H, Jimbow K. Papulon ecrotic tuberculid-like eruptions after Bacille Calmette-Guerin v accination.",OADS,/arxiv_data1/oa_pdf/3d/6d/khvi-12-11-1208329.PMC5137533.pdf
"J De rmatol 2007; 34:183-8; PMID:17291299; http://dx.doi.org/10.1111/j.1346-8138.2007.00246.x [10] Ishigaki M, Oishi Y, Asou S. Two cases of Papulonecrotic tuberculid after Bacille Calmette-Guerin (BCG) vaccinatation.",Non-OADS,/arxiv_data1/oa_pdf/3d/6d/khvi-12-11-1208329.PMC5137533.pdf
"Pediatr Infect Dis J 2010; 29:430-3; PMID:20032807; http://dx.doi.org/10.1097/INF.0b013e3181cacede [12] Sireci G, Dieli F, Salerno A. T cells recognize an immunodominant epitope of heat shock protein 65 in Kawasaki disease.",Non-OADS,/arxiv_data1/oa_pdf/3d/6d/khvi-12-11-1208329.PMC5137533.pdf
"Clin Rheumatol 2003; 22:461-3; PMID:14677029; http://dx.doi.org/10.1007/s10067-003-0785-3 [14] Shimada S, Watanabe T, Sato S. A Patient with Kawasaki Disease Following In ﬂuenza Vaccinations.",Non-OADS,/arxiv_data1/oa_pdf/3d/6d/khvi-12-11-1208329.PMC5137533.pdf
"Pediatr Infect Dis J 2015; 34:913; PMID:26376188; http://dx.doi.org/10.1097/INF.0000000000000713 [15] Seo JH, Yu JJ, Ko HK, Choi HS, Kim YH, Ko JK.",OADS,/arxiv_data1/oa_pdf/3d/6d/khvi-12-11-1208329.PMC5137533.pdf
"Korean Circ J 2012; 42:823- 9; PMID:23323120; http://dx.doi.org/10.4070/kcj.2012.42.12.823 [16] Lai CC, Lee PC, Wang CC, Hwang BT, Meng CC, Tsai MC.",OADS,/arxiv_data1/oa_pdf/3d/6d/khvi-12-11-1208329.PMC5137533.pdf
"Pediatr Neonatol 2013; 54:43-8; PMID:23445742; http://dx.doi.org/10.1016/j.pedneo.2012.10.003 [17] Yin S, Liubao P, Chongqing T, Xiaomin W. The ﬁrst case of Kawa- saki disease in a 20-month old baby following immunization with rotavirus vaccine and hepatitis A vaccine in China: A case report.",Non-OADS,/arxiv_data1/oa_pdf/3d/6d/khvi-12-11-1208329.PMC5137533.pdf
"Hum Vaccin Immunother 2015; 11:2740-3; PMID:26158590; http://dx.doi.org/10.1080/21645515.2015.1050571 [18] Hua W, Izurieta HS, Slade B, Belay ED, Haber P, Tiernan R, Woo EJ, Iskander J, Braun MM, Ball R. Kawasaki disease after vaccination: reports to the vaccine adverse event reporting system 1990 –2007.",Non-OADS,/arxiv_data1/oa_pdf/3d/6d/khvi-12-11-1208329.PMC5137533.pdf
"Pediatr Infect Dis J 2009; 28:943-7; PMID:19755926; http://dx.doi.org/10.1097/INF.0b013e3181a66471 [19] Abrams JY, Weintraub ES, Baggs JM, McCarthy NL, Schonberger LB, Lee GM, Klein NP, Belongia EA, Jackson ML, Naleway AL, et al.Childhood vaccines and Kawasaki disease, Vaccine Safety Datalink,HUMAN VACCINES & IMMUNOTHERAPEUTICS 2775",Non-OADS,/arxiv_data1/oa_pdf/3d/6d/khvi-12-11-1208329.PMC5137533.pdf
Vaccine 2015; 33:382-7; PMID:25444786; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/3d/6d/khvi-12-11-1208329.PMC5137533.pdf
"J Am Acad Dermatol 1999; 41:262-4; PMID:10426899; http://dx.doi.org/ 10.1016/S0190-9622(99)70059-9 [21] Figueiredo A, Poiares-Baptista A, Branco M, da Mota HC.",OADS,/arxiv_data1/oa_pdf/3d/6d/khvi-12-11-1208329.PMC5137533.pdf
"Int J Dermatol 1987; 26:291-4; PMID:3610434; http://dx.doi.org/10.1111/j.1365-4362.1987.tb00191.x [22] Evans RG, Warner J. Lichen scrofulosorum following B.C.G.",Non-OADS,/arxiv_data1/oa_pdf/3d/6d/khvi-12-11-1208329.PMC5137533.pdf
"Arch Dis Child 1967; 42:448; PMID:4951645; http://dx.doi.org/10.1136/ adc.42.224.448[23] Za €ıem A, El Ferjani S, Lakhoua G, Sahnoun R, Badri T, Kastalli S, Daghfous R, Lakhal M, El Aidli S. Probable disseminated BCG infec-tion in a 10-month-old child after BCG vaccination.",Non-OADS,/arxiv_data1/oa_pdf/3d/6d/khvi-12-11-1208329.PMC5137533.pdf
"Hum VaccinImmunother 2014; 10:2081-2; PMID:25424819; http://dx.doi.org/ 10.4161/hv.28913 [24] Karte K, Wollina U. Postvaccination in ﬂammatory papules of the skin –think of Bacille Calmette-Gu /C19erin (BCG).",Non-OADS,/arxiv_data1/oa_pdf/3d/6d/khvi-12-11-1208329.PMC5137533.pdf
"Pediatr Dermatol 1998; 15:73-4; PMID:9496818; http://dx.doi.org/10.1046/j.1525- 1470.1998.1998015073.x [25] Atasoy M, Alia /C21gao/C21g l uC ,E r d e mT ,O z d e m i rS ,A k t a ¸s A. Scrofuloderma following BCG vaccination.",Non-OADS,/arxiv_data1/oa_pdf/3d/6d/khvi-12-11-1208329.PMC5137533.pdf
Pediatr Dermatol 2005; 22:179-80; PMID:15804315; http://dx.doi.org/10.1111/j.1525-1470.2005.22222.x2776 H. YAMADA ET AL.,OADS,/arxiv_data1/oa_pdf/3d/6d/khvi-12-11-1208329.PMC5137533.pdf
"11, 2984 –2987 http://dx.doi.org/10.1080/21645515.2016.1198456",Non-OADS,/arxiv_data1/oa_pdf/4c/7f/khvi-12-11-1198456.PMC5137540.pdf
Am J Prev Med 2015; 49(6 Suppl 4):S391-8; PMID:26337116; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/4c/7f/khvi-12-11-1198456.PMC5137540.pdf
Vaccine 2015; 33 (34):4161-4; PMID:25896383; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/4c/7f/khvi-12-11-1198456.PMC5137540.pdf
"PLoS One 2016; 11(3):e0151258; PMID:26982071; http://dx.doi.org/10.1371/ journal.pone.0151258 [5] Odone A, Fara GM, Giammanco G, Blangiardi F, Signorelli C. The Future of immunization policies in Italy and in the Euro- pean Union: the Declaration of Erice.",Non-OADS,/arxiv_data1/oa_pdf/4c/7f/khvi-12-11-1198456.PMC5137540.pdf
"Hum Vaccin Immunother2015; 11(5):1268-71; PMID:25806425; http://dx.doi.org/10.1080/21645515.2015.1019980 [6] Signorelli C, Odone A.",Non-OADS,/arxiv_data1/oa_pdf/4c/7f/khvi-12-11-1198456.PMC5137540.pdf
"Available from:http://www.quotidianosanita.it/allegati/allegato1955037.pdf; last access 2016 May 10 [8] Bonanni P, Azzari C, Castiglia P, Chiamenti G, Conforti G, Con- versano M, Corsello G, Ferrera G, Ferro A, Icardi G, et al.",Non-OADS,/arxiv_data1/oa_pdf/4c/7f/khvi-12-11-1198456.PMC5137540.pdf
Vaccine 2015; 33(34):4212-4; PMID:25896382; http://dx.doi.org/ 10.1016/j.vaccine.2015.04.042 [10] Bedford H. Pro-vaccine messages may be counterproductive among vaccine-hesitant parents.,Non-OADS,/arxiv_data1/oa_pdf/4c/7f/khvi-12-11-1198456.PMC5137540.pdf
Evid Based Med 2014; 19(6):219; PMID:25185270; http://dx.doi.org/10.1136/ebmed-2014-110037 [11] Regione V. Progetto “Indagine sui Determinanti del Ri ﬁuto dell ’Of- ferta Vaccinale nella Regione Veneto.,OADS,/arxiv_data1/oa_pdf/4c/7f/khvi-12-11-1198456.PMC5137540.pdf
Pediatrics 2014; 133(4):e835-42;PMID:24590751; http://dx.doi.org/10.1542/peds.2013-2365 [13] Censis.,Non-OADS,/arxiv_data1/oa_pdf/4c/7f/khvi-12-11-1198456.PMC5137540.pdf
"Available from: http://www.censis.it/7?shadow_ comunicato_stampa=120978 ; last accessed 2016 May 10 [14] Fadda M, Allam A, Schulz PJ.",Non-OADS,/arxiv_data1/oa_pdf/4c/7f/khvi-12-11-1198456.PMC5137540.pdf
Vaccine 2015; 33(51):7152-9; PMID:26592140; http://dx.doi.org/10.1016/j.vaccine.2015.11.007 [15] Ministero della S. Progetto CCM 2013: Strategie e interventi di comunicazione sanitaria multi-obiettivo sulle malattie infettive pre-venibili e sulle vaccinazioni per aumentare le coperture vaccinalinella popolazione.,Non-OADS,/arxiv_data1/oa_pdf/4c/7f/khvi-12-11-1198456.PMC5137540.pdf
"Available from: http://www.epicentro.iss.it/temi/ vaccinazioni/DocumentazioneRegioni.asp ; last accessed 2016 May 10 [16] Odone A, Ferrari A, Spagnoli F, Visciarelli S, Shefer A, Pasquarella C, Signorelli C. Effectiveness of interventions that apply new media toimprove vaccine uptake and vaccine coverage.",Non-OADS,/arxiv_data1/oa_pdf/4c/7f/khvi-12-11-1198456.PMC5137540.pdf
Hum Vaccin Immun- other 2015; 11(1):72-82; PMID:25483518; http://dx.doi.org/10.4161/ hv.34313 [17] Carta italiana per la promozione delle vaccinazioni.,Non-OADS,/arxiv_data1/oa_pdf/4c/7f/khvi-12-11-1198456.PMC5137540.pdf
"Available from: http://www.teamvaxitalia.it/download-carta.html ; last accessed 2016 May 10 [18] Ferro A, Odone A, Siddu A, Colucci M, Anello P, Longone M, Mar- con E, Castiglia P, Bonanni P, Signorelli C. Monitoring the web tosupport vaccine coverage: Results of two years of the portal vacci- narS/C18ı.",Non-OADS,/arxiv_data1/oa_pdf/4c/7f/khvi-12-11-1198456.PMC5137540.pdf
"Vaccine 2015; 33(21):2425-31; PMID:25869895; http://dx.doi.org/10.1016/ j.vaccine.2015.04.007 [20] Costantino C, Mazzucco W, Azzolini E, Baldini C, Bergomi M, Biaﬁ ore AD, Bianco M, Borsari L, Cacciari P, Cadeddu C, et al.",Non-OADS,/arxiv_data1/oa_pdf/4c/7f/khvi-12-11-1198456.PMC5137540.pdf
Hum Vaccin Immunother 2014; 10(5):1204-10; PMID:24603089; http://dx.doi.org/10.4161/hv.280812986 L. R. BIASIO ET AL.,Non-OADS,/arxiv_data1/oa_pdf/4c/7f/khvi-12-11-1198456.PMC5137540.pdf
BMC Med Educ 2016 Jan 29; 16:38; PMID:26830337; http://dx.doi.org/10.1186/s12909-016-0558-8 [22] Biasio LR.,OADS,/arxiv_data1/oa_pdf/4c/7f/khvi-12-11-1198456.PMC5137540.pdf
Available from: http://www.epi centro.iss.it/temi/vaccinazioni/HProimmune2014.asp ; last accessed 2016 May 10 [24] Diekema DS.,Non-OADS,/arxiv_data1/oa_pdf/4c/7f/khvi-12-11-1198456.PMC5137540.pdf
"N Engl J Med 2012; 366(5):391-3; PMID:22296072; http://dx.doi.org/10.1056/ NEJMp1113008 [25] Costantino C, Amodio E, Vitale F, Maida C, Maringhini G, Asciutto R, Tramuto F, Calamusa G. Attitudes, behaviours and perceptions ofItalian General Practitioner trainees towards in ﬂuenza vaccination in Western Sicily (Italy).",Non-OADS,/arxiv_data1/oa_pdf/4c/7f/khvi-12-11-1198456.PMC5137540.pdf
Vaccine 2015; PMID:26657186; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/4c/7f/khvi-12-11-1198456.PMC5137540.pdf
"11, 2805 –2812 http://dx.doi.org/10.1080/21645515.2016.1206677",Non-OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Clin Cancer Res 2007; 13:1736-41;PMID:17363526; http://dx.doi.org/10.1158/1078-0432.CCR-06-1746 [2] Cohen SJ, Alpaugh RK, Palazzo I, Meropol NJ, Rogatko A, Xu Z, Hoffman JP, Weiner LM, Cheng JD.",Non-OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Pancreas 2008; 37:154-8; PMID:18665076; http://dx.doi.org/ 10.1097/MPA.0b013e31816618ce [3] Wang LC, Lo A, Scholler J, Sun J, Majumdar RS, Kapoor V, Antzis M, Cotner CE, Johnson LA, Durham AC, et al.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Cancer Immunol Res 2014; 2:154-66; PMID:24778279;http://dx.doi.org/10.1158/2326-6066.CIR-13-0027 [4] Kwakkenbos MJ, Diehl SA, Yasuda E, Bakker AQ, van Geelen CM, Lukens MV, van Bleek GM, Widjojoatmodjo MN, Bogers WM, Mei H, et al.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Nat Med 2010; 16:123-8; PMID:20023635; http://dx.doi.org/10.1038/ nm.2071 [5] Wagner K, Kwakkenbos MJ, Claassen YB, Maijoor K, B €ohne M, van der Sluijs KF, Witte MD, van Zoelen DJ, Cornelissen LA, Beaumont T, et al.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Nat Med 2005; 11:312-9; PMID:15711557; http://dx.doi.org/10.1038/nm1196 [7] Muller AJ, DuHadaway JB, Chang MY, Ramalingam A, Sutanto- Ward E, Boulden J, Soler AP, Mandik-Nayak L, Gilmour SK, Pre- ndergast GC.",Non-OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Immunother 2010; 59:1655-63; PMID:20640572; http://dx.doi.org/ 10.1007/s00262-010-0891-4 [8] Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"J Exp Med 2013; 210:1389-402; PMID:23752227; http://dx.doi.org/10.1084/jem.20130066 [9] Metz R, Rust S, Duhadaway JB, Mautino MR, Munn DH, Vahanian NN, Link CJ, Prendergast GC.",Non-OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Oncoimmunology 2012; 1:1460-8; PMID:23264892; http://dx.doi.org/10.4161/onci.21716 [10] Muller AJ, Sharma MD, Chandler PR, Duhadaway JB, Everhart ME, Johnson BA, 3rd, Kahler DJ, Pihkala J, Soler AP, Munn DH, et al.Chronic in ﬂammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase.",Non-OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Int Immunol 2014; 26:357-67; PMID:24402311; http://dx.doi.org/10.1093/intimm/dxt073 [13] Sotelo J, Brice ~no E, L /C19opez-Gonz /C19alez MA.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Ann Intern Med 2006; 144:337-43; PMID:16520474; http://dx.doi.org/10.7326/0003-4819-144-5-200603070-00008 [14] Pedersen L, Idorn M, Olofsson GH, Lauenborg B, Nookaew I, Han- sen RH, Johannesen HH, Becker JC, Pedersen KS, Dethlefsen C,et al.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Cell Metab 2016; 23:554-62; PMID:26895752; http://dx.doi.org/ 10.1016/j.cmet.2016.01.011 [15] Grundy MA, Zhang T, Sentman CL.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Cancer Immunol Immunother 2007; 56:1153-61; PMID:17160409; http://dx.doi.org/10.1007/s00262-006-0264-1 [16] Liu H, Moynihan KD, Zheng Y, Szeto GL, Li AV, Huang B, Van Ege- ren DS, Park C, Irvine DJ.",Non-OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Nature 2014; 507:519-22;PMID:24531764; http://dx.doi.org/10.1038/nature12978 [17] McLennan DN, Porter CJ, Charman SA.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Drug Discov Today Technol 2005; 2:89- 96; PMID:24981760; http://dx.doi.org/10.1016/j.ddtec.2005.05.006 [18] Pritchard AL, Burel JG, Neller MA, Hayward NK, Lopez JA, Fatho M, Lennerz V, W €olfel T, Schmidt CW.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Cancer Immunol Res 2015; 3:992-8; PMID:26048577; http://dx.doi.org/10.1158/2326-6066.CIR-15-0088 [19] O ’Rourke MG, Johnson M, Lanagan C, See J, Yang J, Bell JR, Slater GJ, Kerr BM, Crowe B, Purdie DM, et al.",Non-OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants.Nat Med 2006; 12:417-24; PMID:16550190; http://dx.doi.org/10.1038/nm1381 [21] Oliveira CC, Querido B, Sluijter M, de Groot AF, van der Zee R, Rabelink MJ, Hoeben RC, Ossendorp F, van der Burg SH, van HallT.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"J Immunol 2013; 191:4020-8; PMID:24048903; http://dx.doi.org/10.4049/jimmunol.1301496 [22] Doorduijn EM, Sluijter M, Querido BJ, Oliveira CC, Achour A, Ossendorp F, van der Burg SH, van Hall T. TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors.",Non-OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"J Clin Invest 2016; 126:784-94; PMID:26784543; http://dx.doi.org/10.1172/JCI83671 [23] Welters MJ, van der Sluis TC, van Meir H, Loof NM, van Ham VJ, van Duikeren S, Santegoets SJ, Arens R, de Kam ML, Cohen AF, et al.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
Sci Transl Med 2016; 8:334ra52; PMID:27075626; http://dx.doi.org/10.1126/scitranslmed.,OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Nat Med 2010; 16:565-70, 1p following 570; PMID:20400962; http://dx.doi.org/10.1038/nm.2128 [25] Provasi E, Genovese P, Lombardo A, Magnani Z, Liu PQ, Reik A, Chu V, Paschon DE, Zhang L, Kuball J, et al.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Nat Med 2012; 18:807-15; PMID:22466705; http://dx.doi.org/10.1038/nm.2700 [26] Oliveira G, Ruggiero E, Stanghellini MT, Cieri N, D ’Agostino M, Fronza R, Lulay C, Dionisio F, Mastaglio S, Greco R, et al.",Non-OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"J Immunother 27:227-31; PMID:15076140; http://dx.doi.org/10.1097/00002371-200405000-00007 [28] Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wun- derlich JR, Somerville RP, Hogan K, Hinrichs CS, et al.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Science 2014; 344:641-5;PMID:24812403; http://dx.doi.org/10.1126/science.1251102 [29] Wang QJ, Hanada KI, Robbins PF, Li YF, Yang JC.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
Cancer Res 2012;72:6119-29; PMID:23071066; http://dx.doi.org/10.1158/0008-5472.,Non-OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"J Immunol 2015; 195:2030-7; PMID:26223658; http://dx.doi.org/10.4049/jimmunol.1500703 [32] Hadrup SR, Bakker AH, Shu CJ, Andersen RS, van Veluw J, Hom- brink P, Castermans E, Thor Straten P, Blank C, Haanen JB, et al.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
Nat Methods 2009; 6:520-6;PMID:19543285; http://dx.doi.org/10.1038/nmeth.1345 [33] Newell EW.,OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Front Immunol 2013; 4:430; PMID:24367368; http://dx.doi.org/10.3389/ ﬁmmu.2013.00430 [34] McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, et al.Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Science 2016; 351:1463-9; PMID:26940869; http://dx.doi.org/10.1126/science.aaf1490 [35] Schwager K, Hemmerle T, Aebischer D, Neri D. The immuno- cytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF.",Non-OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"J Invest Dermatol 2013; 133:751-8; PMID:23096716; http://dx.doi.org/10.1038/jid.2012.376 [36] Weide B, Eigentler TK, P ﬂugfelder A, Zelba H, Martens A, Pawelec G, Giovannoni L, Ruf ﬁni PA, Elia G, Neri D, et al.",Non-OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Immunol Res 2014; 2:668-78; PMID:24906352; http://dx.doi.org/ 10.1158/2326-6066.CIR-13-0206 [37] Danielli R, Patuzzo R, Di Giacomo AM, Gallino G, Maurichi A, Di Florio A, Cutaia O, Lazzeri A, Fazio C, Miracco C, et al.",Non-OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Cancer Immunol Immun-other 2015; 64:999-1009; PMID:25971540; http://dx.doi.org/10.1007/ s00262-015-1704-6 [38] Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV.",Non-OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Cancer Cell 2015; 28:285-95; PMID:26373277; http://dx.doi.org/10.1016/j.ccell.2015.08.004 [39] Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolc hok JD, et al.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"J Exp Med 2013; 210:1695-710; PMID:23897981; http://dx.doi.org/10.1084/jem.20130579 [40] White AL, Chan HT, Roghanian A, French RR, Mockridge CI, Tutt AL, Dixon SV, Ajona D, Verbeek JS, Al-Shamkhani A, et al.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"J Immunol 2011; 187:1754-63;PMID:21742972; http://dx.doi.org/10.4049/jimmunol.1101135 [41] Li F, Ravetch JV.",Non-OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Science 2011; 333:1030-4; PMID:21852502; http://dx.doi.org/10.1126/science.1206954 [42] White AL, Chan HT, French RR, Willoughby J, Mockridge CI, Rog- hanian A, Penfold CA, Booth SG, Dodhy A, Polak ME, et al.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Cancer Cell 2015; 27:138-48; PMID:25500122; http://dx.doi.org/ 10.1016/j.ccell.2014.11.001 [43] Dahan R, Barnhart BC, Li F, Yamniuk AP, Korman AJ, Ravetch JV.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Science 2014; 343:1260-3; PMID:24626930; http://dx.doi.org/10.1126/science.1248943 [45] de Jong RN, Beurskens FJ, Verploegen S, Strumane K, van Kampen MD, Voorhorst M, Horstman W, Engelberts PJ, Oostindie SC, WangG, et al.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"PLoS Biol 2016; 14:e1002344; PMID:26736041; http://dx.doi.org/10.1371/journal.pbio.1002344 [46] Fridman WH, Kourilsky FM.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Nature 1969; 224:277-9; PMID:5259376; http://dx.doi.org/10.1038/224277a0 [47] Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pag /C18es C, Tosolini M, Camus M, Berger A, Wind P, et al.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Science 2006; 313:1960-4;PMID:17008531; http://dx.doi.org/10.1126/science.1129139 [48] Dieu-Nosjean MC, Goc J, Giraldo NA, Saut /C18es-Fridman C, Fridman WH.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"TrendsImmunol 2014; 35:571-80; PMID:25443495; http://dx.doi.org/ 10.1016/j.it.2014.09.006 [49] Goc J, Germain C, Vo-Bourgais TK, Lupo A, Klein C, Knockaert S, de Chaisemartin L, Ouakrim H, Becht E, Alifano M, et al.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Cancer Res 2014; 74:705-15; PMID:24366885; http://dx.doi.org/10.1158/0008-5472.CAN-13-1342 [50] Germain C, Gnjatic S, Tamzalit F, Knockaert S, Remark R, Goc J, Lepelley A, Becht E, Katsahian S, Bizouard G, et al.",Non-OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Am J Respir Crit Care Med 2014; 189:832-44; PMID:24484236; http://dx.doi.org/10.1164/rccm.201309-1611OC [51] Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, et al.",Non-OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Immunity 2013; 39:782-95;PMID:24138885; http://dx.doi.org/10.1016/j.immuni.2013.10.003 [52] Mlecnik B, Bindea G, Angell HK, Sasso MS, Obenauf AC, Fredriksen T, Lafontaine L, Bilocq AM, Kirilovsky A, Tosolini M, et al.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Sci Transl Med 2014; 6:228ra37; PMID:24648340; http://dx.doi.org/10.1126/scitranslmed.3007240 [53] Giraldo NA, Becht E, Pag /C18es F, Skliris G, Verkarre V, Vano Y, Mejean A, Saint-Aubert N, Lacroix L, Natario I, et al.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Clin Cancer Res2015; 21:3031-40; PMID:25688160; http://dx.doi.org/10.1158/1078- 0432.CCR-14-2926 [54] Dieu-Nosjean MC, Giraldo NA, Kaplon H, Germain C, Fridman WH, Saut /C18 es-Fridman C. Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers.",Non-OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
Immunol Rev 2016; 271:260-75; PMID:27088920; http://dx.doi.org/10.1111/imr.12405 [55] Cancer Genome Atlas Network.,Non-OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Nature 2012; 487:330-7; PMID:22810696; http://dx.doi.org/10.1038/nature11252 [56] Guinney J, Dienstmann R, Wang X, de Reyni /C18es A, Schlicker A, Sone- son C, Marisa L, Roepman P, Nyamundanda G, Angelino P, et al.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"Nat Med 2015; 21:1350-6; PMID:26457759; http://dx.doi.org/10.1038/nm.3967 [57] Becht E, de Reyni /C18es A, Giraldo NA, Pilati C, Buttard B, Lacroix L, Selves J, Saut /C18es-Fridman C, Laurent-Puig P, Fridman WH.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
"ClinCancer Res 2016; PMID:26994146; http://dx.doi.org/10.1158/1078-0432.CCR-15-2879 [58] Giannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O, Nishihara R, Bahl S, Cao Y, Amin-Mansour A, Yamauchi M, et al.",OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
Clin Cancer Res 2015; 21:1329-39; PMID:25583177; http://dx.doi.org/10.1158/1078-0432.CCR-14-11282812 L. M. KRANZ ET AL.,Non-OADS,/arxiv_data1/oa_pdf/12/dd/khvi-12-11-1206677.PMC5137546.pdf
Competing Interests All authors have completed the Uni ﬁed Competing Interest form at http://www.icmje.org/coi_disclosure.pdf (availableon request from the corresponding author) and declare: nosupport from any organization for the submitted work; no ﬁ- nancial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have in-ﬂuenced the submitted work.,Non-OADS,/arxiv_data1/oa_pdf/38/76/BCP-82-0965.PMC5137821.pdf
"Available at http://ec.europa.eu/growth/sectors/ healthcare/index_en.htm (last accessed March 2016) 6Russo P, Mennini FS, Siviero PD, Rasi G. Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers.",Non-OADS,/arxiv_data1/oa_pdf/38/76/BCP-82-0965.PMC5137821.pdf
Available at http://www.eunethta.eu/news/call-expression- interest-health-care-product-developers-seed-shaping-european-early-dialogues (last accessed March 2016) 10Best practice guidance for pilot EMA HTA parallel scienti ﬁca d v i c e procedures.,Non-OADS,/arxiv_data1/oa_pdf/38/76/BCP-82-0965.PMC5137821.pdf
Available at http://www.ema.,Non-OADS,/arxiv_data1/oa_pdf/38/76/BCP-82-0965.PMC5137821.pdf
"Available at http://www.europarl.europa.eu/ RegData/etudes/STUD/2015/ 542219/IPOL _STU(2015) 542219_EN.pdf (last accessed March 2016) 15EUnetHTA website, available at http://www.eunethta.eu/ (last accessed March 2016) 16Berntgen M, Gourvil A, Pavlovic M, Goettsch W, Eichler HG, Kristensen FB.",Non-OADS,/arxiv_data1/oa_pdf/38/76/BCP-82-0965.PMC5137821.pdf
available at http://ec.europa.eu/health/ technology_assessment/policy/ network/index_ en.htm (last accessed March 2016) 18Reﬂection paper: EU Health Tec hnology Assessment Network: strategy for EU cooperation on he alth technology assessment.,Non-OADS,/arxiv_data1/oa_pdf/38/76/BCP-82-0965.PMC5137821.pdf
"Available at http://ec.europa.eu/ health/technolog y_assessment/ docs/2014_strategy_eucooper ation_hta_en.pdf (last accessed March 2016) 19Eichler HG1, Baird LG, Barker R, Bloechl-Daum B, Børlum- Kristensen F, Brown J .",Non-OADS,/arxiv_data1/oa_pdf/38/76/BCP-82-0965.PMC5137821.pdf
Available at http://www.ema.europa.eu/ema/index.jsp?,Non-OADS,/arxiv_data1/oa_pdf/38/76/BCP-82-0965.PMC5137821.pdf
curl=pages/regulation/document_listing/ document_listing_000319.jsp (last accessed March 2016) Supporting Information Additional Supporting Information may be found in the online version of this article at the publisher ’s web-site: http://onlinelibrary.wiley.com/doi/10.1111/bcp.1 3023/suppinfo.Table S1 Selected examples showing how the comparisons be- tween regulators and HTA Bodies (HTABs) were carried out and classi ﬁed.,OADS,/arxiv_data1/oa_pdf/38/76/BCP-82-0965.PMC5137821.pdf
"Competing Interests All authors have completed the Uni ﬁed Competing Interest form at http://www.icmje.org/coi_disclosure.pdf (availableon request from the corresponding author) and declare EH,MU and SR are employees of Merck and VW was an employeeof Merck during the planning, conduct and analysis of thisstudy, TM is an employee of Quintiles and is also supportedby the National Institute for Health Research (NIHR) Biomed-ical Research Centre at Guy ’s and St Thomas ’NHS Founda- tion Trust and King ’s College London, PV is an employee of Cytel Inc. and NA is an employee of PAREXEL.",Non-OADS,/arxiv_data1/oa_pdf/b3/89/BCP-82-0983.PMC5137823.pdf
Available at https://www.medicines.org.uk/emc/medicine/21201 (last accessed 11 December 2015).,Non-OADS,/arxiv_data1/oa_pdf/b3/89/BCP-82-0983.PMC5137823.pdf
Available at http://www.ema.europa.,Non-OADS,/arxiv_data1/oa_pdf/b3/89/BCP-82-0983.PMC5137823.pdf
"Supporting Information Additional Supporting Information may be found in the online version of this article at the publisher ’s web-site: http://onlinelibrary.wiley.com/doi/10.1111/bcp.13039/suppinfoFigure S1 Study design for a phase 1, randomized, double- blind, parallel-group, single dos e trial.",Non-OADS,/arxiv_data1/oa_pdf/b3/89/BCP-82-0983.PMC5137823.pdf
"Competing Interests All authors have completed the Uni ﬁed Competing Interest form at http://www.icmje.org/coi_disclosure.pdf (availableon request from the corresponding author) and declare nosupport from any organization for the submitted work, no ﬁ- nancial relationships with any organizations that might havean interest in the submitted work in the previous 3 years andno other relationships or activities that could appear to haveinﬂuenced the submitted work.",Non-OADS,/arxiv_data1/oa_pdf/cc/38/BCP-82-0994.PMC5137824.pdf
http://www.fda.gov/d ownloads/Drugs/.../Guidances/ UCM204959.pdf.,Non-OADS,/arxiv_data1/oa_pdf/cc/38/BCP-82-0994.PMC5137824.pdf
Competing Interests All authors have completed the Uni ﬁed Competing Interest form at http://www.icmje.org/coi_disclosure.pdf (availableon request from the corresponding author) and declare: Thestudy was funded by the European Commission under the7th Framework Program (grant agreement HEALTH-F5-2011-260598).,Non-OADS,/arxiv_data1/oa_pdf/bd/00/BCP-82-1094.PMC5137835.pdf
"EUROCAT registries are funded as fully described in Paper 6 of Report 9 –EUROCAT Member Registries: Organization and Activ- ities, available at http://onlinelibrary.wiley.com/doi/10.1002/bdra.20775/pdf .",Non-OADS,/arxiv_data1/oa_pdf/bd/00/BCP-82-1094.PMC5137835.pdf
Available a t http://www.eurocat-network.,Non-OADS,/arxiv_data1/oa_pdf/bd/00/BCP-82-1094.PMC5137835.pdf
Available at http://www.who.int/mediacentre/factsheets/fs370/en/ (last accessed 18 April 2016).,Non-OADS,/arxiv_data1/oa_pdf/bd/00/BCP-82-1094.PMC5137835.pdf
Available at http://www.eurocat-network.eu/content/Special-Report- Medication-Use-In-Pregnancy.pdf (last accessed 18 April2016).,Non-OADS,/arxiv_data1/oa_pdf/bd/00/BCP-82-1094.PMC5137835.pdf
Available at http://www.eur ocat-network.eu/aboutus/ datacollection/guidelinesforreg istration/guide1_4 (last accessed 18 April 2016).,Non-OADS,/arxiv_data1/oa_pdf/bd/00/BCP-82-1094.PMC5137835.pdf
Available at http://www.mej fm.com/Newarchives2013/ Hypospadias.htm (last accessed 18 April 2016).,Non-OADS,/arxiv_data1/oa_pdf/bd/00/BCP-82-1094.PMC5137835.pdf
Available at http://www.ncbi.nlm.nih.gov/pubmed/6785928 (last accessed 18 April 2016).,OADS,/arxiv_data1/oa_pdf/bd/00/BCP-82-1094.PMC5137835.pdf
Supporting Information Additional Supporting Information may be found in the online version of this article at the publisher ’s web-site: http://onlinelibrary.wiley.com/doi/10.1111/bcp.,Non-OADS,/arxiv_data1/oa_pdf/bd/00/BCP-82-1094.PMC5137835.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/e3/d1/btt-10-157.PMC5137929.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/e3/d1/btt-10-157.PMC5137929.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Biologics: Targets and Therapy 2016:10 157–165Biologics: Targets and Therapy Dovepress submit your manuscript | www.dovepress.com Dovepress  157 Original research open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/BTT .S114625Pharmacoutilization of epoetins in naïve patients  with hematological malignancies in an unselected  italian population under clinical practice setting:  a comparative analysis between originator and biosimilars Valentina Perrone1 stefania saragoni1 stefano Buda1 alessandro Broccoli2 luca Degli esposti1 1clicon s.r.l., health, economics  & Outcomes research, ravenna,  2institute of hematology “ l. e a.   seràgnoli”, University of Bologna,   Bologna, italyAim: The purpose of this study was to assess the prescription of epoetins and consumption  of health care resources (in terms of drug treatments) in naïve patients with hematological  malignancies in a real-world setting; in particular, we compared the results between reference  product and biosimilar products.",Non-OADS,/arxiv_data1/oa_pdf/e3/d1/btt-10-157.PMC5137929.pdf
"Patients with anemia related to cancer, chronic inflammation, correspondence: luca Degli esposti clicon s.r.l., health, economics and Outcomes research, Via salara, 36, 48100 ravenna, italyTel +39 544 38393Fax +39 544 212699email luca.degliesposti@clicon.itJournal name: Biologics: Targets and Therapy Article Designation: OrIgINAL reSeArcHY ear: 2016V olume: 10running head verso: Perrone et alrunning head recto: Pharmacoutilization of epoetins in naïve patientsDOI: http://dx.doi.org/10.2147/BTT.S114625",Non-OADS,/arxiv_data1/oa_pdf/e3/d1/btt-10-157.PMC5137929.pdf
Available from: http://www.sifweb.org/docs/sif_position_paper_revisione_biosimilari_lug14.pdf.,Non-OADS,/arxiv_data1/oa_pdf/e3/d1/btt-10-157.PMC5137929.pdf
Available from: http://www.ema.europa.eu/ema/index.jsp?curl= pages/ regulation/general/general_content_000408.jsp.,Non-OADS,/arxiv_data1/oa_pdf/e3/d1/btt-10-157.PMC5137929.pdf
"Biologics: Targets and Therapy 2016:10submit your manuscript | www.dovepress.com Dovepress Dovepress Biologics: Targets and Therapy Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/biologics-targets-and-therapy-journalBiologics: Targets and Therapy is an international, peer-reviewed journal  focusing on the patho-physiological rationale for and clinical applica-tion of Biologic agents in the management of autoimmune diseases, cancers or other pathologies where a molecular target can be identified.",Non-OADS,/arxiv_data1/oa_pdf/e3/d1/btt-10-157.PMC5137929.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 165 Pharmacoutilization of epoetins in naïve patients  19.,Non-OADS,/arxiv_data1/oa_pdf/e3/d1/btt-10-157.PMC5137929.pdf
Available from: https://www.agenziafarmaco.gov.it/ricclin/sites/default/files/files_wysiwyg/files/cIrcULA rS/circular%2031st%20May%202010.pdf.,Non-OADS,/arxiv_data1/oa_pdf/e3/d1/btt-10-157.PMC5137929.pdf
Available from: http://www.agenziafarmaco.gov.it/sites/default/files/rapporto_OsMed_2014_0.pdf.,OADS,/arxiv_data1/oa_pdf/e3/d1/btt-10-157.PMC5137929.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/fd/47/cia-11-1755.PMC5137930.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Interventions in Aging 2016:11 1755–1762Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  1755OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S11833 0 Carers’ education improves oral health of older  people suffering from dementia – results of an  intervention study Andreas Zenthöfer1 Inga Meyer-Kühling2,3 Anna-luisa hufeland1 Johannes schröder2,3 T omas Cabrera1 Dominik Baumgart1 Peter rammelsberg1 Alexander J hassel1 1Department of Prosthetic Dentistry,   University of heidelberg, 2Institute of  gerontology, University of heidelberg,   3section of geriatric Psychiatry,   Center of Psychiatry, University of  heidelberg, heidelberg, germanyAim:  The aim of this study was to evaluate the effectiveness of carers’ education on  improvements in oral health and denture hygiene of care-dependent and cognitively impaired  older people in nursing homes compared to those without intervention.",Non-OADS,/arxiv_data1/oa_pdf/fd/47/cia-11-1755.PMC5137930.pdf
uni-heid elberg.d e Journal name: Clinical Interventions in Aging Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Zenthöfer et al Running head recto: Improving oral health in older people with dementia DOI: http://dx.doi.org/10.2147/CIA.S118330,Non-OADS,/arxiv_data1/oa_pdf/fd/47/cia-11-1755.PMC5137930.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/fd/47/cia-11-1755.PMC5137930.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/fd/47/cia-11-1755.PMC5137930.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/7f/7e/cia-11-1763.PMC5137931.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Interventions in Aging 2016:11 1763–1771Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  1763OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S11899 5 effects of short-term nordic walking training on  sarcopenia-related parameters in women with  low bone mass: a preliminary study Zbigniew Marcin Ossowski1 Wojciech skrobot2 Piotr Aschenbrenner3 Vida Janina Cesnaitiene4 Mirosław Smaruj3 1Department of health Promotion,   2Department of Kinesiology,   3Department of Physical education,   gdansk University of Physical  education and sport, gdansk, Poland;   4Department of health, Physical and  social, lithuanian sports University,   Kaunas, lithuaniaBackground:  Several studies have demonstrated the positive effects of physical activity on  skeletal muscle mass and muscle strength in women with osteoporosis.",Non-OADS,/arxiv_data1/oa_pdf/7f/7e/cia-11-1763.PMC5137931.pdf
"Kazimierza górskiego 1,  80-336 Gdańsk, Poland Tel/fax +48 50 511 3037 email zbigniew.ossowski@awf.gda.p l Journal name: Clinical Interventions in Aging Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Ossowski et al Running head recto: Nordic walking in women with low bone mass DOI: http://dx.doi.org/10.2147/CIA.S118995",Non-OADS,/arxiv_data1/oa_pdf/7f/7e/cia-11-1763.PMC5137931.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/7f/7e/cia-11-1763.PMC5137931.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/7f/7e/cia-11-1763.PMC5137931.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/cf/12/copd-11-3007.PMC5137932.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2016:11 3007–3013International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  3007RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/COPD.S5492 7 Airflow obstruction: is it asthma or is it COPD?",Non-OADS,/arxiv_data1/oa_pdf/cf/12/copd-11-3007.PMC5137932.pdf
DOI: http://dx.doi.org/10.2147/COPD.S54927,Non-OADS,/arxiv_data1/oa_pdf/cf/12/copd-11-3007.PMC5137932.pdf
Available from: https://www.nice.org.uk/guidance/CG10 1.,Non-OADS,/arxiv_data1/oa_pdf/cf/12/copd-11-3007.PMC5137932.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/cf/12/copd-11-3007.PMC5137932.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/cf/12/copd-11-3007.PMC5137932.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/94/3b/ccid-9-461.PMC5137933.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/94/3b/ccid-9-461.PMC5137933.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Clinical, Cosmetic and Investigational Dermatology 2016:9 461–472Clinical, Cosmetic and Investigational Dermatology Dovepress submit your manuscript | www.dovepress.com Dovepress 461 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CCID.S116548 Reactivating the extracellular matrix synthesis of  sulfated glycosaminoglycans and proteoglycans to  improve the human skin aspect and its mechanical  properties Hanane Chajra1  Daniel Auriol1  Francine Joly2  Aurélie Pagnon3  Magda Rodrigues4  Sophie Allart4  Gérard Redziniak5  Fabrice Lefevre1 1Libragen, Induchem (Givaudan Active  Beauty), T oulouse, 2Sephra Pharma,   Puteaux, 3Novotec, Bron, 4Centre de  Physiopathologie de T oulouse-Purpan,   T oulouse, 5Cosmetic Inventions,   Antony, FranceBackground: The aim of this study was to demonstrate that a defined cosmetic composition  is able to induce an increase in the production of sulfated glycosaminoglycans (sGAGs) and/or  proteoglycans and finally to demonstrate that the composition, through its combined action of  enzyme production and synthesis of macromolecules, modulates organization and skin surface  aspect with a benefit in antiaging applications.",Non-OADS,/arxiv_data1/oa_pdf/94/3b/ccid-9-461.PMC5137933.pdf
"GAGs are  Correspondence: Hanane Chajra Libragen, Induchem (part of Givaudan Active Beauty), 3 Rue des Satellites 31400 Toulouse, France Email Hanane.chajra@givaudan.comJournal name: Clinical, Cosmetic and Investigational Dermatology Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 9Running head verso: Chajra et alRunning head recto: Reactivating the extracellular matrix synthesisDOI: http://dx.doi.org/10.2147/CCID.S116548",Non-OADS,/arxiv_data1/oa_pdf/94/3b/ccid-9-461.PMC5137933.pdf
"Clinical, Cosmetic and Investigational Dermatology 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Clinical, Cosmetic and Investigational Dermatology Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/clinical-cosmetic-and-investigational-dermatology-journal Clinical, Cosmetic and Investigational Dermatology is an interna- tional, peer-reviewed, open access, online journal that focuses on   the latest clinical and experimental research in all aspects of skin   disease and cosmetic interventions.",Non-OADS,/arxiv_data1/oa_pdf/94/3b/ccid-9-461.PMC5137933.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authorsDovepress 472 Chajra et al  7.,Non-OADS,/arxiv_data1/oa_pdf/94/3b/ccid-9-461.PMC5137933.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/6a/2f/copd-11-3015.PMC5138020.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2016:11 3015–3022International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  3015OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S11841 5 Computer quantification of “angle of collapse”  on maximum expiratory flow volume curve for  diagnosing asthma-COPD overlap syndrome Wei Wang Mengshuang Xie Shuang Dou liwei Cui Wei Xiao Department of Pulmonary Medicine,   Qilu Hospital, Shandong University,   Jinan, People’s Republic of ChinaBackground:  In a previous study, we demonstrated that asthma patients with signs of  emphysema on quantitative computed tomography (CT) fulfill the diagnosis of asthma-COPD  overlap syndrome (ACOS).",Non-OADS,/arxiv_data1/oa_pdf/6a/2f/copd-11-3015.PMC5138020.pdf
"Keywords:  asthma, COPD, overlap, emphysema, MEFV, airway collapse Introduction Asthma and COPD are major public health issues, due to their elevated prevalence  and high cost to society.1,2 Although asthma and COPD are both chronic inflam - matory diseases affecting the airway and characterized by the presence of airflow  limitation, their etiopathogenesis, diagnostics, and therapeutic and prognostic char - acteristics differ.3,4 In clinical practice, a large proportion of subjects have features of both asthma  and COPD, which is called the asthma-COPD overlap syndrome (ACOS).5 The con - cept of ACOS was formally proposed by international guidelines in 2014 when the Correspondence: Wei Xiao Department of Pulmonary Medicine,  Qilu Hospital, Shandong University,  107 Wenhua West Road, Jinan 250012,  People’s Republic of China Tel +86 531 8216 6294 email xiaowei4226@163.co m Journal name: International Journal of COPD Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Wang et al Running head recto: Computer quantification of AC for diagnosing ACOS DOI: http://dx.doi.org/10.2147/COPD.S118415",Non-OADS,/arxiv_data1/oa_pdf/6a/2f/copd-11-3015.PMC5138020.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/6a/2f/copd-11-3015.PMC5138020.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/6a/2f/copd-11-3015.PMC5138020.pdf
"Available from: http://www.ginasthma.org/local/ uploads/files/AsthmaCOPDOverlap.pd f. Accessed March 10, 2015.",OADS,/arxiv_data1/oa_pdf/6a/2f/copd-11-3015.PMC5138020.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/fc/2e/imcrj-9-377.PMC5138021.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/fc/2e/imcrj-9-377.PMC5138021.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).International Medical Case Reports Journal 2016:9 377–383International Medical Case Reports Journal Dovepress submit your manuscript | www.dovepress.com Dovepress 377 CASE REPORT open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IMCRJ.S118345Long-term follow-up of anatomical and functional  macular changes after a single intravitreal implant  of dexamethasone 0.7 mg for radiation macular  edema secondary to proton beam therapy for choroidal melanoma Francesco Stringa Federico Marzi Laura Giannì Manuela ImparatoAlessandro BianchiPaolo Emilio Bianchi University of Pavia, Faculty of  Medicine, University Eye Clinic,  Fondazione IRCCS Policlinico San Matteo, Pavia,  ItalyPurpose: To describe the efficacy and safety of a single intravitreal implant of dexamethasone  in a patient affected by radiation maculopathy due to proton beam radiotherapy for choroidal  melanoma.",Non-OADS,/arxiv_data1/oa_pdf/fc/2e/imcrj-9-377.PMC5138021.pdf
"2Correspondence: Francesco Stringa University of Pavia, Faculty of Medicine, University Eye Clinic, Fondazione IRCCS Policlinico San Matteo, Viale Camillo Golgi 19, Pavia 27100, ItalyEmail stringa.f86@gmail.comJournal name: International Medical Case Reports Journal Article Designation: CASE REPORTY ear: 2016V olume: 9Running head verso: Stringa et alRunning head recto: Efficacy and safety of a single intravitreal implant of dexamethasoneDOI: http://dx.doi.org/10.2147/IMCRJ.S118345",Non-OADS,/arxiv_data1/oa_pdf/fc/2e/imcrj-9-377.PMC5138021.pdf
"International Medical Case Reports Journal 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress International Medical Case Reports Journal Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/international-medical-case-reports-journal-journalThe International Medical Case Reports Journal is an international,  peer-reviewed open-access journal publishing original case reports from all medical specialties.",Non-OADS,/arxiv_data1/oa_pdf/fc/2e/imcrj-9-377.PMC5138021.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 383 Efficacy and safety of a single intravitreal implant of dexamethasone,Non-OADS,/arxiv_data1/oa_pdf/fc/2e/imcrj-9-377.PMC5138021.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/3f/f4/dddt-10-3933.PMC5138022.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2016:10 3933–3946Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3933Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S11628 6 loading cisplatin onto 6-mercaptopurine  covalently modified MSNS: a nanomedicine  strategy to improve the outcome of cisplatin  therapy Xiaojie lv1 Ming Zhao1,2 Yuiji Wang1 Xi hu1 Jianhui Wu1 Xueyun Jiang1 shan li1 chunying cui1 shiqi Peng1 1Beijing Area Major Laboratory  of Peptide and Small Molecular  Drugs, engineering research center  of endogenous Prophylactic of  Ministry of Education of China,   Beijing Laboratory of Biomedical  Materials, College of Pharmaceutical  Sciences, Capital Medical University,   Beijing, People’s Republic of China;   2Department of Biomedical science  and environmental Biology, Kaohsiung  Medical University, Kaohsiung, TaiwanAbstract:  In the treatment of cancer patients, cisplatin (CDDP) exhibits serious cardiac  and renal toxicities, while classical combinations related to CDDP are unable to solve these  problems and may result in worse prognosis.",Non-OADS,/arxiv_data1/oa_pdf/3f/f4/dddt-10-3933.PMC5138022.pdf
"10, Xitoutiao, You An Men, Beijing,  100069, People’s Republic of China Tel +86 10 8391 1528 Fax +86 10 8391 1533 email sqpeng@bjmu.edu.c n;   mingzhao@bjmu.edu.c n Journal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Lv et al Running head recto: Loading cisplatin onto 6MP covalently modified MSNS DOI: http://dx.doi.org/10.2147/DDDT.S116286",Non-OADS,/arxiv_data1/oa_pdf/3f/f4/dddt-10-3933.PMC5138022.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/3f/f4/dddt-10-3933.PMC5138022.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/3f/f4/dddt-10-3933.PMC5138022.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/d3/b7/ijn-11-6379.PMC5138023.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 6379–6399International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  6379OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S12111 4 Multiple nanoemulsion system for an oral  combinational delivery of oxaliplatin and  5-fluorouracil: preparation and in vivo evaluation rudra Pangeni1,* sang Won choi1,* Ok-cheol Jeon2 Y oungro Byun3 Jin Woo Park1 1Department of Pharmacy, college  of Pharmacy and Natural Medicine  research Institute, Mokpo National  University, Muan-gun, 2Pharosgen  r&D center, asan Institute for life  sciences, 3Department of Molecular  Medicine and Biopharmaceutical  science, graduate school of  convergence science and T echnology,   college of Pharmacy, seoul National  University, seoul, republic of Korea *These authors contributed equally  to this workAbstract:  Oxaliplatin (OXA) is a third-generation cisplatin analog that has been approved as  first-line chemotherapy in combination with 5-fluorouracil (5-FU) for the treatment of resectable  and advanced colorectal cancer.",Non-OADS,/arxiv_data1/oa_pdf/d3/b7/ijn-11-6379.PMC5138023.pdf
"In addition, a prolonged exposure of anticancer  drugs to cancerous cells can be implemented by maintaining an appropriate plasma  drug concentration, which can increase drug efficacy and decrease adverse effects,  as well as facilitate the use of anticancer drugs for chronic treatment regimens as  prophylactics against recurrence and metastasis.1,2 However, oral delivery of antican - cer drugs is a challenge because of their particular physicochemical properties and correspondence: Youngro Byun Department of Molecular Medicine and  Biopharmaceutical science, graduate  school of convergence science and  Technology, college of Pharmacy, seoul  National University, 1 gwanak-ro, seoul  08826, republic of Korea Tel +82 2 880 7866 Fax +82 2 872 7864 email yrbyun@snu.ac.k r  Jin Woo Park Department of Pharmacy, college of  Pharmacy and Natural Medicine research  Institute, Mokpo National University,  1666 Youngsan-ro, Muan-gun, Jeonnam  58554, republic of Korea Tel +82 61 450 2704 Fax +82 61 450 2689 email jwpark@mokpo.ac.k r Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Pangeni et al Running head recto: Oral combinational delivery of oxaliplatin and 5-fluorouracil DOI: http://dx.doi.org/10.2147/IJN.S121114",Non-OADS,/arxiv_data1/oa_pdf/d3/b7/ijn-11-6379.PMC5138023.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/d3/b7/ijn-11-6379.PMC5138023.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/d3/b7/ijn-11-6379.PMC5138023.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/e7/44/ijn-11-6401.PMC5138024.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 6401–6420International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  6401OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S10128 5Upregulation of akt/NF-κB-regulated inflammation  and akt/Bad-related apoptosis signaling pathway  involved in hepatic carcinoma process: suppression  by carnosic acid nanoparticle Bo Tang1,2,* Fang Tang1,2,* Zhenran Wang1,2,* guangying Qi3 Xingsi liang1,2 Bo li1,2 shengguang Yuan1,2 Jie liu1,2 shuiping Yu1,2 songqing he1,2 1Department of hepatobiliary surgery,   guilin Medical University affiliated  hospital, 2laboratory of liver Injury  and repair Molecular Medicine, guilin  Medical University, 3Department of  Pathology and Physiopathology, guilin  Medical University, guilin, guangxi,   People’s republic of china *These authors contributed equally  to this workAbstract:  Primary liver cancer is globally the sixth most frequent cancer, and the second leading  cause of cancer death and its incidence is increasing in many countries, becoming a serious  threat to human health.",Non-OADS,/arxiv_data1/oa_pdf/e7/44/ijn-11-6401.PMC5138024.pdf
"The viruses cause hepatocellular  carcinoma because massive inflammation, fibrosis, and eventual cirrhosis occur within correspondence: songqing he Department of hepatobiliary surgery,  Guilin Medical University Affiliated  hospital, guilin, 541001, 15 lequn road,  guangxi, People’s republic of china Tel +86 773 280 9503 Fax +86 773 282 4373 email dr_hesongqing@163.co m Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Tang et al Running head recto: Carnosic acid nanoparticle suppresses liver cancer DOI: http://dx.doi.org/10.2147/IJN.S101285",Non-OADS,/arxiv_data1/oa_pdf/e7/44/ijn-11-6401.PMC5138024.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/e7/44/ijn-11-6401.PMC5138024.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/e7/44/ijn-11-6401.PMC5138024.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/53/21/ott-9-7309.PMC5138036.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 7309–7314OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  7309Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S11113 7 Long-term benefit of sunitinib in patients  with metastatic renal cell carcinoma in latin  America: retrospective analysis of patient clinical  characteristics Oren smaletz1 Matias chacón2 ludmila de Oliveira Koch1 Daniela r de carvalho  rocha1 Fernanda c cardoso1 1Department of Oncology, Hospital  Israelita Albert Einstein, São  Paulo, Brazil; 2Medical Oncology  Department, Alexander Fleming  Institute, Buenos Aires, ArgentinaObjective:  To describe the clinical characteristics of Latin American patients with metastatic  renal cell carcinoma (mRCC) who experienced a progression-free survival (PFS) for at least  15 months following treatment with sunitinib.",Non-OADS,/arxiv_data1/oa_pdf/53/21/ott-9-7309.PMC5138036.pdf
"Keywords:  renal cell carcinoma, sunitinib, long-term benefit, Latin America Introduction Sunitinib malate (Sutent®; Pfizer Inc., New Y ork, NY, USA) is an orally administered  multitargeted inhibitor of vascular endothelial growth factor receptor, platelet-derived  growth factor receptor, and other receptor tyrosine kinases.1–3 Sunitinib has been  approved worldwide for the treatment of advanced renal cell carcinoma (RCC) based on  its superior efficacy compared with interferon-alpha (IFN- α) as a first-line therapy and  its activity in patients who previously received cytokine therapy.4–8 Prospective studies  of sunitinib have shown median progression-free survival (PFS) of 11  months in patients  with treatment-naïve metastatic RCC (mRCC)6 and median PFS of ~8 months in the  cytokine-refractory setting.4,5 However, there are patients treated with sunitinib who correspondence: Oren smaletz Department of Oncology, Hospital  Israelita Albert Einstein Avenue, Albert  Einstein 627/701, Bl A1 – Room 201,  Morumbi, São Paulo 05652-900, Brazil Tel +55 11 2151 1648 Fax +55 11 2151 1486 email osmaletz@einstein.b r Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Smaletz et al Running head recto: Long-term benefit of sunitinib in mRCC DOI: http://dx.doi.org/10.2147/OTT.S111137",Non-OADS,/arxiv_data1/oa_pdf/53/21/ott-9-7309.PMC5138036.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/53/21/ott-9-7309.PMC5138036.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/53/21/ott-9-7309.PMC5138036.pdf
Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id =607.,Non-OADS,/arxiv_data1/oa_pdf/53/21/ott-9-7309.PMC5138036.pdf
Available from: http://www.ema.europa.eu/ema/ index.jsp?curl =pages/medicines/human/medicines/000687/human_ med_001069.jsp&mid =WC0b01ac058001d12 4.,Non-OADS,/arxiv_data1/oa_pdf/53/21/ott-9-7309.PMC5138036.pdf
"Available  from: http://ctep.cancer.gov/protocolDevelopment/electronic_applica - tions/ctc.ht m. Accessed January 7, 2016.",Non-OADS,/arxiv_data1/oa_pdf/53/21/ott-9-7309.PMC5138036.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/7e/63/ppa-10-2419.PMC5138037.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Patient Preference and Adherence 2016:10 2419–2427Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  2419OriginAl reseArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S11982 5 The design, rationale, and baseline characteristics  of a nationwide cohort registry in china:  blood pressure and clinical outcome in TiA  or ischemic stroke Jie Xu1,2,* Yi liu3,* Y ongli Tao4 Xuewei Xie1,2 hongqiu gu1,2 Yuesong Pan1,2 Xingquan Zhao1,2 Y ongjun Wang1,2 Aoshuang Yan3 Yilong Wang1,2 1Department of neurology, Beijing  Tiantan hospital, capital Medical  University, 2china national clinical  research center for neurological  Diseases, 3Department of  epidemiology and health statistics,   school of Public health, capital  Medical University, Beijing,   4Department of neurology, First  Affiliated hospital of Zhengzhou  University, Zhengzhou, china *These authors contributed equally  to this workBackground:  The relationship between poststroke blood pressure (BP) and clinical outcomes  in ischemic stroke (IS) is still controversial.",Non-OADS,/arxiv_data1/oa_pdf/7e/63/ppa-10-2419.PMC5138037.pdf
"Most  studies10–13 on stroke still use BP values based on traditional office measurements, correspondence: Yilong Wang Department of neurology, Beijing  Tiantan hospital, capital Medical  University, 6 Tiantan Xili, Dongcheng,  Beijing 100050, china Tel +86 10 6709 8350 email yilong528@aliyun.co m Aoshuang Yan Department of epidemiology and  health statistics, school of Public  health, capital Medical University,  10 Xitoutiao, You’anmen Wai, Fengtai,  Beijing 100069, china Tel +86 10 6613 1887 email yanas@139.co m Journal name: Patient Preference and Adherence Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Xu et al Running head recto: Blood pressure in TIA or ischemic stroke DOI: http://dx.doi.org/10.2147/PPA.S119825",Non-OADS,/arxiv_data1/oa_pdf/7e/63/ppa-10-2419.PMC5138037.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/7e/63/ppa-10-2419.PMC5138037.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/69/cf/pgpm-9-131.PMC5138038.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/69/cf/pgpm-9-131.PMC5138038.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Pharmacogenomics and Personalized Medicine 2016:9 131–147Pharmacogenomics and Personalized Medicine Dovepress submit your manuscript | www.dovepress.com Dovepress  131 REVIEW open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PGPM.S107772CYP2D6 polymorphisms and their influence  on risperidone treatment Apichaya Puangpetch1 Natchaya Vanwong1 Nopphadol Nuntamool2 Yaowaluck Hongkaew1 Monpat Chamnanphon1 Chonlaphat Sukasem1 1Division of Pharmacogenomics and  Personalized Medicine, Department  of Pathology, Faculty of Medicine Ramathibodi Hospital,  2Molecular  Medicine, Faculty of Science, Mahidol University, Bangkok, ThailandAbstract:  Cytochrome P450 enzyme especially CYP2D6 plays a major role in biotransfor - mation.",Non-OADS,/arxiv_data1/oa_pdf/69/cf/pgpm-9-131.PMC5138038.pdf
"Correspondence: Chonlaphat Sukasem Division of Pharmacogenetics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, ThailandTel +66 2 200 4331Fax +66 2 200 4332Email chonlaphat.suk@mahidol.ac.thJournal name: Pharmacogenomics and Personalized Medicine Article Designation: REVIEWY ear: 2016V olume: 9Running head verso: Puangpetch et alRunning head recto: Effect of CYP2D6 on risperidone treatmentDOI: http://dx.doi.org/10.2147/PGPM.S107772",Non-OADS,/arxiv_data1/oa_pdf/69/cf/pgpm-9-131.PMC5138038.pdf
Available from: http://www.affymetrix.com.,Non-OADS,/arxiv_data1/oa_pdf/69/cf/pgpm-9-131.PMC5138038.pdf
Available from: http://www.cypalleles.ki.se/cyp2d6.htm.,Non-OADS,/arxiv_data1/oa_pdf/69/cf/pgpm-9-131.PMC5138038.pdf
"Pharmacogenomics and Personalized Medicine 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Pharmacogenomics and Personalized Medicine Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/pharmacogenomics-and-personalized-medicine-journalPharmacogenomics and Personalized Medicine is an international, peer- reviewed, open access journal characterizing the influence of genotype on pharmacology leading to the development of personalized treatment programs and individualized drug selection for improved safety, efficacy and sustainability.",Non-OADS,/arxiv_data1/oa_pdf/69/cf/pgpm-9-131.PMC5138038.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 147 Effect of CYP2D6 on risperidone treatment 80.,Non-OADS,/arxiv_data1/oa_pdf/69/cf/pgpm-9-131.PMC5138038.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/af/49/ott-9-7141.PMC5138039.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 7141–7147OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  7141Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S11316 1 Efficacy of three-dimensional conformal  radiotherapy combined with transarterial  chemoembolization for hepatocellular carcinoma  with portal vein tumor thrombus Fei-Xiang Wu1–3,* Hui-Rong Lu4,* Shao-Liang Zhu1,* Zi-Hui Li1 Ling Zou1 Tao Bai1 Jie chen1 Tian-Bo Yang1 Shi-Xiong Liang4,5 1Department of hepatobiliary surgery,   affiliated Tumor hospital of guangxi  Medical University, nanning, 2guangxi  liver cancer Diagnosis and Treatment  engineering and Technology research  center, nanning, 3Key laboratory  of early Prevention and Treatment  for regional high Frequency T umor,   Ministry of education, shanghai,   4Department of radiation Oncology,   affiliated Tumor hospital of guangxi  Medical University, nanning,   5Department of radiation Oncology,   shanghai Pulmonary hospital, Tongji  University school of Medicine,   shanghai, People’s republic of china *These authors contributed equally  to this workObjective:  The current study aimed to evaluate the efficacy and outcomes of three-dimensional  conformal radiotherapy (3DCRT) combined with transarterial chemoembolization (TACE) for treat - ing patients with hepatocellular carcinoma involving portal vein tumor thrombus.",Non-OADS,/arxiv_data1/oa_pdf/af/49/ott-9-7141.PMC5138039.pdf
"Keywords:  hepatocellular carcinoma, portal vein tumor thrombus, three-dimensional conformal  radiotherapy, transarterial chemoembolization, overall survival Introduction Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related  mortality worldwide.1 Portal vein tumor thrombus (PVTT) is found to have invaded  the main trunk in 10%–15% of patients at the time of diagnosis with HCC.2–4 PVTT  is a particularly frequent complication in patients with advanced HCC.5,6 It is often  accompanied by portal vein hypertension, ascites, tumor dissemination, and deteriora - tion of liver function, resulting in poor prognosis for HCC patients with PVTT, who  survive a median of 2–3 months without treatment.3,7,8 Transarterial chemoembolization (TACE) is considered a standard treatment for  patients with inoperable advanced HCC.9 Evidence suggests that TACE is relatively  safe for HCC patients with PVTT who have good liver function and abundant collateral  circulation,10 but the efficacy of TACE for such patients remains controversial.11–14Correspondence: Shi-Xiong Liang Department of radiation Oncology,  shanghai Pulmonary hospital, Tongji  University school of Medicine,  507 Zhengmin Road, Shanghai 200433,  People’s republic of china Tel +86 139 1771 6605 Fax +86 21 6511 5006 email shixliang@vip.sina.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Wu et al Running head recto: 3DCRT + TACE for HCC with PVTT DOI: http://dx.doi.org/10.2147/OTT.S113161",Non-OADS,/arxiv_data1/oa_pdf/af/49/ott-9-7141.PMC5138039.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/af/49/ott-9-7141.PMC5138039.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/af/49/ott-9-7141.PMC5138039.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/ad/f2/ott-9-7331.PMC5138040.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 7331–7335OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  7331Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S10714 6 Postoperative adjuvant chemotherapy combined  with intracavitary brachytherapy in early-stage  cervical cancer patients with intermediate  risk factors hao Yu1 linlin Zhang2 Xuelian Du1 Xiugui sheng1 1Department of gynecologic  Oncology, shandong cancer hospital  and institute affiliated to shandong  University, 2Department of Obstetrics  and gynecology, Jinan Fourth  People’s  hospital, Jinan, People’s  republic of chinaObjective:  To investigate the impact of postoperative adjuvant therapy on survival of patients  with intermediate risk early-stage cervical squamous cell carcinoma.",Non-OADS,/arxiv_data1/oa_pdf/ad/f2/ott-9-7331.PMC5138040.pdf
"Until  now, CCRT has been considered a primary postoperative therapy for high-risk cervical  cancer.3 However, the treatment regimen for patients with intermediate risk factors,  including deep stromal invasion (DSI), lymph vascular space involvement (LVSI),  low differentiation, and tumor diameters $4 cm remains unclear.correspondence: Xiugui sheng Department of gynecologic Oncology,  shandong cancer hospital and institute  Affiliated to Shandong University,  440 Jiyan road, 250117, Jinan,  People’s republic of china email jnsxg@hotmail.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Yu et al Running head recto: Postoperative adjuvant chemotherapy combined with intracavitary brachytherapy DOI: http://dx.doi.org/10.2147/OTT.S107146",Non-OADS,/arxiv_data1/oa_pdf/ad/f2/ott-9-7331.PMC5138040.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/ad/f2/ott-9-7331.PMC5138040.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/ad/f2/ott-9-7331.PMC5138040.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/56/ec/ott-9-7285.PMC5138041.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 7285–7295OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  7285Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S10892 9 cTgF enhances resistance to 5-FU-mediating cell  apoptosis through F aK/MeK/erK signal pathway  in colorectal cancer Kai Yang Kai gao gui hu Yanguang Wen changwei lin Xiaorong li Department of general surgery, The  Third affiliated hospital of central  south University, central south  University, changsha, hunan, People’s  republic of chinaAbstract:  Colorectal cancer (CRC) is one of the most commonly diagnosed cancers among  both males and females; the chemotherapy drug 5-fluorouracil (5-FU) is one of a doctors’  first lines of defense against CRC.",Non-OADS,/arxiv_data1/oa_pdf/56/ec/ott-9-7285.PMC5138041.pdf
"Therefore, it is very important to find molecular  markers that modulate CRC chemoresistance.3 Connective tissue growth factor (CTGF [CCN2]) is an extracellular matrix (ECM)- associated molecule belonging to the family of growth factors termed the CCN, which  contains cysteine-rich 61 (CCN1), CTGF/CCN2, nephroblastoma overexpressed  (CCN3), Wnt-inducible secreted protein-1 (CCN4), rCop1 (CCN5), and Wisp-3 correspondence: Xiaorong li Department of general surgery,  The Third Affiliated Hospital of  central south University, central south  University, 138 Tongzhipo road, hunan  Province, changsha 410013, People’s  republic of china Tel +86 731 8861 8232 email lixiaorong@medmail.com.c n Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Y ang et al Running head recto: CTGF enhances resistance to 5-FU-mediating cell apoptosis in CRC DOI: http://dx.doi.org/10.2147/OTT.S108929",Non-OADS,/arxiv_data1/oa_pdf/56/ec/ott-9-7285.PMC5138041.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/56/ec/ott-9-7285.PMC5138041.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/56/ec/ott-9-7285.PMC5138041.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/77/ad/jpr-9-1131.PMC5138042.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/77/ad/jpr-9-1131.PMC5138042.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Pain Research  2016:9 1131–1141Journal of Pain Research Dovepress submit your manuscript | www.dovepress.com Dovepress  1131 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JPR.S119845Prevalence of different pain categories based  on pain spreading on the bodies of older adults  in Sweden: a descriptive-level and multilevel  association with demographics, comorbidities, medications, and certain lifestyle factors   (PainS65+) E Dragioti1  B Larsson1  L Bernfort2  LÅ Levin2  B Gerdle1 1Pain and Rehabilitation Medicine,   2Division of Health Care Analysis,   Department of Medical and Health  Sciences (IMH), Faculty of Health Sciences, Linköping University,  Linköping, SwedenBackground and objective: There is limited knowledge about the prevalence of pain and its  relation to comorbidities, medication, and certain lifestyle factors in older adults.",Non-OADS,/arxiv_data1/oa_pdf/77/ad/jpr-9-1131.PMC5138042.pdf
"Keywords: pain spreading, chronic pain, older adults, aging, medication, comorbidity Introduction Pain is a common cause of disability in older adults.1–6 Among its consequences are  risk of future fall injuries,7 reduced life satisfaction and quality of life, increased mood Correspondence: E Dragioti   Pain and Rehabilitation Medicine,  Department of Medical and Health Sciences (IMH), Faculty of Health Sciences, University of Linköping,  SE-581 85 Linköping, Sweden Tel +46 7 6325 1361   Email elena.dragioti@liu.seJournal name: Journal of Pain Research  Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 9Running head verso: Dragioti et alRunning head recto: Spreading of pain in older adultsDOI: http://dx.doi.org/10.2147/JPR.S119845",Non-OADS,/arxiv_data1/oa_pdf/77/ad/jpr-9-1131.PMC5138042.pdf
"Journal of Pain Research  2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Pain Research  Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/journal-of-pain-research-journal The Journal of Pain Research is an international, peer reviewed, open  access, online journal that welcomes laboratory and clinical findings   in the fields of pain research and the prevention and management of pain.",Non-OADS,/arxiv_data1/oa_pdf/77/ad/jpr-9-1131.PMC5138042.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 1141 Spreading of pain in older adults  27.,Non-OADS,/arxiv_data1/oa_pdf/77/ad/jpr-9-1131.PMC5138042.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/51/55/ott-9-7337.PMC5138043.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 7337–7343OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  7337Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OTT .S11117 6 History and progression of Fat cadherins in health  and disease Xiaofeng Zhang1,2,* Jinghua Liu3,* Xiao Liang1,2 Jiang Chen1,2 Junjie Hong1,2 Libo Li1 Qiang He3 Xiujun Cai1,2 1Department of General Surgery,   2Key Laboratory of Surgery of  Zhejiang Province, Sir Run Run  Shaw Hospital, Zhejiang University,   Hangzhou, Zhejiang, 3Department of  Hepatobiliary Surgery, Linyi People’s  Hospital, Linyi, Shandong, People’s  Republic of China *These authors contribute equally  to this workAbstract:  Intercellular adhesions are vital hubs for signaling pathways during multicellular  development and animal morphogenesis.",Non-OADS,/arxiv_data1/oa_pdf/51/55/ott-9-7337.PMC5138043.pdf
"In the past  two decades, the Fat family was demonstrated to be a tumor suppressor.1 In reality, Correspondence: Xiujun Cai Department of General Surgery, Sir Run  Run Shaw Hospital, Zhejiang University,  Hangzhou 310016, Zhejiang, People’s  Republic of China Tel/fax +86 571 8600 6605 email cxjzu@zju.edu.c n  Qiang He Department of Hepatobiliary Surgery,  Linyi People’s Hospital, 27 east Jiefang  Road, Linyi 276000, Shandong, People’s  Republic of China Tel/fax +86 539 807 8508 email heq_lyrmyy@163.co m Journal name: OncoTargets and Therapy Article Designation: Review Y ear: 2016 Volume: 9 Running head verso: Zhang et al Running head recto: History and progression of Fat cadherins DOI: http://dx.doi.org/10.2147/OTT.S111176",Non-OADS,/arxiv_data1/oa_pdf/51/55/ott-9-7337.PMC5138043.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/51/55/ott-9-7337.PMC5138043.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/51/55/ott-9-7337.PMC5138043.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/58/ae/ndt-12-3061.PMC5138044.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 3061–3067Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  3061OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S12078 6 association between serotonin transporter  gene polymorphisms and heroin dependence:  a meta-analytic study Pao-Yen lin* Yi-shan Wu* Department of Psychiatry, Kaohsiung  chang gung Memorial hospital and  chang gung University college of  Medicine, Kaohsiung, Taiwan *These authors contributed equally  to this workBackground:  Studies have examined the association between heroin dependence and serotonin  transporter gene polymorphisms but yielded inconsistent results.",Non-OADS,/arxiv_data1/oa_pdf/58/ae/ndt-12-3061.PMC5138044.pdf
"Previous literature has proposed that the  serotonin (5-hydroxytryptamine, 5-HT) system, through modifying dopamine transmis - sion, is involved in the deficiency in reward system in drug dependence.3 The study  examining monoamine markers in the brains of chronic heroin users found decreased   level of 5-hydroxyindoleacetic acid, a serotonin metabolite, in striatum.4 Neuroimaging  studies have shown that the association between dopamine and serotonin transporter  availability and addictive behaviors, indicating a role of serotonin in HD.5–7 Also, dys - function of 5-HT system is associated with impulsivity, disordered behavioral inhibi - tion, and depression, which are all frequently observed in drug addicts.8 Hence, in search correspondence: Pao-Yen lin Department of Psychiatry, Kaohsiung  chang gung Memorial hospital 123 Dapi road, Niaosong District,  Kaohsiung city 833, Taiwan Tel +886 7 731 7123 ext 8751 Fax +886 7 732 6817 email py1029@adm.cgmh.org.t w Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Lin and Wu Running head recto: 5-HTT gene and heroin dependence DOI: http://dx.doi.org/10.2147/NDT.S120786",Non-OADS,/arxiv_data1/oa_pdf/58/ae/ndt-12-3061.PMC5138044.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/58/ae/ndt-12-3061.PMC5138044.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/58/ae/ndt-12-3061.PMC5138044.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/a1/5b/jbm-7-275.PMC5138045.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/a1/5b/jbm-7-275.PMC5138045.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Blood Medicine 2016:7 275–282Journal of Blood Medicine Dovepress submit your manuscript | www.dovepress.com Dovepress  275 Review open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JBM.S84597Once-weekly prophylactic dosing of recombinant  factor iX improves adherence in hemophilia B Claudia Djambas Khayat Pediatric Department, Hôtel-Dieu de  France Hospital, Beirut, LebanonAbstract: Regular prophylactic treatment in severe hemophilia should be considered an  optimal treatment.",Non-OADS,/arxiv_data1/oa_pdf/a1/5b/jbm-7-275.PMC5138045.pdf
"Missense, frameshift, and nonsense mutations  are the most frequently seen, and deletions are rarely described.2Correspondence: Claudia Djambas  KhayatPediatric Department, Hôtel-Dieu de France Hospital, Alfred Naccache Boulevard, Beirut, LebanonTel +961 3 704 864Fax +961 1 613 273email claudiakhayat@yahoo.frJournal name: Journal of Blood Medicine Article Designation: ReviewY ear: 2016V olume: 7Running head verso: Djambas KhayatRunning head recto: Once-weekly recombinant factor IX improves adherence in hemophilia BDOI: http://dx.doi.org/10.2147/JBM.S84597",Non-OADS,/arxiv_data1/oa_pdf/a1/5b/jbm-7-275.PMC5138045.pdf
Available from: http://www.ukneqasbc.org/Documents/S207%20report%20v1.0(1).pdf.,Non-OADS,/arxiv_data1/oa_pdf/a1/5b/jbm-7-275.PMC5138045.pdf
Available from: http://www.ukhcdo.org/ wp-content/uploads/uploads/216/02/bleeding-disordre-statistics-for-April-2014-to-March-2015-v2-for-website.pdf.,Non-OADS,/arxiv_data1/oa_pdf/a1/5b/jbm-7-275.PMC5138045.pdf
Available from: https://www2a.cdc.gov/ncbddd/htcweb/UDC_Report/UDC_view1.asp?para1=NATION&para2=TREATH&para3=&ScreenWidth=1920&ScreenHeight=1080.,OADS,/arxiv_data1/oa_pdf/a1/5b/jbm-7-275.PMC5138045.pdf
"Journal of Blood Medicine 2016:7submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Blood Medicine Publish your work in this journal Submit your manuscript here: http://www.dovepress.com/journal-of-blood-medicine-journalThe Journal of Blood Medicine is an international, peer-reviewed, open  access, online journal publishing laboratory, experimental and clinical aspects   of all aspect pertaining to blood based medicine including but not limited to:   Transfusion Medicine; Blood collection, Donor issues, Transmittable diseases,   and Blood banking logistics; Immunohematology; Artificial and alternative blood based therapeutics; Hematology; Biotechnology/nanotechnology of blood related medicine; Legal aspects of blood medicine; Historical perspec-tives.",Non-OADS,/arxiv_data1/oa_pdf/a1/5b/jbm-7-275.PMC5138045.pdf
Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors.Dovepress 282 Djambas Khayat,Non-OADS,/arxiv_data1/oa_pdf/a1/5b/jbm-7-275.PMC5138045.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/1c/13/ott-9-7297.PMC5138046.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 7297–7307OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  7297Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S11129 1 silencing of mir-1247 by Dna methylation  promoted non-small-cell lung cancer cell invasion  and migration by effects of sTMn1 Juan Zhang1,2 Jun Fu1 Yuliang Pan2 Xi Zhang2 liangfang shen1 1Department of Oncology  radiotherapy, Xiangya hospital,   2Department of Oncology, The Third  Xiangya hospital, central southern  University, changsha, hunan, People’s  republic of chinaAbstract:  MicroRNAs (miRNAs) play an important role in cancer development and progression,  altering several biological functions by affecting targets through either degradation of mRNAs  or suppression of protein translation.",Non-OADS,/arxiv_data1/oa_pdf/1c/13/ott-9-7297.PMC5138046.pdf
"MicroRNAs (miRNAs) are a class of short ( ~22 nt), non-coding, regulatory RNAs  involved in multiple biological processes, including cell invasion, metastasis, angio - genesis, and apoptosis.6 Accumulating evidence has shown that .50% of miRNA  genes are situated in fragile sites and are involved in tumor pathogenesis, including  NSCLC.7–9 MiR-1247 has previously been identified to be downregulated in prostate  cancer, pancreatic cancer, and osteosarcoma.10–13 Upregulation of miR-1247 inhibited  cell proliferation and metastasis in pancreatic cancer and was therefore recognized  as a tumor suppressor.10 Moreover, the expression of miR-1247 has been found to  be decreased in osteosarcoma cancer stem cells and influences human osteosarcoma  oncogenesis by the regulation of MAP3K9 .11 Furthermore, miR-1247 was found to  be downregulated in lung adenocarcinoma and squamous carcinoma cancer tissue  compared with normal tissues.14 Y et the function and mechanism of miR-1247 in correspondence: liangfang shen Department of Oncology radiotherapy,  Xiangya hospital, central southern  University, no 87, Xiangya road,   changsha 410008, hunan,  People’s republic of china Tel +86 731 88618240 email lfshen2008@163.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Zhang et al Running head recto: Silencing of miR-1247 by DNA methylation DOI: http://dx.doi.org/10.2147/OTT.S111291",Non-OADS,/arxiv_data1/oa_pdf/1c/13/ott-9-7297.PMC5138046.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/1c/13/ott-9-7297.PMC5138046.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/1c/13/ott-9-7297.PMC5138046.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/97/d0/ott-9-7275.PMC5138047.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 7275–7283OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  7275Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S10918 6 a randomized Phase ii trial of the tumor  vascular disrupting agent ca4P (fosbretabulin  tromethamine) with carboplatin, paclitaxel,  and bevacizumab in advanced nonsquamous  non-small-cell lung cancer edward B garon1,2 Jeffrey D n eidhart3 nashat Y gabrail4 Moacyr r de Oliveira5 Jai Balkissoon6 Fairooz Kabbinavar1,2 1Department of Medicine,   2Department of hematology and  Oncology, David geffen school of  Medicine at University of california  los angeles, los angeles, ca, 3san  Juan Oncology associates, Farmington,   nM, 4gabrail cancer center, canton,   Oh, 5northwest Medical specialties,   Tacoma, W a, 6global Product  Development and immuno-Oncology,   PPD, Wilmington, nc , UsaIntroduction:  Combretastatin A4-phosphate, fosbretabulin tromethamine (CA4P) is a vascular  disrupting agent that targets tumor vasculature.",Non-OADS,/arxiv_data1/oa_pdf/97/d0/ott-9-7275.PMC5138047.pdf
"Keywords:  CA4P, bevacizumab, paclitaxel, carboplatin, NSCLC Introduction Lung cancer was responsible for more than a quarter ( ~160,000) of all cancer-related  deaths in 2015, and remains the leading cause of cancer-related mortality in the US.1  Non-small-cell lung cancer (NSCLC), which has a 5-year survival rate of 1% in those  with metastatic disease, accounted for ~85% of the total.2 While there have recently  been important therapeutic advances in the field for patients with relapsed nonsquamous  NSCLC – including recent approval of immune checkpoint inhibitors3,4 in previously  treated patients – and patients with abnormalities in epidermal growth factor receptor correspondence: edward B garon David geffen school of Medicine at  University of california los angeles, los  angeles, 2825 santa Monica Blvd, suite  200, santa Monica, ca 90404, Usa Tel +1 310 586 2098 Fax +1 310 586 0841 email egaron@mednet.ucla.ed u Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Garon et al Running head recto: Carboplatin, paclitaxel and bevacizumab ± CA4P in NSCLC DOI: http://dx.doi.org/10.2147/OTT.S109186",Non-OADS,/arxiv_data1/oa_pdf/97/d0/ott-9-7275.PMC5138047.pdf
"Avail - able from: http://www.cancer.org/cancer/lungcancer-non-smallcell/ detailedguide/non-small-cell-lung-cancer-what-is-non-small-cell-lung- cance r. Accessed January 4, 2016.",Non-OADS,/arxiv_data1/oa_pdf/97/d0/ott-9-7275.PMC5138047.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/97/d0/ott-9-7275.PMC5138047.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/97/d0/ott-9-7275.PMC5138047.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/3f/48/jpr-9-1143.PMC5138048.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/3f/48/jpr-9-1143.PMC5138048.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Pain Research  2016:9 1143–1151Journal of Pain Research Dovepress submit your manuscript | www.dovepress.com Dovepress  1143 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JPR.S118945Risks associated with borrowing and sharing of  prescription analgesics among patients observed  by pain management physicians in Croatia: a  qualitative study Filipa Markotic1 Livia Puljak2 1Centre for Clinical Pharmacology,   University Clinical Hospital Mostar,   Mostar, Bosnia and Herzegovina;   2Laboratory for Pain Research,   University of Split School of Medicine,  Split, CroatiaBackground: Understanding and improving patient safety is a key issue in medicine.",Non-OADS,/arxiv_data1/oa_pdf/3f/48/jpr-9-1143.PMC5138048.pdf
"6 The term “lending” drugs would indicate that it was a temporary transfer of  the drug on condition that the amount borrowed be returned; however, a person “bor - rowing” a drug usually does not give back the drug to the person who is “lending” it.7 It has been shown that analgesics are among the top three medications most often  shared among patients.1,2,8,9 In the study of Ward et al, 116 (18%) respondents declared  that they borrowed prescription medication from others and 89 of them listed the names Correspondence: Livia Puljak Laboratory for Pain Research, University of Split School of Medicine, Soltanska 2, 21000 Split, CroatiaTel +385 21 557 807Fax +385 21 557 811Email livia@mefst.hrJournal name: Journal of Pain Research  Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 9Running head verso: Markotic and PuljakRunning head recto: Risks associated with borrowing and sharing of prescription analgesicsDOI: http://dx.doi.org/10.2147/JPR.S118945",Non-OADS,/arxiv_data1/oa_pdf/3f/48/jpr-9-1143.PMC5138048.pdf
"Journal of Pain Research  2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Pain Research  Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/journal-of-pain-research-journal The Journal of Pain Research is an international, peer reviewed, open  access, online journal that welcomes laboratory and clinical findings   in the fields of pain research and the prevention and management of pain.",Non-OADS,/arxiv_data1/oa_pdf/3f/48/jpr-9-1143.PMC5138048.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 1151 Risks associated with borrowing and sharing of prescription analgesics  13.,Non-OADS,/arxiv_data1/oa_pdf/3f/48/jpr-9-1143.PMC5138048.pdf
Available from: http://www.hdlb.,Non-OADS,/arxiv_data1/oa_pdf/3f/48/jpr-9-1143.PMC5138048.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/f7/2d/ijn-11-6421.PMC5138053.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 6421–6433International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  6421RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IJN.S12123 8 Nanotoxicity: emerging concerns regarding  nanomaterial safety and occupational hard metal  (wC-Co) nanoparticle exposure Andrea L Armstead1,2 Bingyun Li1–3 1Department of Orthopaedics, School  of Medicine, 2School of Pharmacy,   west virginia University, 3Mary  Babb Randolph Cancer Center,   Morgantown, wv, USAAbstract:  As the number of commercial and consumer products containing engineered  nanomaterials (ENMs) continually rises, the increased use and production of these ENMs pres - ents an important toxicological concern.",Non-OADS,/arxiv_data1/oa_pdf/f7/2d/ijn-11-6421.PMC5138053.pdf
"The term ENM broadly encompasses  a number of nano-sized materials that vary in shape, such as nanotubes, nanowires,  or nanoparticles (NPs), which are generally defined as “any material having at least  one dimension smaller than 100 nm.”1 Because of their extremely small size and high  surface area, NPs offer a number of advantages over traditional “bulk” materials and  are suitable for a wide variety of applications in consumer goods,2,3 medical devices  and diagnostics,4–6 pharmaceutical products,4,7–10 fuel additives,11,12 and other industrial  uses.13–17 As a result, the number of manufactured goods containing NPs is continually  rising; in 2006, manufacturers reported that NPs were incorporated in over 600 con - sumer products worth $50 billion in market value,18 a number which has doubled  to .1,600 NP-containing consumer products in 2013.19 Correspondence: Bingyun Li Biomaterials, Bioengineering &  Nanotechnology Laboratory, Department  of Orthopaedics, School of Medicine,  west virginia University, 1 Medical  Center Drive, Morgantown,  wv 26506-9196, USA Tel +1 304 293 1075 Fax +1 304 293 7070 email bili@hsc.wvu.ed u Journal name: International Journal of Nanomedicine Article Designation: Review Y ear: 2016 Volume: 11 Running head verso: Armstead and Li Running head recto: WC-Co nanoparticle exposure and nanomaterial safety DOI: http://dx.doi.org/10.2147/IJN.S121238",Non-OADS,/arxiv_data1/oa_pdf/f7/2d/ijn-11-6421.PMC5138053.pdf
Available from: http://www.nanotechproject.org/cpi/about/analysi s/.,OADS,/arxiv_data1/oa_pdf/f7/2d/ijn-11-6421.PMC5138053.pdf
"Available from:  http://www.matmod.com/publications/armor_1.pd f. Accessed October  21, 2014.",OADS,/arxiv_data1/oa_pdf/f7/2d/ijn-11-6421.PMC5138053.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/f7/2d/ijn-11-6421.PMC5138053.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/f7/2d/ijn-11-6421.PMC5138053.pdf
"The full terms of this license are available at https://www.dovepress.com/ terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/7d/73/amep-7-647.PMC5138054.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Advances in Medical Education and Practice Advances in Medical Education and Practice 2016:7 647–652Dove press submit your manuscript | www.dovepress.co m Dove press  COMMENTARYopen access to scientific and medical research Open Access Full T ext Article 647 http: //dx.doi.org/10.2147/AMEP .S9632 0Tips for using mobile audience response systems  in medical education Michael Gousseau Connor Sommerfeld Adrian Gooi Department of Otolaryngology –  Head and Neck Surgery, University of  Manitoba, Winnipeg, Canada Correspondence: Adrian Gooi   790 Sherbrook Street,   Winnipeg MB R3A 1M3, Canada   T el +1 204 999 8454   Fax +1 204 789 9225   Email adriangooi@gmail.co mBackground:  With growing evidence on the benefits of active learning, audience response  systems (ARSs) have been increasingly used in conferences, business, and education.",Non-OADS,/arxiv_data1/oa_pdf/7d/73/amep-7-647.PMC5138054.pdf
"Advances in Medical Education and Practice Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/advances-in-medical-education-and-practice-journa lAdvances in Medical Education and Practice is an international, peer- reviewed, open access journal that aims to present and publish research  on Medical Education covering medical, dental, nursing and allied  health care professional education.",Non-OADS,/arxiv_data1/oa_pdf/7d/73/amep-7-647.PMC5138054.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/7d/73/amep-7-647.PMC5138054.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/9c/ac/ijn-11-6435.PMC5138055.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 6435–6448International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  6435OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S11052 5 synergistic locoregional chemoradiotherapy  using a composite liposome-in-gel system  as an injectable drug depot shruti guha sarkar1 Kamal Pathak2 Niyati sudhalkar3 Prachi More1 Jayant sastri goda3 Vikram gota2 rinti Banerjee1 1Department of Biosciences and  Bioengineering, Indian Institute  of T echnology Bombay, Mumbai,   2Department of clinical Pharmacology,   3Department of radiation Oncology,   advanced centre for Treatment  research and education in cancer,   Navi Mumbai, Maharashtra, IndiaAbstract:  The use of radiosensitizers in clinical radiotherapy is limited by systemic toxicity.",Non-OADS,/arxiv_data1/oa_pdf/9c/ac/ijn-11-6435.PMC5138055.pdf
"Attempts to improve outcomes  of RT have largely focused on 1) radiation dose escalation,2,7 2) using altered fraction  RT schedules,7–9 3) sensitizing the radioresistant fraction of tumor cells to conventional  doses of radiation by using conventional chemotherapeutic drugs,10 and 4) biologically  targeting cancer cells specifically with concurrent RT.6,11 A highly researched strategy  of cancer therapy is the use of radiosensitizers in conjunction with radiotherapy, which  are therapeutic moieties that can be used prior to, during, or after radiation to augment  its effect.12 Chemotherapeutic agents, such as PTX,13 have been used to arrest tumor correspondence: rinti Banerjee Department of Biosciences and  Bioengineering, Indian Institute of  Technology Bombay, Powai, Mumbai  400076, Maharashtra, India Tel +91 22 2576 7868 email rinti@iitb.ac.i n Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: GuhaSarkar et al Running head recto: Injectable liposome-in-gel for localized synergistic chemoradiotherapy DOI: http://dx.doi.org/10.2147/IJN.S110525",Non-OADS,/arxiv_data1/oa_pdf/9c/ac/ijn-11-6435.PMC5138055.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/9c/ac/ijn-11-6435.PMC5138055.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/9c/ac/ijn-11-6435.PMC5138055.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/9e/1d/tacg-9-169.PMC5138056.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/9e/1d/tacg-9-169.PMC5138056.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).The Application of Clinical Genetics 2016:9 169–177The Application of Clinical Genetics Dovepress submit your manuscript | www.dovepress.com Dovepress 169 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/TACG.S122250 Analysis of binary responses with outcome- specific misclassification probability in   genome-wide association studies Romdhane Rekaya1–3 Shannon Smith4 El Hamidi Hay5 Nourhene Farhat6 Samuel E Aggrey3,7 1Department of Animal and Dairy  Science, College of Agricultural  and Environmental Sciences,   2Department of Statistics, Franklin  College of Arts and Sciences,   3Institute of Bioinformatics, The  University of Georgia, Athens, GA,   4Zoetis, Kalamazoo, MI, 5United  States Department of Agriculture,  Agricultural Research Service,  Beltsville, MD,  6Carolinas HealthCare  System Blue Ridge, Morganton,  NC,  7Department of Poultry  Science, College of Agricultural and Environmental Sciences, University of Georgia, Athens, GA, USAAbstract: Errors in the binary status of some response traits are frequent in human, animal, and  plant applications.",Non-OADS,/arxiv_data1/oa_pdf/9e/1d/tacg-9-169.PMC5138056.pdf
"Several reviews have been published in order to assess the variation Correspondence: Romdhane Rekaya 348 Animal and Dairy Science Building, The University of Georgia, 425 River Road, Athens, GA 30024, USAEmail rrekaya@uga.eduJournal name: The Application of Clinical Genetics Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 9Running head verso: Rekaya et alRunning head recto: Analysis of binary responses with misclassification probabilityDOI: http://dx.doi.org/10.2147/TACG.S122250",Non-OADS,/arxiv_data1/oa_pdf/9e/1d/tacg-9-169.PMC5138056.pdf
Avail- able from: http://emedicine.medscape.com/article/773832-overview.,Non-OADS,/arxiv_data1/oa_pdf/9e/1d/tacg-9-169.PMC5138056.pdf
"The Application of Clinical Genetics 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress The Application of Clinical Genetics Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/the-application-of-clinical-genetics-journalThe Application of Clinical Genetics is an international, peer-reviewed  open access journal that welcomes laboratory and clinical findings in the field of human genetics.",Non-OADS,/arxiv_data1/oa_pdf/9e/1d/tacg-9-169.PMC5138056.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes   from published authors.Dovepress 177 Analysis of binary responses with misclassification probability  8.,Non-OADS,/arxiv_data1/oa_pdf/9e/1d/tacg-9-169.PMC5138056.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/2a/20/prbm-9-317.PMC5138072.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/2a/20/prbm-9-317.PMC5138072.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Psychology Research and Behavior Management 2016:9 317–327Psychology Research and Behavior Management Dovepress submit your manuscript | www.dovepress.com Dovepress 317 REVIEW open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PRBM.S114906 Seasonal affective disorder, winter type: current  insights and treatment options Ybe Meesters1 Marijke CM Gordijn2,3 1University Center for Psychiatry,   University Medical Center Groningen,   2Department of Chronobiology,   GeLifes, University of Groningen,   Groningen, the Netherlands;   3Chrono@Work B.V., Groningen,    the NetherlandsAbstract:  Seasonal affective disorder (SAD), winter type, is a seasonal pattern of recurrent  major depressive episodes most commonly occurring in autumn or winter and remitting in  spring/summer.",Non-OADS,/arxiv_data1/oa_pdf/2a/20/prbm-9-317.PMC5138072.pdf
"Therefore, it is important to formulate distinct categories.Correspondence: Ybe Meesters University Center for Psychiatry, University Medical Center Groningen, PO Box 30 001, 9700 RB Groningen,   the NetherlandsEmail y.meesters@umcg.nlJournal name: Psychology Research and Behavior Management Article Designation: REVIEWY ear: 2016V olume: 9Running head verso: Meesters and GordijnRunning head recto: Seasonal affective disorder, winter typeDOI: http://dx.doi.org/10.2147/PRBM.S114906",Non-OADS,/arxiv_data1/oa_pdf/2a/20/prbm-9-317.PMC5138072.pdf
"Psychology Research and Behavior Management 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Psychology Research and Behavior Management Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/psychology-research-and-behavior-management-journalPsychology Research and Behavior Management is an international, peer- reviewed, open access journal focusing on the science of psychology and its  application in behavior management to develop improved outcomes in the  clinical, educational, sports and business arenas.",Non-OADS,/arxiv_data1/oa_pdf/2a/20/prbm-9-317.PMC5138072.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/43/20/ijem-14-03-37635.PMC5138281.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/39/64/ijem-14-03-38440.PMC5138377.pdf
e-mail:	amurata@mail.ecc.u-tokyo.ac.jp ©2016	The	Japanese	Society	of	 Veterinary	Science This	is	an	open-access	 article	distributed 	under	the	terms	of	the	Creative	 Commons	 Attribution	 Non-Commercial	 No	Derivatives	 (by-nc-nd)	 License	<http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/bb/f2/jvms-78-1643.PMC5138415.pdf
e-mail: nkoizumi@niid.go.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/2d/7f/jvms-78-1649.PMC5138416.pdf
e-mail: nishii@gifu-u.ac.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/bb/da/jvms-78-1657.PMC5138417.pdf
e-mail: zhaoxx@gsau.edu.cn ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/6f/f2/jvms-78-1663.PMC5138418.pdf
https://www.ag.ndsu.edu/pubs/ansci/dairy/as1129.pdf.,Non-OADS,/arxiv_data1/oa_pdf/6f/f2/jvms-78-1663.PMC5138418.pdf
e-mail: k-hagi@rakuno.ac.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/a5/5f/jvms-78-1669.PMC5138419.pdf
e-mail t-kaneda@nvlu.ac.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/d9/93/jvms-78-1673.PMC5138420.pdf
e-mail: kshimizu@med.hokudai.ac.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/ee/ac/jvms-78-1677.PMC5138421.pdf
©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/f0/5e/jvms-78-1683.PMC5138422.pdf
Primers were designed using Primer - 3Plus (http://primer3plus.com) and Amplify-3 (http://engels.genetics.wisc.edu/amplify/) computer software.,OADS,/arxiv_data1/oa_pdf/f0/5e/jvms-78-1683.PMC5138422.pdf
e-mail: eomkd@konkuk.ac.kr ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/98/ba/jvms-78-1693.PMC5138423.pdf
e-mail: hiroya@yamaguchi-u.ac.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/8b/5d/jvms-78-1699.PMC5138424.pdf
e-mail: yuya-nakamoto@kyotoar.com ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/0a/ab/jvms-78-1703.PMC5138425.pdf
e-mail: akane@cc.tuat.ac.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/26/94/jvms-78-1709.PMC5138426.pdf
©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/6e/59/jvms-78-1713.PMC5138427.pdf
e-mail: scchang@dragon.nchu.edu.tw ©2016	The	Japanese	Society	of	 Veterinary	Science This	is	an	open-access	 article	distributed 	under	the	terms	of	the	Creative	 Commons Attribution Non-Commercial No Derivatives (by-nc-nd)  License	<http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/78/e4/jvms-78-1717.PMC5138428.pdf
e-mail: dmkwak@knu.ac.kr ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/48/09/jvms-78-1723.PMC5138429.pdf
e-mail: mhorie@vet.kagoshima-u.ac.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/9f/d6/jvms-78-1727.PMC5138430.pdf
e-mail:takehisa-soma@ah.ds-pharma.co.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/9b/42/jvms-78-1731.PMC5138431.pdf
e-mail: osam@vet.kagoshima-u.ac.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/4b/78/jvms-78-1737.PMC5138432.pdf
e-mail: osamu.katsuta@santen.co.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/d6/30/jvms-78-1741.PMC5138433.pdf
e-mail: itagaki@iwate-u.ac.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/fc/83/jvms-78-1745.PMC5138434.pdf
e-mail: une@azabu-u.ac.jp ©2016 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.,Non-OADS,/arxiv_data1/oa_pdf/f9/ea/jvms-78-1749.PMC5138435.pdf
"KI Reports (2016) 1,73–84;http://dx.doi.org/10.1016/j.ekir.2016.05.002 KEYWORDS: cyclosporine; membranous nephropathy; nephrotic syndrome; rituximab Published by Elsevier Inc. on behalf of International Society of Nephrology.",Non-OADS,/arxiv_data1/oa_pdf/37/23/main.PMC5138549.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/37/23/main.PMC5138549.pdf
"Kidney Int Rep (2016) 1,221 –229; http://dx.doi.org/10.1016/j.ekir.2016.07.008 KEYWORDS: deceased donor quality; dual organ allocation; propensity score matching; simultaneous liver-kidneytransplantation; UNOS ª2016 International Society of Nephrology.",Non-OADS,/arxiv_data1/oa_pdf/57/21/main.PMC5138564.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/57/21/main.PMC5138564.pdf
"Within each stratum (LK1 –LK4), we used nearest-neighbor Maha- lanobis metric matching with a bias correction term(http://www.stata.com/manuals13/teteffectsnnmatch.pdf ) to match and allocate patients to the respective groups.",Non-OADS,/arxiv_data1/oa_pdf/57/21/main.PMC5138564.pdf
"Key Words :Observational learning, Flipped training, Summ ative assessment, Complete denture prosthesis Received: May 20, 2016 •Revised: July 30, 2016 •Accepted: September 22, 2016 Corresponding Author:  Anbarasi K (http://orcid.org/0000-0002-7667-8112) Department of Oral Medicine and Radiology, Faculty of Dental Sc iences, Sri Ramachandra University,  Porur, Chennai 600116, India Tel: +91.4445928600  Fax: +91.4445928643  email: anbarasi815@gm a i l .",Non-OADS,/arxiv_data1/oa_pdf/47/53/kjme-2016-39.PMC5138569.pdf
c o m         Korean J Med Educ 2016 Dec; 28(4): 333-342. https://doi.org/10.3946/kjme.2016.,Non-OADS,/arxiv_data1/oa_pdf/47/53/kjme-2016-39.PMC5138569.pdf
"ORCID:  Anbarasi K: http://orcid.org/0000-0002-7667-8112; Kasim Mohamed K: http://orcid.org/0000-0002-4173-7944; Phagalvarthy Vijayaraghavan: http://orcid.org/0000-0003-2159-6336 ; Deivanayagam Kandaswamy: http://orcid.org/0000-0001-9228-4781 Acknowledgements:  We would like to thank Dr. M.  Umamaheswari, Department of Prosthodontics, Sri Rama- chandra University for her active involvement and technical support in this work.",Non-OADS,/arxiv_data1/oa_pdf/47/53/kjme-2016-39.PMC5138569.pdf
"Key Words :Medical education, Social media Received: March 15, 2016 •Revised: May 26, 2016 •Accepted: July 6, 2016 Corresponding Author:  Anas Khaleel Alsuraihi (http://orcid.org/0000-0002-7803-2737) King Saud bin Abdulaziz University for Health Sciences College of Medicine, King Abdulaziz  Medical City, P.O.Box 9515, Jeddah 21423, Saudi Arabia  Tel: +966-12-2266666  Fax: +966-12-2266200  email: Anas.k.s@hot m a i l .",Non-OADS,/arxiv_data1/oa_pdf/c3/05/kjme-2016-40.PMC5138570.pdf
c o m         Korean J Med Educ 2016 Dec; 28(4): 343-354. https://doi.org/10.3946/kjme.2016.,Non-OADS,/arxiv_data1/oa_pdf/c3/05/kjme-2016-40.PMC5138570.pdf
"ORCID:   Anas Khaleel Alsuraihi: http://orcid.org/0000-0002-7803-2737;  Ahmed Saeed Almaqati: http://orcid.org/0000-0002-0557-0219; Sultan Adnan Abughanim: http://orcid.org/0000-0001-9856-6069;  Nisreen Abdulrahman Jastaniah: http://orcid.org/0000-0003-4917- 5381 Acknowledgements:  We are deeply grateful to Dr. Basim  Alsaywid, pediatric urology consultant, Department of  Surgery, King Abdulaziz Medical City, Jeddah, Saudi Arabia, for his contribution to the data analysis and for his critical review of our study.",Non-OADS,/arxiv_data1/oa_pdf/c3/05/kjme-2016-40.PMC5138570.pdf
Available from: http://www.chcf.org/topics/chronicdisease/index.cfm?,Non-OADS,/arxiv_data1/oa_pdf/c3/05/kjme-2016-40.PMC5138570.pdf
Available from: http://www.im.org/p/cm/ ld/fid=1017.,Non-OADS,/arxiv_data1/oa_pdf/c3/05/kjme-2016-40.PMC5138570.pdf
Available from: http://www.internet.sa/ ar/internet-in-saudi-arabia/#more-98.,Non-OADS,/arxiv_data1/oa_pdf/c3/05/kjme-2016-40.PMC5138570.pdf
"Key Words :Education, Medical education, Emergency medicine, Pre-residency Received: July 18, 2016 •Revised: September 12, 2016 •Accepted: September 22, 2016 Corresponding Author:  Young-Mee Lee (http://orcid.org/0000-0002-4685-9465) Department of Medical Humanities, Korea University College of M edicine, 73 Inchon-ro,  Seongbuk-gu, Seoul 02841, Korea Tel: +82.10.90866433  Fax: +82.2.921.4068  email: ymleehj@korea .",Non-OADS,/arxiv_data1/oa_pdf/3e/b4/kjme-2016-41.PMC5138571.pdf
k r         Korean J Med Educ 2016 Dec; 28(4): 355-371. https://doi.org/10.3946/kjme.2016.,Non-OADS,/arxiv_data1/oa_pdf/3e/b4/kjme-2016-41.PMC5138571.pdf
"ORCID:  Eusang Ahn: http://orcid.org/0000-0002-7725-7491;  Ducksun Ahn: http://orcid.org/0000-0003-2762-0026;  Young-Mee Lee: http://orcid.org/0000-0002-4685-9465 Acknowledgements:  We thank Hyung Im for providing  technical support with SPSS analysis, Dr. Jung-Yul Park  and Meyoung-Kon Kim for sound advice on the study design, on behalf of the Department of Medical Humanities of Korea U niversity C ollege of M edicine.",Non-OADS,/arxiv_data1/oa_pdf/3e/b4/kjme-2016-41.PMC5138571.pdf
Available from: http://www.ecfmg.org/ echo/acgme-core-competencies.html.,Non-OADS,/arxiv_data1/oa_pdf/3e/b4/kjme-2016-41.PMC5138571.pdf
Available from: https://www.ucsf.edu/ news/2014/09/117371/teaching-classroom-clinic.,Non-OADS,/arxiv_data1/oa_pdf/3e/b4/kjme-2016-41.PMC5138571.pdf
"Key Words :Foreign medical graduates, Clinical competency, Democratic People’s Republic of Korea, Refugees Received: May 28, 2016 •Revised: July 22, 2016 •Accepted: August 8, 2016 Corresponding Author:  Seok Hoon Kang (http://orcid.org/0000-0002-2881-8774) Department of Medical Education, Kangwon National University Sc hool of Medicine,  1 Gangwondaehak-gil, Chuncheon 24341, Korea Tel: +82.33.258.9206  Fax: +82.504.477.4271  email: kingla@kang w o n .",Non-OADS,/arxiv_data1/oa_pdf/79/9d/kjme-2016-42.PMC5138572.pdf
k r         Korean J Med Educ 2016 Dec; 28(4): 373-380. https://doi.org/10.3946/kjme.2016.,Non-OADS,/arxiv_data1/oa_pdf/79/9d/kjme-2016-42.PMC5138572.pdf
ORCID:  Sung Uk Chae: http://orcid.org/0000-0002-6158-1182;,Non-OADS,/arxiv_data1/oa_pdf/79/9d/kjme-2016-42.PMC5138572.pdf
"Sung Uk Chae, et al : Experience of re-education for North Korea  refugee doctors   380 Korean J Med Educ 2016 Dec; 28(4): 373-380.Jeong Hee Yang: http://orcid.org/0000-0001-8646-6247;  Joon Seop Hyun: http://orcid.org/0000-0001-9529-4133; June Hee Kim: http://orcid.org/0000-0002-0813-1465; Seok Hoon Kang: http://orcid.org/0000-0002-2881-8774  Acknowledgements:  A u t h o r s  e x p r e s s  o u r  g r a t i t u d e  t o  Hanawon and Kangwon National University School of  Medicine for their support for “profession transition course  for doctors, ” i n  2 0 1 3 ,  a n d  a l s o  t o  M e d i c a l  E d u c a t i o n   Assessment Consortium for their agreement on analyzing the scores of the preliminary examinations.",Non-OADS,/arxiv_data1/oa_pdf/79/9d/kjme-2016-42.PMC5138572.pdf
"Key Words :Transnational collaboration, Faculty development, Health professions education Received: July 19, 2016 •Revised: September 8, 2016 •Accepted: October 6, 2016 Corresponding Author:  Jwa-Seop Shin (http://orcid.org/0000-0002-6251-3616) Department of Medical Education, Seoul National University Coll ege of Medicine, 103 Daehak-ro,  Jongno-gu, Seoul 03080, Korea Tel: +82.2.740.8175  Fax: +82.2.741.1186  email: hismed1@snu.ac .",Non-OADS,/arxiv_data1/oa_pdf/59/25/kjme-2016-43.PMC5138573.pdf
k r         Korean J Med Educ 2016 Dec; 28(4): 381-390. https://doi.org/10.3946/kjme.2016.,Non-OADS,/arxiv_data1/oa_pdf/59/25/kjme-2016-43.PMC5138573.pdf
ORCID:  Hyun Bae Yoon: http://orcid.org/0000-0003-4367-5350;  Jwa-Seop Shin: http://orcid.org/http://orcid.org/0000-0002-6251 -3616;  Seung-Hee Lee: http://orcid.org/0000-0001-8672-5253; Do-Hwan Kim: http://orcid.org/0000-0003-4137-7130  Acknowledgements:  The Institutional Review Board of  Seoul National University College of Medicine and Seoul  National University Hospital exempted this study from review since it was an analysis of de-identified data (E-1605-007-758).,Non-OADS,/arxiv_data1/oa_pdf/59/25/kjme-2016-43.PMC5138573.pdf
"Key Words :Education, Online search, Information literacy, Medical students, Health services Received: July 5, 2016 •Revised: September 13, 2016 •Accepted: October 17, 2016 Corresponding Author:  Afsaneh Dehnad (http://orcid.org/0000-0001-9874-3045) Department of Foreign Language, School of Health Management and  Information Sciences, Iran  University of Medical Sciences, Valiaser ave. Rashid yasemi ave ., Iran Tel: +98-04133251378  Fax: +98-04133251378  email: afsanehdehna d @ g m a i l .",Non-OADS,/arxiv_data1/oa_pdf/a5/9f/kjme-2016-44.PMC5138574.pdf
c o m         Korean J Med Educ 2016 Dec; 28(4): 391-395. https://doi.org/10.3946/kjme.2016.,Non-OADS,/arxiv_data1/oa_pdf/a5/9f/kjme-2016-44.PMC5138574.pdf
ORCID:   Mohammadhiwa Abdekhoda: http://orcid.org/0000-0001-9874-3045;  Afsaneh Dehnad: http://orcid.org/0000-0001-5731-8894;  Mahmood Yousefi: http://orcid.org/0000-0003-3406-5040 Acknowledgements:  N one.,Non-OADS,/arxiv_data1/oa_pdf/a5/9f/kjme-2016-44.PMC5138574.pdf
"Ann Rolfe Mentoring Works, Umina Beach, Australia Korean J Med Educ 2016 Dec; 28(4): 397-399. https://doi.org/10.3946/kjme.2016.",Non-OADS,/arxiv_data1/oa_pdf/28/f0/kjme-2016-45.PMC5138575.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/82/bd/kfw171.PMC5139069.pdf
Available at: http://www.ich.org/ﬁl eadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7B/Step4/S7B_Guideline.pdf.,Non-OADS,/arxiv_data1/oa_pdf/82/bd/kfw171.PMC5139069.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/79/74/kfw174.PMC5139071.pdf
SUPPLEMENTARY DATA Supplementary data are available online at http://toxsci.oxford journals.org/.,Non-OADS,/arxiv_data1/oa_pdf/79/74/kfw174.PMC5139071.pdf
"International Journal of Preventive Medicine 2016, 7:121 http://www.ijpvmjournal.net/content/7/1/121low body mass index (BMI) and waist circumference  was associated with high DDS, so concluded that DDS  was reversely correlate with abdominal adiposity and  obesity among female students.",Non-OADS,/arxiv_data1/oa_pdf/31/0b/IJPVM-7-121.PMC5139448.pdf
"International Journal of Preventive Medicine 2016, 7:121 http://www.ijpvmjournal.net/content/7/1/121program includes exercise training, nutrition consultation,  and psychological treatment.",Non-OADS,/arxiv_data1/oa_pdf/31/0b/IJPVM-7-121.PMC5139448.pdf
"International Journal of Preventive Medicine 2016, 7:121 http://www.ijpvmjournal.net/content/7/1/121and obesity.",Non-OADS,/arxiv_data1/oa_pdf/31/0b/IJPVM-7-121.PMC5139448.pdf
"International Journal of Preventive Medicine 2016, 7:121 http://www.ijpvmjournal.net/content/7/1/121the strength of this study because dietary intake of each  patient was compared with itself, so the effect of within  variation was decreased.",Non-OADS,/arxiv_data1/oa_pdf/31/0b/IJPVM-7-121.PMC5139448.pdf
Available FREE in open access from: http://www.jpathinformatics.org/text.,Non-OADS,/arxiv_data1/oa_pdf/0e/8c/JPI-7-46.PMC5139449.pdf
"J Pathol Inform 2016, 1:46  http://www.jpathinformatics.org/content/7/1/46standardize care and track outcomes.",Non-OADS,/arxiv_data1/oa_pdf/0e/8c/JPI-7-46.PMC5139449.pdf
"J Pathol Inform 2016, 1:46  http://www.jpathinformatics.org/content/7/1/46patients having EGD done and 0 otherwise (V1).",Non-OADS,/arxiv_data1/oa_pdf/0e/8c/JPI-7-46.PMC5139449.pdf
"J Pathol Inform 2016, 1:46  http://www.jpathinformatics.org/content/7/1/46in the Weka tool we used.",OADS,/arxiv_data1/oa_pdf/0e/8c/JPI-7-46.PMC5139449.pdf
"J Pathol Inform 2016, 1:46  http://www.jpathinformatics.org/content/7/1/46highest to the lowest.",Non-OADS,/arxiv_data1/oa_pdf/0e/8c/JPI-7-46.PMC5139449.pdf
"J Pathol Inform 2016, 1:46  http://www.jpathinformatics.org/content/7/1/46The number of laboratories done was as effective as  the actual lab results reported in our case for CD  classification (AUC of 0.71 vs. 0.83).",Non-OADS,/arxiv_data1/oa_pdf/0e/8c/JPI-7-46.PMC5139449.pdf
"J Pathol Inform 2016, 1:46  http://www.jpathinformatics.org/content/7/1/462012;107:1538‑44.",Non-OADS,/arxiv_data1/oa_pdf/0e/8c/JPI-7-46.PMC5139449.pdf
Available from: https://www.lri.fr/~pierres/ donn%E9es/save/these/articles/lpr ‑queue/hall99correlationbased.pdf.,Non-OADS,/arxiv_data1/oa_pdf/0e/8c/JPI-7-46.PMC5139449.pdf
Available FREE in open access from: http://www.jpathinformatics.org/text.,Non-OADS,/arxiv_data1/oa_pdf/f5/c7/JPI-7-48.PMC5139450.pdf
"J Pathol Inform 2016, 1:48  http://www.jpathinformatics.org/content/7/1/48INTRODUCTION Endometrial carcinoma (EC) is the most common  extracolonic malignant neoplasm associated with Lynch  syndrome (LS),[1] which is caused by autosomal dominant  germline mutations in DNA mismatch repair (MMR)  genes.",Non-OADS,/arxiv_data1/oa_pdf/f5/c7/JPI-7-48.PMC5139450.pdf
"J Pathol Inform 2016, 1:48  http://www.jpathinformatics.org/content/7/1/48that included worksheet responses and IHC ordering  information were extracted from PowerPath for all cases  in which an EC synoptic template was chosen during  this period.",OADS,/arxiv_data1/oa_pdf/f5/c7/JPI-7-48.PMC5139450.pdf
"J Pathol Inform 2016, 1:48  http://www.jpathinformatics.org/content/7/1/48per member on molecular and genetic tests increased by  about 14% between 2008 and 2010 across their healthcare  plans, primarily due to increased utilization.",Non-OADS,/arxiv_data1/oa_pdf/f5/c7/JPI-7-48.PMC5139450.pdf
"J Pathol Inform 2016, 1:48  http://www.jpathinformatics.org/content/7/1/48REFERENCES 1.",Non-OADS,/arxiv_data1/oa_pdf/f5/c7/JPI-7-48.PMC5139450.pdf
Available FREE in open access from: http://www.jpathinformatics.org/text.,Non-OADS,/arxiv_data1/oa_pdf/13/78/JPI-7-45.PMC5139451.pdf
"J Pathol Inform 2016, 1:45  http://www.jpathinformatics.org/content/7/1/45referred to as microservices (or microservice architecture).",OADS,/arxiv_data1/oa_pdf/13/78/JPI-7-45.PMC5139451.pdf
"J Pathol Inform 2016, 1:45  http://www.jpathinformatics.org/content/7/1/45sense that output is determined solely by the current  input and independent of previous inputs) or at least  having no internal state, meaning they can be aborted  and restarted without losing information.",Non-OADS,/arxiv_data1/oa_pdf/13/78/JPI-7-45.PMC5139451.pdf
Adapted from https://hub.docker.com/r/ gliderlabs/alpine,Non-OADS,/arxiv_data1/oa_pdf/13/78/JPI-7-45.PMC5139451.pdf
"J Pathol Inform 2016, 1:45  http://www.jpathinformatics.org/content/7/1/45of limited flexibility and customization.",Non-OADS,/arxiv_data1/oa_pdf/13/78/JPI-7-45.PMC5139451.pdf
"On a more practical note, while there are multiple  implementations of the container methodology in  industry, the Docker (https://www.docker.com/) ecosystem  of tools is the most widely publicized, and it can serve  as a useful source of information for learning the basics  of Linux containers.",Non-OADS,/arxiv_data1/oa_pdf/13/78/JPI-7-45.PMC5139451.pdf
There are also  at least two projects aimed at sharing bioinformatics  based Docker images: bioboxes (http://bioboxes.org) and  BioDocker (http://biodocker.org).,Non-OADS,/arxiv_data1/oa_pdf/13/78/JPI-7-45.PMC5139451.pdf
Available from:  http://www.cybera.ca/news‑and‑events/tech‑radar/contain‑your‑enthusi asm‑part‑one‑a‑history‑of‑operating‑system‑containers/.,Non-OADS,/arxiv_data1/oa_pdf/13/78/JPI-7-45.PMC5139451.pdf
Available from: http://blogs.wsj.,Non-OADS,/arxiv_data1/oa_pdf/13/78/JPI-7-45.PMC5139451.pdf
Available  from: https://www.docker.com/customers/ge‑uses‑docker ‑enable‑self‑ service‑their ‑developers.,Non-OADS,/arxiv_data1/oa_pdf/13/78/JPI-7-45.PMC5139451.pdf
Available from: http://h22168.www2.hpe.com/us/ en/partners/docker/.,OADS,/arxiv_data1/oa_pdf/13/78/JPI-7-45.PMC5139451.pdf
Available from: http://apigee.com/about/ blog/developer/microservices‑amazon.,Non-OADS,/arxiv_data1/oa_pdf/13/78/JPI-7-45.PMC5139451.pdf
Available from: http://www.thenewstack.io/ the‑windows‑and‑linux‑container‑era‑is‑here/.,Non-OADS,/arxiv_data1/oa_pdf/13/78/JPI-7-45.PMC5139451.pdf
Available from: https://www.linkedin.,Non-OADS,/arxiv_data1/oa_pdf/13/78/JPI-7-45.PMC5139451.pdf
Available from: www: http://grants.nih.gov/ reproducibility/index.htm.,Non-OADS,/arxiv_data1/oa_pdf/13/78/JPI-7-45.PMC5139451.pdf
Available from: https://www.nextflow.io/docs/ latest/docker.html.,OADS,/arxiv_data1/oa_pdf/13/78/JPI-7-45.PMC5139451.pdf
Available from: https://www.icgc.org/ working‑pancancer‑data‑aws.,OADS,/arxiv_data1/oa_pdf/13/78/JPI-7-45.PMC5139451.pdf
"International Journal of Preventive Medicine 2016, 7:124 http://www.ijpvmjournal.net/content/7/1/124previous publications, we needed 33 people in each  group.",Non-OADS,/arxiv_data1/oa_pdf/f6/f0/IJPVM-7-124.PMC5139452.pdf
"International Journal of Preventive Medicine 2016, 7:124 http://www.ijpvmjournal.net/content/7/1/124Compliance to treatment was determined based on the  number of returned capsules by each patient.",Non-OADS,/arxiv_data1/oa_pdf/f6/f0/IJPVM-7-124.PMC5139452.pdf
"International Journal of Preventive Medicine 2016, 7:124 http://www.ijpvmjournal.net/content/7/1/124were significant in comparison with the placebo group  (P < 0.05) [ Table  4].",Non-OADS,/arxiv_data1/oa_pdf/f6/f0/IJPVM-7-124.PMC5139452.pdf
"International Journal of Preventive Medicine 2016, 7:124 http://www.ijpvmjournal.net/content/7/1/124conducted on mice, Miranda et al.",Non-OADS,/arxiv_data1/oa_pdf/f6/f0/IJPVM-7-124.PMC5139452.pdf
"International Journal of Preventive Medicine 2016, 7:124 http://www.ijpvmjournal.net/content/7/1/124Further studies are needed to evaluate the effect of PSO  supplementation in diabetic patients.",Non-OADS,/arxiv_data1/oa_pdf/f6/f0/IJPVM-7-124.PMC5139452.pdf
"International Journal of Preventive Medicine 2016, 7:122 http://www.ijpvmjournal.net/content/7/1/122INTRODUCTION The ultimate aim of all health systems is clients’  well‑being, which is related to the efficiency of the  health‑care system.",Non-OADS,/arxiv_data1/oa_pdf/82/98/IJPVM-7-122.PMC5139453.pdf
"International Journal of Preventive Medicine 2016, 7:122 http://www.ijpvmjournal.net/content/7/1/122“quite satisfied” regarding accessibility of health‑care  service, waiting time, patient’s privacy when receiving  health‑care service, and its cost.",Non-OADS,/arxiv_data1/oa_pdf/82/98/IJPVM-7-122.PMC5139453.pdf
"International Journal of Preventive Medicine 2016, 7:122 http://www.ijpvmjournal.net/content/7/1/122Table 2: Satisfaction level of the participants regarding their family physician based on five measurement items 6 months  before the study n Satisfaction frequency, n (%) Very satisfied Satisfied Neither satisfied  nor dissatisfiedDissatisfied Very dissatisfied Overall satisfaction 2329 131 (5.6) 1107 (47.5) 221 (9.5) 564 (24.2) 306 (3.1) Waiting time for admission 2330 145 (6.2) 1431 (61.4) 159 (6.8) 445 (19.1) 150 (0.4) Waiting time at the doctor’s clinic 2330 129 (5.5) 1443 (61.9) 177 (7.6) 453 (19.4) 128 (0.5) Quality of service 2319 145 (6.3) 1298 (56) 222 (9.6) 497 (21.4) 157 (0.8) Cleanliness of clinic 2323 109 (4.7) 325 (14) 155 (6.7) 1494 (64.3) 109 (3.2) Quality of referral to a specialist 2326 177 (7.6) 1179 (50.7) 278 (12) 474 (20.4) 218 (6.4) Table 3: Levels of satisfaction based on the measurement of five items among studied population 6 months before the study Level of satisfaction Distance, n (%) Waiting time for  admission, n (%)Waiting time at  the clinic, n (%)Patient’s privacy when  receiving care, n (%)Cost of health‑care  service received, n (%) Family physician Dissatisfied 240 (11.4) 278 (13.3) 311 (14.8) 215 (10.3) 266 (12.7) Fair 151 (7.2) 207 (9.9) 246 (7.2) 66 (3.1) 131 (6.3) Satisfied 1706 (81.4) 1611 (76.9) 1538 (73.4) 1815 (86.6) 1699 (81.1) Governmental clinic Dissatisfied 224 (12.6) 262 (14.8) 302 (17.1) 99 (5.6) 262 (14.8) Fair 294 (16.6) 260 (14.7) 309 (17.5) 98 (5.5) 238 (13.5) Satisfied 1253 (71.8) 1246 (70.5) 1159 (65.5) 1572 (88.9) 1268 (71.7) Private clinic Dissatisfied 113 (19.3) 85 (14.5) 89 (15.2) 23 (3.9) 224 (38.3) Fair 119 (20.3) 109 (18.6) 121 (20.7) 16 (2.7) 110 (18.8) Satisfied 354 (60.4) 391 (66.8) 375 (64.1) 546 (93.3) 251 (42.9) Specialist clinic Dissatisfied 406 (33.3) 242 (19.9) 288 (23.6) 65 (5.3) 638 (52.4) Fair 257 (21.1) 235 (19.3) 221 (18.1) 22 (1.8) 201 (16.5) Satisfied 555 (45.6) 740 (60.8) 710 (58.2) 1130 (92.9) 378 (31.1) Midwifery clinic Dissatisfied 62 (28.8) 45 (21) 52 (24.3) 29 (13.6) 64 (29.9) Fair 44 (20.5) 22 (10.3) 29 (13.6) 7 (3.3) 33 (15.4) Satisfied 109 (50.7) 147 (68.7) 133 (62.1) 177 (83.1) 117 (54.7) Nutrition specialist Dissatisfied 18 (22.5) 16 (20.3) 20 (25.3) 6 (7.6) 18 (22.8) Fair 17 (21.3) 7 (8.9) 4 (5.1) 1 (1.3) 10 (12.7) Satisfied 45 (56.3) 56 (70.9) 55 (69.6) 72 (91.1) 51 (64.6) Physiotherapy clinic Dissatisfied 28 (19.3) 18 (12.4) 17 (11.7) 3 (2.1) 41 (28.3) Fair 22 (15.2) 11 (7.6) 19 (13.1) 4 (2.8) 21 (14.5) Satisfied 95 (65.5) 116 (80) 109 (75.2) 138 (95.2) 83 (57.2) Governmental hospital Dissatisfied 191 (22) 162 (18.8) 209 (24.1) 67 (7.7) 116 (13.4) Fair 200 (23.1) 177 (20.6) 174 (20.1) 45 (5.2) 122 (14.1) Satisfied 476 (54.9) 522 (60.6) 484 (55.8) 755 (87.1) 626 (72.5) Private hospital Dissatisfied 151 (39.9) 51 (13.5) 47 (12.4) 8 (2.1) 170 (45) Fair 68 (18) 53 (14) 56 (14.8) 10 (2.6) 62 (16.4) Satisfied 159 (42.1) 274 (72.5) 275 (72.8) 360 (95.2) 146 (38.6)",Non-OADS,/arxiv_data1/oa_pdf/82/98/IJPVM-7-122.PMC5139453.pdf
"International Journal of Preventive Medicine 2016, 7:122 http://www.ijpvmjournal.net/content/7/1/122rate was reported about the cost of specialists’ clinic,  followed by the cost of admission in private hospital.",Non-OADS,/arxiv_data1/oa_pdf/82/98/IJPVM-7-122.PMC5139453.pdf
"International Journal of Preventive Medicine 2016, 7:122 http://www.ijpvmjournal.net/content/7/1/122satisfaction rate of the health‑care system in our study  was 67.4%; of which, 5.5% were very satisfied while 61.9%  were satisfied.",Non-OADS,/arxiv_data1/oa_pdf/82/98/IJPVM-7-122.PMC5139453.pdf
"International Journal of Preventive Medicine 2016, 7:122 http://www.ijpvmjournal.net/content/7/1/122efficiency of Iran’s health policy.",Non-OADS,/arxiv_data1/oa_pdf/82/98/IJPVM-7-122.PMC5139453.pdf
Available FREE in open access from: http://www.jpathinformatics.org/text.,Non-OADS,/arxiv_data1/oa_pdf/92/63/JPI-7-49.PMC5139454.pdf
"J Pathol Inform 2016, 1:49  http://www.jpathinformatics.org/content/7/1/49number of sites, number of readers, experience of readers,  number of cases, complexity of cases, procedure type,  period of washout, arbitration, and analysis methods.",OADS,/arxiv_data1/oa_pdf/92/63/JPI-7-49.PMC5139454.pdf
"J Pathol Inform 2016, 1:49  http://www.jpathinformatics.org/content/7/1/49was one categorical case report form checklist used for  all organs (i.e., benign, atypical, and malignant) and one  lymph node checklist for a total of 15 case report form  checklists.",Non-OADS,/arxiv_data1/oa_pdf/92/63/JPI-7-49.PMC5139454.pdf
"J Pathol Inform 2016, 1:49  http://www.jpathinformatics.org/content/7/1/49possible hypothetical error was systematically entered for  the test method.",Non-OADS,/arxiv_data1/oa_pdf/92/63/JPI-7-49.PMC5139454.pdf
"J Pathol Inform 2016, 1:49  http://www.jpathinformatics.org/content/7/1/49de‑identified, signed‑out cases (comprising 1 part each)  were procured from SUNY‑Syracuse University Hospital  (Syracuse, NY) and used to train at all sites.",Non-OADS,/arxiv_data1/oa_pdf/92/63/JPI-7-49.PMC5139454.pdf
"J Pathol Inform 2016, 1:49  http://www.jpathinformatics.org/content/7/1/49same manner as the reviewers’ diagnoses in the EDC.",Non-OADS,/arxiv_data1/oa_pdf/92/63/JPI-7-49.PMC5139454.pdf
"J Pathol Inform 2016, 1:49  http://www.jpathinformatics.org/content/7/1/49out of the total for each site and across all sites.",OADS,/arxiv_data1/oa_pdf/92/63/JPI-7-49.PMC5139454.pdf
"J Pathol Inform 2016, 1:49  http://www.jpathinformatics.org/content/7/1/49of diagnosis.",Non-OADS,/arxiv_data1/oa_pdf/92/63/JPI-7-49.PMC5139454.pdf
"J Pathol Inform 2016, 1:49  http://www.jpathinformatics.org/content/7/1/493000 arbitrations.",Non-OADS,/arxiv_data1/oa_pdf/92/63/JPI-7-49.PMC5139454.pdf
"J Pathol Inform 2016, 1:49  http://www.jpathinformatics.org/content/7/1/49were purposely enriched for complex cases and most  readers did not have the required specialty training  needed for high accuracy.",Non-OADS,/arxiv_data1/oa_pdf/92/63/JPI-7-49.PMC5139454.pdf
"J Pathol Inform 2016, 1:49  http://www.jpathinformatics.org/content/7/1/49as well as reproducibility.",Non-OADS,/arxiv_data1/oa_pdf/92/63/JPI-7-49.PMC5139454.pdf
Available FREE in open access from: http://www.jpathinformatics.org/text.,Non-OADS,/arxiv_data1/oa_pdf/22/55/JPI-7-47.PMC5139455.pdf
"J Pathol Inform 2016, 1:47  http://www.jpathinformatics.org/content/7/1/47INTRODUCTION For many malignancies, molecular and cellular  heterogeneity is a prominent feature among tumors  from different patients, between different sites of  neoplasia in a single patient and within a single tumor.",Non-OADS,/arxiv_data1/oa_pdf/22/55/JPI-7-47.PMC5139455.pdf
"J Pathol Inform 2016, 1:47  http://www.jpathinformatics.org/content/7/1/47Spatial analyses using light microscope imaging facilitate  analysis of large areas of tissue sections and/or multiple  tumor microarray sections at the cellular and subcellular  levels.",OADS,/arxiv_data1/oa_pdf/22/55/JPI-7-47.PMC5139455.pdf
"J Pathol Inform 2016, 1:47  http://www.jpathinformatics.org/content/7/1/47Bank under the Institutional Review Board approved  protocol (PRO13080285).",Non-OADS,/arxiv_data1/oa_pdf/22/55/JPI-7-47.PMC5139455.pdf
"J Pathol Inform 2016, 1:47  http://www.jpathinformatics.org/content/7/1/471D5, #M7047, DAKO, used at 10 µg/mL); Round 2:  PR (Cy3 conjugate, 13095, used at 5 µg/mL), HER2 (Cy5  conjugate of rabbit anti‑HER2 clone D8F12.#4290,  cell signaling, used at 5 µg/mL); Round 3:  pan‑cytokeratin (pan‑CK) (Cy3 conjugate, 13010/13421,  2.5 µg/mL), Na+/K+‑ATPase (plasma membrane)  (Cy5 conjugate of rabbit anti‑sodium‑potassium‑ATPase,  clone EP1845Y, #2047‑1, epitomics, used at 5 µg/mL);  and Round 4: pan‑cadherin (PCad) (Cy3 conjugate  of rabbit anti‑pan cadherin [RB‑9036; Thermo  Scientific], stained at 5 µg/mL), epidermal growth factor  receptor (EGFR) (Cy5 conjugate of rabbit‑anti‑EGFR  clone D38B1 [4267; cell signaling], used at 1 µg/mL).",Non-OADS,/arxiv_data1/oa_pdf/22/55/JPI-7-47.PMC5139455.pdf
"J Pathol Inform 2016, 1:47  http://www.jpathinformatics.org/content/7/1/47the high‑intensity subpopulation if any one of its mean  biomarker values was greater than its respective threshold.",Non-OADS,/arxiv_data1/oa_pdf/22/55/JPI-7-47.PMC5139455.pdf
"J Pathol Inform 2016, 1:47  http://www.jpathinformatics.org/content/7/1/47 Figure 4: Learning a dictionary of cellular expression patterns.",OADS,/arxiv_data1/oa_pdf/22/55/JPI-7-47.PMC5139455.pdf
"J Pathol Inform 2016, 1:47  http://www.jpathinformatics.org/content/7/1/47have a sparse coding, i.e., each cell is phenotyped with  only one or few of the biomarker patterns.",OADS,/arxiv_data1/oa_pdf/22/55/JPI-7-47.PMC5139455.pdf
"J Pathol Inform 2016, 1:47  http://www.jpathinformatics.org/content/7/1/47assign each cell to have a phenotype fi, where i is the  nonzero index in column wk of W. A potential pitfall  of the algorithm is that high‑ and low‑signal intensity  cells can be assigned to the same cell phenotype (more  discussion of this in the Results section).",Non-OADS,/arxiv_data1/oa_pdf/22/55/JPI-7-47.PMC5139455.pdf
This toolbox also requires the use  of an orthogonal matching pursuit implementation in  MATLAB from http://www.cs.technion.ac.il/~ronrubin/ Software/ompbo × 10.zip.,Non-OADS,/arxiv_data1/oa_pdf/22/55/JPI-7-47.PMC5139455.pdf
"J Pathol Inform 2016, 1:47  http://www.jpathinformatics.org/content/7/1/47to the construction of the PMI map, a linear search may be  executed on the tissue data to look for the specific pairwise  interactions of cell phenotypes requested [ Figure  5].",OADS,/arxiv_data1/oa_pdf/22/55/JPI-7-47.PMC5139455.pdf
"J Pathol Inform 2016, 1:47  http://www.jpathinformatics.org/content/7/1/47T able 1: Tissue microarray data with cohorts from  (a) estrogen receptor(+) invasive ductal carcinoma,  (b) estrogen receptor(+) invasive lobular carcinoma,  (c) estrogen receptor( −) invasive ductal carcinoma,  and (d) human epidermal growth factor 2(+) invasive  ductal carcinoma.",OADS,/arxiv_data1/oa_pdf/22/55/JPI-7-47.PMC5139455.pdf
"J Pathol Inform 2016, 1:47  http://www.jpathinformatics.org/content/7/1/47degree of heterogeneity is apparent.",Non-OADS,/arxiv_data1/oa_pdf/22/55/JPI-7-47.PMC5139455.pdf
"J Pathol Inform 2016, 1:47  http://www.jpathinformatics.org/content/7/1/47We also display matrix DW to portray the similarity  between the actual data matrix and its reconstruction.",OADS,/arxiv_data1/oa_pdf/22/55/JPI-7-47.PMC5139455.pdf
"J Pathol Inform 2016, 1:47  http://www.jpathinformatics.org/content/7/1/47high, PR low).",Non-OADS,/arxiv_data1/oa_pdf/22/55/JPI-7-47.PMC5139455.pdf
"J Pathol Inform 2016, 1:47  http://www.jpathinformatics.org/content/7/1/47tumor with several highly localized self‑interactions of  specific cell phenotypes, thus signifying a tumor sample  exhibiting local homogeneity but global heterogeneity.",Non-OADS,/arxiv_data1/oa_pdf/22/55/JPI-7-47.PMC5139455.pdf
"J Pathol Inform 2016, 1:47  http://www.jpathinformatics.org/content/7/1/47observations in Figure  6 where patient‑level PMI maps do  not necessarily correlate to their replicate core PMI maps,  highlighting a degree of spatial heterogeneity between  cores.",Non-OADS,/arxiv_data1/oa_pdf/22/55/JPI-7-47.PMC5139455.pdf
"J Pathol Inform 2016, 1:47  http://www.jpathinformatics.org/content/7/1/4719.",Non-OADS,/arxiv_data1/oa_pdf/22/55/JPI-7-47.PMC5139455.pdf
Available from: http://www.who.int/blindness/Prevention%20 of%20Blindness%20from%20Diabetes%20Mellitus‑with‑cover‑ small.pdf.,Non-OADS,/arxiv_data1/oa_pdf/a2/b2/JOVR-11-394.PMC5139552.pdf
Available from: http://www.diabetesatlas.org/component/  attachments/?task=download & id=116.,OADS,/arxiv_data1/oa_pdf/a2/b2/JOVR-11-394.PMC5139552.pdf
Available from: http://www.one.aao.org/ guidelines‑preferredpracticepatterns.,Non-OADS,/arxiv_data1/oa_pdf/a2/b2/JOVR-11-394.PMC5139552.pdf
Available from: http://www.hbi.ir/NSite/FullStory/ News/?Id=1200.,Non-OADS,/arxiv_data1/oa_pdf/a2/b2/JOVR-11-394.PMC5139552.pdf
Available at: http://rc.majlis.ir/fa/law/ show/790196.,Non-OADS,/arxiv_data1/oa_pdf/a2/b2/JOVR-11-394.PMC5139552.pdf
Available from: http://www.agreetrust.org/.,Non-OADS,/arxiv_data1/oa_pdf/a2/b2/JOVR-11-394.PMC5139552.pdf
Available from: http://www.rcophth.,Non-OADS,/arxiv_data1/oa_pdf/a2/b2/JOVR-11-394.PMC5139552.pdf
Available from: http://www.retinalscreening.,Non-OADS,/arxiv_data1/oa_pdf/a2/b2/JOVR-11-394.PMC5139552.pdf
Available from: http://www.ndrs.scot.nhs.uk/.,Non-OADS,/arxiv_data1/oa_pdf/a2/b2/JOVR-11-394.PMC5139552.pdf
Available from: http://www.wales.nhs.uk/sitesplus/864/ page/42582.,Non-OADS,/arxiv_data1/oa_pdf/a2/b2/JOVR-11-394.PMC5139552.pdf
Available from:  https://www.nice.org.uk/guidance/ph  10/documents/ smoking‑cessation‑services‑in‑primary‑care‑pharmacies‑local‑ authorities‑and‑workplaces‑particularly‑for‑manual‑working‑ groups ‑pregnant‑ women ‑and‑hard ‑to‑reach‑ communities‑revi ew‑proposal‑consultation2.,Non-OADS,/arxiv_data1/oa_pdf/a2/b2/JOVR-11-394.PMC5139552.pdf
Available from: http://www.sign.ac.uk/pdf/sign116.,Non-OADS,/arxiv_data1/oa_pdf/a2/b2/JOVR-11-394.PMC5139552.pdf
Available from: http://www.aao.org/clinical‑statement/ international-clinical-classification-system-diabe.,Non-OADS,/arxiv_data1/oa_pdf/a2/b2/JOVR-11-394.PMC5139552.pdf
[http://www.who.int/immunization/hpv/learn/guidelines_to_assure_ the_quality_safety_and_efficacity_ecbs_2006.pdf] [2] Strategy for the active offer of the HPV vaccine in Italy.,Non-OADS,/arxiv_data1/oa_pdf/8a/97/2421-4248-57-E121.PMC5139606.pdf
[http://www.epicentro.iss.it/problemi/hpv/pdf/ Aggiornamento_HPV_31122013.pdf] [6]  Vaccination report for Piedimont Region in 2011.,Non-OADS,/arxiv_data1/oa_pdf/8a/97/2421-4248-57-E121.PMC5139606.pdf
"[http://www.epicentro.iss.it/temi/vaccinazioni/DocumentazioneRegioni.asp] [7] Kessels SJ, Marshall HS, Watson M, Braunack-Mayer AJ, Reu- zel R, Tooher RL.",Non-OADS,/arxiv_data1/oa_pdf/8a/97/2421-4248-57-E121.PMC5139606.pdf
Report on the data of the Italian international HBSC study. [http://www.hbsc.unito.it/hbsc/files/stilidivita1_file%20stampa.pdf].,Non-OADS,/arxiv_data1/oa_pdf/8a/97/2421-4248-57-E121.PMC5139606.pdf
[http://www.epicentro.iss.it/focus/guadagnare_salute/pdf/Hbsc2010.,Non-OADS,/arxiv_data1/oa_pdf/8a/97/2421-4248-57-E121.PMC5139606.pdf
[http://www.censis.it/14?shadow_ricer - ca=113853].,Non-OADS,/arxiv_data1/oa_pdf/8a/97/2421-4248-57-E121.PMC5139606.pdf
Available at: http://ecdc.europa.eu/en/publications/publica-tions/0805_ter_review_of_chlamydia_control_activities.pdf  Accessed on: 29/06/2016.,Non-OADS,/arxiv_data1/oa_pdf/8d/c4/2421-4248-57-E128.PMC5139607.pdf
Available at: http://ecdc.europa.eu/en/publica- tions/Publications/0906_GUI_Chlamydia_Control_in_Europe.,Non-OADS,/arxiv_data1/oa_pdf/8d/c4/2421-4248-57-E128.PMC5139607.pdf
Available at: http://ecdc.europa.eu/en/publi- cations/Publications/110526_SUR_STI_in_Europe_1990-2009.,Non-OADS,/arxiv_data1/oa_pdf/8d/c4/2421-4248-57-E128.PMC5139607.pdf
Available from: http://www.gazzettaufficiale.biz/ atti/2012/20120072/12A03185.htm.,Non-OADS,/arxiv_data1/oa_pdf/8d/c4/2421-4248-57-E128.PMC5139607.pdf
Available at: http://www.ncbi.nlm.,Non-OADS,/arxiv_data1/oa_pdf/8d/c4/2421-4248-57-E128.PMC5139607.pdf
"OpenEpi: Open Source Epi- demiologic Statistics for Public Health, Version 2.3.1. http://www.OpenEpi.com[29] Weinstock H, Berman S, Cates W Jr. Sexually transmitted dis- eases among American youth: incidence and prevalence es- timates, 2000.",Non-OADS,/arxiv_data1/oa_pdf/8d/c4/2421-4248-57-E128.PMC5139607.pdf
Available at http://www.cdc.,Non-OADS,/arxiv_data1/oa_pdf/8d/c4/2421-4248-57-E128.PMC5139607.pdf
Available at: http://www.epicentro.iss.it/problemi/infezioni_correlate/epid.asp.,Non-OADS,/arxiv_data1/oa_pdf/15/a3/2421-4248-57-E135.PMC5139608.pdf
Available  at: http://ecdc.europa.eu/en/activities/surveillance/hai/about_ hai-net/pages/pps.aspx.,Non-OADS,/arxiv_data1/oa_pdf/15/a3/2421-4248-57-E135.PMC5139608.pdf
Available at: http://ecdc.europa.eu/en/publica- tions/Publications/healthcare-associated-infections-antimicro-bial-use-PPS.pdf.,Non-OADS,/arxiv_data1/oa_pdf/15/a3/2421-4248-57-E135.PMC5139608.pdf
Available at: http://www.who.,Non-OADS,/arxiv_data1/oa_pdf/15/a3/2421-4248-57-E135.PMC5139608.pdf
Biomolecular analysis The isolates from 72 of the in-hospital cases underwent  molecular typing by means of the MLST technique (http://www.pasteur.fr/recherche/genopole/PF8/mlst/Kpneumoniae.html).,Non-OADS,/arxiv_data1/oa_pdf/73/71/2421-4248-57-E149.PMC5139610.pdf
"The se-quences obtained were compared with those available in the NCBI database (http://blast.ncbi.nlm.nih.gov/Blast.cgi), which enabled the bla KPC gene to be characterized.",OADS,/arxiv_data1/oa_pdf/73/71/2421-4248-57-E149.PMC5139610.pdf
Version 3.1. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/Breakpoint_table_v_3.1.pdf.,OADS,/arxiv_data1/oa_pdf/73/71/2421-4248-57-E149.PMC5139610.pdf
http://www.cdc.gov/HAI/pdfs/labSettings/HodgeTest_Carbapenemase_Enterobacteriaceae.pdf.,Non-OADS,/arxiv_data1/oa_pdf/73/71/2421-4248-57-E149.PMC5139610.pdf
2004. http://ltc.nutes.ufrj.br/constructore/objetos/ Todar-microbiology.pdf.,Non-OADS,/arxiv_data1/oa_pdf/42/05/2421-4248-57-E157.PMC5139611.pdf
"Nigeria is the most populous country in Af- rica (over 170 million in 2012; http://esa.un.org/wpp/ASCII-Data/DISK_ NA VIGATION_ASCII.htm) with  an estimated livestock population of 20.49 million cat- tle, 23.07 million sheep, 28.07 million goats, 6.54 mil- lion pigs (http://www.fao.org/ag/againfo/ resources/ en/glw/GLW_dens.html),18,200-90,000 camels, and  210,000 horses (http://faostat.fao.org/site/573/default.",Non-OADS,/arxiv_data1/oa_pdf/e4/5e/2421-4248-57-E164.PMC5139612.pdf
"Nairobi, Kenya: ILRI, 2012.  http://cgspace.cgiar.org/handle/10568/21161.",Non-OADS,/arxiv_data1/oa_pdf/e4/5e/2421-4248-57-E164.PMC5139612.pdf
Available at: http://ec.europa.eu/public_opinion/archives/ ebs/ebs_238_en.pdf (Accessed September 04 2015).,Non-OADS,/arxiv_data1/oa_pdf/e4/5e/2421-4248-57-E164.PMC5139612.pdf
Available from: http://www.who.int/uv/faq/skincancer/en/index1.html.,Non-OADS,/arxiv_data1/oa_pdf/1e/eb/2421-4248-57-E172.PMC5139613.pdf
Available from: http://www.who.int/features/qa/40/en/.,OADS,/arxiv_data1/oa_pdf/1e/eb/2421-4248-57-E172.PMC5139613.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License ( http://creativecommons.org/licenses/by-nc/3.0/ ), which permits unre- stricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
"11, e1232223 (14 pages)http://dx.doi.org/10.1080/2162402X.2016.1232223",Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Science 2014; 342:1432-3; PMID:24357284; http://dx.doi.org/ 10.1126/science.342.6165.1432 2.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Nature 2012; 480:480-9; PMID:22193102; http://dx.doi.org/ 10.1038/nature10673 3.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Front Med 2012; 5:323-32;PMID:22198743; http://dx.doi.org/10.1007/s11684-011-0172-4 4.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Immunity 2008; 29:372-83; PMID:18799145; http://dx.doi.org/10.1016/j.immuni.2008.08.004 5.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Nature 2007; 449:419-26; PMID:17898760; http://dx.doi.org/10.1038/ nature06175 6.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Nat Rev Cancer 2012; 12:265-77; PMID:22437871; http://dx.doi.org/ 10.1038/nrc3258 7.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Cell Death Differ 2008; 15:39-50; PMID:17948027; http://dx.doi.org/ 10.1038/sj.cdd.4402247 8.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
J Clin Invest 2007; 117:1155-66; PMID:17476345; http://dx.doi.org/10.1172/JCI31422 9.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Immunol Rev 2008; 222:162-79; PMID:18364001; http://dx.doi.org/10.1111/j.1600-065X.2008.00602.x 10.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Immunol Cell Biol 2005; 83:451-61; PMID:16174093; http://dx.doi.org/10.1111/j.1440- 1711.2005.01371.x 11.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Cancer Res 2010; 70:3119-27; PMID:20354188; http://dx.doi.org/10.1158/0008-5472.CAN-09-4250 12.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
J Pathol 2005; 207:243-9; PMID:16041695; http://dx.doi.org/10.1002/path.1825 13.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Hepatology 2009; 50:1152-61; PMID:19711427; http://dx.doi.org/10.1002/hep.23100 14.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Proc Natl Acad Sci U S A 2006; 103:2257-61; PMID:16461460; http://dx.doi.org/ 10.1073/pnas.0510565103 15.,OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
J Pathol 2009; 219:214-21; PMID:19593777; http://dx.doi.org/10.1002/path.2586 16.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
EMBO Mol Med 2012; 4:143-59; PMID:22351564; http://dx.doi.org/10.1002/ emmm.201100209 17.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Blood 2012; 120:1678-86;PMID:22797699; http://dx.doi.org/10.1182/blood-2012-02-410647 18.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
J ControlRelease 2013; 168:251-61; PMID:23567045; http://dx.doi.org/10.1016/j.jconrel.2013.03.020 1 9 .,OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Biochem Pharmacol 2011; 82:1416-29; PMID:21864506;http://dx.doi.org/10.1016/j.bcp.2011.08.007 20.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Proc NatlAcad Sci USA 2014; 111:4536-41; PMID:24616504; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Blood 2011; 117:4293-303;PMID:21355095; http://dx.doi.org/10.1182/blood-2010-12-322503 23.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Immunol Rev 2013; 253:146-57; PMID:23550644; http://dx.doi.org/10.1111/imr.12057 24.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Immunity 2010; 33:607-19; PMID:20888269; http://dx.doi.org/10.1016/j.immuni.2010.09.009 25.,OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Immunity 2007; 27:847-59; PMID:18055230; http://dx.doi.org/ 10.1016/j.immuni.2007.10.009 26.,OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Cell Metab 2012; 15:545-53; PMID:22445600; http://dx.doi.org/10.1016/j.cmet.2012.01.022 27.,OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Int J Cancer 2015; 136:E602-13;PMID:25143000; http://dx.doi.org/10.1002/ijc.29151 28.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Mol Cancer Res 2013;11:923-36; PMID:23666369; http://dx.doi.org/10.1158/1541-7786.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Blood 2011; 117:4490-500; PMID:21385848; http://dx.doi.org/10.1182/blood-2010-09-308064 31.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
J Immunol 2014; 193:1690-700; PMID:25009204; http://dx.doi.org/10.4049/jimmunol.1301913 32.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Curr Opin Immunol 2014; 27:26-32;PMID:24513968; http://dx.doi.org/10.1016/j.coi.2014.01.005 33.,OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Clin Cancer Res 2007; 13:4677-85; PMID:17699845; http://dx.doi.org/10.1158/1078-0432.CCR-07-0776 34.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
J Immu- nol 2008; 181:8576-84; PMID:19050277; http://dx.doi.org/10.4049/ jimmunol.181.12.8576 35.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Nat Rev Immunol 2008; 8:362-71; PMID:18379575; http://dx.doi.org/10.1038/nri2297 36.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Nat Cell Biol 2010; 12:618-24; PMID:20473294;http://dx.doi.org/10.1038/ncb2065 38.,OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
J Virol 2009; 83:12009-17; PMID:19759154; http://dx.doi.org/10.1128/JVI.01182-09 39.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Immunity 2014; 40:865-79; PMID:24856900; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
J ExpMed 1999; 190:1417-26; PMID:10562317; http://dx.doi.org/10.1084/ jem.190.10.1417 41.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
J Immu- nol 2004; 173:3844-54; PMID:15356132; http://dx.doi.org/10.4049/ jimmunol.173.6.3844 43.,OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Annu Rev Immunol 2004; 22:891-928; PMID:15032599; http://dx.doi.org/ 10.1146/annurev.immunol.22.012703.104543 44.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
J Immunol 2015; 195:4632-40; PMID:26447227; http://dx.doi.org/10.4049/ jimmunol.1302941 47.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Proc Soc Exp Biol Med 1951; 77:358-62; PMID:14854049; http://dx.doi.org/10.3181/00379727-77- 18779 48.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
PLoS One 2012; 7:e51525;PMID:23272114; http://dx.doi.org/10.1371/journal.pone.0051525 49.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Breast Cancer Res Treat 2014; 148:291-302; PMID:25311112; http://dx.doi.org/10.1007/ s10549-014-3164-7 50.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
Clin Cancer Res 2016; 22:2993-3004; PMID:26861455; http://dx.doi.org/10.1158/1078-0432.CCR-15-1839e1232223-14 J. WANG ET AL.,Non-OADS,/arxiv_data1/oa_pdf/0a/0f/koni-05-11-1232223.PMC5139631.pdf
"11, e1196310 (9 pages)http://dx.doi.org/10.1080/2162402X.2016.1196310",Non-OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
"To further validate what we have revealed inCGGA dataset, we obtained RNAseq data of glioma fromTCGA network ( http://cancergenome.nih.gov/ ) and found that the consistency of results between two cohorts was fairlysatisfying.",OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
"To yield an accurate result, sig-niﬁcantly related genes that were shared by two dataset were cho- sen for Gene Ontology analysis with online methods (DAVID,https://david.ncifcrf.gov/ ).",OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
CA 2010; 60:166-93; PMID:20445000; http://dx.doi.org/10.3322/caac.20069 2 .,OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
Oncotarget2015; 6:40896-906; PMID:26503470; http://dx.doi.org/10.18632/oncotarget.5683 3.,OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
Neuro Oncol 2006; 8:261-79; PMID:16775224; http://dx.doi.org/10.1215/15228517-2006-008 4.,Non-OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239 7 .,Non-OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
N Eng J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694 8.,OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
Breast Cancer Res 2009; 11:R15; PMID:19272155; http://dx.doi.org/10.1186/bcr2234 9.,Non-OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
The stromal gene encoding the CD274 antigen as a genetic modi ﬁer controlling survival of mice with gamma-radiation-induced T-cell lymphoblastic lymphomas.Oncogene 2010; 29:5265-73; PMID:20639904; http://dx.doi.org/ 10.1038/onc.2010.280 10.,Non-OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
Ann Oncol 2014; 25:1935-40;PMID:25009014; http://dx.doi.org/10.1093/annonc/mdu242 11.,Non-OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
Scienti ﬁc Reports 2015; 5:13110; PMID:26279307; http://dx.doi.org/10.1038/srep13110 12.,Non-OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
"Berghoff AS, Ricken G, Widhalm G, Rajky O, Hainfellner JA, Birner P, Raderer M, Preusser M. PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL).Clin Neuropathol 2014; 33:42-9; PMID:24359606; http://dx.doi.org/ 10.5414/NP300698 13.",OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
Ann Oncol 2014; 25:2178-84; PMID:25193987; http://dx.doi.org/10.1093/annonc/mdu445 14.,Non-OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
Oncoimmunology 2015; 4:e1002729; PMID:26155391; http://dx.doi.org/10.1080/2162402X.2014.100272915.,Non-OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
The Lancet Oncology 2015; 16:e11; PMID:25638546; http://dx.doi.org/10.1016/S1470-2045(14)71167-2 16.,Non-OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
Oncotarget 2015; 6:5449-64;PMID:25669979; http://dx.doi.org/10.18632/oncotarget.3216 17.,OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
Oncoimmunology 2012; 1:1223-5; PMID:23243584;http://dx.doi.org/10.4161/onci.21335 19.,Non-OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
Neuro-Oncol 2016; 18:195-205; PMID:26323609; http://dx.doi.org/10.1093/neuonc/nov172 22.,Non-OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
Neuro Oncol 2012; 14:1432-40; PMID:23090983; http://dx.doi.org/10.1093/neuonc/nos263 23.,Non-OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
PLoS One 2012; 7:e30339; PMID:22291938;http://dx.doi.org/10.1371/journal.pone.0030339 24.,Non-OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
"R Foundation for Statistical Computing, Vienna, Austria.URL https://www.Rproject.org/.",Non-OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
BMC Bioinformat 2011; 12:77; PMID:21414208; http://dx.doi.org/10.1186/1471-2105-12-77 27.,OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
"Gu Z, Gu L, Eils R, Schlesner M, Brors B. circlize Implements and enhances circular visualization in R. Bioinformatics 2014; 30:2811-2;PMID:24930139; http://dx.doi.org/10.1093/bioinformatics/btu393 28.",OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
J Natl Cancer Inst 2016; 108; PMID:26577528; http://dx.doi.org/10.1093/jnci/djv303 29.,Non-OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
Nat Rev Clin Oncol 2016; 13:202-3; PMID:26977783; http://dx.doi.org/10.1038/nrclinonc.2016.40 30.,Non-OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
Nat Commun 2016; 7:10501; PMID:26883990; http://dx.doi.org/10.1038/ncomms10501 31.,OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
Oncol Lett 2016; 11:1829-34; PMID:26998085; http://dx.doi.org/10.3892/ol.2016.4142 32.,Non-OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
BMC Bioinformatics 2013; 14:7;PMID:23323831; http://dx.doi.org/10.1186/1471-2105-14-7 33.,OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
Mol Therapy 2013;21:1297-305; PMID:23648695; http://dx.doi.org/10.1038/mt.2013.80e1196310-8 Z. WANG ET AL.,OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
Neuro Oncol2011; 13:3-13; PMID:21149252; http://dx.doi.org/10.1093/neuonc/noq16935.,Non-OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
Nature 2015;523:337-41; PMID:26030524; http://dx.doi.org/10.1038/nature14432ONCOIMMUNOLOGY e1196310-9,Non-OADS,/arxiv_data1/oa_pdf/86/a9/koni-05-11-1196310.PMC5139638.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License ( http://creativecommons.org/licenses/by-nc/3.0/ ), which permits unre- stricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
"11, e1238542 (8 pages)http://dx.doi.org/10.1080/2162402X.2016.1238542",Non-OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
Gynecol Oncol 2012; 126:481 –90; PMID:22525820; http://dx.doi.org/10.1016/j.ygyno.2012.04.021 2.,Non-OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
Gynecol Oncol 2008; 109:370 –6; PMID:18395777; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
Gynecol Oncol 2007; 105:404 –8; PMID:17292461; http://dx.doi.org/10.1016/j.ygyno.2006.12.024 4.,Non-OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
Low response rate of second-line chemotherapy for recurrent or refractory clear cell carci- noma of the ovary: a retrospective Japan clear cell carcinoma study.Int J Gynecol Cancer 2008; 18:937 –42; PMID:18081792; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
Int J Gynecol Cancer 2012; 22:801 –6; PMID:22617480; http://dx.doi.org/ 10.1097/IGC.0b013e3182540145 7.,Non-OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
Clin Cancer Res 2012; 18:6497 –508; PMID:23032745; http://dx.doi.org/10.1158/1078-0432.CCR-12-2189 8.,Non-OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
Int J Cancer 2009; 125:2104 –13; PMID:19621448; http://dx.doi.org/ 10.1002/ijc.24597 9.,Non-OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
J Immunother 2008; 31:420 –30; PMID:18391753; http://dx.doi.org/10.1097/CJI.0b013e31816dad10ONCOIMMUNOLOGY e1238542-7,Non-OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
Clin Cancer Res 2004; 10:1580 –7; PMID:15014007; http://dx.doi.org/ 10.1158/1078-0432.CCR-03-0056 11.,Non-OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
Cancer Sci 2011; 102:1622 –9; PMID:21668581; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
Biochem Biophys Res Commun 2003; 306:16 –25; PMID:12788060; http://dx.doi.org/10.1016/S0006-291X(03)00908-2 14.,OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
Mod Pathol 2009; 22:824 –32; PMID:19329941; http://dx.doi.org/10.1038/modpathol.2009.40 15.,Non-OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
Clin Cancer Res 2004; 10:6612 –21; PMID:15475451; http://dx.doi.org/10.1158/1078-0432.CCR-04-0348 16.,Non-OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
Int J Cancer 2000; 89:418 –22; PMID:11008203; http://dx.doi.org/ 10.1002/1097-0215(20000920)89:5%3c418::AID-IJC4%3e3.0.CO;2-I 17.,Non-OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
J Pediatr Hematol Oncol 2001; 23:496 –9; PMID:11878776; http://dx.doi.org/10.1097/00043426-200111000-00006 18.,Non-OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
Mod Pathol 2008; 21:817 –25; PMID:18469798; http://dx.doi.org/10.1038/modpathol.2008.37 19.,Non-OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
Clin Cancer Res 2006; 12:2689 –97; PMID:16675560; http://dx.doi.org/ 10.1158/1078-0432.CCR-05-2267 20.,Non-OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
Clin Cancer Res 2012; 18:3686 –96; PMID:22577059; http://dx.doi.org/10.1158/1078-0432.CCR-11-3044 21.,Non-OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
Oncoim- munology 2012; 1:1448 –50; PMID:23243625; http://dx.doi.org/ 10.4161/onci.21351 22.,Non-OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
Hum Vaccin Immunother 2014; 10:338 –43; PMID:24252799; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
OncoImmu- nology 2016; 5:e1129483; PMID:27467945; http://dx.doi.org/ 10.1080/2162402X.2015.1129483 24.,Non-OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
Int J Clin Oncol 2013; 18:148 –53; PMID:22160560; http://dx.doi.org/10.1007/s10147-011-0357-5 25.,Non-OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
N Engl J Med 2012; 366:2443 –54; PMID:22658127; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
N Engl J Med 2012; 366:2455 –65; PMID:22658128; http://dx.doi.org/10.1056/NEJ Moa1200694 27.,Non-OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
J Clin Oncol 2015; 33:4015 –22; PMID:26351349; http://dx.doi.org/10.1200/JCO.2015.62.3397 28.,Non-OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
Curr Opin Immunol 2015; 33:23 – 35; PMID:25621841; http://dx.doi.org/10.1016/j.coi.2015.01.006 29.,OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
Int J Oncol 2015; 46:28 –36; PMID:25354479; http://dx.doi.org/10.3892/ ijo.2014.2737 30.,OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
Int Immunol 2016; 28:319-28;PMID:27235694; http://dx.doi.org/10.1093/intimm/dxw027.,OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
Oncoimmunology 2016; 5:e1062209; PMID:26942076; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
Cancer Sci 2011; 102:918 –25; PMID:21281401; http://dx.doi.org/10.1111/j.1349-7006.2011.01896.xe1238542-8 S. SUZUKI ET AL.,Non-OADS,/arxiv_data1/oa_pdf/8f/19/koni-05-11-1238542.PMC5139642.pdf
"11, e1234565 (12 pages)http://dx.doi.org/10.1080/2162402X.2016.1234565",Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
ORCID Vaihere Delaune http://orcid.org/0000-0001-8931-0977 References 1.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
Nat Rev Immunol 2010; 10:753-66; PMID:20972472; http://dx.doi.org/10.1038/nri2858 2.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
JClin Invest 2014; 124:812-23; PMID:24430180; http://dx.doi.org/10.1172/JCI66776 3.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
Hepatol Baltim Md 2008; 48:978-90; PMID:18712788; http://dx.doi.org/10.1002/hep.22395 4.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
J Hepatol 2011; 54:357-65; PMID:21084131; http://dx.doi.org/10.1016/j.jhep.2010.10.005 5.,OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
J Immu- nol Baltim Md 1950 2015; 195:3100-9; PMID:26304988; http://dx.doi.org/10.4049/jimmunol.1500839 6.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
J Hepatol 2013; 59:1094-106; PMID:23811302; http://dx.doi.org/10.1016/j.jhep.2013.06.017 7.,OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
J Hepatol 2009; 51:212-23; PMID:19447517; http://dx.doi.org/ 10.1016/j.jhep.2009.03.008 8.,OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
J Hepatol 2015; 62:458-68; PMID:25315649; http://dx.doi.org/10.1016/j.jhep.2014.10.006 9.,OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
J Hepatol 2010; 53:903-10; PMID:20739085; http://dx.doi.org/10.1016/j.jhep.2010.04.037 10.,OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
Blood 2007; 110:4077-85; PMID:17690256; http://dx.doi.org/10.1182/blood-2007- 02-073841 11.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
Immunol Cell Biol 2005; 83:336-43; PMID:16033528; http://dx.doi.org/10.1111/j.1440-1711.2005.01323.x 12.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
Nat Rev Cancer 2013; 13:739-52; PMID:24060865; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
J Immunol Baltim Md 1950 2012; 189:1843-9; PMID:22798671; http://dx.doi.org/10.4049/ jimmunol.1200584 14.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
J Immunol Baltim Md 1950 2008; 181:5791-802; PMID:18832739; http://dx.doi.org/10.4049/jimmunol.181.8.5791 15.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
J Leukoc Biol 2014; 96:1109-18; PMID:25170116; http://dx.doi.org/10.1189/jlb.3A0414-210R 16.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
"Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and mac-rophages subverts tumor immuni ty toward a type 2 response.J Immunol Baltim Md 1950 2007; 179:977-83; PMID:17617589; http://dx.doi.org/10.4049/jimmunol.179.2.977 17.",Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
J Hepatol 2013; 59:921-3; PMID:23958935; http://dx.doi.org/ 10.1016/j.jhep.2013.08.003 18.,OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
J Hepatol 2013; 59:1007-13; PMID:23796475; http://dx.doi.org/10.1016/j.jhep.2013.06.010 19.,OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
Scand J Immunol 2008; 67:453-63;PMID:18405323; http://dx.doi.org/10.1111/j.1365-3083.2008.02091.x 20.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
Hepatology 2014; 59:1060-72; PMID:24481979; http://dx.doi.org/10.1002/hep.26783 22.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
Respir Res 2007; 8:71; PMID:17916230;http://dx.doi.org/10.1186/1465-9921-8-71 23.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
Hepatol Baltim Md 2005; 42:193-9; PMID:15962311; http://dx.doi.org/10.1002/hep.20756 24.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
J Leukoc Biol 2012; 91:167-81;PMID:21954284; http://dx.doi.org/10.1189/jlb.0311177 25.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
Cancer Immunol Immun-other CII 2010; 59:1593-600; PMID:20414655; http://dx.doi.org/10.1007/s00262-010-0855-8 26.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
TrendsImmunol 2003; 24:301-5; PMID:19941314; http://dx.doi.org/10.1016/ S1471-4906(03)00132-7 27.,OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
Int J Cancer 2002; 99:713-20; PMID:12115505; http://dx.doi.org/10.1002/ijc.10412 28.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
Hepatology 1996; 23:1224- 31; PMID:8621157; http://dx.doi.org/10.1002/hep.510230542 29.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
Cell Immunol 1995; 165:141-7; PMID:7671318; http://dx.doi.org/10.1006/cimm.1995.1197 30.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
Cancer Res2012; 72:3977-86; PMID:22719066; http://dx.doi.org/10.1158/0008-5472.CAN-12-0938 31.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
"Nat Cell Biol 2014; 16:972-81, 1-7; PMID:25173978; http://dx.doi.org/10.1038/ncb3031 32.",OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
Rev Immunol 2014; 14:181-94; PMID:24566915; http://dx.doi.org/ 10.1038/nri3623 33.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
Can-cer Res 2009; 69:5514-21; PMID:19549903; http://dx.doi.org/10.1158/ 0008-5472.CAN-08-4625 35.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
Eur J Immunol 2010; 40:22-35; PMID:19941314; http://dx.doi.org/10.1002/eji.200939903 36.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
Cancer Immunol Immunother 2013; 62:1663- 73; PMID:23982485; http://dx.doi.org/10.1007/s00262-013-1470-2 37.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
J Exp Med 2010; 207:2439-53; PMID:20876310;http://dx.doi.org/10.1084/jem.20100587 38.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
Immunol Invest 2012;41:595-613; PMID:23017137; http://dx.doi.org/10.3109/08820139.2012.673191 39.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
Nat Immunol 2013; 14:1212-8; PMID:24240160; http://dx.doi.org/10.1038/ni.276240.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
J Exp Med 2000; 192:1027-34; PMID:11015443; http://dx.doi.org/10.1084/jem.192.7.1027 41.,OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
J Leukoc Biol 2012; 92:1199-206; PMID:23077247; http://dx.doi.org/10.1189/jlb.0212059 42.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
OncoImmunology 2015; 4:e954829; PMID:25949858; http://dx.doi.org/10.4161/21624011.2014.954829 43.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
Cancer Res 2010; 70:3052-61; PMID:20388795; http://dx.doi.org/10.1158/0008-5472.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
Nat Med 2014; 20:676-81; PMID:24859530; http://dx.doi.org/10.1038/nm.3560 45.,OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
Oncoim- munology 2015; 4:e983961; PMID:25949898; http://dx.doi.org/10.4161/2162402X.2014.983761 46.,Non-OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
Hum GeneTher 2010; 21:611-21; PMID:20064014; http://dx.doi.org/10.1089/ hum.2009.187e1234565-12 S. LACOTTE ET AL.,OADS,/arxiv_data1/oa_pdf/98/d4/koni-05-11-1234565.PMC5139644.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License ( http://creativecommons.org/licenses/by-nc/3.0/ ), which permits unre- stricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
"11, e1219008 (12 pages)http://dx.doi.org/10.1080/2162402X.2016.1219008",Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Nat Rev Drug Discov 2012; 11:215-33; PMID:22301798; http://dx.doi.org/10.1038/nrd3626 2.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Oncotarget 2014; 5:6558-72; PMID:25115382; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Cancer Res 2013; 73:7265-76; PMID:24158093; http://dx.doi.org/10.1158/0008-5472.CAN-13-0890 4.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Oncogene 2007; 26:5541-52;PMID:17694093; http://dx.doi.org/10.1038/sj.onc.1210620 5.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Mol Cancer Res 2007; 5:981-9; PMID:17951399; http://dx.doi.org/10.1158/1541-7786.MCR-07-0324 6.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
J Clin Oncol 2013; 31:2128-35; PMID:23650416; http://dx.doi.org/10.1200/JCO.2012.43.7251 7.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Cell Immunol 2009; 257:97-104;PMID:19358983; http://dx.doi.org/10.1016/j.cellimm.2009.03.004 8.,OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Prostate 2012; 72:90-9; PMID:21538420; http://dx.doi.org/10.1002/pros.21410 9.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
PLoS One 2012; 7:e30815; PMID:22303460; http://dx.doi.org/ 10.1371/journal.pone.0030815 10.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Mol Ther 2013;21:887-94; PMID:23295947; http://dx.doi.org/10.1038/mt.2012.265 11.,OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Proc Natl Acad Sci U S A 2014; 111:11774-9; PMID:25071169; http://dx.doi.org/10.1073/ pnas.1410626111 12.,OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Front Immunol 2014; 5:147; PMID:24772111; http://dx.doi.org/10.3389/ﬁmmu.2014.00147 13.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Clin Can- cer Res 2015; 21:4224-33; PMID:25999436; http://dx.doi.org/10.1158/1078-0432.CCR-15-0260 14.,OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Immune independent crosstalk between lymphoma and myeloid sup- pressor CD14HLA-DR monocytes mediates chemotherapy resistance.Oncoimmunology 2015; 4:e996470; PMID:26137410; http://dx.doi.org/10.1080/2162402X.2014.996470e1219008-10 Y. TOMITA ET AL.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
J Immu-nol 2000; 165:7017-24; PMID:11120829; http://dx.doi.org/10.4049/ jimmunol.165.12.7017 16.,OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Immunology 2008; 123:218-27;PMID:17725605; http://dx.doi.org/10.1111/j.1365-2567.2007.02689.x 17.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Immunol Cell Biol 2012; 90:55-65;PMID:22105512; http://dx.doi.org/10.1038/icb.2011.96 18.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Hum Vaccin Immun-other 2013; 9:784-9; PMID:23328677; http://dx.doi.org/10.4161/ hv.23085 19.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
J Clin Oncol 2011; 29:2052-9; PMID:21502553;http://dx.doi.org/10.1200/JCO.2010.32.4467 20.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Clin Immunol 2012; 144:250-68; PMID:22858650; http://dx.doi.org/10.1016/j.clim.2012.06.003 21.,OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Nat Rev Cancer 2013; 13:739-52; PMID:24060865; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Oncoimmunology 2015; 4:e954829; PMID:25949858; http://dx.doi.org/10.4161/21624011.2014.954829 23.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Cytometry B Clin Cytom 2015; 88:77-91; PMID:25504825; http://dx.doi.org/10.1002/cyto.b.21206 24.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Cancer Res 2010; 70:99-108;PMID:19996287; http://dx.doi.org/10.1158/0008-5472.CAN-09-1882 25.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
AnnN Y Acad Sci 2014; 1319:47-65; PMID:24965257; http://dx.doi.org/10.1111/nyas.12469 26.,OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
PLoS Biol 2011; 9: e1001162; PMID:21980263; http://dx.doi.org/10.1371/journal.,OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Blood 2008;111:4233-44; PMID:18272812; http://dx.doi.org/10.1182/blood-2007- 07-099226 28.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Nat Med 2012; 18:1254-61; PMID:22842478; http://dx.doi.org/10.1038/nm.2883 29.,OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Cancer Res 2005; 65:3044-8;PMID:15833831; http://dx.doi.org/10.1158/0008-5472.CAN-04-4505 31.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Clin Cancer Res 2007; 13:1083-8; PMID:17317815; http://dx.doi.org/10.1158/1078-0432.CCR-06-1893 32.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Blood 2012;120:3030-8; PMID:22932804; http://dx.doi.org/10.1182/blood-2012-05-427799 33.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Melanoma Res 2013; 23:341-8; PMID:23963286; http://dx.doi.org/ 10.1097/CMR.0b013e328364c0ed 34.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Blood 2008; 111:5054-63;PMID:18349319; http://dx.doi.org/10.1182/blood-2007-12-130609 35.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Nat Med 2007; 13:1299-307;PMID:17922010; http://dx.doi.org/10.1038/nm1652 3 6 .,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Clin Immunol 2010; 136:348-63; PMID:20478744; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
"Clin Dev Immunol 2013; 2013:679804; PMID:23737814; http://dx.doi.org/10.1155/2013/679804 38. de Zoeten EF, Wang L, Butler K, Beier UH, Akimova T, Sai H, Bradner JE, Mazitschek R, Kozikowski AP, Matthias P et al.",OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Mol Cell Biol 2011; 31:2066-78; PMID:21444725; http://dx.doi.org/10.1128/MCB.05155-11 39.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Oncoimmunol- ogy 2012; 1:948-50; PMID:23162767; http://dx.doi.org/10.4161/ onci.20306 40.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
"A phase I/II trial of beli- nostat in combination with cisplatin, doxorubicin, and cyclophospha-mide in thymic epithelial tumors: a clinical and translational study.Clin Cancer Res 2014; 20:5392-402; PMID:25189481; http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Curr Opin Oncol 2015; 27:191-200;PMID:25811346; http://dx.doi.org/10.1097/CCO.0000000000000177 42.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Curr OpinUrol 2015; 25:586-96; PMID:26372038; http://dx.doi.org/10.1097/ MOU.0000000000000213 4 3 .,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Cancer Cell 2015; 27:450-61; PMID:25858804; http://dx.doi.org/10.1016/j.ccell.2015.03.001 44.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Science 2015; 348:56-61; PMID:25838373; http://dx.doi.org/10.1126/science.aaa8172 45.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Lancet Oncol 2014; 15:191-200; PMID:24439931; http://dx.doi.org/10.1016/ S1470-2045(13)70596-5 47.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
2016 Oct; 118(4):590-7; PMID:26780387; http://dx.doi.org/10.1111/bju.1341248.,OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
Ann Oncol 2016; 27:693-9; PMID:26802155; http://dx.doi.org/10.1093/annonc/mdw008 49.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
J Immunol 2010; 185:2273-84; PMID:20644162; http://dx.doi.org/10.4049/jimmunol.1000901 50.,Non-OADS,/arxiv_data1/oa_pdf/e0/b5/koni-05-11-1219008.PMC5139687.pdf
@ERSpublications Infection rates different between two Australian paediatric cystic fibrosis patient cohortshttp://ow.ly/PAmG302IYL4 The content of this work is copyright of the authors or their employers.,Non-OADS,/arxiv_data1/oa_pdf/6f/5c/00014-2016.PMC5140014.pdf
@ERSpublications Sleep disturbances are a weak correlate of cognitive functioning in COPD http://ow.ly/gUhD301PvcQ Copyright ©ERS 2016.,Non-OADS,/arxiv_data1/oa_pdf/7b/07/00054-2016.PMC5140015.pdf
"@ERSpublications In the healthy elderly with unrecognised OSA, the risk of blunted baroreceptor sensitivity was low http://ow.ly/kofu302IZWS Copyright ©ERS 2016.",Non-OADS,/arxiv_data1/oa_pdf/2d/38/00072-2016.PMC5140016.pdf
@ERSpublications Lipoxin A4 promotes epithelial repair while inhibiting fibroproliferation in vitro in human alveolar epithelial cells http://ow.ly/SxMu301cBRP Copyright ©ERS 2016.,Non-OADS,/arxiv_data1/oa_pdf/e2/da/00079-2015.PMC5140017.pdf
@ERSpublications Breathing retraining improves the quality of life and symptoms of children with dysfunctional breathing http://ow.ly/qg1c302sYAF Copyright ©ERS 2016.,Non-OADS,/arxiv_data1/oa_pdf/36/f0/00103-2015.PMC5140018.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/ec/55/ott-9-7263.PMC5140029.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 7263–7274OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  7263Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OTT .S11717 6 Androgen deprivation therapy as backbone  therapy in the management of prostate cancer Axel S Merseburger1 Antonio Alcaraz2 Christoph A von Klot3 1Department of Urology, University  Hospital Schleswig-Holstein, Campus  Lübeck, Germany; 2Department of  Urology, Hospital Clínic, Barcelona,   Spain; 3Department of Urology and  Urologic Oncology, Hannover Medical  School, Hannover, GermanyAbstract:  Androgen deprivation therapy (ADT) is well established as a backbone therapy for  metastatic prostate cancer (mPCa), and both European and American guidelines emphasize  the importance of maintaining ADT after progression to metastatic castration-resistant pros - tate cancer (CRPC).",Non-OADS,/arxiv_data1/oa_pdf/ec/55/ott-9-7263.PMC5140029.pdf
"The National Comprehensive Cancer Network (NCCN) now states that  medical castration is as effective as bilateral orchiectomy.4 ADT can delay metastatic PCa (mPCa) progression for around 2 years on average,  but most patients will eventually develop castration-resistant PCa (CRPC).5 PCa growth  remains dependent on androgen receptor (AR) signaling, even after the development  of CRPC, highlighting the need to maintain ADT.6 This review outlines the importance of ADT as backbone therapy in CRPC  and considers its continued use with existing and new treatment modalities  in CRPC.Correspondence: Axel S Merseburger Department of Urology, University  Hospital Schleswig-Holstein, Campus  Lübeck, Ratzeburger Allee 160,  23562 Lübeck, Germany Tel +49 451 500 2271 Fax +49 451 500 3388 email axel.merseburger@uksh.d e Journal name: OncoTargets and Therapy Article Designation: Review Y ear: 2016 Volume: 9 Running head verso: Merseburger et al Running head recto: ADT in the management of prostate cancer DOI: http://dx.doi.org/10.2147/OTT.S117176",Non-OADS,/arxiv_data1/oa_pdf/ec/55/ott-9-7263.PMC5140029.pdf
Available from: https://www.nccn.org/patients/ guidelines/prostate /.,Non-OADS,/arxiv_data1/oa_pdf/ec/55/ott-9-7263.PMC5140029.pdf
"Available from: http://www.ema.europa.eu/docs/en_GB/ document_library/EPAR_-_Product_Information/human/000073/ WC500035264.pd f. Accessed April 22, 2016.",Non-OADS,/arxiv_data1/oa_pdf/ec/55/ott-9-7263.PMC5140029.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/ec/55/ott-9-7263.PMC5140029.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/ec/55/ott-9-7263.PMC5140029.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/76/a4/tcrm-12-1811.PMC5140030.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Therapeutics and Clinical Risk Management 2016:12 1811–1826Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  1811Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/TCRM.S12081 1 Ceftolozane/tazobactam and ceftazidime/ avibactam for the treatment of complicated  intra-abdominal infections Kellie J Goodlet1 David P Nicolau2 Michael D Nailor1,3 1Department of Pharmacy Services,   Hartford Hospital, Hartford, CT, USA;   2Center of Anti-infective Research,   Hartford Hospital, Hartford, CT, USA;   3Department of Pharmacy Practice,   School of Pharmacy, University of  Connecticut, Storrs, CT, USAAbstract:  Complicated intra-abdominal infections (cIAI) represent a large proportion of all  hospital admissions and are a major cause of morbidity and mortality in the intensive care unit.",Non-OADS,/arxiv_data1/oa_pdf/76/a4/tcrm-12-1811.PMC5140030.pdf
"Uncomplicated IAIs are differentiated from cIAI by Correspondence: Michael D Nailor Hartford Hospital, 80 Seymour Street,  Hartford, CT 06102, USA Tel +1 860 972 2221 Fax +1 860 972 2910 email michael.nailor@hhchealth.or g Journal name: Therapeutics and Clinical Risk Management Article Designation: Review Y ear: 2016 Volume: 12 Running head verso: Goodlet et al Running head recto: Novel antibiotics for complicated intra-abdominal infections DOI: http://dx.doi.org/10.2147/TCRM.S120811",Non-OADS,/arxiv_data1/oa_pdf/76/a4/tcrm-12-1811.PMC5140030.pdf
"Available from: http://www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ucm321390.pd f.  Accessed June 15, 2016.",Non-OADS,/arxiv_data1/oa_pdf/76/a4/tcrm-12-1811.PMC5140030.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/76/a4/tcrm-12-1811.PMC5140030.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/76/a4/tcrm-12-1811.PMC5140030.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/4e/40/mder-9-423.PMC5140031.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/4e/40/mder-9-423.PMC5140031.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Medical Devices: Evidence and Research 2016:9 423–427Medical Devices: Evidence and Research Dovepress submit your manuscript | www.dovepress.com Dovepress 423 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/MDER.S119887 Design evolution enhances patient compliance for  low-intensity pulsed ultrasound device usage Neill M Pounder   John T Jones   Kevin J Tanis Bioventus LLC, Durham, NC, USAAbstract: Poor patient compliance or nonadherence with prescribed treatments can have a  significant unfavorable impact on medical costs and clinical outcomes.",Non-OADS,/arxiv_data1/oa_pdf/4e/40/mder-9-423.PMC5140031.pdf
"Correspondence: Neill M Pounder   Bioventus LLC, 4721 Emperor Boulevard,  Suite 100, Durham, NC 27703, USA Tel +1 919 474 6738   Email neill.pounder@bioventusglobal.comJournal name: Medical Devices: Evidence and Research Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 9Running head verso: Pounder et alRunning head recto: LIPUS device design and patient complianceDOI: http://dx.doi.org/10.2147/MDER.S119887 Video abstract Point your SmartPhone at the code above.",Non-OADS,/arxiv_data1/oa_pdf/4e/40/mder-9-423.PMC5140031.pdf
Or use: http://youtu.be/3WMVzrro_o4,Non-OADS,/arxiv_data1/oa_pdf/4e/40/mder-9-423.PMC5140031.pdf
"Medical Devices: Evidence and Research 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Medical Devices: Evidence and Research Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/medical-devices-evidence-and-research-journalMedical Devices: Evidence and Research is an international, peer- reviewed, open access journal that focuses on the evidence, technology, research, and expert opinion supporting the use and application of   medical devices in the diagnosis, monitoring, treatment and management of clinical conditions and physiological processes.",Non-OADS,/arxiv_data1/oa_pdf/4e/40/mder-9-423.PMC5140031.pdf
Available from: https://clinicaltrials.gov/show/NCT00667849.,Non-OADS,/arxiv_data1/oa_pdf/4e/40/mder-9-423.PMC5140031.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/c2/00/rmhp-9-261.PMC5140032.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/c2/00/rmhp-9-261.PMC5140032.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Risk Management and Healthcare Policy 2016:9 261–269Risk Management and Healthcare Policy Dovepress submit your manuscript | www.dovepress.com Dovepress 261 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/RMHP .S117173 Impact of the health insurance scheme for  stateless people on inpatient utilization in Kraburi  Hospital, Thailand Rapeepong  Suphanchaimat1,2 Phusit Prakongsai1 Supon Limwattananon1,3 Anne Mills2 1International Health Policy Program  (IHPP), Ministry of Public Health,   Faculty of Public Health and Policy,  Nonthaburi, Thailand;  2London School  of Hygiene and Tropical Medicine,  London, UK;  3Khon Kaen University,   Khon Kaen, ThailandObjectives: This study sought to investigate the impact of the Thai “Health Insurance for People  with Citizenship Problems” (HI-PCP) on access to care for stateless patients, compared to Univer - sal Coverage Scheme patients and the uninsured, using inpatient utilization as a proxy for impact.",Non-OADS,/arxiv_data1/oa_pdf/c2/00/rmhp-9-261.PMC5140032.pdf
"2 The United Nations High Commissioner for Refugees  (UNHCR) estimated that, globally, to date, more than 10 million people are stateless, and Correspondence: Rapeepong  SuphanchaimatInternational Health Policy Program, Ministry of Public Health, Tiwanon Road, Nonthaburi 11000, ThailandTel +66 2590 2366Fax +66 2590 2385Email rapeepong@ihpp.thaigov.netJournal name: Risk Management and Healthcare Policy Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 9Running head verso: Suphanchaimat et alRunning head recto: Impact of health insurance scheme for stateless people on inpatient utilizationDOI: http://dx.doi.org/10.2147/RMHP .S117173",Non-OADS,/arxiv_data1/oa_pdf/c2/00/rmhp-9-261.PMC5140032.pdf
"Risk Management and Healthcare Policy 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Risk Management and Healthcare Policy Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/risk-management-and-healthcare-policy-journalRisk Management and Healthcare Policy is an international, peer-reviewed,  open access journal focusing on all aspects of public health, policy, and preventative measures to promote good health and improve morbidity and mortality in the population.",Non-OADS,/arxiv_data1/oa_pdf/c2/00/rmhp-9-261.PMC5140032.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 269 Impact of health insurance scheme for stateless people on inpatient utilization References  1.,Non-OADS,/arxiv_data1/oa_pdf/c2/00/rmhp-9-261.PMC5140032.pdf
"[cited July 1, 2016]; Available from: hhttp://www.unhcr.org/protection/statelessness/4039fbba2/1954-convention-relating-status-stateless-persons-implementation-european.html.",Non-OADS,/arxiv_data1/oa_pdf/c2/00/rmhp-9-261.PMC5140032.pdf
Available from: http://apps.who.int/iris/bitstream/10665/   44844/1/9789241564441_eng.pdf?ua= 1.,OADS,/arxiv_data1/oa_pdf/c2/00/rmhp-9-261.PMC5140032.pdf
"[cited January 4, 2015]; Available from: http://www.kkpho.go.th/homes/index.php/2011-05-04-08-31-08/60-2011-05-05-07-35-00/1990-stateless.html.",Non-OADS,/arxiv_data1/oa_pdf/c2/00/rmhp-9-261.PMC5140032.pdf
"creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permiss ion provided the original work is attributed as specified on the SAGE and Open Access page (https://uk.sagepub.com/en-us/nam/open-access-at-sage).Journal of the Royal Society of Medicine Open; 7(12) 1–5 DOI: 10.1177/2054270416675560",Non-OADS,/arxiv_data1/oa_pdf/6b/6a/10.1177_2054270416675560.PMC5140040.pdf
Available from: https://index.rsf.org/#!/ 2.,Non-OADS,/arxiv_data1/oa_pdf/6b/6a/10.1177_2054270416675560.PMC5140040.pdf
Available from: https://cpj.org/mideast/iran/ 3.,Non-OADS,/arxiv_data1/oa_pdf/6b/6a/10.1177_2054270416675560.PMC5140040.pdf
Available from: https://cjfe.org 4.,Non-OADS,/arxiv_data1/oa_pdf/6b/6a/10.1177_2054270416675560.PMC5140040.pdf
"creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permiss ion provided the original work is attributed as specified on the SAGE and Open Access page (https://uk.sagepub.com/en-us/nam/open-access-at-sage).Journal of the Royal Society of Medicine Open; 7(12) 1–5 DOI: 10.1177/2054270416675082",Non-OADS,/arxiv_data1/oa_pdf/90/43/10.1177_2054270416675082.PMC5140041.pdf
"For reprints and permission queries, plea se visit SAGE’s Web site at http://www.sagepub.com/journalsPermissions.nav.",Non-OADS,/arxiv_data1/oa_pdf/4f/05/10.1177_2325967116673356.PMC5140042.pdf
"We searched The Cancer Genome Atlas database (https://tcga-data.nci.nih.gov/tcga/) and found that heterozygous FEN1 somaticmutations are present in the tumor tissues of most cancer types, 33 with colorectal cancer showing the highest FEN1 mutation frequency (Figure 1a).",OADS,/arxiv_data1/oa_pdf/be/63/onc2016188a.PMC5140775.pdf
"To view a copy of this license, visit http:// creativecommons.org/licenses/by-nc-nd/4.0/ Supplementary Information accompanies this paper on the Oncogene website (http://www.nature.com/onc)Functional de ﬁciency of human FEN1 L209P mutation H Sun et al 207 © 2017 Macmillan Publishers Limited, part of Springer Nature.",Non-OADS,/arxiv_data1/oa_pdf/be/63/onc2016188a.PMC5140775.pdf
"Finally, we examined the expression of proteins encoded by genes deleted on chr 9p21 using publically available data(http://www.proteinatlas.org).",OADS,/arxiv_data1/oa_pdf/7d/d6/onc2016172a.PMC5140783.pdf
The tri-nucleotidecontext of variants that were not observed in the 1000 Genomes Project samples 53was examined using twoBitToFa (http://hgdownload.soe.ucsc.,OADS,/arxiv_data1/oa_pdf/7d/d6/onc2016172a.PMC5140783.pdf
"NGS analysis utilized the high-performance computational capabilities of the Biowulf Linux cluster at the National Institutes of Health (Bethesda, MD, USA) (http://biowulf.nih.gov).",OADS,/arxiv_data1/oa_pdf/7d/d6/onc2016172a.PMC5140783.pdf
Drug treatment information for all patients in the TCGA cohort was taken from a clinical data ﬁle (https://tcga-data.nci.nih.,OADS,/arxiv_data1/oa_pdf/7d/d6/onc2016172a.PMC5140783.pdf
"The Wilcoxon rank sum test was used to compare the distribution of mutations and copy numbers between patient and cell lines.UC40 gene expression and dose response We used the gene expression (GSE5845) and dose response for cisplatin for the UC40 BCa cell lines as reported in Lee et al.22 PARADIGM analyses PARADIGM (http://sbenz.github.io/Paradigm/), an integrative -omics tool for inferring pathway activities, was used to calculate IPA by integratingCNA and gene expression data for each patient and cell line.37Patient input data consisted of the TCGA gene expression (RSEM55normalized RNAseq) and segmented, log-transformed copy number values fromGISTIC2.4Cell line input data consisted of RMA-normalized gene expression22and segmented, log-transformed copy number values from Earl et al.23using GISTIC2.",OADS,/arxiv_data1/oa_pdf/7d/d6/onc2016172a.PMC5140783.pdf
"Available from http://www.bioconductor.org.55 Li B, Dewey CNN.",OADS,/arxiv_data1/oa_pdf/7d/d6/onc2016172a.PMC5140783.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ Supplementary Information accompanies this paper on the Oncogene website (http://www.nature.com/onc)Translational genomics of bladder cancer cell lines ML Nickerson et al 46 Oncogene (2017) 35 –46 © 2017 Macmillan Publishers Limited, part of Springer Nature.",Non-OADS,/arxiv_data1/oa_pdf/7d/d6/onc2016172a.PMC5140783.pdf
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd)  License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Original Article  The Journal of Physical Therapy Science,Non-OADS,/arxiv_data1/oa_pdf/2e/08/jpts-28-2991.PMC5140787.pdf
This	is	an	open-access	 article	distributed	 under	the	terms	of	the	Creative	Commons	 Attribution	 Non-Commercial	 No	Derivatives	 (by-nc-nd)	 License	<http://creativecommons.org/licenses/by-nc-nd/4.0/>.Original	Article  The Journal of Physical Therapy Science,Non-OADS,/arxiv_data1/oa_pdf/af/e4/jpts-28-2999.PMC5140788.pdf
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd)  License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Original Article  The Journal of Physical Therapy Science,Non-OADS,/arxiv_data1/oa_pdf/c7/19/jpts-28-3003.PMC5140789.pdf
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd)  License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Original Article  The Journal of Physical Therapy Science,Non-OADS,/arxiv_data1/oa_pdf/51/41/jpts-28-3007.PMC5140790.pdf
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd)  License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Original Article  The Journal of Physical Therapy Science,Non-OADS,/arxiv_data1/oa_pdf/6d/4b/jpts-28-3011.PMC5140791.pdf
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd)  License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Original Article  The Journal of Physical Therapy Science,Non-OADS,/arxiv_data1/oa_pdf/53/05/jpts-28-3015.PMC5140792.pdf
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd)  License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Original Article  The Journal of Physical Therapy Science,Non-OADS,/arxiv_data1/oa_pdf/b3/a2/jpts-28-3020.PMC5140793.pdf
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd)  License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Original Article  The Journal of Physical Therapy Science,Non-OADS,/arxiv_data1/oa_pdf/df/41/jpts-28-3030.PMC5140794.pdf
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd)  License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Original Article  The Journal of Physical Therapy Science,Non-OADS,/arxiv_data1/oa_pdf/aa/15/jpts-28-3036.PMC5140795.pdf
This	is	an	open-access	 article	distributed	 under	the	terms	of	the	Creative	Commons	 Attribution	 Non-Commercial	 No	Derivatives	 (by-nc-nd)	 License	<http://creativecommons.org/licenses/by-nc-nd/4.0/>.Original Article  The Journal of Physical Therapy Science,Non-OADS,/arxiv_data1/oa_pdf/70/13/jpts-28-3041.PMC5140796.pdf
This	is	an	open-access	 article	distributed	 under	the	terms	of	the	Creative	Commons	 Attribution	 Non-Commercial	 No	Derivatives	 (by-nc-nd)	 License	<http://creativecommons.org/licenses/by-nc-nd/4.0/>.Original	Article  The Journal of Physical Therapy Science,Non-OADS,/arxiv_data1/oa_pdf/ce/26/jpts-28-3047.PMC5140797.pdf
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd)  License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Original Article  The Journal of Physical Therapy Science,Non-OADS,/arxiv_data1/oa_pdf/32/35/jpts-28-3054.PMC5140798.pdf
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd)  License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Original Article  The Journal of Physical Therapy Science,Non-OADS,/arxiv_data1/oa_pdf/5b/b6/jpts-28-3060.PMC5140799.pdf
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd)  License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Original Article  The Journal of Physical Therapy Science,Non-OADS,/arxiv_data1/oa_pdf/5f/9b/jpts-28-3063.PMC5140800.pdf
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd)  License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Original Article  The Journal of Physical Therapy Science,Non-OADS,/arxiv_data1/oa_pdf/a2/e2/jpts-28-3066.PMC5140801.pdf
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd)  License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Original Article  The Journal of Physical Therapy Science,Non-OADS,/arxiv_data1/oa_pdf/50/48/jpts-28-3070.PMC5140802.pdf
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd)  License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Original Article  The Journal of Physical Therapy Science,Non-OADS,/arxiv_data1/oa_pdf/b1/25/jpts-28-3074.PMC5140803.pdf
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd)  License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Original Article  The Journal of Physical Therapy Science,Non-OADS,/arxiv_data1/oa_pdf/7e/d0/jpts-28-3078.PMC5140804.pdf
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd)  License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Original Article  The Journal of Physical Therapy Science,Non-OADS,/arxiv_data1/oa_pdf/19/cd/jpts-28-3084.PMC5140805.pdf
This	is	an	open-access	 article	distributed	 under	the	terms	of	the	Creative	Commons	 Attribution	 Non-Commercial	 No	Derivatives	 (by-nc-nd)	 License	<http://creativecommons.org/licenses/by-nc-nd/4.0/>.Original Article  The Journal of Physical Therapy Science,Non-OADS,/arxiv_data1/oa_pdf/dd/d5/jpts-28-3088.PMC5140806.pdf
http://www.wcpt.org/ iseapt (Accessed Jun.,Non-OADS,/arxiv_data1/oa_pdf/dd/d5/jpts-28-3088.PMC5140806.pdf
33) Japanese Physical Therapy Association member statistics: Employment distribution for March 2015. http://www.japanpt.or.jp/about/data/ (Accessed Jun.,Non-OADS,/arxiv_data1/oa_pdf/dd/d5/jpts-28-3088.PMC5140806.pdf
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd)  License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Original Article  The Journal of Physical Therapy Science,Non-OADS,/arxiv_data1/oa_pdf/92/f2/jpts-28-3095.PMC5140807.pdf
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd)  License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Original Article  The Journal of Physical Therapy Science,Non-OADS,/arxiv_data1/oa_pdf/19/4a/jpts-28-3099.PMC5140808.pdf
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd)  License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Original Article  The Journal of Physical Therapy Science,Non-OADS,/arxiv_data1/oa_pdf/3d/4d/jpts-28-3105.PMC5140809.pdf
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd)  License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Original Article  The Journal of Physical Therapy Science,Non-OADS,/arxiv_data1/oa_pdf/95/a7/jpts-28-3112.PMC5140810.pdf
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd)  License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Original Article  The Journal of Physical Therapy Science,Non-OADS,/arxiv_data1/oa_pdf/cf/0c/jpts-28-3116.PMC5140811.pdf
